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 i 
Abstract  
 
After decades of research there is now a plethora of cell-based therapies traversing through different 
phases of clinical trials. However, there remains work to be done regarding optimising the quality and 
production efficiency of these therapies, as well as economic considerations to validate their 
commercial viability. This project focuses on the process development of a candidate human embryonic 
stem cell (hESC) based therapy for Parkinson’s disease (PD) and the related health economics. 
 
This work set out to identify the key translational requirements for successful, robust and reproducible 
manufacture of a cell-based therapy for PD, by optimising a preclinical validated differentiation 
protocol. Design of experiment (DoE) approaches were employed to investigate the effect of small 
molecule concentrations, seeding density and feeding regime on process outputs. Orthogonal analysis 
of flow cytometry, cell growth and metabolomics was used to ascertain the relationship between critical 
process parameters and their impact on critical quality attributes. The results demonstrated that higher 
seeding densities (15,000 cells/cm2 and above) and specific small molecule concentrations such as 1 -
1.5 µM CHIRR99021 are required for cell survival and desired cell differentiation. Moreover, the 
results revealed an interaction between phenotype and feeding regime that may not be accurately 
reflected in growth rate but is linked to the specific metabolic rate. This emphasised the need for 
standardised protocols that control for culture procedures and feeding based on cell metabolic rate and 
growth dynamics.  
 
In addition to the process development work carried out, a complimentary work-stream developed 
models incorporating economic evaluation, reimbursement price modelling and cost of goods 
modelling to ascertain the commercial viability and potential cost-effectiveness of the hESC-based 
therapy for PD. The results illustrated that a hESC based therapy would be a cost-effective treatment 
for PD at prices ranging from £180,000 to £255,000, with the potential to be cost saving and 
significantly reduce the economic burden of PD. Furthermore, such a therapy has the potential to 
generate revenue and provide  profits while affording health gains presently unattainable through 
current treatments. Thus, the present work has exhibited that a hESC-based therapy for PD has the 
potential to provide value to multiple stakeholders, providing it achieves the translational requirements 
to ensure robust evidence generation for successful regulatory and reimbursement approval. 
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Figure 30: (A) SGR data revealed no retention of cell metabolic state as the SGR changes from passage 
1 to passage 2 of the experiment (****, p<0.0001).  Error bars indicate standard deviation, n=2 for each 
condition; n=2 for SMR data; n=4 for SGR data, “***” indicates p< 0.001, and “****” indicates 
p<0.0001. (B-D) Three graphical representations used to show the different behaviours exhibited by 
SMRs of the different condition. Passage points shown in (C) correspond to: 1 = passage 1 feed day; 2 
= passage 1 harvest/reset day; 3 = passage 2 feed day; 4 = passage 2 harvest day). .......................... 119 
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Figure 31: (A) SGR data for all the conditions, most of the variation was observed at passage 1. (B) 
SMR data over the two passages, significant difference observed with passage 1 only, “****” indicates 
p<0. 0001. Percentage levels of experience for the flow cytometry pluripotency maker panel used, (C) 
OCT3/4 positive marker, (D) SSEA-1 negative marker and (E) SSEA-4 positive marker. Significant 
difference between the two passages overall was only observed for the OCT/34 marker (**, p=0.001).  
Error bars indicate standard deviation, n=2 for each condition; n=2 for SMR data; n=4 for SGR data .. - 
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Figure 32: (A) SGR of the conditions investigated in the experiment. (B) Differences in SMR between 
conditions were only observed at passage 1, conditions with significant differences are highlight “**” 
indicates p< 0.01, “***” indicates p< 0.001. (C) Significant difference in % expression between passage 
1 and 2 for OCT3/4 was noted overall for all the conditions in each passage, (**, p=0.0011). (D) 
Expression in SSEA-1 was observed most notably at passage 2, however this was not significant. 
(E)The phenotypic marker expression profile did not change significantly from passage 1 to 2 for 
SSEA-4. Error bars indicate standard deviation, n=2 for each condition; n=2 for SMR data; n=4 for 
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Figure 33. (A) Specific growth rate trend for route A1 and A2 over ten passages, showing a fluctuation 
in SGR throughout all ten passages that follows the same trend regardless of route, n=3 error bars 
showing standard deviation, SD. (B) Cell viability trend of route A1 and A2 over ten passages both 
routes follow a similar trend in viability throughout all passages cycles, route A1 is shown to have lower 
viability during five of the passage cycles (4 -8) in comparison to route A2, n=2 error bars showing SD. 
(C) Cell diameters of route A1 and A2 over ten passages showing synchronised trend; some difference 
between the two routes is observed at passage cycle 3, 4 and 6, , n=3 error bars showing standard 
deviation, SD. (D) Glucose SMR from passage cycle 2 to 10 showing a significant difference between 
passages (***p<0.001), at each individual passage cycle route A2 is significantly higher than route A1 
(****p<0.0001) (E) OCT3/4 marker expression percentages for experiment Cat passage cycle 1, 3, 7 
and 9 significant differences between passages (****p<0.0001) and significant differences between 
culture route  A1 and A2 (p=0.0004, n=3). ................................................................................... - 130 - 
 
Figure 34.Flow cytometry dot plot profiles showing marker expression change from (A) passage cycle 
1 to (B) passage cycle 7. OCT3/4 expression decreased from passage cycle 1 to 7 and an increase in 
SSEA-1 was observed, highlighted by the red hatched boxes. Oct 3/4 and SSEA-4 are positive markers 
for pluripotent human embryonic stems, SSEA-1 is a negative marker associated with pluripotency of 
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Figure 35: Gene expression analysis of experiment A at four passage points over the then passages, 
expression was measured by real-time quantitative reverse transcription-polymerase chain reaction 
(qRT-PCR). Fold change was calculated using the relative quantity of each gene was calculated by the 
DDCt method, using a correction for the amplification efficiency of that gene, and normalised to the 
geometric mean of two housekeeping genes: glyceraldehyde-3-phosphate dehydrogenase and b-actin. 
Significant differences in fold change at different passage cycles were seen only for A -DNMT3B (***, 
p=0.0007), NANOG (*, p=0.01) and SOX2 (**, p=0.004). Significant differences between route A1 and 
A2 were seen only for A -DNMT3B (**, p=0.0032) and F-SOX2 (**, p-0.006). Differences between the 
two routes within a passage cycle were only observed for G-TDGF (passage cycle 3, **, p=0.018), A -
DNMT3B (passage cycle 7, *, p=0.0221; passage cycle 9, **, p=0.0073), and F-SOX2 (passage cycle 
9, *, p=0.0191). Error bars indicate standard deviation (n=3 for all graphs). ................................ - 134 - 
 
Figure 36. Growth data of the reversal route experiment over three analysis time points. B1 previously 
A2 overall has lower cell viability and SGR values compared to B2, previously A1, which had an 
increase in both cell viability and SGR. ......................................................................................... - 135 - 
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Figure 37.  (A)Lactate SMR demonstrating a change in SMR due to culture route, B2 previously A1 
has an increase in SMR. (B) Percentage expression levels at the reversal point and after 2 passages in 
the reversal experiment (reversal harvest), both B1 and B2 had an increase in OCT3/4 expression. (C) 
SSEA-1 percentage positive levels illustrating a decrease in expression for B1 and an increase for B2, 
demonstrating a change in phenotype express due to the exchange of culture conditions. ........... - 136 - 
 
Figure 38: (A) SGR over three passages, similar values were observed in all culture routes, apart from 
C4 at passage 3 (n=2). (B) Glucose SMR over three passages demonstrating that route conditions C2 
and C4 that had no medium exchange after 48 h had higher SMR compared to route C1 and C3. 
Significant difference between routes at each passage shown on the graph highlight that seeding density, 
feeding regime and a combination of both parameters resulted in a different SMRs (n=2). (C) OCT3/4 
marker expression over three passages, expression levels are similar between routes, significant 
difference observed between passage 2 and 3 for all routes (*p<0.05) except route C4. .............. - 137 - 
 
Figure 39. Schematic of the experimental design used to assess the reproducibility and variability of 
vials from the H9 bank of cells. Each of the three vials was thawed and seeded at 2 densities 10,000 
cells/cm2 (10K) and 20,000 cells/cm2 (20K) and cultured for two passages: n=3 for each condition. ... - 
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Figure 40. xCelligence® RTCA E-Plate® layout. Two densities, 10,000 and 20,000 cells/cm2, were 
seeded onto E-Plate® 96-well microtiter plates with medium containing four different concentrations 
of ROCKi ranging from 0 to 15 µM: n=6 for each condition used. .............................................. - 153 - 
 
Figure 41. Schematic of the experimental setup used to determine the growth curve of three different 
seeding densities: 10,000 cells/cm2 (10K); 20,000 cells/cm2 (20K) and 30,000 cells/cm2 (30K). n=3 for 
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Figure 42. (A) Data was collected everyday over two five-day passages. SGR is shown to increase each 
day, with the greatest increases from day 1 to day 2. Cells at passage 2 started to decrease their SGR 
from day 4 while at passage 1 the cells still had an increase in SGR from day 4 to day 5. There is a 
significant difference overall in SGR between passage 1 and passage 2 on all of the days except day 5 
p<0.0001 (****). (B) Overall, passage 2 cells had significantly higher cell viabilities that eventually 
dropped at day 4 (p<0.0001 (****), while passage 1 cells continue to increase in cell viability from day 
2 to day 5. (C) Glucose SMR data of the cells throughout the five-day culture period of each passage. 
SMR is higher in passage 2 compared passage 1, however in both instances there was a general trend 
of a decrease in glucose SMR. Error bars indicate standard deviation, n=6 for SGR and cell viability 
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Figure 43. Karyotype analysis of H9 cells showing normal XX chromosomes, a sample of cells from 
passage 2 was used to produce this karyogram. ............................................................................. - 158 - 
 
Figure 44. (A) Lactate and (B) LDH SMR data. Both lactate and LDH SMRs increased from passage 
1 to passage 2. However, only vial 1 at 10,000 cells/cm2 had a significant increase in lactate SMR, for 
LDH all conditions except vial 2 at 20,000 cells/cm2 had a significant increase in LDH SMR. Error bars 
indicate standard deviation, n=3. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 
0.001, and “****” indicates p<0.0001. .......................................................................................... - 159 - 
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Figure 45. Growth dynamics results. (A) SGR increases from passage 1 to passage 2, only vial 1 at 
10,000 cells/cm2 did not have a significant increase in SGR. (B) All of the 20,000 cells/cm2 had a 
significant increase in cell number from passage 1 to passage 2. (C) Only vial 1 and vial 2, both at 
10,000 cells/cm2 had significant decreases in cell viability from passage 1 to passage 2. (D) vials 2 and 
3 had similar cell numbers directly from being thawed after cryopreservation and before being cultured, 
however no difference was determined between the three vials. Error bars indicate standard deviation, 
n=6. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates 
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Figure 46. MedFI values for OCT3/4, Ki67 and PAX6.There is a decrease in MedFI from passage 1 to 
passage 2 in all conditions for both OCT3/4(A) and Ki67(B). PAX6 expression levels were low in 
comparison to OCT3/4 and Ki67, inset shows the very low levels of PAX6, all conditions are under 
800 for their MedFI values (C). Error bars indicate standard deviation, n=3. “*” indicates p<0.05, “**” 
indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates p<0.0001. ............................. - 162 - 
 
Figure 47. xCelligence® RTCA graphical summary of the Cell Index of values of the different ROCKi 
concentrations. The 10 µM condition had the highest overall Cell Index for the grouped data of both 
10,000 cells/cm2 and 20,000 cells/cm2. Error bars indicate standard deviation, n=12. ................. - 164 - 
 
Figure 48. xCelligence® RTCA Cell Index of the two densities with four different concentrations of 
ROCKi. Only the 0 µM condition had a significant difference in Cell Index between 10,000 and 20,000 
cells/cm2. Overall, cells seeded at 20,000 cells/cm2 had a higher Cell Index, across the four ROCKi 
concentrations that were investigated. Error bars indicate standard deviation, n=6. “*” indicates p<0.05, 
“**” indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates p<0.0001. ..................... - 164 - 
 
Figure 49. Growth dynamics. (A) SGR increased from negative SGR to positive SGR from day 2 to 
day 4 for all three densities. (B) Cell number decreased from day 0 to day 2 and then increased from 
day 2 to day 4, the 10,000 cell/cm2 density does not have significant increase in cell number during the 
4-day passage. (C) All three densities had a decrease in cell viability from day 0 to day 2 which 
increased from day 2 to day 4. Error bars indicate standard deviation, n=3. “*” indicates p<0.05, “**” 
indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates p<0.0001 .............................. - 166 - 
 
Figure 50. MedFI values for OCT3/4, Ki67 and PAX6. OCT3/4(A) and Ki67(C) were both highly 
expressed. (B) PAX6 expression levels are lower in comparison to OCT3/4 and Ki67. .............. - 167 - 
 
Figure 51. Growth dynamics. (A) SGR decreases from passage 1 to passage 2 for the control and route 
1 conditions, no significant difference was observed for route 2 while route 3 significantly increased 
from passage 1 to passage 2. (B) The same trend observed in the SGR was observed with the cell 
number yields from passage 1 to passage 2 i.e. only route 2 did not have a significant change in cell 
number between the two passages. (C) The control, route 1 and route 2 all have a decrease in cell 
viability from passage 1 to passage 2, which was not observed for route 3. Error bars indicate standard 
deviation, n=3. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 0.001, and “****” 
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Figure 52. MedFI values for OCT3/4, Ki67 and PAX6. OCT3/4(A) and Ki67(C) were both highly 
expressed. (B) PAX6 expression levels were very low in comparison to OCT3/4 and Ki67, inset shows 
the very low levels of PAX6, all conditions are under 1500 for their MedFI values. Uns = unstained; 
Iso = isotype; D0 = cells at day 0; R1 = route 1; R2 = route 2; R3 = route 3. ............................... - 170 - 
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Figure 53. Growth dynamics (run 2). (A) Overall the SGR is lower at passage 1, with all four conditions 
having negative SGRs until day 3 of passage 1. (D)At passage 2, route 2 and route 3 had a positive SGR 
from day 1 onwards, only route 3 had a significant decrease in SGR by day 3 of passage 2. At both 
passages the cell number increased from day 0 to day 3, however at passage 1 (B) there was a decrease 
in cell number from day 0 to day 1, not observed at passage 2 (E). Generally, cell viability increased 
throughout passage 1, except for route 1 which had a decrease on day 2 (C). At passage 2, route 2 and 
route 3 had variable cell viabilities from day to day, while the control and route 1 had increased cell 
viabilities from day to day (F). Error bars indicate standard deviation, n=6. ............................... - 173 - 
 
Figure 54. MedFI values for OCT3/4, Ki67 and PAX6 (run 2). OCT3/4(A) and Ki67(B) were both 
highly expressed. (C)PAX6 expression levels were very low in comparison to OCT3/4 and Ki67, inset 
shows the very low levels of PAX6, all conditions are under 800 for their MedFI values. Generally, 
OCT3/4 increased from passage 1 to 2 and Ki67 decreased from passage 1 to passage 2, however the 
changes were not determined to be statistically significant. N.B. Control Thaw = cells analysed for cell 
phenotype immediately following thawing from cryopreservation, without being cultured. ........ - 174 - 
 
Figure 55. Lactate and LDH SMR data (run 2). Lactate SMR increased from passage 1 (A) to passage 
2 (C), at passage 2 lactate SMR decreased for all routes except route 3. LDH SMR is highest for route 
3 at passage 1 (B) and passage 2 (D), generally LDH SMR decreases for all routes except route 3 at 
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Figure 56. Lactate and LDH SMR data. Lactate SMR decreases throughout the passage for DF, OF 
decreases until day 5 to day 6 where it increases significantly (p=0.0079) (A). LDH SMR is highest 
from day 5 to day 6 for the OF condition, the DF condition has low levels of LDH production over the 
7-day passage (B). Significant differences in SMR between the two. conditions for both lactate and 
LDH are observed at day 6 (p<0.0001) and day 7 (p<0.0001). Error bars indicate standard deviation, 
n=3. ................................................................................................................................................ - 177 - 
 
Figure 57. Growth dynamics. (A) SGR increased from negative SGR to positive SGR from day 3 
onwards peaking at day 4 for the DF condition and day 3 for the OF condition. OF had a greater decrease 
in SGR over the 7-day passage, SGR differed between the two condition on day 1 (p=0.0012). (B) Cell 
number decreased from day 5 onwards for both conditions, similar to the SGR OF had the most 
significant decrease in cell number and cell viability (C). From day 4 onwards there was a significant 
difference in cell number yield between the two conditions: day 4 (p<0.0001); day 5 (p=0.0002); day 6 
(p<0.0001); day 7 (p<0.0001). Error bars indicate standard deviation, n=6. ................................ - 178 - 
 
Figure 58. MedFI values for OCT3/4, Ki67 and PAX6. OCT3/4(A) and Ki67(C) were both highly 
expressed in both conditions. (B)PAX6 expression levels were lower in comparison to OCT3/4 and 
Ki67, inset shows the very low levels of PAX6, all conditions are under 800 for their MedFI values. 
OCT3/4 and Ki67 decreased from day 6 to day 7, resulting in lower expression levels overall when 
compared to the control (day 0) and both conditions at day 7. ...................................................... - 179 - 
 
Figure 59. Schematic of the complete differentiation process from hESCs into late ventral 
mesencephalic dopaminergic progenitors. Medium exchanges are performed on day 2,4,7,9 and 14; on 
day 11 the cells are harvested and reseeded. ROCK inhibitor is added on day 0 and 11. SB431542 and 
noggin are used as neurulation factors in the medium, whilst SHH-C24II and CHIR99021 are used to 
pattern then neural stem cells towards a ventral midbrain linage. The timeline illustrates the time points 
at which the various differentiation molecules are added into the process. Image adapted from Nolbrant 
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Figure 60. Cause and effect diagram (Ishikawa diagram) detailing potential causes of a poor 
experimental or manufacturing process for a cell-based product. Eight causal categories were used to 
determine potential root causes of an undesired effect. ................................................................. - 195 - 
 
Figure 61. Schematic of the well plate formats used in the experiment to determine a suitable well plate 
format for a higher resolution DSD. 6-well and 12-well plate formats were used for the three densities 
10,000 cells/cm2 (10K); 20,000 cells/cm2 (20K) and 30,000 cells/cm2 (30K). n=2 for each condition 
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Figure 62. Representative light microscope image of the cells from DR1 (A) and DR2 (B) showing 
small sparse colonies and detached cells floating. Scale bar = 400 µm. ....................................... - 209 - 
 
Figure 63. Progressive cell detachment during the early stages of differentiation using medium 
containing 0.6μM CHIR99021. Light microscope images show cell morphology and the progressive 
cell detachment. (A) Cells at day 1 imaged prior to medium exchange, showing a large number of 
unattached cells. (B) Cells at day 1 following medium exchange, showing very few attached to the 
culture surface. (C) Cells at day 2 imaged prior to medium exchange, showing a lot of cell debris. (D) 
Cells at day 2 imaged following medium exchange, showing colony formation and increase surface 
coverage. (E) Cells at day 3 imaged following medium exchange, poor cell attachment and cell lifting 
from the surface is observed. (F) Cells at day 4 imaged following medium exchange, very few 
individual cells are observed on the surface and all colonies from day 3 have detached.  Scale bar = 400 
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Figure 64: A comparative timeline illustrating cell death time points during the differentiation process. 
The end points represent the day that the respective condition was terminated due to excess cell death 
within the culture condition. Three conditions (10k 0.3µM CHIR + B27, 10k 0.5 µM CHIR + B27, and 
15k 0.5 µM CHIR + B27) had inconsistent behaviour between their biological repeats, the single 
surviving wells were carried forward (shown in pink). ................................................................... -212- 
 
Figure 65. An overview of H9 hESC to vmDA progenitor differentiation. Single cell suspensions were 
seeded (A) which attached start to proliferate and form colonies (B and C). By day 6 (D) the cultures 
were mostly confluent and increased in confluency to cover the culture surface by day 9 and 11 (E and 
F). Following replating at day 11 the cells were fully confluent with no visible culture surface, an 
increase in cell detachment was observed from day 14 (G: inset) and continued to day 16 (H: inset). 
A=Day 0; B=Day 2; C=Day 4; D=Day 6; E=Day 9; F=Day 11; G=Day 14; H=Day 16.  Scale bar = 
400 µm, insets scale bar = 100 µm. ............................................................................................... - 213 - 
 
Figure 66. A graph displaying the initial replating density at day 11 plotted against the final density on 
day 16. On day 11, cells were harvested and reseeded at 800,000 cells/cm2 where possible. The replating 
densities were calculated for the conditions seeded below 800,000 cells/cm2. Conditions replated at 
800,000 cells/cm2 had a range of final cell densities from 14,000 to 833,000 cells/cm2; this corresponded 
to 125,000 to 7.4 million total cells per well. Conditions replated at densities <800,000 cells/cm2 also 
had a range of final densities with some of them having higher final densities than the conditions at 
800,000 cells/cm2. N.B. A, B and C relate to the replicate within each condition. ....................... - 214 - 
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Figure 67. (A) Specific growth rate (SGR) and (B)total harvested cell numbers from each of the culture 
conditions that survived in DR4 at both day 11 and 16. The SGR data demonstrated that there were 
inconsistencies in growth within the conditions, with significant differences in SGR from day 11 to 16 
within each condition. The total cell number data demonstrated an increase in cells from day 0 to day 
11, followed by a decrease in cell number when the cells were harvested on day 16. In the conditions 
that did not perform as well such as 10k [0.5] there was little difference in cell number between day 11 
and day 16. Conversely, in conditions that initially performed well such as 20k [0.5] the cell number 
decreases from day 11 to 16 i.e. less than half the cells that were reseeded on day 11 were harvested on 
day 16. Error bars indicate standard deviation, n=2 for each count. “*” indicates p<0.05, “**” indicates 
p< 0.01, “***” indicates p< 0.001, and “****” indicates p<0.0001. ............................................... -215- 
 
Figure 68. Dot plots of the pluripotent cells, the 0.3 and 0.5 µM CHIR99021 at 20,000 cells/cm2 with 
B27 conditions. The key difference between the cell samples is the concentration of CHIR99210. The 
results show that there was no phenotypic marker profile difference due to CHIR99210 concentration. 
In the two conditions the seeding density and B27 supplementation remained the same. In comparison 
to the control, both differentiated sample cells demonstrated a decrease in OCT3/4 and a population 
shift in terms of reduced proliferation marker Ki67. However, the samples expressed PAX6 at day 16 
which is not representative of the desired vmDA cell phenotype. ................................................. - 216 - 
 
Figure 69. Comparable to panel 1 the cells have differing CHIR99021 concentration (0.3 vs 0.5 µM), 
however the seeding density was equivalent and B27 was supplemented at day 0. In this panel (Miltenyi 
panel 2) the differentiated cells for both conditions showed little difference in comparison to the 
pluripotent control cells. The dot plots demonstrate that both of the differentiated conditions are 
negative for FOXA2 and OTX2 in comparison to the pluripotent cells. Only the IAP markers showed a 
slight increase in expression when compared to the pluripotent controls. ..................................... - 217 - 
 
Figure 70. Panel 3 demonstrates the negative expression of NKX6.1 and NKX2.1; however, expression 
of SOX1 was observed. For the desired cell phenotype all three markers should be negative as these 
markers are associated with lateral or rostral cell fates which would be considered a contaminant cell 
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Figure 71. A comparative timeline illustrating point of cell death during differentiation run 5. The end 
points represent the day that the respective condition was terminated due to excess cell death within the 
culture condition, if early than day 16. Higher levels of consistency were observed in DR5 in 
comparison to DR4, all replicates with the conditions behaved the same in DR5, the earliest termination 
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Figure 72. (A)Specific growth rate (SGR) and (B)total harvested cell numbers from the conditions that 
survived in DR5 at both day 11 and 16. The SGR data demonstrated a significant difference between 
day 11 and day 16 in all of the experimental conditions. The cell number data showed an increase in 
total cell number from day 0 to day 11 and from day 11 to day 16 in all of the conditions. This illustrates 
a greater consistency and performance in all of the conditions in comparison to DR4. Error bars indicate 
standard deviation, n=3. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 0.001, and 
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Figure 73. Median fluorescence intensity values of the different markers for all experimental 
conditions. The OCT3/4 MFI data showed that there was negligible expression of OCT3/4 by day 16. 
There were varying levels of Ki67 expression in the experimental conditions, however they were all 
lower compared to the untreated pluripotent cell control samples. For the panel 2 markers the MedFI 
values showed that none of the experimental conditions had higher expression of the putative vmDA 
markers FOXA2 and OTX2 than the control. Panel 3 showed that all conditions were lower in 
comparison to the control for NKX6.1 yet some of the conditions had higher NKX.2.1 MedFI value 
compared to the controls. SOX1 MedFI values showed similar or lower values compared to the controls. 
The x axis codes are detailed in Table 40 . ................................................................................... - 223 - 
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Figure 74.Schematic detailing the termination time points for DSD1. The lighter blue colour represents 
conditions that were inconsistent throughout the experiment. For instance, some replicates under the 
M2 conditions were terminated at day 7; however, some were continued until day 11 prior to harvest. 
The darker blue colour demonstrates the conditions that behaved consistently throughout the 
experiment both in terms of when they were terminated and when they were harvested i.e. all replicates 
in M8 were terminated on day 9. M12 and 13 were the first conditions to be terminated due to extensive 
detachment at cell death by day 7. ................................................................................................. - 225 - 
 
Figure 75. Cell growth and viability data of the different conditions of the definitive screen. For the 
majority of the culture conditions, the population doubling rate was 0.5 doublings per day, resulting in 
~6 population doublings over the 11-day culture period (A). The number of cells harvested at day 11 
ranged from 5x105 to 2.1x106 with M2 having the lowest cell yield and M6 having the highest (B). The 
cell viabilities ranged from 84 % to 98 %, M2 had the lowest and M6 the highest viability (C). Error 
bars indicate standard deviation, n=4. ........................................................................................... - 226 - 
 
Figure 76. Median fluorescence values. (A) Ki67 was observed to decrease from day 4 to 9 in the 
majority of the conditions. (B) SOX1 decreased from day 4 to day 9 and remained at similar levels at 
day 11. (C) PAX6 expression varied amongst the different conditions, initially expressing low 
fluorescence prior to increasing in some of the experimental conditions (M2, M3 and M5); whilst in 
other conditions PAX6 expression remained low throughout the eleven-day culture period (M1, M6 
andM9), other conditions had a decrease in PAX6 MedFI (M4, M7 and M10). Conditions M2, M8, 
M12 and M13 were terminated prior to the day 11 time-point, therefore no values were obtained. Uns 
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Figure 77. (A) OCT3/4 decreased from day 4 to day 9 followed by an increase from day 9 to 11, 
however this was not to the same level as the MedFI values on day 4. (B) FOXA2 increased from day 
4 to day 9 in all the conditions except for M3 and M7 where they decreased from day 4 to 9. Some 
conditions had a decrease in FOXA2 MedFI from day 9 to 11(M4, M5, M10 and M11) while other 
conditions had an increase in fluorescence (M1, M6 and M7) with M1 having the highest MedFI of all 
the conditions investigated. Conditions M2, M8, M12 and M13 were terminated prior to day 11, 
therefore no values were obtained. Uns = unstained; Iso = isotype. .............................................. - 228 - 
 
 Figure 78. (A) Main effects plot of the factors that impacted population doubling rate at the 
experimental end point day 11. N2 and SHH-C24II had a significant impact on the population doubling 
rate, higher concentrations of both factors resulted in an increase of doubling rate. (B)Pareto chart 
detailing the level of effect that the different factors had on population doublings at the experimental 
end point day 11. N2 and SHH-C24II, combined and individually had the largest effect on population 
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Figure 79. Pareto chart detailing the level of effect the different experimental factors had on FOXA2 
expression at the experimental end point day 11. SHH-C24II had the largest impact on FOXA2 
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Figure 80. Pareto chart detailing the level of effect the different experimental factors had on PAX6 
expression at the experimental end point day 11. N2 supplement by itself and in combination with other 
factors such as SHH-C24II and noggin influenced PAX6 expression. .......................................... - 231 - 
 
Figure 81. Pareto chart detailing the level of effect the different experimental factors had on SOX1 
expression at the experimental end point day 11. N2 supplement, CHIR99021, SHH-C24II and noggin 
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Figure 82. Main effects plot of the factors and their influence on marker expression at the experimental 
end point day 11. (A) N2 supplement, noggin and CHIR99021 exhibited a linear relationship to SOX1 
expression, SHH-C24II concentration at the ranges used did not have an impact on SOX 1 expression. 
(B) PAX6 expression had a strong positive linear relationship to N2 supplement and ROCK-inhibitor, 
SHH-C24II and CHIR99021 had a strong negative correlation to PAX6 expression. (C) FOXA2 marker 
expression main effects, noggin and SHH-C24II had a positive linear relationship with FOXA2 
expression, higher levels of both factors resulted in higher levels of FOXA2 MedFI. CHIR99021 had a 
non-linear relationship to FOXA2 expression, the mid-point concentration afforded the lowest levels of 
FOXA2 MedFI. .............................................................................................................................. - 234 - 
 
Figure 83. Cell growth dynamics detailing the SGR, total cell number per well and cell viability. (A) 
SGR significantly decreased from day 4 to day 9 and from day 9 to day 11 for all conditions. (B) Cell 
number decreased overall for the 12-well plate format at 15,000 cells/cm2 and 20,000 cells/cm2, all other 
conditions had a significant increase overall in cell number by day 11. (C) All of the conditions had a 
significant decrease in cell viability by day 11, apart from the 6-well plate format seeded at 25,000 
cells/cm2. The 12-well plate format seeded at 15,000 cells/cm2 and 20,000 cells/cm2 had the greatest 
decrease in cell viability from day 9 to day 11, compared to the other conditions.  Error bars indicate 
standard deviation, n=2. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 0.001, and 
“****” indicates p<0.0001. ............................................................................................................ - 237 - 
 
Figure 84. Growth dynamics detailing the SGR, total cell number per condition and cell viability. (A) 
SGR significantly decreased from day 14 to day 16 in all of the conditions p=0.0443 (*). The 400,000 
cells/cm2 density conditions (C1, C3, C5 and C7) had SGR values over 0.005 hour-1 whilst the 
conditions replated at 800,000 cells/cm2 had very low (<0.001 hour-1) or negative SGR values (B) 
Overall, the cell number increased for all the conditions with average yields between 2x106 and 3.5x106 
per well at day 16; p>0.0001 (****). (C) Conditions C1 to C6 had a slight increase in cell viability from 
day 14 to day 16, while C7, C8 and C9 had a decrease in cell viability. Error bars indicate standard 
deviation, n=2. ............................................................................................................................... - 238 - 
 
Figure 85. The SGR decreased overall from time point to time point p<0.0001 (****), the majority of 
the conditions had a negative SGR by day 16, when there was the most significant decrease in SGR. 
Error bars indicate standard deviation, n=4. .................................................................................. - 240 - 
 
Figure 86. The cell number yields differed amongst the conditions, in particular at day 11 and 16, 
overall there was an increase in cell yield, however in more than half of the conditions cell number 
yield decreased from day 11 to 16. Conversely, the other conditions had their highest cell yields on day 
16, these conditions were: 2, 3, 6, 8, 10, 13 and 15. Both the time point (p<0.0001 (****)) and the 
culture condition culture (p<0.0001 (****)) resulted in significant differences in cell yield. Error bars 
indicate standard deviation, n=4. ................................................................................................... - 241 - 
 
Figure 87. The cell viabilities were high across the 17 different conditions; all conditions were above 
85% viability. All conditions except condition 5 and 13, had their most significant increases in cell 
viability from day 4 to 9; at day 16 the average cell viability was 97.4 ±1.1. Both the time point (p<0.0001 
(****)) and the condition of culture (p<0.0001 (****)) resulted in significant differences in cell yield. Error 
bars indicate standard deviation, n=4. ........................................................................................... - 242 - 
 
Figure 88. (A) OCT3/4 MedFI significantly decreased in expression of OCT3/4 for all conditions when 
compared to the pluripotent control p<0.0001 (****). Overall, the conditions retained a low level of 
OCT3/4 expression. (B)  Ki67 MedFI values at day 4 were not significantly different between the 
pluripotent control and the culture 17 conditions, with the exception of condition 7. However, for all 17 
conditions the MedFI at day 4 was significantly higher compared to day 9, 11 and 16, p <0.0001 (****). 
At day 9 all of conditions differed in Ki67 MedFI compared to the control, p<0.0001 (****). Error bars 
indicate standard deviation, n=2. ................................................................................................... - 243 - 
 xviii 
Figure 89. (A) FOXA2 MedFI values did not increase significantly over the time points; Except for 
conditions 1, 9, 11, 16 and 17 at varying time points. Some conditions, such as 12 and 13 had significant 
decreases in FOXA2 MedFI expression, particularly from day 11 to 16. At day 16 conditions 1 
(p=0.0001 (***)); 5 (p=0.0306 (*)); 9 (p=0.0025 (**)); 11 (p=0.0025 (**)); 16 (p=0.0079 (**)) and 17 
(p=0.204 (*)) were the only conditions with significantly higher FOXA2 values when compared to the 
pluripotent controls. (B) In general, there was an increase in the percentage of cells that were FOXA2 
positive compared to the pluripotent controls. Between day 4 and 9 there was a significant difference 
in the percentage of FOXA2 positive cells p<0.0001 (****). Between day 9 day 11 there was no 
significant difference whilst between day 11 and 16 there was a lesser degree of significance (p=0.0224 
(*) compared to day 4 to day 11 p<0.0001 (****) and day 4 to  16 p<0.0001 (****). Error bars indicate 
standard deviation, n=2. ................................................................................................................. - 244 - 
 
Figure 90. (A) Overall, the OTX2 MedFI values did not increase significantly over the time points in 
comparison to the pluripotent controls, except for condition 2 (p=0.0143 (*)) and 6 p=0.0003 (***)) on 
day 4, conditions 6 (p=0.0074 (**)) and 15 (p=0.0007 (***)) on day 11. (B) The OTX2 percentage 
positive date illustrates that, with the exception of condition 5 (day 4 to 11 p<0.0001(****); day 9 to 
11 p<0.0001(****); day 11 to 16 p<0.0001 (****)) and condition 14 (day 4 to 11 p<0.0001(****); day 
9 to 11 p<0.0001(****); day 11 to 16 p<0.0001 (****)) there was no significant difference in the 
percentage of OTX2 positive cells across the different conditions and across the different time points. 
Furthermore, the percentage of OTX2 positive cells in the culture condition 17 was not significantly 
different to the untreated pluripotent control. Error bars indicate standard deviation, n=2. ......... - 245 - 
Figure 91. (A) Conditions 2, 6, 8, 10 and 15 were significantly different to the pluripotent control on 
day 4 with higher expression of PAX6. After day 4 the conditions had decreased PAX6 MedFI 
expression p<0.0001(****), which decreased to similar or lower levels compared to the pluripotent 
controls at subsequent time points. (B) SOX1 MedFI expression was highest at day 4 for all conditions; 
conditions 1, 4, 5, 7, 9, 11, 12, 14, 16 and 17 had the highest SOX1 MedFI expression overall, which 
were significantly higher in comparison to all other conditions p<0.0001(****). Error bars indicate 
standard deviation, n=2. ................................................................................................................. - 246 - 
 
Figure 92. Main effects plot of the factors that impacted marker expression and population doublings 
at the experimental end point day 16. (A) FOXA2 marker expression main effects, both seeding density 
and SHH-C24II have a positive linear relationship with FOXA2 expression, higher levels of both result 
in higher levels of FOXA2 MedFI. CHIR99021 has a non-linear relationship to FOXA2 expression the 
mid-point concentration affording the highest levels of FOXA2 MedFI. (B) Seeding density, N2 
supplement and noggin have a positive linear relationship to OTX2 expression whilst CHIR99021 and 
FGF-8b have a negative correlation; SHH-C2411 has non-linear relationship where the mid-point 
resulted in lower OTX2 expression. (C) Five of the factors showing differing levels of effect and no 
effect, in the case of N2 supplement, on the population doubling rate. ......................................... - 248 - 
 
Figure 93. Pareto chart detailing the level of effect the different experimental factors had on population 
doubling rate at the experimental end point day 16.  Seeding density, CHIR99021 and SHH-C24II, 
individually and when combine with other factors, had the most significant impact on population 
doubling rate. SB431542 and FGF-8b demonstrated no significant impact on population doubling rate.
 ........................................................................................................................................................ - 249 - 
 
Figure 94. Pareto chart detailing the level of effect the different experimental factors had on FOXA2 
expression at the experimental end point day 16. The most significant factor on FOXA2 expression was 
CHIR99021; SB431542 did not have a significant effect. CHIR99021 and SHH-C24II combined, had 
a significant effect on FOXA2 MedFI expression. ........................................................................ - 250 - 
 
Figure 95. Pareto chart detailing the level of effect the different experimental factors had on OTX2 
expression at the experimental end point day 16. The most significant factor on OTX2 expression was 
CHIR99021; SHH-C24II and SB431542 did not have a significant effect. CHIR99021 and SHH-C24II 
combined had a significant effect on OTX2 MedFI expression. ................................................... - 251 - 
 xix 
Figure 96. (A) Images of cell at day 11 before replating, inset shows zoomed in sections of the well. 
(B) Image of cells at day 11, two hours after replating, the culture surface is fully covered, the inset 
image shows cells attached (black arrows) and unattached cell (red arrows) due to lack of available 
culture surface. Scale bar = 400 µm, inset scale bar = 100 µm. .................................................... - 255 - 
 
Figure 97. Process Transfer diagram, showing the range of densities and CHIR99021 concentrations 
explored. Central purple area shows the space studied, parameters in purple text represent the protocol 
conditions and the perforated boxes show the range of conditions that resulted in cell survival and/or 
vmDA differentiation. The grey box and crosses represent the parameter conditions that were observed 
to be optimal for cell survival given the results from DR4 and DR5. The blue box and crosses represent 
parameters from DSD1 and DSD2 that induced vmDA cell phenotype and cell survival. 20,000 
cells/cm2 is a common feature in the best performing conditions, while the prescribed Lund protocol 
density, 10,000 cells/cm2 and central CHIR99021 concentrations (0.6-0.9 µM) do not perform well in 
the range of conditions explored. ................................................................................................... - 265 - 
 
Figure 98. The process of healthcare provision, from treatment to payment under the PbR national tariff 
payment system. ............................................................................................................................. - 274 - 
 
Figure 99. Schematic of the action research methodology framework employed, detailing the five-step 
process used to investigate the challenges in the adoption of CTPs. ............................................. - 281 - 
 
Figure 100. The seven elements that NICE uses to determine value of a health technology during 
technology appraisals. Adapted with permission from NICE. ....................................................... - 293 - 
 
Figure 101. Taxonomy depiction of the price reduction schemes that can be used for both outcome and 
non-outcome based managed entry reimbursement agreements. Adapted from Grimm et al (2016). .... - 
297 - 
 
Figure 102. Adoption challenges being explored under the ATTC model. Adapted from the Cell and 
Gene Therapy Catapult. ................................................................................................................. - 301 - 
 
Figure 103. Summary of the economic burden of Parkinson’s disease. Data obtained from the literature 
191,347,348. .......................................................................................................................................... - 310 - 
 
Figure 104. Summary data of economic evaluations for the treatment of PD, detailing the interventions 
evaluated and the countries that have carried out evaluations. Numbers in brackets indicate the amount 
of studies that have been carried for the respective intervention and the amount of studies carried out in 
the respective country. Information summarised from literature searches and studies by Folse et al 
(2018), Nagpal et al (2019) and Becerra et al (2017). ................................................................... - 312 - 
 
Figure 105. Tornado plot showing the influence of each variable on the final total cost of DopaCell to 
the payer in the first year. Miscellaneous costs which represent the use of immunosuppressants are 
shown to be the most influential variable on final total cost. The lighter colour (left hand side) 
demonstrates the level of cost decrease from the baseline (centre line) due to the respective variable. 
The darker colour (right hand side) demonstrates the level of cost increase from the baseline due to the 
respective variable. ......................................................................................................................... - 322 - 
 
Figure 106. Tornado plot showing the influence of each variable on the final total cost of DBS to the 
payer in the first year. Device costs are shown to be the most influential variable on final total cost. The 
lighter colour (left hand side) demonstrates the level of cost decrease from the baseline (centre line) due 
to the respective variable. The darker colour (right hand side) demonstrates the level of cost increase 
from the baseline due to the respective variable. ........................................................................... - 324 - 
  
 xx 
Figure 107. Tornado plot showing the influence of each variable on the final total cost of medication 
therapy. Loss of productivity costs are shown to be the most influential variable on final total cost. The 
lighter colour (left hand side) demonstrates the level of cost decrease from the baseline (centre line) due 
to the respective variable. The darker colour (right hand side) demonstrates the level of cost increase 
from the baseline due to the respective variable. ........................................................................... - 326 - 
 
Figure 108. A comparison of the costs of the interventions over a ten-year period demonstrated that 
both DopaCell and DBS have significant decreases in costs at year two and at year five. Medication 
costs are shown to increase over the ten-year period, amounting to £53,962 per year, by year ten.- 332 
- 
 
Figure 109. Cost savings for both DopaCell and DBS are observed from year 2 onwards, DopaCell 
results in higher savings compared to DBS from year five onwards. The cumulative cost savings over 
the ten-year period are £304,951 and £317,270 for DopaCell/DopaCell adjusted and DBS, respectively. 
Bars above £0 indicate cost savings. .............................................................................................. - 333 - 
 
Figure 110. The cost per QALY data shows that from year two onwards the DopaCell/DopaCell 
adjusted and DBS all fall under the £30,000 per QALY cost-effectiveness threshold (red dotted line). 
Medication therapy costs per QALY increase over the ten-year period. ....................................... - 334 - 
 
Figure 111. Cost-effectiveness ratios (CER) of the CTP under two health utility assumptions (DopaCell 
and DopaCell adjusted) with the use of immunosuppressants, DBS and medication over a ten-year 
period. DopaCell had the lowest cost per QALY, and medication therapy had the highest cost per 
QALY. Red lines represent the lower and upper willingness to pay thresholds, £20,000 and £30,000 per 
QALY (indicated by red dotted lines). All of the alternative interventions are below the two thresholds 
while medication therapy is notably above the upper threshold. ................................................... - 335 - 
 
Figure 112. Comparison of costs per QALY for DopaCell and DopaCell (adjusted) over a ten-year 
period. Data shows the cost per QALY as a result of different sale prices. DopaCell crossed over the 
£30,000 WTP upper threshold at a sale price of £255,000 (cost/QALY = £31,284) while DopaCell 
(adjusted) crosses the threshold at a lower sale price of £180,000 (cost/QALY = £30,951). ....... - 336 - 
 
Figure 113. Cost-effectiveness plane shows that DopaCell, DopaCell adjusted (DopaCell ad) and DBS 
treatment options are all more cost-effective than medication therapy (Meds) over the ten-year period 
shown by their position in the bottom right hand quadrant. Therefore, medication therapy is dominated 
by all the other treatment options analysed. Medication therapy is positioned in the top right-hand 
quadrant and above the WTP threshold of £30,000 (represented by the red line). ........................ - 337 - 
  
 xxi 
List of Tables 
 
Table 1. Details of the different types of Parkinsonism and their presentations ............................. - 13 - 
 
Table 2. Matrix of health related coefficients used to determine an overall health state190. For each 
health state, the attribute level selected in the response is entered into the health utility equation 
(Equation 1). A health utility score of 1 represents perfect health while a negative health utility 
represents extreme poor health. ....................................................................................................... - 48 - 
 
Table 3. Transition matrix showing the different transition probabilities (tp) from one state to another. 
This matrix works on the principle of staying in the same state or progressing to the next state, but not 
being able to go back into a previous state – as indicated by the direction of the arrows in Figure 15. . - 
59 - 
 
Table 4. Components used in the N2 base medium formulation. ................................................... - 67 - 
 
Table 5. Components used in the B27 base medium formulation. .................................................. - 68 - 
 
Table 6. Components used in the media formulation for the differentiation process. Table details the 
small molecules added at specific time points of the process. * Use an appropriate volume for the 
conditions being cultured. ** Y-27632 is a RHO kinase (ROCK) inhibitor that increases cell survival 
following dissociation, therefore it is added only at day 0 seeding and on day 11 for the replating.- 69 
- 
 
Table 7. An example of how a FMO matrix is setup, the example shows an FMO matric for a three 
colour panel. Separate samples are stained with a staining mix that is missing one of the fluorophores.
 .......................................................................................................................................................... - 86 - 
 
Table 8. Culture details for experiments 3.1 to 3.4 ....................................................................... - 102 - 
 
Table 9. Parameters used in experiment 3.1. ................................................................................. - 103 - 
 
Table 10. Conjugated antibodies used for flow cytometry to determine pluripotency state of the cells
 .................................................................................................................................................... …- 107 - 
 
Table 11. The genes used for qRT-PCR analysis of the EC 2102Ep cells in experiment 4230. ..... - 108 - 
 
Table 12. Experiment 2 SGR. Tukey’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions on that day. Summary shows only the conditions with 
significant differences, at day 1 it is evident that the 10,000 cells/cm2 condition had a higher SGR than 
all other conditions. At day 2 only two of the conditions were different and no differences between 
conditions were noted at day 3. ...................................................................................................... - 112 - 
 
Table 13. Experiment 2 SMR. Tukey’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions on that day. Summary shows only the conditions with 
significant differences, at day 1 it is evident that the 5,000 cells/cm2 condition had a higher SMR than 
the other conditions. At day 2 the differences observed in SMR were predominantly between the lower 
densities and the higher densities, highlighting the grouped behaviour shown in Figure 28A and C. The 
lowest density and the two highest densities were the only conditions noted to be different at day 3.
 ................................................................................................................................................... ….- 114 - 
  
 xxii 
Table 14: Experiment 3.1 SGR. Tukey’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions during that passage. The only difference observed was 
between the lowest density and highest density with normal and low feed volume, respectively. No 
differences in SGR were observed between conditions at the reset passage (passage2). .............. - 117 - 
 
Table 15. Experiment 3.1 SMR. Sidak’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions during that passage. Differences between the majority of 
the conditions were observed at passage 1, whilst at passage 2 when the conditions were reset 
differences were only observed between the lowest density and all the other condition. ............. - 117 - 
 
Table 16. Experiment 3.2 SGR. Sidak’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions during that passage. Differences were observed in most of 
the conditions at passage 1. At passages 2 regardless of being reset to the same culture condition the 
flasks demonstrated  significant inter-flask variation of SMRs ..................................................... - 120 - 
 
Table 17. Experiment 3.2 SMR. Sidak’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions during that passage. Most of the conditions had different 
SMRs compared to each other at passage 1, whilst no difference in SMR is observed at passage 2 when 
all the flasks were reset to the same culture condition. .................................................................. - 121 - 
 
Table 18: Experiment 3.3 SGR. Sidak’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions during that passage. The main differences were between 
the lowest density 20,000 cells/cm2 at both feed volumes and all the conditions at passage 1. Fewer 
differences were observed at passage 2 between the flasks upon reseeding at the condition 66,667 
cells/cm2 (5 mL) ............................................................................................................................. - 123 - 
 
Table 19. Experiment 3.3 SMR. Sidak’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions during that passage. 20,000 cells/cm2 at both feed volumes 
and 40,000 cells/cm2 (1.5ml) were different to all the other conditions during passage 1, when all flasks 
were reset to the same culture condition at passage 2 no differences were observed between flasks. .... - 
124 - 
 
Table 20. Experiment 3.4 SGR. Sidak’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions during that passage. Differences in flasks under the various 
culture conditions were observed during passage 1, similar to previous experiments no differences were 
observed between flasks at passage 2. ........................................................................................... - 127 - 
 
Table 21. Experiment 3.4 SMR. Sidak’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions during that passage. Main differences observed between 
conditions at passage 1 were when between the lowest and highest densities within the experiment. No 
differences observed during passage 2. .......................................................................................... - 127 - 
 
Table 22. Summary of the significance values at each passage, comparing the SMRs of the different 
routes using Tukey’s multiple comparisons test. Both seeding density and feeding regime were shown 
to result in significant difference between the four routes. The highest significant differences between 
routes, within passages, were observed when both parameters were changed e.g. C2 vs C3, (n=2 for 
each condition). .............................................................................................................................. - 138 - 
 
Table 23. xCelligence® RTCA schedule used to measure the Cell Index. ................................... - 153 - 
 
Table 24. Details of the different experimental culture routes investigated. Control was subjected to 
M. Ex daily; route 1 was subjected to M. Ex on day 1 only; route 2 on day 2 only and route 3 was not 
subjected to a M. Ex throughout the passage. n=3 for each condition was used. M. Ex = medium 
exchange ......................................................................................................................................... - 155 - 
 xxiii 
Table 25. Details of the two conditions used to investigate density and nutrient availability-based 
growth inhibition. The DF condition was subjected to M. Ex daily, while the OF condition was 
subjected to M. Ex on day 1 only. Cells were harvested and counted everyday: n=3 for each condition 
was used. M. Ex = medium exchange; DF = daily feed; OF = one feed. ...................................... - 155 - 
 
Table 26. Sidak’s multiple comparisons test of the MedFI the two markers that were positively 
expressed by the pluripotent cells. The table indicates the conditions that were significantly different 
from passage 1 to passage 2. .......................................................................................................... - 163 - 
 
Table 27. Tukey’s multiple comparisons test of the mean lactate SMR in each condition compared the 
means of the other conditions during that passage. Differences were observed mainly between route 3 
and the other conditions, however at passage 2 most of the conditions were different to each other. .... - 
176 - 
 
Table 28. Tukey’s multiple comparisons test of the mean LDH SMR in each condition compared the 
means of the other conditions during that passage. Differences were observed in most of the conditions 
at passage 2, at passage 1 differences were only between route 3 and the other conditions. ........ - 176 - 
 
Table 29. Genes used for qRT-PCR analysis by Lund University, table adapted from Nolbrant et al, 
2017. ............................................................................................................................................... - 191 - 
 
Table 30. Flow cytometry markers and fluorophores used in the prescribed Miltenyi Biotech 
characterisation protocol. ............................................................................................................... - 192 - 
 
Table 31. Failure mode and effects analysis of the key process steps of the vmDA differentiation 
protocol, determined by discussion with collaborators at Lund University. The risk priority number was 
obtained by multiplying the severity ranking by the occurrence rating and by the detection rating 
(severity x occurrence x detection). The rankings were assigned values from 1 to 10, higher values for 
the severity and occurrence indicate a failure that would have a severe effect on the process and a high 
likelihood of occurring, respectively. For the detection rankings, a low value indicates a failure mode 
that would be easy to detect, while a higher value indicates a failure mode that is difficult to detect or 
not detectable until the end of the process. .................................................................................... - 196 - 
 
Table 32. CHIR99021 concentrations used within experiment DR3. N=3 for each condition was used.
 ........................................................................................................................................................ - 199 - 
 
Table 33. Experimental design for experiments DR4 and DR5 denoting the concentrations and densities 
used in the experiments. n=3 for each condition was used. .......................................................... - 200 - 
 
Table 34. The reseeding densities of the remaining experimental conditions at day 11. Densities were 
calculated for the conditions that did not have enough cells to seed at 800,000 cells/cm2. The replicate 
column indicates the number of replicates surviving at day 11. .................................................... - 201 - 
 
Table 35. Definitive Screen Design matrix of the different concentrations used within experiment 
DSD1. n=2 for each condition was used. ....................................................................................... - 202 - 
 
Table 36. Experimental design matrix of the different concentrations and densities used within the 
day11 replating experiment. n=2 for each condition was used. .................................................... - 204 - 
 
Table 37. Definitive Screen Design matrix of the different concentrations used within experiment 
DSD2. n=2 for each condition was used. ...................................................................................... - 205 - 
 
Table 38. The three panels used in the Miltenyi Biotec protocol, each panel contains three phenotypic 
markers used to determine the differentiation outcome and loss of H9 pluripotency. The colour of the 
text represents the laser that excites the fluorophore. .................................................................... - 207 - 
 xxiv 
Table 39. The in-house six colour flow cytometry panel used for DSD1 and DSD2. The colour of the 
text represents the laser that excites the fluorophore. .................................................................... - 208 - 
 
Table 40. Condition labels used in the differentiation run 4 and 5 (DR4 and DR5) experiments, detailing 
both the density and concentration of CHIR99021 used. .............................................................. - 214 - 
 
Table 41. Adjusted FMEA of Table 31. Detailing the process optimisation steps taken to improve or 
understand the corresponding failure mode. Recommended actions to improve the protocol are given 
as a result of the experiments and observations of the present work. ............................................ - 262 - 
 
Table 42. Summary for the four main payment models used in the UK healthcare system, adapted from 
Wright et al (2017)285. .................................................................................................................... - 273 - 
 
Table 43. Definitions of the typical outcome measurements used in the oncology area for CAR-T trials.
 ........................................................................................................................................................ - 287 - 
 
Table 44. A comparison of the elements evaluated in CADTH’s HTA process under the drugs and 
clinical intervention deliberative frameworks. These elements are used to determine the value of a 
technology and whether or not it should be adopted. Adapted with permission from CADTH. ... - 295 - 
 
Table 45. Summary of economic evaluations for the treatment of PD, detailing the measured efficacy 
outcomes and the PD characteristics of the populations that been evaluated. Information summarised 
from literature searches and studies by Folse et al (2018), Nagpal et al (2019) and Becerra et al (2017).  
PD = Parkinson’s disease; H&Y= Hoehn & Yahr; QoL = quality of life; UPDRS = Unified Parkinson’s 
Disease Rating Scale. ..................................................................................................................... - 313 - 
 
Table 46. The cost inputs that have been considered for cost-effectiveness analysis. .................. - 318 - 
 
Table 47. DBS heath utility data obtained from the literature and the averaged value used for the present 
work. .............................................................................................................................................. - 319 - 
 
Table 48. Heath utility data for medication therapy obtained from the literature and the averaged value 
used for the present work. .............................................................................................................. - 319 - 
 
Table 49. DopaCell costs, the costs are the same for both DopaCell and DopaCell adjusted. The CTP 
variable cost represents the development costs as determined by the in-house CoGs model with a 50% 
mark-up. All other variables were sourced from current literature. ............................................... - 321 - 
 
Table 50. Input variables for the total cost of DBS in the first year, the values reported are averages 
from data sourced from the literature. ............................................................................................ - 323 - 
 
Table 51. Input variables for the total cost of medication therapy in the first year, the values reported 
are averages from data sourced from the literature. ....................................................................... - 325 - 
 
Table 52. QALY calculation input variables for both the DopaCell/DopaCell adjusted. ............. - 328 - 
 
Table 53. Headroom calculation input variables. .......................................................................... - 329 - 
 
Table 54. Market informed headroom input variables. ................................................................. - 329 - 
 
Table 55. Return on investment input variables for the first year, based on the treatment of 100 patients.
 ........................................................................................................................................................ - 330 - 
 
  
 xxv 
List of Frequently Used Abbreviations  
 
 
AGP Annual Gross Profit  
ATMP Advanced Therapy Medicinal Products  
ATTC Advanced Therapy Treatment Centre 
CADTH  Canadian Agency for Drugs and Technologies in Health 
CGTC  Cell and Gene Therapy Catapult 
CTI Cell therapy industry  
CTP  Cell therapy product  
CNS Central nervous system 
CCRM  Centre for Commercialization of Regenerative Medicine 
CHART Challenges in the Adoption of Regenerative Medicine Therapies  
cDNA  Complimentary deoxyribonucleic acid  
CoGs Cost of goods 
CMA  Critical material attribute  
CQA  Critical quality attribute 
CPP  Critical process parameter 
DBS  Deep brain stimulation 
DoE Design of experiments  
DALY  Disability adjusted life years  
DA  Dopaminergic  
EMA  European Medicines Agency 
FMEA  Failure mode and effects analysis 
FCS Flow Cytometry Standard  
FDA  Food and Drug Administration  
FCS Forward Scatter  
gDNA  Genomic deoxyribonucleic acid  
HTA  Health Technology Assessment  
HrQoL Health-related quality of life 
HRG Healthcare resource group  
H&Y  Hoehn & Yahr 
hESC Human embryonic stem cell 
ICER  Incremental cost effectiveness ratio 
LB  Lewy bodies  
MEA Managed entry agreement 
MedFI Median fluorescence intensity 
 xxvi 
MbD Medicine by Design  
NHS  National Health Service  
NICE  National Institute for Health and Care Excellence 
PD Parkinson's disease  
PCR  Polymerase chain reaction  
Pd Population doubling 
QALY  Quality adjusted life years  
QbD Quality by design 
QTPP Quality target product profile 
qRT-PCR  Quantitative real time polymerase chain reaction 
RNA  Ribonucleic acid  
SSC Side Scatter  
SGR  Specific growth rate  
SMR  Specific metabolic rate  
SbD Summer by Design 
THETA  Toronto Health Economics and Technology Assessment 
UPDRS Unified Parkinson’s Disease Rating Scale 
vm Ventral mesencephalon/midbrain  
vmDA  Ventral mesencephalon/midbrain dopaminergic  
WTP  Willingness to pay 
  
  
 
  
 xxvii 
List of Journal Publications 
 
Published:   
 
• Ventral midbrain dopaminergic neuron differentiation from human embryonic stem cells: Key 
manufacturing recommendations for the cell therapy industry. 
 
Submitted:  
  
• An investigation into protocol standardisation using the 2102Ep reference cell line - under 
review 
 
Manuscripts in Progress: 
 
• Pluripotent cell culture and protocol standardisation using H9 human embryonic stems cells: 
obtaining better defined input cells for differentiation.  
 
• White Paper: Challenges in the Adoption of Regenerative Medicine Therapies
 - 1 - 
 
 
 
 
Chapter 1: 
 
Introduction 
  
 - 2 - 
Chapter 1. Introduction 
 
1.1. Background  
 
Parkinson’s disease (PD) is an incurable and debilitating neurodegenerative disease. The current forms 
of treatment including medication therapy aim to increase the amount of dopamine in the brain, which 
is a mode of treatment first used the 1950s1–3. Although new drugs/medications have been developed, 
they still do not slow or stop the progression of the disease. There has been limited  progress in the past 
half century since current therapies presently only alleviate/control the symptoms experienced by 
people with PD. Furthermore, medication therapies often cause unwanted side effects including 
dyskinesia due to the unregulated influx of dopamine4–7. The limited success of the current modes of 
treatment have necessitated the development of alternatives that can truly change the course of the 
disease. Clinical trials using foetal tissue sourced ventral mesencephalic dopaminergic (vmDA) 
neuroprogenitors cells have illustrated that transplanted cells can re-innvervate into the striatum and 
restore dopamine synthesis8–12. This is a magnitude of improvement for patient outcomes in comparison 
to medication treatments, as patients who have undergone cell transplantation therapy have had restored 
dopamine synthesis. In addition, some patients have also regained cognitive function and experienced 
reversal of their symptoms, even after they have stopped taking their anti-Parkinsonisian medicine. 
However, due to issues such as cell source sustainability this mode of treatment has resulted in varying 
levels of efficacy13–17. In addition, the ethical issues associated with a therapy derived from foetal tissue 
does not place the therapy in a favourable position from a regulatory standpoint. Therefore, a global 
effort has been directed at producing vmDA cells from human embryonic stem cells (hESCs) as a 
standardised cell source, that has a lower ethical burden9,10. 
 
In the latter years of the 20th century cell and gene-based therapies were promised to be the treatments 
of the future, however almost three decades later they have failed to become mainstream modes of 
treatment. This is due to the complex nature of their product development cycle, which has proven to 
be more complicated than initially perceived, especially in comparison to traditional pharmaceutical 
and biologics product development. This has led to the retardation of products reaching the market, 
which has been exacerbated by significant failures in the field, particularly those that have resulted in 
adverse effects including patient mortality18–21. Thus, it is apparent that many challenges need to be 
addressed in order to successfully cross the product development ‘valley of death’. Current limitations 
of cell therapy products (CTPs) include the need for in depth product understanding that ensures that 
the products are potent, safe and free of any impurities. This has required a paradigm shift in thinking 
since unlike biologics manufacturing, the cells are both the process and the product. Furthermore, new 
tools have had to be developed and validated in order to address issues such as scale up of cell 
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production, in addition potency, safety and identity assays have had to be developed, which is necessary 
for process control, product validation and release2 
 
This project is set in the context of the onset of cell therapy products traversing the product development 
pathway. A plethora of work has been carried out in academic institutions and small biotechnology 
companies, this has led to innovative cell and gene therapies that have the potential to revolutionise 
current modes of treatments and even potentially cure a wide range of disease indications. Regarding 
the present work, research regarding cell-based therapies for PD has advanced in recent years. Refined 
differentiation protocols have resulted in the successful and efficient generation of transplantable 
vmDA cells derived from hESCs as a therapy for PD9,22–25. Prior to these cells being used as a PD cell 
replacement therapy, it is important to gain detailed understanding of the cell production process, in 
order to implement manufacturing process changes. The detailed understanding is essential in providing 
knowledge that facilitates process control, which in turn provides understanding of the key process 
parameters. These parameters once understood form the basis of the tolerances of the process, allowing 
for the potential of an adaptive manufacturing process that is validated and robust within the defined 
set of parameters that allow for greater process control.  
 
Prior to clinical realisation, there is a requirement for robust well-defined protocols to ensure 
comparability and reproducibility, however in many cases effective comparisons of data can be 
encumbered by the lack of standardised culture protocols. This lack of conformity often results in 
variation of the measured process outputs, as a result obtaining regulatory approval becomes a challenge 
that is not easily overcome. This requires translational work to be carried out, in order to understand 
complex cell dynamics and to standardise protocols for the manufacture of cell therapy products. These 
protocols need to provide robust and reproducible manufacturing processes that can withstand the high 
scrutiny of regulators such as the Food and Drug Administration (FDA) and European Medicines 
Agency (EMA).  
 
Although fulfilling regulatory requirements is an accomplishment for developers, in isolation it is not 
adequate to ensure the success of a product being adopted and reaching patients. In addition, it is 
important to understand the commercial viability of the product, in order to avoid cases such as Glybera, 
where the product was scientifically sound, yet it was deemed not to be cost-effective or affordable26. 
Therefore, this work also discusses the value of early health economic evaluations and their ability to 
act as a decision tool for a wide range of stakeholders. For developers and investors, being equipped 
with the concepts of health economics and a firm understanding of their product, its costs and the impact 
of its health outcomes can increase the commercial viability of their product. For payers, health 
economics provides valuable information regarding the cost-effectiveness of a therapy and its impact 
on their budget. This highlights the multifaceted nature of successfully translating research from 
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‘bench’ to ‘bedside’; developers must endeavour to swiftly traverse this translational space in order to 
get their products onto the market so as to benefit the patients that need them. 
 
This work sets out to identify the key translational requirements for successful, robust and reproducible 
manufacture of a cell-based therapy for PD, via the optimisation of a preclinical validated differentiation 
protocol provided by Lund University in Sweden (referred to as the candidate therapy). Analysis of the 
density and metabolite relationship of the cells during both expansion and differentiation phases is 
pivotal to understanding their roles in cell system growth dynamics. This has been achieved through 
orthogonal analysis using metabolic analysis, flow cytometry and cell growth analysis. The aim of these 
analyses was to implement the information obtained to develop robust in-process assays that can be 
linked to both the biological function and critical quality attributes of the CTP. This is to better 
understand the product so that process control and product quality can be obtained using a robust 
protocol. The lack of robust protocols has encumbered the success of CTPs to date, as many of these 
protocols are currently reliant upon human intervention, resulting in the endemic issue of variation in 
cell manufacturing. This is due to the subjective nature of the protocols, since typically critical decision-
making processes are left in the hands of the operator; as operators change the variation in product 
output is compounded. This is an issue that has been highlighted in the present work as efforts have 
been made to show the importance of standardisation and protocols that minimise operator intervention 
as much as possible.    
 
1.2. Objectives  
 
The overall objective of this project was to investigate the translational requirements necessary to 
facilitate the “bench to beside” translation of the prescribed protocol for obtaining transplantable vmDA 
cells. A dual work-stream approach was used with the aim of progressing the preclinical protocol into 
a defined and standardised protocol suitable for manufacturing. One stream was a lab based 
experimental program helping to develop process understanding of the differentiation procedure and 
the differentiated cells through metabolic analysis, flow cytometry and cell growth rate analysis 
(Schematic 1). While a complimentary desk-based work-stream aimed to develop reimbursement 
models for the candidate therapy by incorporating economic evaluation, reimbursement price modelling 
and cost of goods modelling. 
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Schematic 1. From left to right, progression of the candidate therapy’s development from protocol 
generation to manufacturing. The focus of the present work is on the middle section and in particular, 
the points in orange.  
 
The key undertakings:  
 
One of the initial undertakings of the project was to use a simple cell line to train the author and to 
develop protocols and skills to use for the clinically relevant cell line. To this effect, work was carried 
out using the embryonic carcinoma EC 2102Ep reference cell line to produce a standardised cell culture 
protocol.  
 
The next stage of the project was to obtain a working cell bank of the clinically relevant H9 cell line 
and carry out experiments to understand the culture and expansion dynamics of the cells in their 
pluripotent state, prior to differentiation.  
 
• This included analysis of: 
o Cell growth after the cells were thawed from cryopreservation. 
o Optimal seeding density for cell growth without inhibition.  
o Different feeding regimes during pluripotent expansion.   
o The stability of cell characteristics over a range of time.  
 
GMP 
Protocol Generation 
• Lund 
• Proof concept
• Cell line selection
• GMP reagent selection
• In vivo efficacy testing
• Miltenyi
• Cell characterisation and 
sorting 
• Flow Cytometry protocol
GMP 
Protocol Adaptation 
Loughborough 
• Protocol optimisation 
• Protocol standardisation 
• Assay development 
• Process automation 
• Standardised banking and 
thawing  
GMP 
Manufacturing 
• Royal Free Hospital
• GMP quality control
• Preclinical safety and 
efficacy testing
• Phase I/II clinical batch 
manufacturing
• Storage and shipping 
solutions 
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For the differentiation process it was necessary to fully understand the protocol prior to conversion into 
a robust and translatable protocol for commercial scale manufacturing. This meant identification of and 
understanding of which parameters were important for the Quality Target Product Profile (QTPP). 
Therefore, failure mode and effect analysis (FMEA) and Design of Experiment (DoE) approaches were 
used to try and elucidate which protocol parameters were the most important to control in order to 
obtain a robust, reproducible protocol for efficient hESC to vmDA differentiation. High resolution 
growth dynamic and phenotype analysis was carried out to understand the differentiation process and 
the impact of the different parameters on cell differentiation.  
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1.3. Thesis Structure  
 
1.3.1. Chapter Summaries: 
 
Chapter 1 - General Introduction  
 
This chapter provides the context and background in which this work is set, the general introduction 
also details the overall objectives of the project.  
 
Chapter 2 - Literature Review 
   
Chapter 2 provides a comprehensive review of the existing literature related to the work presented in 
this thesis. The review is presented in four distinct, yet interrelated sections; firstly, a review of PD 
detailing the epidemiology, current modes of treatment and PD cell-based therapies, including the use 
of dopaminergic neurons. Secondly, dopaminergic neurons are described in further detail, providing 
information of the in vivo and in vitro neurulation and patterning processes, specifically for ventral 
midbrain dopaminergic neurons. The third section in the review alludes to key translational 
requirements that must be considered for cell-based therapy manufacturing; these include defining and 
determining product purity, identity and potency. Finally, a discussion of the translational requirements 
from a commercialisation standpoint are discussed; specifically, health economic considerations and 
the current state of reimbursement and adoption for cell therapy products.  
  
N.B. Nomenclature for genes, transcription factors and proteins: 
 
Genes – capitalised and italicised e.g. FOXA2 the gene  
 
Transcription factor – small case and italicised e.g. foxa2 the transcription factor  
 
Proteins/antibodies/morphogens – just capitalised e.g. FOXA2 the protein expressed/antibody 
used/morphogen secreted  
 
Chapter 3 – Material and Methods 
 
Detailed procedures used for the experimental work carried out are provided in this chapter. Due to the 
prevalent focus of the importance of protocol standardisation that is presented in this body of work, 
very detailed accounts of the cell manipulations carried out are provided to ensure ease of translation 
by making the processes transparent. Background information regarding the techniques and the 
analytical tools implemented are provided 
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Chapter 4 - EC 2102Ep 
 
EC 2101Ep cells were utilised in the studies presented in this chapter due to their ‘robust’ nature. This 
made them an ideal candidate for training the author in cell culture techniques whilst also allowing for 
the development of appropriate analytical skills and techniques that would be applied to the clinically 
relevant cells line. From the training, informative data regarding protocol standardisation and cell 
system dynamics was obtained, forming the basis of the work presented in this chapter. As the work 
carried out in this chapter was iterative, the methods and results sections are accompanied with 
narratives for each experiment to give context to both the experimental design and results obtained with 
each iteration.  
 
Chapter 5 – H9 Pluripotent Understanding  
 
 This chapter focuses on the cell dynamics of H9 cells which are a clinically relevant hESC cell line 
that have been used by collaborators in both Sweden (Lund University) and Germany (Miltenyi Biotec). 
This chapter is comprised of a series of experiments of H9 cells in their pluripotent state during 
expansion, prior to differentiation. This is important as having standardised and well characterised input 
cells should provide less variation within the differentiation process. The results from this chapter are 
pivotal to understanding the intrinsic behaviour of the cells. This understanding is vital to providing a 
standardised bank of pluripotent cells that can be used for further, more complex experimentation, 
including differentiation. Specifically, the differentiation of H9 cells to vmDA cells, i.e. the cell therapy 
product 
 
Chapter 6 – H9 Differentiation Understanding  
 
 Chapter 6 utilises the defined H9 cells banked in chapter 5 to adapt a research-based differentiation 
process into a reliable and reproducible manufacturing process. This chapter applies a highly process-
development-based approach therefore, akin to chapter 4, the methods and results sections are 
accompanied by a narrative. The purpose of the narrative is to contextualise the meaning of the data 
obtained and how it was used to design the following experimental designs.  
 
A range of multivariate experiments and DoE approaches were used to ascertain information regarding 
optimum protocol conditions, specifically the derivation of the precise small molecule concentrations 
that are required to obtain the desired ventral midbrain dopaminergic neuroprogenitors. Flow cytometry 
protocol optimisation is also discussed as an in-house panel was created to compliment the experimental 
designs utilised. 
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 Chapter 7 – Challenges in the Adoption of Regenerative Medicine Therapies  
 
Chapter 7 discusses UK and Canadian healthcare systems, in particular the mechanisms of HTA and 
reimbursement. The key challenges for CTP adoption are also discussed in the context of a workshop 
organised by the author entitled ‘Challenges in the Adoption of Regenerative Medicine Therapies’ 
(CHART). 
 
Chapter 8 – Headroom Assessment 
 
This chapter builds upon the commercialisation requirements discussed in chapter 2 as it looks into 
assessing CTP commercial viability. The headroom method was used to assess the reimbursement 
potential of the candidate cell therapy product. The results provide information on the cost-
effectiveness, adoption and gross profit potential of the candidate cell therapy product. 
 
Chapter 9 – Conclusions  
 
This chapter provides an overall summary of the work that has been carried out. Here, the translational 
requirements that have been identified, investigated and presented in this body of work are reviewed.  
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Chapter 2. Literature Review  
 
2.1. Parkinson’s Disease 
 
Parkinson’s disease (PD) is an incurable, chronic neurodegenerative disease named after James 
Parkinson, who published the first detailed description of the disease in 1817 in ‘An Essay on the 
Shaking Palsy’3,27. PD is one of the most common neurodegenerative diseases, particularly in western 
and developed countries where the aging population is higher3,27. As such, PD is mainly seen in the 
elderly, as the aging population increases it is estimated that the cases of PD will also increase. In the 
UK 1 in 550 adults are diagnosed with PD over the age of 60, and worldwide more than six million 
people are affected28,29 (Figure 1). Dorsey et al (2007) reported “the number of people with PD will 
rise from 4.1-4.6 million in 2005 by two times to 8.7-9.3 million in the year 2030” based on studies of 
the ten most populous countries30,31. 
 
 
Figure 1. Broad overview of Parkinson’s disease epidemiology. Data obtained from the literature28,29.  
 
PD is  hallmarked by the discriminatory depletion of dopaminergic (DA) neurons in the substantia nigra 
pars compacta (SNc) located in the midbrain1,3,32,33.  Substantia nigra which translates to ‘black 
substance’ is so called due to its darker appearance as a result of higher neuromelanin levels compared 
to its neighbouring areas27,34. The SNc is part of the basal ganglia which controls movement, forming 
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part of the nigrostriatal pathway, which functions as a regulator of both the direct and indirect pathway 
of movement32. A decrease in the density of DA neurons results in diminished function of the 
nigrostriatal pathway and the concomitant motor problems such as hypokinesia, rigidity and tremors 
that are associated with PD (Figure 2).  
 
There are different types of PD, namely vascular, drug induced parkinsonism and idiopathic 
Parkinson’s, the latter being the focus of this work due to it being the most common type of PD (Table 
1). Although most cases of PD are idiopathic; age, genes, gender, exposure to toxins and ethnicity can 
increase the risk of developing PD. The disease does not directly cause death, however due to 
complications, co-morbidities and risks of falls it does increase mortality rates. Typically, those 
diagnosed with PD have near normal life expectancy, however their quality of life is significantly 
diminished due to the debilitating results of the symptoms including tremors, muscle rigidity and the 
eventual onset of dementia in up to 75% of patients4. The pathology and symptoms of PD are 
summarised in Figure 3, along with the treatment options that are employed at the different stages of 
the disease.  
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Table 1. Details of the different types of Parkinsonism and their presentations 
Type Details
IDIOPATHIC
Idiopathic Parkinson's disease - or Parkinson's - is the most common type of parkinsonism.
Idiopathic means that the cause is unknown. The main symptoms of idiopathic Parkinson's
are tremor, rigidity (stiffness) and slowness of movement. (Shulman et al, 2011)
VASCULAR 
Vascular parkinsonism (also known as arteriosclerotic parkinsonism) affects people with
restricted blood supply to the brain - usually older people who have health issues such as
diabetes. (Kalia et al, 2015)
DRUG-INDUCED
Neuroleptic drugs (used to treat schizophrenia and other psychotic disorders) which block
the action of dopamine are thought to be the biggest cause of drug-induced parkinsonism.
The symptoms of drug-induced parkinsonism tend to be static. Only in rare cases do they
change in the manner that the symptoms of Parkinson's do. Symptoms are reversible upon
cessation of the drug that is the cause. (Parkinson’s UK, 2019)
MULTIPLE 
SYSTEM 
ATROPHY (MSA)
Both multiple system atrophy and Parkinson's cause stiffness and slowness of movement
in the early stages. People with multiple system atrophy can also develop symptoms such
as incontinence, difficulty with swallowing and dizziness, these symptoms are unusual in
early Parkinson’s. The condition used to be known as striatonigral degeneration, Shy-
Drager syndrome, or olivopontocerebellar atrophy. (Parkinson’s UK, 2019)
PROGRESSIVE 
SUPRANUCLEAR 
PALSY (PSP)
Progressive supranuclear palsy affects eye movement, balance, mobility, speech and
swallowing. It is sometimes called Steele-Richardson-Olszewski syndrome. (Parkinson’s
UK, 2019)
NORMAL 
PRESSURE 
HYDROCEPHALU
S
The symptoms of normal pressure hydrocephalus mainly affect the lower half of the body.
The common symptoms are walking difficulties, urinary incontinence and memory
problems. Removing some cerebrospinal fluid can help with these symptoms in the short
term. If there is improvement after this procedure, an operation to divert the spinal fluid
permanently (known as lumbar puncture) can help in the long term. (Parkinson’s UK,
2019)
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2.1.1. Clinical Features  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic representation of the most common motor and non-motor PD symptoms  
 
Patients of PD suffer from disturbances in regular movement; this includes bradykinesia which is a term 
used to describe a slowness in the execution of movement. In some severe cases, decreased activity of 
the direct pathway of movement results in akinesia, which is the inability to adequately initiate 
movement5,35,36. Tremors due to involuntary shaking are usually present at rest, with the tremor often 
becoming more distinguished as the disease progresses, although this symptom tends to diminish with 
movement1,32. Rigidity is experienced during movement due to stiffness in the limb causing resistance 
during movement, and as the disease progresses the rigidity becomes more widespread until it  
eventually impairs the individual’s ability to move32,37. Postural instability affects the balance of PD 
patients, causing them to have a characteristic lean or stooped posture4,38. This symptom is usually 
observed in the latter stages of the disease and often leads to frequent falls due to the imbalance which 
is experienced. Furthermore, lack of facial expression, change in gait and dysphagia are other motor 
related symptoms that can be experienced as well as depression, dementia and sleep disturbances32,39–
41.   
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Figure 3. Summary of pathology, treatment and symptoms of PD. 
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2.1.1. Dopamine 
 
Dopamine is a neurotransmitter that is produced by dopaminergic (DA) neurons, it is involved in a 
range of functions such as neuromodulation, reward behaviours and important to PD, motor utility of 
the direct and indirect pathway of movement35. It has been reported that a high flux of dopamine can 
be associated with alterations in behaviours as experienced in diseases such as schizophrenia and 
attention deficit hyperactivity disorder (ADHD)34. Dopamine is produced in the body but its production 
is mainly restricted to neuronal cells and the adrenal glands in the kidneys34. Of importance to PD 
reduced levels of dopamine result in deficiencies in motor pathways within the brain, this is mainly due 
to the loss of dopamine production by the A8, A9 and A10 cell groups which are found in the pars 
compacta of the substantia nigra3,27,34. Dopamine replacement in the brain is one of the predominant 
strategies currently used to treat PD as the depletion of dopamine is a key aspect of the disease. This is 
mainly through the use of medical drugs such as levodopa, dopamine agonists and glutamate antagonists 
that increase dopamine and/or stop its degradation34.   
 
2.1.2. Proposed causes & Risk Factors of PD 
 
Although the putative loss of dopaminergic neurons is known to be linked to the progression of the 
disease, there is currently no consensus with regards to the aetiology of PD, despite a plethora of 
research. Specifically, disaccord comes from the mode in which the specific cell death of the DA 
neurons is initiated42. There is a solid body of work that considers the molecular causes of PD such as 
the genes and transcription factors involved in PD pathogenesis 2,43,44. In addition metabolic botheration 
such as mitochondrial dysfunction has been considered27,45,46, in addition protein phosphorylation47,48, 
protein accumulation3,49–51 and oxidative stress have also been implicated in the pathogenesis of PD48. 
Apoptosis and autophagy have been proposed as mechanisms of cell death in DA neurons, although the 
triggers are not well understood and this is an area of extensive research50,52–55. Current methods of 
detecting cell death such as cell staining, cell morphology microscopy, immunolabelling and DNA-
labelling, are not conclusive enough to determine the cause of PD cell death52.  
 
PD is normally observed in the elderly particularly those over the age of 60, however there are rare 
cases of early-onset PD. Early onset PD is commonly seen when there is a hereditary link to PD, in 
these cases genes play a role and increase the chances of developing PD. These include but are not 
limited to mutations to the DJ-1, α-synuclein (SNCA), parkin (PRKN), leucine-rich repeat kinase 2 
(LRRK2) and PTEN-induced putative kinase I (PINK1) genes1,31,56. Current research has also shown 
that males are more likely to develop PD than females at a ratio of 3:2, however the reason for this 
disparity is yet to be established29,31,57,58. Other research suggests that there is a slight risk increase of 
developing PD due to long term exposure to pesticides and herbicides31,46,58. It must be noted that 
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currently the evidence of the roles of sex and exposure to toxins is limited or only a probability at 
most31. A study in Northern California found that Hispanics and Whites (non-Hispanic) had higher 
incidences of PD compared to Asians and Blacks, however more research needs to be carried out on a 
larger and geographically diverse scale57.  
 
2.1.3. Genes and Transcription Factors    
 
Although most cases of PD are idiopathic, there have been studies that have correlated PD with genetic 
predisposition31,48,56.  In the case of idiopathic PD the roles of transcription factors has been of 
considerable interest both historically and more recently, as it has been illustrated that the timings and 
levels of essential factors for dopaminergic neurogenesis during development can have a subsequent 
effect on the onset of DA cell death; in some cases causing premature DA cell death42. This is also 
likely to be the case for factors such as nuclear-receptor-related-1 (nurr1), Fibroblast Growth Factor 8 
(fgf8), Sonic hedgehog (shh) and Pentraxin 3 (ptx3), particularly nurr1 which is essential for DA 
viability under both normal and stress conditions48.  
  
There are both dominant and recessive forms of the mutations which occur in specific genes that are 
linked to hereditary forms of PD42. Barzilai and Melamed (2003) highlight some of these genes, for 
instance Parkin which is important for the ubiquitin-targeted pathway, which was discovered in 
Japanese families with autosomal recessive early-onset PD43,59.  Other predisposed genes include a-
synuclein (SNCA), Ubiquitin C-terminal hydrolase L1(UCH-L1) and DJ1 which have all been alluded 
to involvement in oxidative stress response42. A review by Kaczmar et al (2006) also explores genes 
thought to be associated with PD including LRRK2, PINK1 as well as SNCA and DJI as mentioned 
above 48. Whilst there are many facets that contribute to the onset and progression of PD including the 
aforementioned genes, the focus of this work will be on strategies for the replacement of dopamine. 
 
2.1.4. Proteins  
 
In a wide range of neurodegenerative diseases, a common hallmark is the presence of Lewy bodies 
(LBs), which are irregular protein aggregates observed in the nerve cells, which cause displacement of 
other cell components3,50,56. However, it remains to be elucidated whether the LBs cause PD in a 
pathogenic manner; or conversely if LBs are a consequence of an unknown pathogenic factor of PD48. 
What is known is that, LBs can be comprised of a-synuclein, ubiquitin and neurofilament protein, 
however the mechanisms that cause the fibrils of these proteins form LBs are currently unknown50. LBs 
persist within the cells as they are insoluble, which impairs the normal function of the ubiquitin–
proteasome system (UPS). The UPS is an intracellular mechanism for the removal of  abnormal proteins 
in eukaryotic cells, again whether or not this is the cause of DA cell death, remains unknown42.   
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2.1.5. Diagnosis 
 
Currently there are no tests that allow for definitive diagnosis of PD. Diagnosis of PD is a combinatory 
process that is performed by clinical specialists who carry out comprehensive medical and neurological 
testing. In the early stages of disease progression, it is difficult to distinguish PD from other types of 
parkinsonisms as the initial presentations and symptoms are all similar. In many cases the symptoms 
that allow for specific diagnosis to be made, only become apparent as the disease progresses. The most 
common mode of diagnosing PD is evaluating a patient’s response to dopamine-replacing medication 
such as levodopa3,32,60. If a patient’s symptoms improve as a result of taking the medication it is likely 
that they have PD (idiopathic), furthermore, if cessation or reduction of their dose makes the symptoms 
reappear it is an additional indicator that the patient has PD. Generally, patients that have non-PD 
parkinsonisms will not respond well, or at all to dopamine-replacing medication. However, since this 
is not always the case, other tools are required in combination to aid the diagnosis process. A dopamine 
transporter chemical (DaT) scan using single-photon emission computed tomography (SPECT) 
scanning can be employed to assess the levels of dopamine in the brain3,32,60. PD clinical specialists will 
also examine a patient’s ability to write, draw, walk, freely move their limbs, speak and move their face 
to create facial expressions when diagnosing for PD: these diagnostics are used to inform the course of 
treatment. 
 
2.1.6. Current Treatments for Parkinson’s Disease  
 
Most of the treatments for PD tend to only aid with the symptoms, as none of the current treatments 
stop the neurodegeneration process32,61. As a result, current strategies focus of increasing dopamine for 
signalling or in the case of deep brain stimulation (DBS), counteracting the aberrant signalling that is 
observed in the pathways that regulate movement.  
 
2.1.6.1. Anti-parkinsonian medication 
 
Treatment strategies primarily concern exogenous dopamine replacement; with extensive 
pharmaceutical therapies available; most aim to provide cells with dopamine by either: increasing 
levels, preventing degradation; or stimulating receptors. Current medication therapies are unable to 
modify the disease state in terms of slowing, stopping or reversing progression.  
 
Levodopa (L-DOPA) is an amino acid based drug that is used to provide cells with exogenous 
dopamine32,61,62. Naturally L-DOPA is the precursor of dopamine, L-DOPA is prescribed instead of 
dopamine because dopamine is degraded peripherally before it can cross the blood-brain barrier. 
Typically, L-DOPA is co-administered with catechol-O-methyltransferase (COMT) and monoamine 
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oxidase B (MAO-B) inhibitors which help to prolong the presence of L-DOPA by preventing its 
enzymatic degradation. L-DOPA is often prescribed under the brand names : Madopar, Duodopa, 
Sinemet and Lecado which can be used at all stages of the disease61. Dopamine agonists may also be 
prescribed to stimulate dopamine receptors by mimicking the dopamine that would be produced under 
normal conditions with the aim of inducing an effect on the cells i.e. to facilitate motor functions. There 
is a wide range of dopamine agonists that can be prescribed these include but are not limited to: 
Bromocriptine, Pramipexoe and Ropinirole which can be used at all stage of PD61. 
 
Akin to all medication, PD medication has potential side effects including: liver toxicity, sleep 
disturbances, hallucinations, delusions, dyskinesia and sometimes impulsive/compulsive 
behaviours32,63,64. Furthermore, use of medication therapy results in polypharmacy to ease side effects 
such as anxiety and constipation65. As PD is progressive, pharmaceutical efficacy diminishes over time; 
resulting in increased strength and dosing frequency as the medication becomes inadequate and 
symptoms are more pronounced. Furthermore, the therapeutic window whereby the patient is ‘on’ 
decreases, resulting in more ‘off’ periods (when the drug effect ceases prior to the next dose) and 
occurrences of dyskinesia caused by dosage increases (Figure 4) 4,6,66–68. 
 
Figure 4. Illustrative example of the ‘on/off’ effect of PD medication, showing how the therapeutic 
window (green space) of the medication decreases as the disease progresses. In addition, more doses of 
medication (signified by the arrows) are needed to control the motor fluctuations however more time is 
spent in the ‘off’ periods and experiencing akinesia or dyskinesia as the disease progresses even with 
increased doses due to the loss of neurons. L-DOPA = levodopa, representing PD medication with a 
mechanism of action that provides L-DOPA. Image adapted from Worth, 2013.  
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 2.1.6.2. Surgical Interventions to manage PD symptoms 
 
Deep brain stimulation (DBS) is a surgical technique that is used to help with movement control; 
however, it is not curative. One of the reasons for choosing DBS as a mode of treatment, is that it can 
result in the patients being able to take less medication. This is ideal as it avoids some of the side effects 
that are associated with taking PD medication. However, mixed results for DBS treatment have been 
observed, as some patients do not experience any benefits from undergoing the operation61. During 
DBS a pulse generator is used to deliver high frequency stimulation, with the intention of producing an 
alteration to the irregular electrical signals due to the lack of the dopamine neurotransmitter that results 
in PD symptoms61,62. The procedure is non-destructive and can be reversible, as a part of the process 
patients get a programmable portable computer that is used to control the stimulations61.  
 
Other surgical procedures include lesioning surgery, unlike DBS lesioning procedures are irreversible 
as they involve selective damage to cells in a specific part of the brain. Electrodes are introduced to the 
target site, which is located using computerised tomography (CT) or magnetic resonance imaging 
(MRI) brain scans. An electric current is then passed through to cells that are involved in the control of 
movement, therefore potentially reducing movement problems. There are three main types of lesioning 
surgery used, thalamotomy, pallidotomy and subthalamotomy which involve making lesions in the 
thalamus, globus pallidus and the subthalamic nucleus respectively61. The latter is used in countries 
such as Northern Ireland and Wales were DBS is not available as a form of surgery.  
 
2.1.6.3. Cell Therapy for Parkinson’s  
 
Although PD pharmaceutical therapies offer alleviation of some of the symptoms of PD, it is evident 
that medication has its limitations and in some cases complications when it comes to the treatment of 
PD32,69,70. As a result, there have been efforts in determining alternative sources to treat and potentially 
cure PD, with the concept of cell replacement strategies becoming more prevalent over the three last 
decades. This is due to early work in cell replacement strategies that showed sustained symptomatic 
relief and significant motor improvements could be realised in human subjects71,72. One of the strategies 
uses tissue grafting of ventral mesencephalic dopaminergic neurons into the putamen. Thus far, human 
allogenic grafts of ventral mesencephalic tissue have been shown to survive at the site of implantation 
for up to 24 years and improve motor function, in addition the engraftment restored dopamine synthesis 
and storage71,72.  Consequent to such findings, interest in engraftment rose as it provides a quasi-natural 
form of producing and storing the depleted dopamine, which cannot be achieved with current 
treatments. Post-mortem analysis of a patient with PD who underwent dopaminergic neuron 
transplantation 24 years earlier showed “near-normal graft-derived dopaminergic reinnervation of the 
putamen”71. However, in the current state there is still a lot of work that needs to be done for cell 
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therapies to be first choice treatment for PD. Some of the hindrances include current regulations in the 
cell therapy industry (CTI), the cost of the therapies and most importantly the need for more in depth 
understanding of the ways in which the transplanted cells work, particularly, once engrafted. 
Furthermore, the CTI needs to establish how to produce reliable, reproducible and cost-effective cell 
based therapies73,74. Current results of cell replacement strategies show great promise and potential 
benefits for PD patients that cannot be currently achieved using pharmaceutical treatments and surgical 
interventions. However, it is worth noting that even after successful engraftment, the disease will still 
continue to progresses and will eventually have a detrimental effect on the grafted cells as well71. 
Nonetheless, it should be noted that this progression occurs over a prolonged period of time i.e. 14 years 
posttransplantation71, thus providing the patient with a significantly improved quality of life during this 
timeframe. Therefore, part of the fundamental work that needs to be carried out in order to discover a 
cure for PD is gaining an understanding the underlying mechanisms that drive the pathogenesis of the 
disease. This mechanistic understanding will hopefully, with time, allow for researchers to focus their 
efforts on preventative measures to stop the progression of the disease. However, this is presently out 
of the scope of the current work. The following sections will discuss how cell replacement strategies 
and dopaminergic neuron protocols have developed and evolved. The work of Anders Björklund and 
Olle Lindvall has been used as the key exemplar, as they are the forerunners of the area of PD cell 
therapy and they are linked closely to the present work. It should be noted that this exemplar may not 
be applicable to all forms of PD. 
 
2.1.7. The Lund method  
 
The hESC based therapy that this work aims to contribute to was developed from collaborators at Lund 
University in the 1980s who pioneered the field of cell transplantation for the treatment of PD. The 
world’s first ventral mesencephalic tissue cell transplantation for the treatment of PD was done in Lund 
in 1989 in work led by Anders Björklund and Olle Lindvall. Björklund et al showed that taking tissue 
from the human foetus, specifically ventral mesencephalic tissue that derives dopaminergic neurons, 
and transplanting it into a human subject had beneficial results for PD patients12,75. The transplantation 
of ventral mesencephalic tissue improved motor function and the engraftment restored dopamine 
synthesis and storage71,72. Prior to transplantation the patients had difficulty walking and were unable 
to make normal sized movements, typically they had smaller, slowed movements with obvious body 
rigidity. Post transplantation (five years after, during the foetal trial) walking eased and less rigidity was 
observed in patients, which was an unprecedented level of symptomatic relief, in comparison to 
pharmaceutical therapies such as L-DOPA76–79. In some cases, patients who have been followed up have 
ceased their use of anti-Parkinsonian medication for up to sixteen years post transplantation80.  
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At present, over 100 patients have been grafted in Lund and other parts of the world that use cell 
transplantation (of vmDA progenitors) for PD treatment. Patient follow up prior to post mortem analysis 
has also shown dopamine synthesis post transplantation, using fluoro-DOPA (F-DOPA) positron 
emission tomography (PET) scanning81–83. Furthermore, it has been shown is that there no evidence of 
a-synuclein with the grafts up to 14 years post transplantation in human subjects. However, a-synuclein 
is present within the host cells, suggesting that although remarkable symptomatic relief can be achieved, 
PD disease progression still continues irrespective of the cell transplantation treatment.  
 
2.1.7.1. How therapy is conducted 
 
Different cell transplantation trials using foetal vmDA tissue, induced pluripotent stem cells (iPSc), 
parthenogenetic derived DA neurons and neuro stem cells have been conducted84. However, the focus 
of the present work will be on the Lund consortium trials as they are directly related to this work. In 
brief, the foetal based cell therapy requires three to five foetuses for each side in a bilateral 
transplantation, from elective abortion foetuses (six to eight weeks old). The foetuses have to be freshly 
obtained on the same day and utilised within four hours to maintain the viability of the tissue. The foetal 
neural tissue, specifically of the ventral mesencephalic region is treated to obtain the cells through a 
range of wash and purification steps72. The patients have to undergo immunosuppression the day before 
transplantation and remain on immunosuppression medication for at least one-year post transplantation. 
The transplantation is then carried out using minimally invasive stereotactic surgery, which uses three-
dimensional coordinates to deposit the cells as a suspension into the putamen. Patients can be discharged 
48-hours post-surgery, typically they followed up six and twelve months post-surgery. F-DOPA PET 
scan imaging is used to determine dopamine activity within the brain. A range of motor and behavioural 
assessments are also carried out to ascertain the level of clinical symptomatic relief afforded by the 
therapy. In summary, current trials have demonstrated that dopamine neuron cell replacement therapies 
work and can survive long term, i.e. up to 24 years in the host brain whilst efficiently re-innervating the 
ventral mesencephalon into the dorsal striatum, “near-normal graft-derived dopaminergic reinnervation 
of the putamen”71. This results in restoration of DA synthesis and release, which ultimately provides 
long-term clinical improvement, showing proof of concept. However, as it stands the results are variable 
even though many successes have been afforded from the ~ 100 patients that have gone through the 
transplantation procedure. One major factor of variation is the foetal source of the cell material which 
highlights the need to have cell preparations that are optimised and standardised. Furthermore, a foetal 
tissue-based therapy poses many challenges from regulatory, reproducibility and ethical stand points. 
As such, efforts have been made to produce the vmDA progenitors from a more sustainable and 
ethically less constrictive source, i.e. hESCs as opposed to foetal derived tissue. Efforts at Lund and 
internationally have resulted in the generation of protocols for deriving vmDA neuroprogenitors from 
hESCs that show comparative efficacy and potency to foetal tissue derived vmDA neuroprogenitors85.  
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2.2. Dopaminergic neurons   
 
2.2.1. Dopaminergic neurons 
 
Dopaminergic (DA) neurons are located in the midbrain, with ~ 590,000 found in the adult human 
brain; this number is age dependent and depletes with increasing age3,34,86. Dopamine producing cells 
in humans are found in the A8, A9 and A10 cells groups on the substantia nigra (Figure 5)27,34,42. The 
intrinsic development of DA neurons is marked by a complex combination of secreted factors, gene 
expression and transcription factors. There are different transcription and soluble factors that are 
expressed and secreted dependent upon the stage of differentiation. Stages such as early midbrain 
patterning, specification of mitotic precursors, post-mitotic development, and functional maturation all 
have varying soluble factors and transcription factors associated with them86–88. By researching the 
developmental processes of the neural tube, specifically the processes that lead to the generation of DA 
neurons, it has been possible to carry out fate mapping studies studies89–91. These studies have guided 
the understanding of the cues and distinctive markers associated with DA neurons: highlighting 
precisely the factors and cues that drive the patterning and maturation of the cells both in vivo and in 
vitro25,92. This facilitates in vitro differentiation methods to afford the desired vmDA cells types. 
Hegarty et al (2013) and Arenas et al (2015) provide an in-depth review and primer, respectively, which 
offer comprehensive vmDA generation and development knowledge93,94. 
 
 
Figure 5. Coronal section view showing the A8, A9 and A10 dopaminergic cell groups. SNr = 
substantial nigra Image sourced from Arena et al, 2015. 
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2.2.2.  The differentiation into vmDA neuroprogenitors   
 
Understanding the development cues of the vmDA is key to the success of the therapy for the treatment 
of PD, as this allows for the derivation of protocols that reliably produce the desired vmDA for 
transplantation. The following sections discuss in a concise manner the key aspects of neurulation and 
development of the mesencephalon, specifically focussing on the development of the ventral 
mesencephalon which gives rise to the desired vmDA neuroprogenitors.  
 
2.2.2.1. Neurulation  
 
Once the three germ layers (endoderm, mesoderm and ectoderm) are formed as part of the gastrulation 
process, the central nervous system (CNS) through neurulation is first system formed during embryonic 
development. The development of the CNS starts around the third week of embryonic development94,95. 
The CNS originates from the ectoderm layer which thickens and forms neural plate through 
neuroectoderm cells, a process referred to as neurulation. Neurulation begins once the notochord is 
formed within the mesoderm layer. The notochord induces the thickening of the ectoderm in order to 
form the neural tube, by stimulating the invagination of the neural plate to form the neural groove and 
form the neural folds. The plate begins to fold inwards and forms what is referenced to as the neural 
groove which is in the centre and the neural folds which are on either side of the neural groove. By the 
end of the third week neural folds begin to fuse together forming the neural tube (CNS) and neural crest 
(peripheral nervous system) which eventually develops into the brain and spinal cord, respectively25,96–
98 (Figure 6). The protein sonic hedgehog (SHH), secreted by the notochord, is responsible for 
specification of the most ventral region of the neural tube which is the floor plate. With time (28 to 32 
days) the neural tube closes, resulting in a bulging and bending of the neural tube97,98. This results in 
the formation of three distinctive areas known as the primary vesicles, comprising of the 
prosencephalon (forms the cerebrum), mesencephalon (forms the midbrain, deriving the substantia 
nigra) and metencephalon/rhombencephalon (forms the brain stem and cerebellum)94,97. At this point 
there are many pathways, factors, morphogens and signalling centres that simultaneously occur to allow 
for patterning of different regions of the brain93: As aforementioned, this work will focus on the 
development and patterning of the mesencephalon as it is the area which vmDA are derived  from.  
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Figure 6. Depiction of the areas of the neural tube (blue) during neurulation showing the floor plate 
and roof plate regions (yellow), neural crest cells (red), the epidermis and notochord, both in grey. 
Image adapted from Green et al, 2015. 
 
2.2.2.2. Patterning 
 
The patterning of the mesencephalon from the neural tube is directed by two signalling centres and a 
series of morphogen gradients. One of the key gradients and centres is the roof plate-floor plate of the 
neural tube that directs either rostral or caudal ventralisation. This signalling centre involves gradients 
of bone morphogenetic protein (BMP) and SHH, both implicated in the patterning of the dorsal and 
ventral regions (Figure 7). High BMP concentrations at the roof plate drive towards dorsal 
regionalisation and high concentrations of SHH from the floor plate result in a ventralisation86,95,99. The 
second signalling centre is the isthmic organizer (IsO) which results in the midbrain-hindbrain boundary 
(MHB)94,100,101. Patterning of the MHB is mediated by OTX2 and GBX2 which regulate the expression 
of WNT, EN1 (mesencephalon) and  fibroblast growth factor-8 (FGF8) (metencephalon) using the 
resulting morphogen proteins95,102,103. Concentration gradients of FGF8 and WNT induce the IsO, higher 
concentrations of FGF8 result in the metencephalon, whilst lower gradients result in the 
mesencephalon94. WNT gradients pattern posterior to anterior, with higher concentrations resulting in 
the posterior/caudal regions94,95,104. Both centres (BMP/SHH and FGF8/WNT) through transcription 
factors and morphogens give rise to the regional identity of the ventral mesencephalon region. 
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 Figure 7. (A) Schematic of the concentration gradients of BMP, SHH and WNT involved in the 
patterning of the neural tube towards the three primary brain vesicles (B) forebrain (i), midbrain (ii), 
hindbrain (iii) and the spinal cord (iv). Image adapted from Kirkeby and Palmar, 2012. 
 
For the patterning of the cells SHH plays an important role in the specification and patterning of the 
early neural tube. A gradient effect of SHH and WNT distinguishes between the ventral and dorsal 
regions, whereas gradients between SHH and BMP result in the floor plate and roof plate 
respectively86,91,92,105. FGF8 is also involved in patterning as it is a morphogen, specifically for the 
organisation and maintenance of the mid/hindbrain boundary94,106.  
 
2.2.3. In vitro differentiation of pluripotent cells into vmDA 
 
The rational for using cell replacement strategies for the treatment of PD is based on a wide range of 
factors such as the evident benefits discussed in section 2.1.6.3 . However, currently these methods are 
hindered by ethical issues, reproducibility and cell source sustainability, availability and quality. 
Therefore, there is a demand in the area to find ways to obtain suitable cells for transplantation (of 
vmDA progenitors). This has led to the current plethora of work that provides protocols to easily, 
quickly and successfully produce neural cell lineages, from embryonic and pluripotent cell lines, that 
are stable and can be used as disease models as well as for transplantation25,87,107. The cells that are 
generated are similar to the foetal cells, in terms of their morphology, surface antigen and protein 
expression, functionality and have comparable potency24. In terms of transplantation, Grealish et al 
(2014) show that hESC derived cells are akin to their foetal derived counterparts; for instance, with 
regards to their ability to grow and sufficiently reinnervate allowing for the restoration of DA 
neurotransmission85,108. Neural differentiation has thus far been achieved through three key methods: 
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embryoid body (EBs) based differentiation, feeder based differentiation, and monolayer differentiation 
with dual SMAD inhibition107,109.  
 
Section 2.2.2 briefly describes the neurulation process, which has formed the basis of many 
differentiation protocols that aim to obtain vmDA. The protocols discussed in this section are 
specifically those that utilise hESCs for their differentiation process. It is worth noting that other cell 
sources for vmDA differentiation have been explored, such as somatic cell reprogramming (using 
lmx1a, nurr1, foxa2, en1 and pixt3) 8,94,110,111 and neural stem cells112–114, however both are out of the 
scope of this work which is hESC based.  
 
It is important to emphasise that the brain is often considered to be the most complex entity in the 
universe. Therefore, it comes as no surprise that the differentiation of neuronal cell types is an onerous 
challenge that involves intricate nuanced combinations of signalling pathways, transcription factors and 
morphogens interacting a complex network. Understanding and controlling this network is crucial to 
successfully obtaining the desired neuronal subtype, as even the slightest of deviations will result in 
unwanted subtypes due to the infinitesimal proximity of cell nuclei groups in the brain and their 
sensitivity to signalling and factors. For instance, the A8, A9 an A10 cell nuclei are all dopamine 
producing and all found in the mesencephalon, however not all involved in the aetiology or potential 
cell-based treatments of PD. 
 
In the present work the objective is to obtain DA neurons, specifically those in the substantia nigra of 
the mesencephalon (midbrain) originating from the ventral region of the mesencephalon, specifically 
from the FOXA2+/LMX1A+ floor plate. These vmDA are tyrosine hydroxylase (TH+) neurons that 
produce the catecholamine neurotransmitter dopamine. Furthermore, we need to specify the specific 
nuclei of cells as several groups of DA neurons exist in the brain, three of which (A8, A9 and A10) are 
found in the mesencephalon115–117. The A9 cell nuclei of the substantia nigra pars compacta is therapy-
specific as they produce dopamine and importantly, the cells project axons to innervate the dorsal 
striatum, integrating into the nigrostriatal pathway which is responsible for motor function regulation. 
Loss of this A9 nuclei of vmDA neurons is the hallmark indicator of PD as loss of vmDA neuron 
innervation into the striatum is the pathological basis of PD. The following section highlight the key 
protocol develops in the area of vmDA differentiation. 
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Figure 8. A timeline of 
vmDA cell 
transplantation 
progression over five 
decades. Highlights 
include the first 
transplantations in 1989 
and 1992; different 
protocols that have been 
developed to produce 
transplantable vmDA 
progenitors including 
the dual SMAD 
inhibition protocol by 
Chambers et al (2009) 
and the latest protocol 
from Lund University 
(Kirkeby et al, 2017). 
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2.2.3.1. The protocols 
 
Initial protocols did not derive homogenous floor plate vmDA neurons, instead a mix of neuronal cells 
were obtained94,95. Indeed, these protocols produced TH+ cells however the cells were not authentic 
vmDA neurons that were suitably functional for transplantation. This work has endeavoured to produce 
a very concise review of the key protocol adjustments that have been made for differentiation of vmDA 
neurons over the last decade and a half, focussing on the latter ten years as this are the most useful 
protocols to consider (Figure 8).  
 
 
2.2.3.1.a. Initial protocols  
 
Initial protocols aimed to produce TH+ cells as this was believed sufficient for dopamine synthesis118,119. 
Although seemingly successful, it was apparent these cells were inadequately specific therapeutically, 
since other neuronal cells are TH+ and produce dopamine. Typically, these protocols were from a 
FOXA2-/PAX6+ neural stem lineage grown from EBs and feeder cells with activation of SHH and 
FGF8 pathways to mimic embryonic development. However the resultant cells had reduced viability 
post-transplantation and formed nonspecific axonal outgrowth in rats94.This showed that just having 
dopamine producing cell (TH+) was not the only requisite for effective therapeutic benefit, as the cells 
being produced by these protocols were not adequately specified the into the desired vmDA A9 group 
that can innervation into the striatum, restoring the nigrostriatal pathway.  
 
2.2.3.1.b. LMX1A protocols  
 
The next generation of protocols took cues from the natural vmDA development during embryogenesis. 
These protocols homed on the necessity of LMX1A as an indispensable marker for appropriate vmDA 
lineage commitment as LMX1A suppresses basal plate cell fates within the floor plate34,120. Expression 
of lmx1a was achieved using hESCs in the presence of SHH and FGF8 to pattern for the ventral 
regionalisation. FOXA2, another important ventral patterning maker, suppresses lateral cell fates by 
inhibiting NKX2.2. In studies where FOXA2 was absent, NKX2.2 was not inhibited, resulting in both 
ventral and lateral mesencephalon cell fates94. This highlights that appropriate ventralisation is achieved 
by network interactions between WNT1-LMX1A and SHH-FOXA2 in the mesencephalon floor plate95. 
This network is not only important during the specification process but also for neurogenesis, 
differentiation and vmDA survival. The move to LMX1A+/FOXA2+ specification resulted in 
appropriate vmDA neuroprogenitors that proceeded to express late vmDA markers LMX1B, NURR1, 
PITX3 and DAT. However, cells obtained were heterogeneous populations contaminated by 
glutamatergic subtypes resulting in low yields of vmDA progenitors92,121.  
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2.2.3.1.c. Dual SMAD protocols 
 
Taking influence from embryonic development, subsequent protocols were more rigorous in 
recapitulating patterning factors and morphogens, facilitating more efficient vmDA neuroprogenitors. 
Chambers et al (2009) introduced the dual SMAD approach which firstly ensures neural induction of 
hESCs followed by patterning of the neural stem cell towards the ventral mesencephalic fate107,122.  
These protocols typically avoided EB use. The dual SMAD approach inhibits BMP and TGFβ, resulting 
in feeder-free, efficient neural induction. The inhibition is dual as, blocking only one pathway is 
insufficient for effective neural conversion. The addition of both noggin and SB431425 blocks BMP 
and TGFb signalling pathways, resulting in differentiation to the neuroectoderm by blocking SMAD 
transduction and decreasing pluripotency markers including OCT3/4 (POU5F1) and the presence of 
neurostem marker PAX6 at day 7-8107,122. This allows complete neural conversation of hESCs in 
adherent conditions in the presence of RHO kinase inhibitor (ROCKi), negating the need for stromal 
and astrocyte feeder layers. 
  
2.2.3.1.d.  WNT/b-catenin pathway protocols 
 
The dual SMAD approach afforded neural induction however adjustments were necessary to ensure 
that the appropriate vmDA patterning trajectory. Krisk et al (2011) showed that although efficient 
neural induction was achieved using the dual SMAD approach, the midbrain specificity into vmDA was 
not correct as WNT/B catenin signalling was not initiated. Thus, an iteration introducing glycogen 
synthase kinase 3 inhibitor (GSK3i) allowed activation of the WNT/B catenin pathway, affording 
ventral-caudal patterning, resulting in cells with high co-localisation of LMX1A and FOXA294,123. 
GSK3i and SHH concentrations are integral to ventral mesencephalic patterning; lack of GSK3i and 
SHH results in dorsal fate neurons and high concentrations result in hindbrain neurons, neither are TH+. 
Therefore, it is important to determine appropriate concentration balances to achieve correct patterning, 
especially as many protocols prescribe differing concentrations of GSK3i. Dual SMAD/GSK3i 
protocols have produced in vitro yields up to 75% vmDA-identity cells, resulting in functional recovery 
of motor behaviour in PD animal studies75,94,107. 
 
2.2.3.1.e. Preclinical and GMP adapted protocols  
 
Since 2012 the dual SMAD/GSK3i approach formed the basis of vmDA differentiation 
protocols75,87,122,124–127. Grealish et al (2014) used this for preclinical studies and animal models, 
demonstrating appropriate vmDA specified cells, capable of innervation with no overgrowth or 
progeny85,94,106,108. The functional cells have long-term survival post-transplantation, produce dopamine 
and demonstrate improved motor behaviour in rat models124,128. Kirkeby et al (2012, 2014, 2017) have 
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since produced a series of protocol iterations based on the dual SMAD/GSK3i which have currently 
transitioned from EB-based to adherent culture on Laminin. Kirkeby et al (2017) ascertained that 
precise cell patterning with carefully timed FGF8 addition is required for high yields of vmDA 
neurons129. Moreover, Grealish et al (2014) demonstrated functional capacity of hESCs-derived vmDA 
neuroprogenitors using the SMAD/GSK3i approach is functionally comparable to foetal-derived vmDA 
neuroprogenitors24.  
 
2.2.4. Summary  
 
Evidently mimicking embryogenesis is the most appropriate basis for contemporary hESC 
differentiation protocols. The challenge remaining concerns addressing translational requirements to 
achieve robust manufacturing processes capable of meeting clinical need and scale. Thus, it is important 
that protocols can be reliably scaled-up using defined components and reagents to ensure good 
manufacturing practice (GMP) compliance. This requires manufacturing process consideration to 
satisfy regulatory elements including quality, purity and adequate process controls, characterisation and 
validation. This is an onerous task for CTPs as they are a living entity and the cells themselves are the 
product and not just as part of the process, dissimilar to antibody/biologics production. The following 
sections highlight key considerations for process and protocol development to efficiently and 
effectively translate protocols into a manufactured CTP. 
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2.3. Manufacturing considerations   
 
The area of regenerative medicine and the cell therapy industry (CTI) is growing exponentially both in terms 
of research and economically130,131. However, the full potential of the area has yet to be fully realised, in part 
due to the many process challenges that developers have faced along the way (Figure 9). As a result, the 
cell therapy market lacks products that provide the ‘regenerative’ properties to treat and cure ‘all’ diseases 
as promised during the conception of the area. The CTI and regenerative medicine field by their very nature 
are multidisciplinary, and as such there is a wide range of aspects that have retarded progression in the area; 
from a process and manufacturing development point of view, there a variety of bottlenecks that have a 
major impact. The following sections discuss some of the key aspects currently hampering protocol 
translation such as; cell purity, stringent identity assays and effective potency assays, that are 
established and validated during product development and used for manufacturing. Furthermore, 
considerations regarding potential adverse effects including tumorigenicity and assays should reliably 
ensure that product deviations are identified prior to release. 
 
 
Figure 9. Process map of the key stages of CTP` development. Starting with conception of the product 
and ending with clinical/commercial product manufacture. 
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2.3.1. Purity 
Traditional pharmaceuticals assure high purity levels, however, purity presents a greater challenge for 
CTPs132–134, due to the inherent nature of cells which are a living material interacting with intrinsic and/or 
extrinsic factors. Unpredictable process variables pose problems where high purity yield is critical to 
functionality, and efficacy. For instance, only vmDA would be required to ensure efficacy and innervation 
of the correct cell type into the appropriate regions of the dorsal striatum. Understandably regulators expect 
proof of high purity, to assure that only the cells of interest are procured for patients135,136. The challenge 
remains in achieving high purity with such complex products i.e. ensuring all cells are differentiated or 
manipulated to the desired state and crucially, retain that state from bench to patient. This is important from 
a safety perspective and is scrutinised by regulators, since any undesired cells may potentially cause 
unwanted/unforeseen effects. This would be highly problematic and should be addressed through rigorous 
identity/purity testing and clear understanding of the mode of action. As a requirement, when a dossier is 
filed to the regulators, purity measures within the manufacturing process should be pre-established. In the 
case of vmDA manufacturing, appropriate cell identification and sorting assays should be considered 
throughout the whole product development cycle, resulting in robustly validated purity release criteria. 
 
2.3.2. Impurities  
 
Impurities present another bottleneck which can hinder clinical use and/or commercialisation of a CTP. 
Impurities usually fall into two broad categories: product-related impurities (e.g. cell fragments); and 
process-related impurities (antibiotics, cell culture reagents etc.) that need to be removed before regulators 
can deem a product acceptable for clinical manufacture133,137. Regulators tend to, understandably, have a 
strict view on all impurities and suggest that they should be addressed in the risk analysis138. In addition, 
impurities such as metabolites should be tested and/or have their removal demonstrated through validation. 
For the most part, the issue of impurities can be addressed by using monoclonal antibodies to remove the 
cells and leave behind the unwanted fragments using methods such as fluorescence-activated cell sorting 
(FACS). Furthermore, testing for the absence of bacteria, fungi and mycoplasma is essential, there are many 
techniques and organisations that can be employed to carry out such tests132,133. In some cases, if accredited, 
in-house tests can be used to screen the product and this can be integrated into the process quality 
management of the development and manufacturing process139. It is important to note that tests and 
interventions to remove impurities must consider that cells are a living material and therefore cannot undergo 
rigorous sterilisation and purification steps such as irradiation; that occurs during the manufacturing process 
of traditional pharmaceuticals. Thus acceptable limits have been established for (most) CTP process related 
impurities, however the onus is on the manufacturer to set specifications regarding product related impurities 
based on factors such: as pre-clinical and clinical safety studies, the capability of the process to remove the 
impurities and also related products/ historical data138,140,141. These specifications must be in line with the 
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existing guidelines and criteria of the regulators. As a result, the product developer/owner must submit 
impurity specifications that reflect an understanding of the individual phases of development, impurity risk 
and process capacity to produce a product with a safe impurity profile. Embracing such an integrated 
approach to dealing with impurities allows research and products to overcome this hindrance to CTP 
commercialisation and clinical use.  
 
2.3.3. Identity  
 
Knowledge of the identity of a product is required, it is crucial that the correct cells are identified and only 
those that are desired are used for the product. If undesired cells remain in the product and are administered 
to the patient, they may alter the product’s mechanism of action or result in spontaneous and potentially 
tumorigenic differentiation i.e. with remnant pluripotent cells.  Cluster of differentiation (CD) markers are 
one of the most prominent methods of identifying cells, via their cell surface molecules138,142. For instance, 
the co-expression of FOXA2 and OTX2 alludes to differentiation towards a vmDA cell linage. However, 
like many aspects of CTPs there are nuances that present some identification challenges. For instance, similar 
CD marker combinations can be found on very different cell types; and/or the marker expression profiles 
can be transient over time. Therefore, identity parameters should be established for the specific product based 
on validated evidence and tests. The European Medicines Agency (EMA)  says that “identity of the cellular 
components should be based on phenotypic and/or genotypic markers”143. As a result, it means that the test 
methods used need to be specific for the cells of interest. Hence why, when addressing phenotype, relevant 
analyses should be used such as gene expression, antigen presentation and specific biochemical activity in 
an orthogonal manner 132,144. For allogeneic CTPs, it is imperative that the identity profile should include 
histocompatibility markers, as the cells will be heavily scrutinised by immune system. For vmDA 
transplantation this is imperative as grafts could be rejected, resulting no innervation and lack of efficacy. In 
addition, morphological analysis for adherent cells may be useful, as morphology can have an important role 
on the function133. However, this should be in conjunction with other analyses as cells can exhibit similar 
morphologies under light microscopy which can be difficult to distinguish.  
 
2.3.4. Tumorigenicity 
 
Tumorigenesis presents trepidation with CTPs, particularly those using heavily manipulated or genetically 
edited cells, since they may undergo transformation, whereby chromosomal instability is possible143,145; thus, 
impeding authorisation. This relates back to the issue of purity, in the event that pluripotent cells are present 
in the end product, there is a risk that the cells would continue to proliferate and potentially become 
tumorigenic. For this reason, post mitotic vmDAs are desired for transplantations so that they cell do not 
continue to proliferate. When using unestablished cell lines, karyology tests should be considered to 
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investigate the tumorigenic potential of the cells143,146,147, particularly when the cells themselves would be 
transplanted into the patients. Novel approaches to ensuring CTP safety are being devised, for instance 
the introduction of a suicide gene can reduce the risk of tumorgenicity for products differentiated from 
pluripotent cells148,149. The suicide gene can be activated in the cell product, thereby selectively 
removing undifferentiated cells from the product, thus increasing product purity and safety149. The 
challenge for CTPs is that they often require the use of pluripotent cells, extended cell culture periods, cell 
banking and the use of growth factors, all which have the potential to result in a tumorigenic profile. It is 
worth noting that, if a CTP cell line is found to have tumorigenic concerns the EMA states that “Use of cell 
lines known to be tumorigenic or to possess abnormal karyology should be evaluated in terms of risk-benefit 
for each product application”147.  
 
2.3.5. Potency 
 
The challenges mentioned above relate to obtaining the right cells and having them as pure as possible. 
Potency according to the EMA  “should be based on the intended biological effect which should ideally be 
related to the clinical response”150. With some CTPs this can be easy to prove, however when potency tests 
must also show clinically meaningful changes it becomes difficult for some CTPs to demonstrate potency 
prior to human clinical trial data. Clinical changes in health utility for PD can be measured by cognitive 
behaviour and motor assessments, through tools such as the Unified Parkinson’s Disease Rating Scale and 
the Hoehn and Yahr scale. Due to the complex nature of CTPs  prior to this data being available, developers 
may face unanswerable questions regarding product potency; however some answers can be achieved 
through in vitro and/or in vivo assays, or assays based on surrogate markers132,138,151. These can include but 
not limited to gene expression profiles, flow cytometry immunoassays and metabolite release assays. For 
example, dopamine release assays for vmDA neuroprogenitors can be used ascertain potential dopamine 
levels which can be related to improvements in motor symptoms.  Such an assay would benefit from being 
non-destructive to the cells and the ability to be employed in real-time as dopamine release would be critical 
in the differentiation of vmDA for transplantation. An ideal potency assay would rapidly and reliably 
produce real-time data using inline manufacturing systems, permitting continuous process monitoring 
to facilitate informed proactive process changes and improved process control based on real-time data. 
In cases where potency can be easily addressed, it is due to the product’s ability to clearly demonstrate its 
effectiveness when directly compared to other products currently on the market, however this is not the case 
for all CTPs152. For this reason, developers and regulators must work together to facilitate the creation of 
potency assays that provide valuable process information which can be utilised for quality control and release 
of manufactured CTPs.  
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2.3.6. Supply chain 
 
Supply chain reliability is often overlooked; however reagents require batch validation with deviances 
being accounted for, or demonstrating non detrimental effects on the end product 132,134,138,153. Therefore, 
it is important to consider reagents during process development to ensure manufacturing sustainability. 
Furthermore, when assays come in contact with the product, GMP-compliant reagents are essential as 
the end product will be introduced into the patient, therefore it should be free of any harmful substances. 
The GMP compliance of suppliers should be rigorously validated to ensure that reagents are truly GMP 
compliant154,155. This can be done by auditing suppliers, their premises, their staffs’ GMP training and 
even their suppliers. Although it might seem tedious and laborious, it is an effective means of risk 
mitigation that would need be required by regulators to ensure appropriate compliance. Supply chain 
control and contingences are recommended to reduce variability, especially if contingencies are tested 
within the product’s tolerance and design space74,138. This is pertinent for the differentiation of vmDA 
neuro progenitors as it requires a range of different supplements and small molecules (discussed in 
Chapter 6). Therefore, they should be simultaneously available for the process to work or appropriate 
validated substitutes should be identified as part of the product development process. The latter activity 
may help overcome comparability issues further down the product time-line, especially if suppliers 
become obsolete. Single supplier issues need to be addressed as they can render product development 
and manufacturing to a halt155. Therefore, the risk of raw material availability should be a key activity 
that is carried out during the development stages. It is encouraged that developers discuss with their 
suppliers about procuring future stocks that meet their projected needs in case of a shortage of key 
resources. Manufacturing process flexibility is important, allowing assay amenability throughout the 
product’s lifecyle134. For supply chain management, product and assay development should be reliable 
and effective whilst considering associated costs, as hindrances to many CTPs is their cost-intensive 
development. This links to the need to consider reagents use and understanding the overall process unit 
costs25. 
 
2.3.7. Process Understanding   
 
The aforementioned challenges are addressed or well mitigated in well-established industries including 
antibody and pharmaceutical production, thus providing learning platform for CTPs. For instance, the 
use of Juran’s concept of quality by design (QbD) facilitates product and process development that is 
data, risk and knowledge driven; ensuring in-built quality from the outset156–158 (Figure 10). QbD key 
aspects include defining a quality target product profile (QTPP) utilised to highlight the desired product 
specifications or critical quality attributes (CQAs). Having both defined QTPP and CQAs is the starting 
point for identifying critical material attributes (CMAs) and critical process parameters (CPPs). QbD 
concepts facilitate protocol and process development conceived with control strategies in place, aiming 
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to ensure that QTPP is met in every production run. This is via identifying and understanding the design 
space in which the CPPs result in the CQA and QTPP. The design space helps developers attain process 
controls given the CPPs, furthermore, the use of process analytical technology (PAT) allows for 
iterative, data rich development processes that are able to ascertain process capability. 
 
Figure 10. The elements of the quality by design (QbD) framework for product manufacturing. 
 
Characterisation is fundamental to CTP manufacturing; it is important to characterise and identify both 
input CMAs and output cells of a manufacturing process. This facilitates input quality, ensuring 
materials are process appropriate; output characterisation evaluates product manufacturing success. 
Imperative to CTPs is that the cell characterisation can provide information regarding the functionality 
of the cells, therefore making potency assays a crucial tool in CTPs process development and 
manufacturing132,133. For instance, identification of a CQA cellular marker that could be linked to the 
function of a particular cell type. An example would be an assay that confirms the presence of CD19 
on chimeric antigen receptor T cells (CAR-T cells, definition in section 2.4), since the presence of CD19 
is linked to recognition and attachment to tumour cells which initiates destruction of the tumour159.  
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 This highlights the importance of CQAs to product understanding and the need to explicitly define a 
product’s CQAs prior to approval. CQAs are functionality-based characteristics; these can be physical 
or chemical and linked to potency, identity and purity160. These characteristics can be identified by cell 
morphology, phenotypic markers and secreted factors, which can be potentially linked to functionality 
and clinical response i.e. detection of secreted dopamine144,152,161. It is important that developers are 
selective and robust in their characterisation, for instance, distinct marker profiles should be used to 
confirm identity. This is crucial for CTPs such as vmDA cells for transplantation as subtle differences 
appear between DA neurons and neighbouring neuronal cells. However, vmDA lineages restricted to 
the caudal ventral midbrain can be identified by FOXA2, LMX1A, CORIN, OTX2 and EN1 co-
expression. 85,94. Therefore, using high specificity characterisation criteria is a necessity for robust CTP 
assay development. Characterisation during product development can provide validated and 
quantitative data applicable to potency assay development. Flow cytometry and genetic analysis are 
robust methods for analysing identity, which can be used to track changes during 
expansion/differentiation. Molecular or chemical based methods including ELISAs can also be used to 
analyse secreted chemicals, which in some cases can be indicative of function161,162. For instance, 
detection of dopamine release by differentiated cells would imply successful lineage differentiation, 
moreover dopamine release is directly linked to the functionality and MOA of a dopaminergic cell 
based CTP24,71,86.  Therefore, potency assays based on the observed MOA and concurred by the 
literature around PD treatment109,132 could be used to characterise products prior to being released.  
 
2.3.7.1. Phenotypic markers  
 
Phenotypic markers can be used to ensure the CPPs and design space efficiently yield the desired CQAs. 
For instance, which small molecule concentrations and cell densities result in the desired cell markers 
and thus the CQAs. Intracellular and extracellular markers can be transient, thus are appropriate for 
monitoring process progression including differentiation, using techniques including flow cytometry or 
gene expression analysis. For the candidate therapy, hESCs are differentiated into vmDA neuro-
progenitor cells, both cell types have distinctive identity profiles. Positive expression of SSEA-4 and 
OCT3/4 signifies undifferentiated cells, whilst decreased expression of these markers and transient 
presence of PAX6 demonstrates neural stem cell lineage progression25,107163. The desired differentiated 
end product can be identified by FOXA2/OTX2 co-expression25,164. Therefore, these markers can be 
assigned as process CQAs since expression corresponds to specific stages, permitting development of 
in-process assays set against these CQAs. Furthermore, markers such as EN1 and TH have been linked 
to vmDA function in animal models. If real-time information is obtained, it presents a powerful tool for 
process development monitoring and CPP capability. This is easily achievable for suspension cells as 
the culture vessels can have the ability to be directly linked to a flow cytometer, allowing for real-time 
analysis of the cells and process. 
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2.3.7.3. Secreted substances 
 
Substances such as dopamine, hepatocyte growth factor and other growth factors are secreted from cells 
and can be utilised as a mode of assessing product potency and thus functionality. In addition, the 
secretome of cells can be used in process development as a mode of quality checking and ensuring that 
the cells are progressing towards the desired route of differentiation or cell state. In the case of the 
candidate cell therapy, there are specific factors that are secreted which have been linked to specific 
stages of DA neuron differentiation86,109.  By applying the knowledge of the specific time point at which 
these compounds are released, it is possible to take samples to assess if the cells are proceeding in the 
desired manner. SHH and FGF8 are secreted during DA neuron development and have been shown to 
induce midbrain development in pluripotent cells25,48,86,107. Other soluble factors that are implicated in 
midbrain development processes include brain-derived neurotrophic factor (BDNF) and glial cell-
derived neurotrophic factor (GDNF)25.This ability to map and assign factors to time frames is extremely 
valuable in a manufacturing setting as it can allow for detection of failure modes before the end product 
is tested, saving both economic and time resources. Fundamentally, these substances are released at 
distinct stages, therefore a failure to detect them can act as go/no-go tool for the progress of the cell 
differentiation/manufacturing process, allowing for process intervention to evaluate if the observation 
will have an impact on the final product’s functionality.  
  
2.3.8. Safety 
 
Product safety is paramount and a regulatory requirement, it is one of the key aspects of phase I clinical 
trials and a key consideration by healthcare payers (definition in section 2.4). Prior to phase I clinical 
studies, there needs to be preclinical product safety testing and product characterisation. Product safety 
links to topics such as purity, potency and identity discussed above, which aim to ensure that the 
products meets the desired CQAs and is safe for administration. In addition to assays and activities such 
as chromosome karyotyping and tumorigenicity testing developers should also focus their efforts on 
the biodistribution and targeting of administered cells, as this can have potential side effects165,166. CTPs 
differ from other biological medicines as the cells have the potential to persist in the patient for their 
lifetime (which may or may not be desired – if desired long term safety studies should be conducted); 
they can replicate or to mature in vivo after they have been administered (which is a functionality that 
should be well understood) and the cells can migrate and distribute to tissues or organs other than the 
one intended167–169.   
Assessing and confirming the biodistribution, engraftment and persistence of the administered cells is 
required as cells respond to their environment and interact with other cells and extracellular fluids in 
ways which are not encountered with traditional pharmaceutical and biologics167. Biodistribution and 
 - 39 - 
persistence tests can be done preclinical using appropriate animal and/or disease models, it is important 
to note that these tests should be scientifically and rationally validated to ensure that the evaluation 
criteria truly demonstrates meaningful data regarding product safety165. In combination to 
biodistribution tests, appropriate and maximal dosage levels should be ascertained to ensure that the 
potential adverse effects of cell administration are mitigated against165,167,170. This is pertinent in 
products such as CAR-T therapies which involve systematic administration of the product to the patient. 
Early assessment of product safety is vital, preclinical safety studies in animal models are a great mode 
of acquiring safety data early on, however it is recognised that the value of these models can be limited 
due to species-specificity167. As a result, some responses might only be observed in certain species, thus 
a product that satisfies safety testing in an animal model might induce an adverse effect in humans. 
Therefore, this is a challenge that needs to be addressed, perhaps the use of human or patient specific 
disease models can alleviate the drawbacks faced with species-specificity171,172. 
The raw materials used in product development and manufacturing are a crucial element in product 
safety155, thus it is mandatory for materials and reagents to meet the required levels of compliance and 
are tested for sterility, contaminants and microorganisms that could compromise the safety of a 
product165,167. Supplier validation and auditing, again, becomes a necessary activity to carry out. In 
addition, another area of importance is the safety of biologically active transformation agents such as 
such transgenes. Their MOA, sterility and safety should be addressed and verified, as well as the 
structure and characteristics of the transgenic construct, to safeguard safety through the whole supply 
chain and process148,166. 
It is worth noting that speaking to regulators as early as possible is imperative as regulators can give 
advice on the product safety requirements. In the development stage this a worthy activity to engage in 
as guidance on how to accrue appropriate safety data is invaluable, as insight on appropriate assays and 
activities can be gained, resulting in well-informed product development160,170,173. This can potentially 
de-risk the developer’s regulatory approval submission as it would have been formulated and compiled 
with a clear understanding of how to meet the requirements of the regulator. 
 
2.3.9. Technology 
 
Innovative adaption and transformation of available technologies to meet new processes and product 
requirements is becoming commonplace. Instances include the creation of integrated systems 
resembling a modular process comprised of complimentary technologies74,142,174. These aim to provide 
essential CTP monitoring capabilities, production control and production capacity to meet potential 
clinical demand. Scale up technologies are necessary for efficient manufacturing however, adequate 
control and monitoring technologies are equally essential for downstream manufacturing process 
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optimisation such as cell sorting, purification and filling142. Technologies such as fluorescence-
activated cell sorting and automated controlled rate freezing offer some solutions. 
 
Truly integrated inline systems, capable of monitoring, characterising and sorting cells would allow for 
highly pure products to be obtained, facilitating both process control and quality assurance. 
Furthermore, non-destructive PAT that can analyse cell-secreted substances in real-time would allow 
for process mapping, as discrete secretome profiles are evident throughout the differentiation stages. 
Failure to detect can act as go/no-go tools for the progress of cell differentiation/manufacturing 
processes, allowing for process interventions to evaluate if the observation will impact final product 
quality and functionality. Furthermore, substance detection concomitant to product functionality would 
present a powerful potency assay. For the candidate therapy an assay confirming dopamine production 
would corroborate desired biological function85,108. This can be achieved with PATs directly linked to 
the culture vessel and detect the desired substance i.e. metabolite analysers; allowing for real-time 
process analysis.  
 
2.3.10. Summary  
 
The sections above detail the requirements and considerations that are integral to CTP process 
manufacturing, however even when equipped with this knowledge there are still other challenges that 
developers face. For instance, creating assays that are convenient, informative and non-destructive to 
the cells presents a major challenge. In addition to ease of use, an efficient assay should also be rapid 
in its production of data. An ideal assay should be able to produce real-time data using inline systems, 
as this would afford the opportunity to monitor processes continuously and facilitate informative 
proactive process changes based on real-time data.  
 
In relation to process development, knowledge is certainly power, particularly for assay development 
as robust data is desired for their development. The combination of a QbD mind-set and development 
of in-process assays provides powerful toolsets for developers to understand their products and 
processes as they embark upon CTP manufacturing challenges. A proactive stance to assay 
development is encouraged, considering how the product works and batch analysis at an early stage can 
mitigate risks during later stages of process and manufacturing development. A plethora of information 
demonstrating a clear understanding of the process and product is likely to favoured by regulators, as it 
demonstrates due-diligence throughout the development stages. An in-depth understanding of both 
process and product design spaces makes the product amenable to change, where necessary, negating 
further comparability studies and the concomitant extensive paperwork. This fundamentally permits 
more informed, less hindered pathways to product authorisation as “Early and sustained investment in 
a bona fide potency program is essential for maximising a product’s commercial success”138.    
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2.4. Translational considerations  
 
Glossary: 
 
Adoption – the procurement and implementation process of espousing health technologies in to the 
healthcare system. This covers a wide range of activities in including health technology assessment, 
price negotiations, personnel training and infrastructure considerations.  
 
Amortisation – a mechanism in which the full payment is spread over a period of time and multiple 
instalments are made, typically over the expected duration of benefit.  
 
Chimeric antigen receptor T-cell therapy (CAR-T therapy) – is a treatment for advanced B-cell 
acute lymphoblastic leukaemia (ALL), diffuse large B-cell lymphoma (DLBCL) and primary 
mediastinal B-cell lymphoma (PMBCL) cancers, that is used after other available treatments have 
failed. The treatment involves harvesting immune cells (T-cells) from the cancer patient and then 
genetic reprogramming them to specifically target their cancer by making them express the chimeric 
antigen on their surface. The process of making a CAR-T therapy is complex and involves apheresis, 
genetic engineering, cell expansion and then infusion back into the patient, this process takes 
approximately three weeks and can require patients to stay between one to one and a half weeks in 
hospital. Investigational work is still being carried out and all the possible side effects are still not 
known, however cytokine release syndrome and B cell depletion are two of the currently known side 
effects. Two CAR-T therapies are currently approved for use in the UK, Kymriah and Yescarta175,176.  
 
Drug plan - provincial and territorial organisations in Canada that are in charge of paying for 
prescription medication for eligible members of the population such as seniors, recipients of social 
assistance, and individuals with diseases or conditions that are associated with high drug costs177.  
 
Equity - the absence of avoidable or remediable differences among groups of people, whether those 
groups are defined socially, economically, demographically, or geographically. 
 
Health technology - the application of organized knowledge and skills in the form of medicines, 
medical devices, vaccines, procedures and systems developed to solve a health problem and improve 
quality of life – definition pr.  N.B. this term has been used interchangeably with the word intervention. 
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 Health technology Assessment - the systematic evaluation of properties, effects, and/or impacts of 
health technology. It is a multidisciplinary process to evaluate the social, economic, organizational and 
ethical issues of a health intervention or health technology. The main purpose of conducting an 
assessment is to inform a policy decision making by considering the clinical and cost effectiveness and 
broader impact of healthcare technologies 
 
Nation Tariff –a set of prices and rules used for the reimbursement of care delivered to patients. 
 
Opportunity cost - the money or other benefits lost when pursuing a particular course of action instead 
of a mutually-exclusive alternative 
 
Pay for performance – a payment mechanism in which healthcare providers are paid depending on the 
level of their performance or their ability to meet the defined outcome measures.  
 
Payer – a body/organisation that pays for the provision of healthcare for an individual or for society. 
Payers are in charge of the financial and operational aspects of providing healthcare to ensure that the 
cost of health services are appropriately reimbursed.  
 
Payment mechanism – a method of paying for health care services i.e. the way in which providers are 
reimbursed. There is no single best method and different countries use a mix of different payment 
mechanisms for different purposes. In general, the methods employed create different sets of incentives 
form the providers such as quality and efficiency.  
 
Reimbursement – the act of paying hospitals, doctors, test centres and health technology suppliers for 
their services in the provision of care.  
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As mentioned in the manufacturing considerations section, there are many challenges that needs to be 
addressed in order to successfully translate developmental therapies to the market, especially as the CTI 
is an area that is growing both in terms of scope and investment131. Recently there has been a faction of 
CTPs and gene therapies traversing through various stages of clinical trials and over the last three years, 
with a number of cell and gene therapies gaining regulatory approval 26,74,178–181. For the majority of 
CTPs, the concomitant scientific aspects have been fine-tuned and shown to be effective. However, 
economic and commercial aspects of CTPs have for the most part, been neglected; this has been 
predominantly due to the fact that developers tend to be based in academic institutions, where economic 
and commercial considerations are not necessarily development priorities 182,183. Thus their products’ 
ability to generate revenue and successfully compete on the market has either not been fully considered, 
or has been neglected until the latter stages of development182. In addition, the CTP industry is emerging 
and there is no/little set precedence, thus many developers have been simultaneously facing similar 
development challenges unbeknown to each other. However, with the growth of the CTI community it 
has become evident that commercial and economic aspects need to be considered at an early stage of 
the development timeline182,183 (Figure 11). As a result, there has been a plethora of literature within 
the last ten years that highlights the importance of early assessment of healthcare technologies. 
 
Health economics is a valuable tool in healthcare, it provides information for both developers and payers 
as well as any other interested stakeholders. For many developers, economic considerations are not 
considered a priority at the early stages of development, however with increasing competitiveness in 
the CTP field, economic considerations are becoming more and more important if the developers hope 
to have a product that is commercially viable. Early economic consideration is slowly becoming trend 
that is growing, particularly with novel interventions such as CTPs as their reimbursement landscape 
is, for the most part, unknown. Therefore, early assessment of potential return on investment and 
reimbursement of their products is vital. 
 
A Health Technology Assessment (HTA) refers to an exercise that can be used to assess the ‘readiness’ 
of a product to be procured into the healthcare system. HTAs cover a wide range of intervention types 
to improve health, these can be pharmaceutical drugs, medical devices and surgical, transplantation or 
replacement therapies182. European Network for Health Technology Assessment (EUnetHTA) define 
HTA as “A multidisciplinary field of (policy) assessment”; essentially HTA assesses the clinical 
effectiveness of an intervention i.e. its patient health benefits compared to alternative interventions or 
the course of no intervention at all184,185. The economic impact of adopting the intervention or the 
alternative (or no intervention) is also analysed to evaluate what the cost to payers such as national 
health services, insurers and society would be. HTA considers the social and ethical implications  
involved with new interventions in addition to any potential health policy changes that may result182,184. 
Therefore, HTA as a process involves the examination of a diverse range of aspects associated with the 
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value of an intervention, which provides a platform for decision making on the adoption of a new 
intervention182,184,186. As a result, HTA is carried out independent of interested parties and must be 
performed in a systematic manner, with transparent results for effective and well informed decision 
making, based on the best current research and data183,187,188. In most countries HTA appraisals are 
performed by an agency that represents the ministry/department of health; in the UK the National 
Institute for Health and Clinical Excellence (NICE) performs HTA appraisals and provides clinical 
guidelines for the Department of Health.
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Figure 11. Schematic of HTA and decision uncertainty based on an illustrative product development timeline. Four stages of HTA analysis are shown with 
very early stage considered at the basic research phase. Most HTA is currently performed at stage 3 after the first clinical trials have been initiated.  Considering 
HTA analysis only at stages 3 and 4 risks the successful reimbursement and adoption potential of a product, if the required evidence was not generated in the 
earlier phases of development. This can result in wasted time and resources efforts as the product will not get adopted if the evidence required by the payers is 
not adequate, regardless of the product receiving regulatory approval. Decision uncertainty refers the uncertainty of market access, post-market success and 
reimbursement decisions. Adapted from IJzerman and Steuten (2011) 
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2.4.1. Health economics  
 
An important element of HTA is the study of health economics, which involves understanding the 
product’s effectiveness and its associated economic impact. Health economics is particularly important 
to healthcare budget administrators as it is the study of the movement and allocation of resources to 
fulfil the health needs/wants of the society under scarce resources188–190. Health economic evaluations 
facilitate the assessment of the reimbursement potential on a product based on its comparable 
effectiveness both in terms of cost and efficacy69,182,191. Therefore, health economics can be used as a 
decision-making tool when it comes to the commercial viability and reimbursement of a new therapy182. 
There are many factors that need to be included when considering health economic evaluations such as 
clinical effectiveness, costs and overall health benefits of the intervention. The models produced as part 
of economic evaluation exercises inform both the developers and investors regarding the commercial 
and economic prowess of the product being evaluated, as well as informing the payer about the 
economic impact an intervention will have on their budget. The models employed use techniques such 
as incremental cost-effectiveness ratios (most appropriate for payers), the headroom method (most 
appropriate for developers) and return on investment (most appropriate for investors), all of which will 
be discussed in later sections182,183,192. There are some keys concepts that need to be considered when 
carrying out health economic evaluations, two integral aspects are the health outcomes and costs related 
to the intervention.  These two aspects and some of the analytical methods that are typically used are 
discussed in the following sections. 
 
2.4.1.1. Health outcomes 
 
How a disease affects a patient’s life is a very important consideration in health economic evaluations. 
If the disease burden is high and results in high healthcare costs, it is in the interest of the healthcare 
provider to treat the disease in the most effective manner in terms of both health outcome and costs. 
Positive health outcomes are important especially when they reduce morbidity, for instance, with PD 
health outcomes that allow patients to prolong their independence are desired from a quality of life and 
healthcare cost reduction perspective, for the patients and healthcare provider, respectively. 
 
In the field of health economics, Quality Adjusted Life Years (QALYs) and Disability Adjusted Life 
Years (DALYs) are the common metrics used to measure health outcomes and to incorporate disease 
related reductions in length of life and the negative effects of morbidity193–195. However, they deliberate 
these from opposite aspects, QALYs evaluate health and higher values are desired: whereas DALYs 
evaluate disease burden and lower values are favourable (Figure 12). Thus, health interventions aim to 
gain QALYs whilst avoiding DALYs. Both metrics are considered to be good measures of assessing 
how well an intervention impacts health outcomes 196,197. QALYs are calculated using health utilities 
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whereas DALYs are calculated using disability weights. This means that there are some fundamental 
differences in how the data for the values is obtained. Disability weights were derived in a single process 
for hundreds of diseases and disease states that are publicly available, which means that there is 
standardisation which facilitates comparison across different diseases and interventions198–200. Health 
utilities are widely used in literature, thus there are many utility values for various health conditions. 
However, they have been measured using different methods, which can result in different utility 
values198. Since QALYs have been heavily discussed in other literature196,198,199,201,202 the current work 
will pay attention on DALYs. 
 
 
Figure 12.  Schematic of how DALY and QALY values are calculated and how each metric aims to 
quantify health outcomes due to disease (DALY) and interventions (QALY). The orange and yellow 
segments show phases where an individual’s disease burden is increased (DALYs) or their health state 
decreased (QALYs) as a result of illness or diseases through their life. 
 
2.4.1.1.a QALYs 
QALYs are a way of assigning a quantitative value to health states using health utility data and health 
questionnaire scores, meaning they can be used as a health metric to measure how well someone feels 
in terms of their health198,199. By multiplying the heath state with the period of time (years) it is 
experienced, a QALY value can be obtained. Values range from 0 to 1, with 0 being dead and 1 being 
perfectly healthy196,198,199.  
 
The Health Utilities Index (HUI) is commonly used for obtaining the health state of individuals. HUI-
3 a system that measures eight health related attributes (vision, hearing, speech, ambulation, dexterity, 
emotion, cognition, and pain) and each attribute is measured on a range from level 1 to 6, with 1 being 
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the best health state for that attribute and 6 being the worst. Each attribute and level is given a coefficient 
that can be used in an equation to give the value of the overall health state of the individual203. Using 
the HUI-3 matrix (Table 2) a perfectly health individual with scores of level 1 on all attributes would 
have a health utility of 1. On the other hand, an individual with level 5 and 6 scores i.e. extremely poor 
health, would have a health utility of 0.36, this negative value would be considered as 0 as that is the 
poorest health state, which is death (Table 2).  
 
These two examples are extremes used for illustrative purposes only, over a 10-year period the healthy 
individual would have a QALY of 10 (1 x 10) meaning that for each year they are in perfect health. In 
comparison, the individual with a negative/utility score of 0 would have 0 QALYs (0 x 10) over the 
same 10-year period i.e. they are dead. It is worth noting that QALYs and health utilities are dynamic 
as they will change throughout the course of normal life, disease and treatment, therefore a person will 
have multiple health states through their life. 
 
Table 2. Matrix of health related coefficients used to determine an overall health state203. For each 
health state, the attribute level selected in the response is entered into the health utility equation 
(Equation 1). A health utility score of 1 represents perfect health while a negative health utility 
represents extreme poor health.  
 
 
 ! = 1.371 × ()*+*,- × ./01*2 × 34//5ℎ × 789:;0<*,- × =/></1*<? × @8,<*,- × A,2-*<*,-× B0*-) − 0.371 
 
Equation 1 
  
Health State Level Vision Hearing Speech Ambulation Dexterity Emotion Cognition Pain 
1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
2 0.98 0.95 0.94 0.93 0.95 0.95 0.92 0.96
3 0.89 0.89 0.89 0.86 0.88 0.85 0.95 0.90
4 0.84 0.80 0.81 0.73 0.76 0.64 0.83 0.77
5 0.75 0.74 0.68 0.65 0.65 0.46 0.60 0.55
6 0.61 0.61 0.58 0.56 0.42
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2.4.1.1.b DALYs 
 
Disability Adjusted Life Years (DALYs) provide a standardised metric that can be used to quantify the 
burden of different diseases197. This is important as it would otherwise be difficult to comparatively 
demonstrate how different diseases compromise the lives of patients. In particular, when there are 
differences such as the populations affected, physiology, complications and most importantly the 
strategies for treatment196,197. DALYs can be used as a tool to combine the negative effects morbidity 
on patient quality of life and early death196,199. DALYs represent the full burden that is imposed by a 
disease in a manner that allows for quantification of disease specific burden.  
 
DALYs are comprised of mortality, which is the loss of life lost due to premature death caused by the 
disease; and morbidity, which is a measure of chronic disability experienced as a consequence of the 
disease. Mortality can be assessed by calculating the life years lost as a result of the disease, i.e. the 
average age of death of an individual with the disease is subtracted from the life expectancy of a healthy 
individual199. Morbidity is calculated by obtaining the disability weight (how much people are disabled 
by the disease) of the specific disease, which ranges from 0 to 1, with 0 being perfectly healthy and 1 
being fully disabled. As the effects of the morbidity can be brief or extended, the duration of disability 
is factored into the metric197. Therefore, it can be used to compare different interventions and show how 
many DALYs can be averted, which is the health outcome of the given intervention. This means that 
the cost-effectiveness of an intervention can be measured using the benefits of the intervention achieved 
through reductions in the severity of disease burden.  
 
In the literature regarding economic evaluation of healthcare interventions, DALYs are not often used 
as the health outcome metric, instead QALYs are the preferred metric of choice. Despite this DALYs 
present an equally valid and useful alternative and in some instances, for example in cases of incurable 
chronic illnesses, it is more appropriate to use DALYs. For example, an intervention might not afford 
an increase in health utility, yet its use would reduce disease burden experienced by the patients; 
resulting in no QALY gains but providing a decrease in DALYs. This is typically the case when 
evaluating PD, as it is a chronic incurable disease and current treatments do not necessarily increase 
health utility and quality of life but can decrease the burden of the disease by temporarily alleviating 
the symptoms. 
 
The benefit of DALYs is that disease burden data and disability weights are readily available and were 
obtained in a standardised exercise unlike QALYs as discussed above195,196,199. Therefore, it is easier to 
compare results from different interventions and even different diseases, to assess cost-effectiveness 
based on a health outcome. This is important when healthcare providers have to assess the opportunity 
cost of choosing one intervention over another. Moreover, the robustness of DALY input data is 
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particularly useful when no efficacy data is available to provide utility scores; as DALYs can provide 
information on the potential reductions in disease burden and therefore the health benefit of an 
intervention. Furthermore, assessing reduction on disease burden can provide payers with more 
information on the cost-effectiveness of an intervention189. For example, the reduction in costs that can 
be afforded by the reduction in disease burden, compared against other interventions. This information 
can highlight that although an intervention might initially be more expensive, it can result in significant 
reductions in disease burden and reductions in future costs be i.e. further hospitalisations. In other 
words, if an intervention results in QALY gains and DALY reductions then it can save costs for the 
healthcare provider by health gains, reduced disease burden and avoiding future health costs 
 
2.4.1.2. Costs 
 
Costs are an important element of health economics, fundamentally when carrying out an economic 
evaluation of an intervention, it is important to know precisely what costs the intervention is comprised 
of. Therefore, it is critical to qualify and quantify the resources used and validate who pays for them, 
this is particularly important in healthcare systems such as an American/privatised system, as they do 
not operate on a single payer healthcare system like the UK’s National Health Service (NHS). This is 
important when considering reimbursement, as different payers will have different priorities and 
budgets, which results in differences of opportunity costs189,191. Furthermore, there should be explicit 
information regarding the region and/or country that the costs are being analysed for, as studies have 
shown that there can be considerable differences between geographic regions41,70. This is predominantly 
due to differences in allocation of care and healthcare resource amongst regions and countries. Costs 
can be separated into direct and indirect costs, direct costs are usually easy to qualify and quantify41,70. 
Indirect costs however are more difficult; this is because there is a wide range of costs that can be 
considered. There is no consensus on what to include for indirect costs, which can lead to differences 
in economic evaluation results. Typically, direct costs include the cost of the procedure/test, the cost of 
the product/device, hospitalisation fees and any other consumables that are directly related to the use of 
the intervention for the payer69,70. Indirect costs can include but are not limited to: productivity loss, 
side effect costs, carer costs, outpatient care and prescription drugs (for co-therapies)70,204. Some authors 
include uncompensated care costs, costs to families, life style adaptation costs and in some cases 
mortality costs204. Evidently, the difference in the included costs can result in significant cost 
differences, some have reported up to 16 –fold variation depending on whether or not indirect costs are 
evaluated69. Additionally, costs should also reflect the appropriate stage of the disease, as severe and 
late stage patients have a propensity to be more resource intensive. This consequently increases the 
costs compared to early stage patients which is highly evident in diseases such as PD and Alzheimer’s 
disease191.  
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Assessing the true cost of an intervention needs to take multiple factors into consideration; in addition, 
the factors discussed in the previous sections, there must also be an assessment of the costs, savings and 
health benefits that can be afforded. It is also important to take note of any potential costs, both in the 
short and long-term, that might be incurred by any adverse effects such as product failure that is 
detrimental or fatal to the patient. Understanding the cost and benefits of an intervention should be done 
in a context that includes wider aspects of the disease and treatment, rather than just the immediate costs 
and benefits178. For example, a therapy might initially be expensive, but it the long term the therapy 
may reduce use of medication, hospitalisations and administration costs, which would offset the initial 
costs in the long-term. This highlights the need to need to analyse costs in a wider context and across 
different time horizons in order to understand the true value of the intervention.  
2.4.1.3. Analysis  
 
Healthcare providers aim to deliver high quality care; however, they have limited financial resources to 
do this. Therefore, they need clinical and health economic data that can allow them to assess 
intervention options, so that they can make informed decisions based on policies and products. There 
are various economic evaluation methods that may be utilised, all which have their merits and short 
falls. Economic evaluations are carried out with budget constraints in mind; therefore inventions being 
assessed must have costs that are deemed acceptable given the constraints. These budget constraints 
vary but usually include the payer’s willingness to pay (WTP) for an intervention. In the UK the WTP 
is set between £20-30,000 per QALY; this means that for each year gained in better or full health, the 
maximum WTP is between £20,000 to £30,000. Interventions costing less than the WTP are likely to 
be recommended for adoption, especially if they are both cheaper and more effective than a comparator 
or the current gold standard. If an intervention exceeds £30,000 per QALY, it is unlikely to be 
recommended for adoption as it would not be deemed cost-effective. In such circumstances, further 
analyses or rationalisations would be required to justify its adoption i.e. it might be the only form of 
treatment available for a particular condition. This is typically the case with orphan disease therapies 
and mostly likely to be the case with cell and gene therapies in the near future, as budget impact and 
long-term cost off setting would need to be considered. Calculation of cost-effectiveness can be carried 
out by a range of different analyses, three of which will be discussed below. The three analyses include: 
cost benefit analysis (CBA); cost utility analysis (CUA) and cost-effectiveness analysis (CEA), with 
the latter being the analysis of focus. 
2.4.1.3.a. Cost benefit analysis  
 
Cost benefit analysis (CBA) is a classical economic/accounting technique that is used to assess the 
benefits of an action with regards to its total costs i.e. choosing a particular intervention over 
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another190,205. Due to its ties to classical economics, CBA utilises monetary units as a metric to compare 
between different actions69,190,206. Although sound as an analytical technique, its applicability in health 
economics is arguable as it is difficult to express outcomes such as health gains in a purely monetary 
manner206. Thus, CBA is rarely used as the sole mode of analysis in a health economic evaluation.  
 
2.4.1.3.b. Cost Utility Analysis  
 
Cost utility analysis (CUA) is a mode of analysis that encompasses different aspects of intervention by 
including the costs and the utility such as satisfaction of the consumer190,201. In health economics terms 
this means that that costs and the reported level of patient well-being, likely to be expressed in QALYs, 
are considered into the analysis201,206,207. Therefore, gains in utility with regards to the cost of different 
interventions are used to assess and inform decision making processes. The inclusion of a health 
outcome (utility) means that the impact on quality of life can also be considered in the analysis, which 
better informs decision makers as resultant significant/insignificant changes in quality of life can 
influence the potential adoption of an intervention. 
 
2.4.1.3.c. Cost-effectiveness analysis  
 
Cost-effectiveness analysis (CEA) assess the cost of interventions not only from the monetary aspect 
of the intervention but also the effectiveness of the health outcomes that are achieved by the 
intervention178,184,208. Effectiveness can be accessed via positive outcomes such reduced hospitalisations 
or less organs transplants required as a result of the intervention. These can be considered as a 
standardised unit of health, so gains or losses in the determined unit can be used to compare the 
effectiveness of different interventions, that aim to produce the same health outcome e.g. number of 
lives saved, complications prevented, or diseases cured. QALYs are often used in CEA to calculate 
what the incremental cost-effectiveness ratio (ICER) is when comparing two or more 
interventions189,198. Therefore, it is integral for ICER to specifically state the interventions being 
compared as intervention analysis cannot be compared in isolation. QALYs and DALYs can be used to 
assign a standardised unit to the outcome of an intervention. ICER values are positive as they show the 
cost of gaining a QALY or adverting a DALY. A negative value has no technical meaning, therefore 
the values are not reported, instead it is reported that the intervention with the negative value is 
dominated by the alternative187,209,210. ICER works on an incremental basis comparing each intervention 
to the next least-expensive (non-dominated option). When the WTP is combined with ICER values, the 
cost-effectiveness plane (Figure 13) can be used to determine how likely it is for the intervention to be 
recommended for adoption and reimbursement. 
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Figure 13. The cost-effectiveness plane is used to visualise how likely it is for an intervention to be 
adopted in comparison to other interventions compared in the ICER, in the context of the WTP. If an 
intervention’s ICER plots below the black line (and shaded area) it is below the WTP which means it 
is likely to be recommended. The best-case scenario is for an intervention to plot on the bottom right 
quadrant (D) as it would be both low cost and highly effective, meaning it dominates in comparison to 
other interventions in the analysis. Typically, cell and gene therapies are in the top right-hand quadrant 
(B) where they are highly effective but are encumbered by high costs.  
  
Cost  
Effectiveness
BEST CASE 
low cost, highly effective  
WORST CASE 
high cost, low effectiveness   
NON IDEAL CASE 
low cost, low effectiveness   
NON IDEAL CASE 
high cost, high effectiveness   
(A) (B)
(C) (D)
Old 
Treatment dominates
New 
Treatment dominates
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Cost-effectiveness analysis thus measures the incremental cost of achieving an incremental health 
benefit, expressed as a particular health outcome that varies according to the indication of the therapy211. 
Examples of ICERs using this approach are: the cost per extra patient improving in motor functions and 
cognition for PD patients or the cost per extra acute rejection episode avoided in patients with kidney 
transplants212. Assessing the value for money of using an intervention requires the extra health benefits 
achieved to be weighed against the extra net cost. This comparison is usually expressed as an ICER 
which is the net incremental cost (costs minus cost offsets) of gaining an incremental health benefit 
over another therapy209,213. The value of these analyses is that they provide developers with an 
understanding of the potential economic impact of the product, so it can be assessed whether the 
expected income will offset the development and production costs associated with the CTP182,183. 
ICERs provide a good basis to work from when it comes to the comparison of different interventions, 
however there some issues that need to be addressed with regards to their appropriateness. This is 
because there is a lot of uncertainty associated with the input variables for instance, the data sources of 
QALYs. These uncertainties become compounded in the ICERs, and as a result sensitivity analysis is 
necessary to deal with the uncertainties187,210. The uncertainty needs to be dealt with systematically, by 
considering each input independently and in combination with other inputs. This is necessary to show 
the robustness of CEA data i.e. that the basic conclusions are the same despite the uncertainties187,214. 
This is especially the case for pivotal uncertainties such as intervention effectiveness and life-time costs 
of a therapy. There are two types of sensitivity analysis, one way and multiway sensitivity analysis; 
both of which can help in the deconvolution of complex models, particularly in terms of the interplay 
of different inputs210,213,215. Using sensitivity analysis can reveal technical errors and can potentially 
uncover interesting dynamics in the outputs of CEA based on different inputs187,216. In addition, 
sensitivity analysis gives transparency to the model as the effect of the different inputs are assessed for 
their importance, which helps when using ICERs for decision making processes. Furthermore, this can 
highlight inputs that are poorly understood allowing for further research to be carried out to establish 
additional data which can be used for re-evaluation 187,189. This can be an iterative process, carried out 
until a robust cost-effective value is obtained from the models and evaluations. 
 
2.4.2. Decision models for health economic evaluation  
 
The points discussed in the previous sections are integral to the study of health economics and health 
economic evaluations which are a complex process that is carried out using health economic decision 
models. In order to formulate robust and effective decision models, there are specific model 
characteristic and aspects that should be considered. These aspects include time horizons, data 
presentation, sources of input data, comparators, model choices and the analytic perspective187,214.  
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2.4.2.1. Time 
 
Timing is vital when it comes modelling for health economics, since the different time periods have an 
effect on the resolution and therefore the power of the information that the models produce. Time 
horizons must be chosen ad hoc, for instance for a rapidly developing illness, days or weeks would be 
an adequate measure to capture the information that would impact on the outcomes and costs of the 
intervention178,217. However, for a chronic illness, months and years would be more appropriate measure 
as the outcomes of the intervention would be realised over a longer period of time, typically covering a 
natural life span188,210. Having such information would add value to the results obtained from the models 
as payers would be able to extrapolate the long-term future costs and savings of different interventions. 
This information would be of greater value in comparison to the current models that have relatively 
short time horizons (one to five years), even for chronic illnesses.  
 
2.4.2.2. Data presentation  
 
Presentation of data and results is important for decision models and particularly useful for decision 
makers187,210. For instance, decision trees are convenient for CEA as they diagrammatically present the 
consequences of two or more different options. This is because decision trees can display potential 
action options, their consequences and the resulting consequences measured in costs and health 
outcomes187. The cost-effectiveness plane is also a convenient tool as it allows for visual representation 
of the ICER of the different interventions. Other useful presentations include one and two-way threshold 
analysis, ICER distribution graphs and cost-effectiveness acceptability curves (CEAC)187,215,218. Most 
importantly with regards to data, is that it must be transparent, as this allows decision makers to truly 
understand or at least have a good basis of understanding of how the models have been conceptualised. 
  
2.4.2.3. Data sources  
 
Continuing with the topic of data, models should be data rich in terms of therapy effects and costs, 
particularly in different scenarios as this results in more informed and robust models which and can be 
used for effective and efficient decision making. There are various sources of data available, ranging 
from trial data and synthesised evidence through methods such as cohort simulation; it is at the 
discretion of analysts to choose appropriate data for their models213,219. When creating models caution 
is necessary, as metrics that do not assume maximum utility are required, unless that is the realistic 
level to be obtained. This means that models that assume maximum utility need to be adjusted so that 
they are more representative of the actual effects of the therapy/product. Input data for CTPs presents a 
challenge as there are limited trials to provide information. Furthermore, due to the unconventional 
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nature of CTPs and their various mechanisms of action, traditional pharmaceutical data cannot be used 
as surrogate data.  
 
2.4.2.4. Comparators  
 
Since methods such as ICER cannot be performed in isolation, it is imperative to have 
comparators214,220. The gold standard and other effective interventions (as many as realistically possible) 
should be compared in order to fully evaluate the true cost-effectiveness of the intervention188,205. If 
relevant comparators are not included, the validity of the results could be brought into question as the 
cost-effectiveness analysis would not be fully representative of the interventions that are available, 
limiting the power of the information and consequently the reliability of the decisions made.   
 
2.4.2.5.  Model choice  
 
Choosing the appropriate model is a key activity as the model should have the ability provide useful 
information relevant the decision that needs to be made. Key aspects to consider during model selection 
include defining the boundaries of the model and the availability of the data required to populate the 
model. Decision trees are useful for comparison of the different outcomes of two intervention options ( 
Figure 14). However, decision trees are limited in their scope as they are typically focussed on a single 
discrete time-period, therefore they cannot be effectively used to model long periods of time without 
becoming overly complicated and ‘bushy’187. In such circumstances, Markov models can be used as 
they have the ability to model longer periods of time219. Markov models are based around stochastic 
process and transition probabilities (Table 3 and Figure 15). Relating back to the importance of time 
horizons, Markov models present a useful tool to model long term treatment effects, which is imperative 
for interventions that target chronic diseases that would need to be modelled over an entire life 
span198,214.   
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Figure 14.  An illustrative example of a decision tree to demonstrate how the effects of two different 
decision pathways can be traced to give an outcome. The decision node represented by the square shows 
the decision being made, the chance nodes (circles) branch out to the different pathways that result due 
to the decision made. The end nodes (triangles) represent the payoff of each pathway of each decision. 
The payoffs are calculated using probabilities of given parameters such as costs and health utilities. 
Therefore, a populated decision tree can be used to model the different costs associated with using 
different treatments as an intervention for a disease.     
A 
B 
Effect 1 
Effect 1 
Effect 2 
Effect 2 
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Figure 15. Markov models are based on stochastic processes which can be on a continuous timeframe. 
This allows them to be used for modelling the transition of an individual or cohort group from one state 
into another. The transitions are based on transition probabilities which can be weighted against health 
outcomes or costs, therefore Markov models can be used to model the costs and health outcomes related 
to a patient or group of patients being in a specific state or transitioning between states. In this 
illustrative example a patient can be asymptomatic of Parkinson’s disease(A), have moderate 
Parkinson’s disease(B), have severe Parkinson’s disease (C) or be in the absorbent state of death (D).  
  
Death 
No PD 
Moderate
(>25% off   time) 
Severe
(<25% off   time) 
Asymptomatic (A)
Progressive (C)
Progressive (B) Absorbent (D)
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Table 3. Transition matrix showing the different transition probabilities (tp) from one state to another. 
This matrix works on the principle of staying in the same state or progressing to the next state, but not 
being able to go back into a previous state – as indicated by the direction of the arrows in Figure 15.   
 
2.4.2.6. Perspective   
 
Finally, it is important to understand the analytical perspective of the evaluations being carried out. All 
parties, from a moral point of view, should have the health outcomes and effectiveness as the priority 
of their intervention187,214. However, monetary considerations are important as budgets are generally 
limited, expectedly developers and payers will have different perspectives. For instance, developers 
will want to be granted the highest possible reimbursement price whilst payers will want the lowest 
reimbursement price for the most effective intervention. Patients are also another stakeholder, their 
perspective (particularly in national healthcare systems) is to have access to the most effective 
interventions136,187,191. With all these different and at times conflicting stakeholder perspectives to 
consider, models need to be as informative and transparent as possible so that all parties are able to infer 
relevant information for their decision-making processes. 
 
2.4.3. Health economics model and concepts summary  
 
The above sections highlight just some the key aspects of health economics analysis and decision 
models. It is evident that this is a complex endeavour with many sources of uncertainty in terms of the 
data utilised. For instance, in most evaluations, meta-analysis of similar trial data or data extrapolation 
is used when the intervention being compared has limited efficacy data, which may not be an accurate 
representation of the intervention. This is an even greater drawback in evaluations of cell and gene 
therapies as there is often no similar trial data to use or the sample sizes used are small in comparison 
to drug trial data. Therefore, sensitivity analysis of the input data used for evaluations must be carried 
out to ensure the results are robust and useful for decision making.  
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In general, health economic evaluations are carried out in the latter stages of the product development 
process as accumulated efficacy data through the development timeline can be used. This results in 
early health economic evaluations being a futile task as there is not enough evidence generated in the 
preclinical stages to ascertain the clinical effectiveness of a product. Thus, there is insufficient data to 
populate the models to run credible analysis of the intervention.  As a result, developers to do not have 
the ability to provide estimations at an early stage of the commercial viability and reimbursement 
potential of their product using traditional HTA methods. 
 
2.4.4. Headroom method  
 
The ability to obtain information about a product’s reimbursement potential at an early stage would be 
a powerful tool for developers to use during their product development. Early economic evaluations 
can allow developers to make more informed decision about costs, pricing and market selection that is 
in line with the payer needs, making their product better placed for reimbursement and adoption. 
Furthermore, by carrying out early economic analysis and market selection developers can provide 
investors with estimates of the potential gross profits that they can expect. 
 
If a product is deemed to not be commercially viable at an early stage, then it would be advisable to 
terminate further development or carry out more research. This would save costs further down the 
development timeline, rather than getting to a stage where a product gets regulatory approval after all 
the cost of clinical trials and development, only to be deemed not cost-effective and to be not 
recommended for adoption and reimbursement. This is a fate that has been suffered by cell and gene 
therapies; such as Uniqure with their product Glybera, which achieved regulatory conditional 
approval26,221. However, it was not deemed adoptable by payers due to the high price of €1,000,000 per 
dose, even under the promise of the treatment being a one dose therapy it was removed from the 
market26,221.  
 
The headroom method is a tool that can be used to determine the maximum potential reimbursement 
price of a new product at an early stage. The headroom method incorporates the demand and supply 
aspect the product. Therefore, it can be used to forecast potential revenues, as it is possible to predict if 
the developers can produce the product at the given imbursement price and development/manufacturing 
cost186,192. As such the headroom method is an early economic evaluation tool that can be used by 
developers to determine if they should proceed or abandon products based on their commercial viability. 
It is worth noting that headroom method analysis is only predictive and therefore should be used as tool 
amongst other considerations, such as the potential to expand into other areas, other non-health related 
preferences and the clinical and market context of the product182,184.  
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There is a wide range of literature based concerning the use of headroom methods, although this tends 
to be heavily focused on the area of medical devices, however the concepts and principles can be applied 
to CTPs186,192,222. The addition of information about future deviations of outcomes into the headroom 
calculations provides more realistic conclusions as it takes into account the non-linearity of inputs and 
outcomes over time 136,220. However, there are limitations as some of the fundamental inputs, such as 
the QALYs, WTP (sometimes) and the expected improvement in clinical performance, can only be 
capriciously assumed because of the uncertainties associated with an undeveloped product or 
technology, particularly in the CTPs industry220,223,224. Thus early evaluation models need to be done 
iteratively as more data is obtained, in order to become more robust so that the business models of CTP 
can facilitate confidence in the commercialisation of CTPs174. 
 
Research and models that combine the headroom method and gross profit have been developed, this 
combination produces “a feasible, useful, and informative tool for assessing the potential commercial 
viability of medical devices under development”186. The advent of economic evaluation in CTPs has 
led to such innovative methods to try and provide information as early as possible. Much of these 
analyses rely on accruing as much information both scientific and economic/commercial, as often 
possible, so that they can be as accurate as possible in their projections. However, it is important to 
consider that, the results are typically based on estimations and assumptions, particularly for CTPs were 
surrogate data is not readily available. Thus due diligence needs to be taken when choosing input 
sources for data, relevant and reliable sources must be sought after to ensure that the resultant outcomes 
are dependable for decision making purposes186. 
 
Using methods of analysis such as those mentioned above it is possible to predict the saleability and 
adoption potential of the product by the various healthcare providers. For instance, the cost-
effectiveness plane, obtained from ICER results, can be used as quick tool to visualise the likelihood of 
the product (s) being adopted. The ideal situation for a new therapy in a competitive market would need 
to be in the lower right quadrant (Figure 13D), as it means that the therapy is more effective and 
economic in comparison to other options and the gold standard. For CTPs this a currently a difficult 
quadrant to enter as costs are currently very high for most CTPs thus, they tend to be found in the top 
right quadrant (Figure 13B). A major challenge for the CTI is to reduce costs to allow for favourable 
reimbursement and adoption of CTPs 186. The value of health economic evaluations is the information 
it provides for investors and payers alike. For developers being equipped with the concepts HTA and a 
firm understanding of their product, its costs and health outcomes should set them up to be in a position 
to successfully traverse through the reimbursement pathway. 
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2.4.5. Health Economics in the context of PD  
 
There some nuances when carrying out health economic evaluations for CTPs compared to 
pharmaceutical or other interventions. This is because clinically, there is limited information regarding 
the long-term effects of CTPs and unlike pharmaceuticals, surrogates and trial data do not yet readily 
exist for CTPs as previously mentioned. Health economic evaluations for other PD interventions such 
as anti-Parkinsonian medication have been carried out39,69,206, however there is a lack of economic 
considerations from the CTPs interventions that are currently being developed. Current therapeutic 
medication does not result in significant improvements to quality of life in the long term, whereas cell 
therapy treatments have the potential to significantly restore native DA neuronal function and greatly 
improving  patient quality of life24,40,225. As a result, cell replacement therapies have the potential to be 
highly effective and potentially cost-effective in cases where the patients are alleviated from symptoms, 
increasing their quality of life therefore negating the use of antiparkinsonian medication and 
rehabilitation.  
 
As PD affects many people around the world it represents a high economic burden due to inpatient care 
(hospital and rehabilitation), outpatient care, antiparkinsonian medication and both formal and informal 
care, all of which are considered to be direct costs of PD41,70. The cost of treating PD varies from country 
to country due to differences in healthcare systems. Western countries on average spend more money 
on managing PD as higher percentages of their health budgets are spent on the geriatric population. 
Different countries cover different aspects of the PD management, in national healthcare systems such 
as the UK, the direct costs are absorbed by the healthcare provider. While in more privatised systems 
such as the United States of America (USA) these costs are absorbed through private health insurance 
or by the patient directly, out of pocket69. These costs have a significant economic impact, in a US study 
of over 40,000 people, it was found that people with PD had over double the direct costs per year 
associated with their health costs in comparison to people without PD226. With adjustment for 
comorbidities and demographics PD patients had costs of $23,101 whilst those without PD were 
$11,247226. 
 
Comorbidities and loss of productivity represent some of the indirect costs that are associated with PD70. 
These costs are incurred due to PD rendering patients incapable of carrying out their daily routines and 
lowering their quality of life, which requires patients to have assistance, particularly at the mid to late 
stages of the disease. The cost of care therefore makes up a large part of the overall cost of PD41,69. For 
instance, institutional and professional care attribute to increased overall cost of managing PD, reported 
to be 4.5 times higher than people who do receive care at home69. Various studies have evaluated the 
costs and economic impact of PD, typically the cost percentage distribution is similar between studies. 
However, the actual costs do differ, as mentioned above costs can vary between regions and countries, 
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which also the case in PD70. A study by von Campenhausen et al (2011) highlights that there are 
considerable differences in PD treatment costs even between European/Western countries70. As a result, 
this will affect reimbursement depending upon the country, however it can be inferred that 
reimbursement would be higher in western countries due to higher life expectancy and greater 
prevalence of PD. Therefore, such countries and their healthcare systems would greatly favour therapies 
such as CTPs that can slow down the disease and reduce costs, potentially for  up to 24 years71. Work 
by Keranen et al (2003), illustrates that costs in PD do increase over time, the more severe the disease 
the costlier it becomes. Therefore, attenuation of the disease is a suitable way of reducing the overall 
costs and increasing patient QoL41. 
 
As discussed previously DALYs can be used for ICER analysis as they represent changes in disease 
burden, for PD the database is formed from retrospectively collected clinical information from a diverse 
PD population. This provides valuable and robust input data for modelling the transition from one 
Hoehn & Yahr (H&Y) stage to the other that can be linked to observed or modelled cost. Therefore, it 
is possible to produce decision models that are more dynamic as the data is based on real occurrences, 
making it possible to realistically assess a patient’s time-period at a particular stage of PD. This can 
provide valuable information about the effectiveness of an intervention across the different stages of 
PD, allowing decision makers to evaluate when the intervention is most cost-effective. The data can 
also be used as a source of transition time and quality of life input for modelling purposes. This can 
provide information about the variability in costs and quality of life produced by an intervention based 
on how long a patient spends in a particular health state195. 
 
2.4.6. Considerations for developers  
 
In any product development process obtaining approval from regulatory bodies such as the FDA and 
EMA are considered to be key milestones. However, further to this, developers have to traverse an 
adoption and reimbursement pathway; this is typically not considered until the later stages of 
development (Figure 11). Failure to consider this pathway can be extremely detrimental to the program 
progression and developers must consider additional time and funding to adequately provide the 
evidence that is required by the payer for adoption and reimbursement. This section briefly highlights 
key considerations for developers, in addition to the early commercial evaluation and analyses discussed 
previously in this chapter, and challenges that must be addressed in order to have an approved, adopted 
and reimbursed product. This is ultimately the end goal for any developer as they need to recuperate 
product development/manufacturing costs and have their product reach the patients to provide benefits.  
 
 Evidence is a key barrier that must be addressed as part of the commercialisation strategy; this is related 
to efficacy and safety evidence as shown in the clinical trials. Furthermore, evidence of long-term 
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clinical effects is required to justify the use of an intervention that is procured by the payer. While safety 
and efficacy are sufficient evidence for regulators, these criteria are not enough to satisfy payer 
requirements; payers are required to make decisions regarding funding interventions under significant 
fiscal pressures. Ideally, all intervention options would be provided to those in need but given the finite 
budget of healthcare services including the NHS, decisions have to be based upon cost-effectiveness 
and overall value. Therefore, for payers the key considerations alongside safety and efficacy are cost, 
value and comparable performance. Payers look for new interventions/technologies that decrease 
overall costs and alleviate their budgets while providing quality and value to the patients. How well a 
new intervention compares to the current gold standard and its usability given the current infrastructure 
are also significant adoption and reimbursement considerations.    
 
If a developer is able to prove that their product meets the aforementioned considerations, there are still 
further translational barriers to overcome, particularly if the intervention is different from the current 
standard. Administrators would need understand how the new intervention would be implemented, 
budgeted for, where the money would come from within the current budget to pay for it, what currency 
codes would be applied, or if new codes need to be created (currencies and code are discussed in a later 
section - 7.1.1.3. The NHS payment and reimbursement system.). Another challenge is overcoming the 
dogma of current standards of care, developers need to have advocates for their interventions so that 
they are successfully adopted and utilised. Resistance to new interventions can result in product failure. 
Therefore, when traversing the adoption pathway, it is important to have key opinion leader (KOLs) on 
side and to engage with them as early as possible once the clinical need has been identified. Failure to 
anticipate and consider such aspects during early development stages will most certainly result in failure 
since resources and time will both have diminished, making late-stage changes nearly impossible to 
implement. By having early economic considerations and a defined adoption pathway as part of the 
development process, developers can be equipped with the translational tools they need to tackle the so 
called “commercialisation valley of death”.  
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Chapter 3. Materials and Methods  
 
3.1 Introduction  
 
This chapter provides details of the fundamental methods utilised in the present work. Due to the 
optimisation and process development nature of the work, deviations have been made in some 
experiments, where they differ to the methods described here; the exact methods used are stated within 
the methods employed section of each chapter. Protocol standardisation is an important element of this 
project in order to produce protocols that are translatable, therefore steps have been described in detail 
to minimise sources of error and variation. All reagents and consumables were obtained from Fisher 
Scientific, UK unless otherwise stated 
 
3.2. Cell culture  
 
Two cell lines were used within this work: EC 2102Ep and H9s. EC 2102Ep (GlobalStem, USA) are 
an embryonic carcinoma cell line provided by the National Institute for Biological Standards and 
Control (NIBSC). H9s (WiCell, cat# hPSCreg WAe009-A) is a human embryonic stem cell line 
obtained from WiCell Research Institute, Incorporated. All cell work and medium formulations were 
performed in a class II biological safety cabinet (BSC) using aseptic technique.  
 
3.2.1. Culture Medium 
 
Different media formulations were used to culture each cell line, H9 medium formulations differed for 
the expansion and differentiation process respectively. The formulations are described in the following 
sections.   
 
3.2.1.1. Media formulation  
 
3.2.1.1.a. EP growth medium  
 
For the culture of EC 2102Ep cells, Gibco Dulbecco’s Modified Eagle Medium (DMEM) high glucose 
with GlutaMaxÔ (cat#10569010), supplemented with Foetal Bovine Serum (10% v/v, cat#10100139) 
herein referred to as EP growth medium was prepared. 
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3.2.1.1.b. Wash medium 
 
A wash medium was prepared using an appropriate amount of 10 % (wt/vol) Human Serum Albumin 
(Irvine Scientific, USA, cat#9988) added to DMEM/F12 for a final concentration of 1% v/v HSA. This 
medium was used for wash steps and resuspension of H9 cells upon resuscitation from cryopreservation.  
 
3.2.1.1.c. H9 expansion medium 
 
The expansion of pluripotent H9 cells was carried out using StemMACS™ iPS-Brew XF (cat# 130-
104-368) supplemented with 10 mL of StemMACS™ iPS-Brew XF supplement (50X) to produce the 
medium herein referred to as H9 expansion medium. 40 mL aliquots of the H9 expansion medium were 
prepared and stored at -20 °C for up to eight weeks. Aliquots were thawed prior to use overnight at 4 
°C, thawed aliquots were then stored 4 °C in between use, for up to fourteen days. 
 
3.2.1.1.d. N2 base medium 
 
For the differentiation of H9s a medium herein referred to as N2 basal medium was prepared at the start 
of the differentiation process and used for medium exchange on day 2, 4, 7 and 9 (Table 4). A range of 
small molecules were added into an aliquot of the N2 basal medium on the days of the medium 
exchange, details of which can be found in section 3.2.1.1.f. This medium was used for neural induction 
and patterning towards a ventral mesencephalic cell fate. 40 mL aliquots of the N2 basal medium were 
prepared and stored at 4 °C for up to two weeks.  
 
Table 4. Components used in the N2 base medium formulation. 
 
  
Reagent Concentration (% vol/vol) Supplier 
DMEM/F-12 49 Invitrogen 
Cat# 21331-020 
Neurobasal CTS 49 Life Technologies
Cat# A13712-01 
N2 Supplement 1 Life Technologies 
Cat# A13707-01 
L-Glutamine 1 Invitrogen 
Cat# 25030-081 
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3.2.1.1.e B27 base medium 
 
Akin to the N2 base medium prepared in section 3.2.1.1.d., a medium herein referred to as B27 base 
medium was prepared as a stock for use during the replating and medium exchange on day 11 (Table 
5). A range of small molecules were added into an aliquot of this medium on day 11 and 14, details of 
which can be found in section 3.2.1.1.f. This medium was used to pattern the early caudal ventral 
mesencephalic progenitors into late stage caudal ventral mesencephalic progenitors. 40 mL aliquots of 
the B27 base medium were prepared and stored at 4 °C for up to two weeks. 
 
Table 5. Components used in the B27 base medium formulation. 
 
3.2.1.1. f.  Differentiation Media  
 
The differentiation process used three different formulations split into sections: 
• Day 0 to 7 (N2 differentiation medium), 
• Day 9 (FGF-8 N2 differentiation medium), 
• Day 11 to 14 (B27 differentiation medium).  
The formulations are specific as they support the cells at their different stages of differentiation. Details 
of the roles of the small molecules are discussed in section 6.1.1.1. 
  
Reagent Concentration (% vol/vol) Supplier 
Neurobasal CTS 97 Life Technologies
Cat# A13712-01 
B27 Supplement 2 Life Technologies 
Cat# A12587-010 
L-Glutamine 1 Invitrogen 
Cat# 25030-081 
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Table 6. Components used in the media formulation for the differentiation process. Table details the 
small molecules added at specific time points of the process. * An appropriate volume for the conditions 
being cultured was used. ** Y-27632 is a RHO kinase (ROCK) inhibitor that increases cell survival 
following dissociation, therefore it was added only at day 0 seeding and on day 11 for the replating.  
 
 
 
3.2.2. Coating flasks  
 
The adherent nature of the cells requires them to be cultured on a surface, for the H9 cells a feeder-free 
and xeno-free natural cell niche is obtained by coating tissue culture treated vessels with human 
recombinant laminin protein.   
 
Tissue culture plastic (TCP) were coated with Biolaminin-521 (cat# LN521, Biolamina, Sweden) for 
H9 expansion or Biolaminin-111 (cat#LN111 , Biolamina, Sweden) for differentiaton, diluted with 
phosphate buffered saline with calcium and magnesium (PBS+/+) at a coating density of 0.5 μg/cm2 or 
Time point Reagent Concentration Supplier 
Day 0, 2, 4 and 7
N2 
differentiation 
medium  
N2 base medium * Prepared as described in section
2.2.1.1.d.
SB431542 (TGFβ inhibitor), StemMACS
GMP
10 µM Miltenyi Biotech, Cologne,
Germany cat# 130-106-543
Recombinant human Noggin, StemMACS
GMP
100 ng/ml Miltenyi Biotech, Cologne,
Germany cat# 130-103-456
CHIR99021 (GSK3 inhibitor), StemMACS
GMP
0.7 µM Miltenyi Biotech, Cologne,
Germany cat# 130-106-539
Human Sonic Hedgehog C24II, StemMACS
GMP,
300 ng/ml Miltenyi Biotech, Cologne,
Germany cat# 130-095-727
Y-27632 StemMACS GMP ** 10 µM Miltenyi Biotech, Cologne,
Germany cat# 130-106-538
Day 9 
FGF-8 N2 
differentiation 
medium
N2 medium * Prepared as described in section
2.2.1.1.d.
Recombinant human FGF-8b, Premium 
grade
100 ng/ml Miltenyi Biotech, Cologne, 
Germany cat#  130-095-740 
Day 11 and 14
B27 
differentiation 
medium
B27 base medium * Prepared as described in section
2.2.1.1.e.
Recombinant human FGF-8b, Premium
grade
100 ng/ml Miltenyi Biotech, Cologne,
Germany cat# 130-095-740
Recombinant human BDNF, GMP 20 ng/ml Miltenyi Biotech, Cologne,
Germany cat# 130-096-286
Ascorbic Acid (Tocris 4055) 0.2 mM Sigma A4403-100MG
Y-27632 StemMACS GMP ** 10 µM Miltenyi Biotech, Cologne,
Germany cat# 130-106-538
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1 μg/cm2, respectively. Biolaminin 521 is used for pluripotent expansion as it is the natural laminin for 
pluripotent cells, whereas Biolaminin-111 is used of the differentiation process as it supports neural 
differentiation while disfavouring pluripotent growth. The laminin/PBS coating solution was added to 
the TCP and incubated at 37°C for 2 h, prior to seeding the cells. Following 2 h the coating solution 
was aspirated and the appropriate medium was added to prevent drying of the coating. 
 
3.2.3. Thawing 
 
Prior to thawing the appropriate basal medium was warmed using a water bath (Sub Aqua 26 Plus, 
Grant Instruments) at 37 °C for a minimum of 20 min. Cells were thawed from cryopreservation by 
placing the cryovial at the front of the middle shelf of an incubator (Panasonic, MCO-17MUVH-PE) 
set at 37°C, 5% CO2 for 7 min or until thawed. A 1000 μL pipette was used to transfer the cell suspension 
dropwise into a 15 mL centrifuge tube. The cryovial was then washed twice with 1 mL basal medium 
to ensure maximum cell retrieval. The resulting cell suspension was centrifuged for 5 min at 350xG 
(Sigma Laboratory Centrifuges, 3-15). 
  
To avoid dislocation of the pellet, the supernatant was carefully removed using an aspirator and pump 
(Welch, 2511 Dry Vacuum Pump). 1 mL of fresh pre-warmed medium (as appropriate to the cell line) 
was added to the pellet using a 1000 μL pipette; the pellet was resuspended by gently pipetting the 
solution up and down 10 times whilst avoiding bubble formation. An additional 4 mL of fresh medium 
was added to cell suspension, giving a total volume of 5 mL cell suspension for all cell counting and 
seeding. 
 
3.2.4. Standard culture  
 
After thawing a cell count was carried out to obtain the volume required to seed at the desired density 
(cell counting procedure is detailed on page - 75 -). The required volume was then transferred to a tissue 
culture vessel using an appropriately sized pipette, the cells were agitated and rocked gently in all 
directions to ensure even distribution across the culture surface. The methods described below are the 
standard conditions and parameters used to culture the cells, any deviation from the described methods 
are noted in the relevant chapters.  
 
3.2.4.1. EP2102 expansion 
 
All reagents/consumables were obtained from Fisher Scientific, UK unless otherwise stated. EC 2102Ep 
cells were thawed and cultured at 37°C, 5% CO2 using EP growth medium (3.2.1.1.a.). For standard 
culture, cells were subjected to a medium exchange following 48 h and passaged following 72 h.   
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3.2.4.1.a. Cell passage  
 
The procedure described here was followed to carry out a standard cell passage. EP growth medium, 
and Trypsin- Ethylenediamine tetracetic acid, 0.25 % (EDTA) (Thermo Scientific, UK, cat#25200072) 
were pre-warmed in the water bath at 37 °C for at least 20 min. The cells were microscopically (AMG, 
EXOS x1) inspected for growth, contamination and attachment before transferring to BSC. The spent 
medium was aspirated, and the cells were washed with PBS (-Ca2+/-Mg2+), 250 µL/cm2. The PBS was 
aspirated and 40 µL/cm2 Trypsin-EDTA was added to the culture vessel which was rocked gently to 
ensure the cells were submerged prior to incubation for 5 min at 37 °C, 5% CO2. Following 5 min the 
cells were observed under the microscope to check detachment from the culture surface, signified by 
the cells rounding up. Wash medium was added at twice the volume of Trypsin-EDTA used, the surface 
of the culture vessel was flushed using a stripette 5 times before transferring the cells into an 
appropriately sized centrifuge tube i.e. 15 mL tube for volumes under 12 mL. The cell suspension was 
centrifuged for 5 min at 300xG. Following centrifugation, the supernatant was aspirated off ensuring 
that the pellet was not disturbed. The pellet was broken down by adding 1 mL EP growth medium to 
the cells and pipetting up and down 10 times using a 1000 µL pipette. A further 4 mL of EP growth 
medium was added. A sample of the cell suspension was taken for cell counting. From the cell count, 
the total live cell number was determined and used to seed the cells at a density of 66,667 cells/cm2 
with 200 µL/cm2 of EP growth medium. The culture vessel was manually rocked in all directions to 
yield homogenous plating of the colonies and then placed in an incubator set at 37 °C, 5% CO2. 
 
3.2.4.2. H9 Expansion: Standard culture route  
 
H9 cells were thawed from cryopreservation and cultured on Lamin-521 coated plastic-ware at 37°C, 
5% CO2 using H9 expansion medium with addition of ROCK inhibitor (10 µM) at every passage point. 
The standard expansion culture routine subjected the cells to a medium exchange every 24 h and a 
passage following five days (120 h) upon thawing and four days (96 h) for routine expansion culture.  
 
3.2.4.2.a. Cell passage  
 
The passaging of the H9 cells followed the same protocol as the EC 2102 Ep cells with the exception 
of H9 growth medium and wash medium replacing the EP growth medium and EDTA was used at the 
dissociation agent instead of Trypsin-EDTA. The wash medium was used to carry out the wash and 
resuspension steps prior to cell counting. The cells were seeded at a density of 10,000 cells/cm2 on a 
Biolaminin-521coated culture vessel with 250 µL/cm2 of H9 growth medium. The culture vessel was 
manually rocked in all directions to yield homogenous plating of the colonies and then placed in an 
incubator set at 37 °C, 5% CO2.  
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3.2.4.3. H9 Differentiation 
 
TCP was coated with Biolaminin 111 as described in section 3.2.2  at a density of 1 μg/cm2. Cells were 
harvested following two passages of H9 expansion culture and cultured under standard conditions 
(37°C, 5% CO2) using N2 differentiation medium with ROCK inhibitor. A combination of small 
molecules ( Table 6) was added on each day of medium exchange. This medium was used to seed the 
cells on day 0 and for medium exchange on day 2 (250 μl/cm2), day 4 (300 μl/cm2) and day 7 (350 
μl/cm2). On day 9 the medium was changed to the FGF-8 N2 differentiation medium (400 μl/cm2). The 
B-27 differentiation medium (Table 6) was used to replate the cells on day 11 (600 μl/cm2) with ROCK 
inhibitor and for medium exchange on day 14 (Figure 16).  
 
  
Figure 16. Schematic of the different media compositions used in the differentiation process.   
3.2.4.3.a. Replating 
 
The procedure used to replate the cells on day 11 and to harvest the cells on day 16 is described in 
section 3.2.4.3.a (page - 72 -) with the following changes implemented. The use of EDTA was replaced 
with the dissociation agent Accutase (Thermo Scientific, UK, cat#A1110501) for 10 min at 37°C and 
5% CO2, B27 base medium was used in place of N2 differentiation medium on day 11 
 
3.2.5. Cryopreservation:   
 
Cells were harvested and counted prior to resuspension in a solution comprised of CryostorÒ CS10 
(cat#C2874-100ML, Sigma Aldrich, UK) and growth medium (10% v/v) to obtain a cell suspension of 
6x106 cells/mL for EC 2102Ep cells. For H9 cells, StemMACS Cryo-Brew (Miltenyi Biotech, Germany, 
cat# 130-109-558) was used to obtain a cell suspension of 1x106 cells/mL. 1 mL aliquots of cell 
suspension were aseptically transferred into cryogenic vials (Corning, USA, cat#430659) and stored in 
a Mr Frosty CoolCell® passive cooling device for 24 h at -80°C before being transferred to the vapour 
phase of liquid nitrogen where they were stored prior to experimentation.  
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Cell counting  
 
3.3.1. NucleoCounter® NC-3000™ 
 
The NC-3000™ automated image cytometer (Chemotec, Denmark) was chosen as the method of 
performing cell counts as it reduces human bias. Fluorescent dyes are used to label and image cells for 
automated image analysis, this permits analysis of characteristics including cell number, average cell 
diameter and cell aggregation levels. Furthermore, the software autonomously performs cell viability 
counts and calculations using validated algorithms. The use of commercially available reagents, 
cassettes and slides significantly reduces errors in sample manipulation and loading. As such, the NC-
3000™ was used for all counts since reproducibility and standardisation are fundamental aspects of the 
experimentation process in the present work. Traditional counting methods such as the use of a 
haemocytometer would not be able to achieve the same levels of reproducibility and standardisation, 
particularly between different operators. Furthermore, the software is formatted to alert the user if 
sample volumes at are out of the optimal range for accurate cell counts, ensuring reliable and 
standardised cell counts. The data is rapidly processed by the computer and results can be collected in 
a range of formats for analysis, including CSV, FSC and PDF reports.  
 
Cell counts and viability were measured using the Cell Viability and Cell Count assay which utilises 
acridine orange base N,’,N’,N'-tetramethylacridine-3,6-diamine monohydrochloride (AO) uptake an’ 
4',6-diamidino-2-phenylindole dilactate (DAPI) exclusion. AO and DAPI work by staining the entire 
cell population and the non-viable cells, respectively. AO and DAPI are spectrally and biologically 
different dyes; AO is a cell permeable dye that binds to cellular material resulting in green fluorescence. 
DAPI strongly binds to adenine-thymine rich regions of DNA that results in blue fluorescence. 
Although DAPI is cell permeable, at low concentrations (such as in this case) it is inefficient at passing 
through intact membranes. Therefore, it strongly interacts with dead cells making it a good candidate 
for determining the number of non-viable cells. The assay counts can be accurately performed with low 
sample volumes which is advantageous when working with precious or limited samples. 
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3.3.1.1 Via1-Cassette™ 
 
Vial-Cassettes™ are calibrated single use cassettes that provide high precision cell counts (Figure 17). 
A sample is loaded by submerging the cassette tip into the cell suspension and depressing the piston, 
this action creates a vacuum that reliably and precisely draws the sample into mixing channels that are 
pre-loaded with AO and DAPI. Once the sample has passed through the channels, the cassette is inserted 
into the NucleoCounter® NC-3000™. The piston is automatically depressed further by the machine to 
deliver the now stained sample into the measuring chamber were the cells are imaged and analysed. 
The analysed sample volume is 3.2 μL. 
 
Figure 17. Image of a Via1-Cassette™ from Chemometec detailing the different components of the 
cassette. Image sourced from NC3000 ™ product brochure227   
 
3.3.1.2. NC-Slide A8 ™ 
 
NC-Slide A8 (Figure 18) use the same principles as the Via1-Cassette™ in terms of the use of AO 
uptake and DAPI exclusion to determine cell number and viability. However, the method differs from 
the Vial-cassette in that the slides are not pre-loaded with fluorescent dyes. Therefore solution 13 
(Chemotec, Denmark, cat#9103013), a commercially available reagent (pre-mix of AO and DAPI) is 
mixed into the cell suspension at a ratio of 1:19 e.g. 10 µL of solution 13 added to 190 µL of cell 
suspension. 10 µl of the solution is then manually pipetted into each of the 8 individual chambers using 
a 20 µL sterile tip. Each slide chamber can be used to analyse a different sample, allowing for high 
throughput cell counting to be performed in a single run. The loading chambers are optically clear, 
allowing for the cells to be imaged and analysed based on their interaction with solution 13 and the 
resultant fluorescence signals.  
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Figure 18.  Image of the NC-Slice A8 ™ showing the 8 chambers that can be used to load the sample 
onto. Each chamber holds 10µL and an average of 2 chambers are required to gain an average count. 
Image sourced from NC3000 ™ product brochure227   
3.3.2. Procedure and sample preparation  
 
Following resuspension with 1 mL of the appropriate medium post centrifugation, the pellet of cells are 
gently pipetted up and down 10 times using a 1000 μL pipette. This step is performed to obtain a 
homogenous cell suspension that is as close to single cells as possible. The suspension is then further 
diluted with an additional 4 mL of the appropriate medium to obtain a stock cell suspension. For 
standard cell counting a sample of the stock cell suspension is taken and added in to a 1.5 mL Eppendorf 
tube, the sample volume used depended of the whether a slide or cassette was used. The sample was 
then vortexed (Barloward Scientific, Stuart Vortex Mixer) for three seconds, then pipetted up and down 
a further 10 times using a 20 μL pipette prior to mixing with Solution 13 for A8 slide counts or being 
loaded into a cassette. This procedure was adhered to for all counts performed as a means of 
standardising the cell counting protocol within the present work. 
 
For Via-1 cassettesä (Chemotec, Denmark, cat#942-0011), a 200 μL cell suspension is added to a 1.5 
mL Eppendorf tube, vortexed for three seconds, pipetted using a 10 μL pipette and then loaded into the 
Via-1 cassetteä prior to analysis on the NucleoCounter® NC-3000™. Via-1 cassetteä were used for 
counts with less than eight samples. For counts with more than eight samples the NC-Slide A8 ™ slides 
(Chemotec, Denmark, cat#942-0003) were used instead. For the slides a 190 μL cell suspension is added 
to a 1.5 mL Eppendorf tube and mixed with 10 μL of Solution 13. This mixture was vortexed three 
seconds and then pipetted up and down ten times with a 20 μL pipette prior to loading into each chamber 
of the slide to breakdown the cell aggregates. A volume of 10.7 μl was used to load each chamber, as 
this was the most suitable volume to ensure coverage of the whole chamber and no air bubble formation, 
two chambers were used for each count of a condition.  
  
 - 76 - 
 
The results were used to obtain the specific growth rate (µ) and Population Doublings (Pd) following 
Equation 2 and Equation 3 published by Heathman et al., 2015228. 
 
SGR value (µ) = FG(HI(J)/HI(L)∆J  
Equation 2 
Where µ is the net specific growth rate (h-1), Cx(t), and Cx(0) are cell number at the end and start of the 
exponential growth phase, respectively and t is time (h).  
 
Population Doubling, (Pd) = NFOP	(R) ∙ ;,2 HI(J)HI(L) 
Equation 3 
 
Where Cx(t), and Cx(0) are cell number at the end and start of the exponential growth phase, 
respectively. 
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3.4. Cell metabolite analysis 
 
Metabolite analysis can be used in manufacturing processes as a means of quality control since the 
levels of analytes such as lactate and lactate dehydrogenase (LDH) produced are putative indicators of 
glucose consumption rates and cell viability, respectively.  
 
3.4.1. Cedex Bio HT Analyzer (Roche)  
 
The Cedex Bio HT Analyzer (Roche) is an automated high throughput bio-analyser that was used to 
determine the levels of a wide range of metabolites/analytes (Figure 19). This allows a user to 
understand the metabolic profiles of the cells from the spent medium. This system is capable of the 
analysis of electrolytes, carbohydrates, amino acids, specific proteins and enzyme activities, all on a 
single system. 
  
There are a variety of different assay tests available that can be used to determine metabolite 
concentration levels; the assays require simple setup, whilst being automated, precise and capable of 
highly accurate reaction experiments; thus allowing for reliable and reproducible results. In addition, 
the system requires minimal manipulation from the user as it has an automated dilution function and 
programmed reagent mixing which minimises the risk of user error. This makes the Cedex an 
indispensable tool for metabolite analysis during process development. Furthermore, the system 
operates in a high throughput manner, with the capacity of loading 90 samples at any one time and 
running up to 200 individual tests per hour. Sample volumes as low as 2 µL can be used, permitting the 
same sample to be used for multiple assays.  
 
To determine analyte concentrations the Cedex uses enzymatic photometric assays; a range of reagents 
appropriate for the analyte of interest are pre-loaded into the commercially available cassettes.  Assay 
tests are performed by mixing the sample and the appropriate reagent cassette using the Cedex’s two 
built-in probes which are capable of sampling intervals of 10.6 seconds (Figure 19 A and B). The 
sample and assay reagent products are delivered to the photometric module where they are analysed, 
concentrations are determined by the absorbance (endpoint or kinetic) of the reaction products. The data 
is recorded on a control unit computer, which can flag test results that are outside of the calibration and 
quality control limits set on the machine. This data can be reviewed, re-run, accepted or declined; 
accepted data can be collected for further analysis as a CSV file which includes all the test result and 
details. 
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Figure 19. Depiction of the Cedex Bio HT instrument showing the main aspects. (A) Cassette rack with 
reagent cassettes. (B) Sample rack with samples in the holder chimneys. (C) Ion Sensitive Electrode 
(ISE) rack with ISE solutions, cleaners and diluents. (D) Reservoir for new cuvettes. (E) Disposable 
waste box for used cuvettes which is autoclavable. (F) Connections to the water and waste are at the 
rear panel, not shown in the image. (G) Data connectors that feed information to the computer control 
unit. Imaged sourced from Cedex Bio HT User Manual229.  
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3.4.2. Sample preparation  
 
Spent media samples, 500 µL, were collected in 1.5 mL Eppendorf tubes then stored at -20°C. Prior to 
analysis, samples were thawed at room temperature (RT), vortexed for five seconds and loaded into the 
sample rack prior to loading on the machine (Figure 19B). The samples were analysed for either 
glucose, lactate, glutamine, ammonia, lactate dehydrogenase or any combination of these metabolites, 
using the Cedex Bio HT Analyzer (Roche, Germany). The results were used to obtain the Specific 
Metabolite Rate mmol.cell-1.d-1 (SMR) following Equation 4 published by Heathman et al., 2015228. 
 
Specific metabolite rate (SMR) = ! "#$(&)( ∙ !#*+,	(.)	–	#*+,	(&)01,23 ( 
Equation 4 
 
Where SMR is the net specific metabolite consumption or production rate, 4  is specific growth rate (h-
1), Cx(0) is cell number at the start of the growth phase, Cmet(t), and Cmet(0) are the metabolite 
concentrations at the end and start of the exponential growth phase, respectively and t is time (hours). 
 
3.4.3. Metabolite test assays  
 
This section uses a glucose assay as an exemplar to explain the principles of the CEDEX test assays. 
Although each analyte is measured with different reagents in an analyte specific cuvette, the principles 
of the assays are the same in that they use a catalyst to react the analyte with other reagents, resulting 
in a product that is measured photometrically.   
 
The Glucose Bio HT cassette (cat#06608418001) contains adenosine triphosphate (ATP), hexokinase 
(HK), Mg2+, nicotinamide adenine dinucleotide phosphate (NADP), glucose-6-phosphate 
dehydrogenase (G-6-PDH), 2-(N-morpholino) ethane sulfonic acid (MES) buffer and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES buffer).  
 
A reaction between glucose and ATP is catalysed by HK producing glucose-6-phosphate (G-6-P) and 
ADP as a by-product, as shown in (Equation 5). The G-6-P is then oxidised by NADH in the presence 
of G-6-PDH to form gluconate-6-P, a hydrogen ion and NADPH. Glucose concentration determination 
is directly proportional to the rate of NADPH formation which is measured by UV-photometry.  
 
 - 81 - 
 
 
Equation 5 
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3.5. Cell phenotyping  
 
3.5.1. Flow cytometry  
 
Flow cytometry is one of the most prevalent means of particle characterisation, the technology is 
commonly laser light based. Flow cytometry is used to analyse the properties of individual particles, 
including cells within a heterogeneous population of cells230,231, which is the focus of this work. As a 
technique flow cytometry is a quantitative mode of analysis which can distinguish individual cells based 
on properties such as cell shape, size and fluorescence. Flow cytometry offers a comparably quicker 
mode of cell characterisation in comparison to real-time polymerase chain reactions (RT-qPCR), 
furthermore it can be used to simultaneously measure multiple parameters in a comparably more 
quantitative manner than immunocytochemistry (ICC) microscopy.  
 
In principle, cell-laser light interactions and label-laser interactions are used to measure properties such 
as cell size/complexity and protein expression (phenotype), respectively. Label-laser interactions rely 
on the antibody targeting the protein of interest by bind to protein specific epitope, the antibody is 
labelled with a fluorescent marker which interacts with the laser light. Detection of a fluorescent signal 
from the marker corresponds to the presence of the target protein, under optimal conditions; detection 
of the fluorescence signal can be used to identify and quantify distinct cell populations. The fluorescent 
marker can be directly conjugated to the antibody or can be added on to the antibody through a primary-
secondary system. The ever-expanding library of antibodies and ability of a single laser to excite several 
different fluorescent markers allows for flow cytometry experiments that can simultaneously measure 
the expression of several proteins. 
  
3.5.1.1. Flow cytometer 
 
Flow cytometers are complex analytical instruments, the key components of a flow cytometer are a 
fluidics system; lasers; optics and detectors230,232. The following sections provide a brief summary of 
the role that each of these components has within a flow cytometry experiment.  
 
3.5.1.1.a. The fluidics system 
 
Fluidics are an integral component element of flow cytometry and the basis of the ‘flow’ part in flow 
cytometry, the fluidics are used for hydrodynamic focusing of the cells sample in to a single line of 
flowing cells (Figure 20). The fluids system allows for the sample to be injected into a central nozzle 
that is surrounded by an outer sheath of fluid, which is typically saline. Both the sample and sheath 
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fluid are directed towards a nozzle which increases the fluid velocity, focusing the cells into a single 
file through the Bernoulli effect230,232. Laminar flow prohibits the mixing of the sample and sheath fluid. 
  
 
 
Figure 20. Illustrative depiction of the fluidics system creating a single line of cells after the 
hydrodynamic focusing region. Once the cells are in a single file, they travel to the interrogation point 
where they interact with a light source, in this case laser light, the cell-light interact is then detected and 
processed.  
3.5.1.1.b. Lasers  
 
The lasers provide the light source in a cytometry experiment, each laser produces a single wavelength 
of light within the visible spectrum of the electromagnetic spectrum; the number of lasers varies 
dependant on the flow cytometer model and manufacturer. The point at which the flow of single cells 
interacts with the laser light is called the interrogation point, the interaction results in the individual cell 
passing through the laser (s) to scatter light and fluoresce, in the case of fluorophore labelled cells or 
cell autofluorescence. Light scattering can be in the forward or side direction; forward scattered light is 
used to determine the size of cells passing through; side scattered light is putatively linked to cell 
complexity e.g. the granularity of the cell. By combining Forward Scatter (FSC) and Side Scatter (SSC) 
cells can be distinguished in a heterogeneous population based on their size and complexity230,232. 
Fluoresce interactions detect the presence of biomarkers (surface protein or intracellular molecules) 
through fluorescently conjugated antibodies that target the biomarker of interest. The emitted light from 
Hydrodynamic 
focusing region 
Sheath 
Fluid
Sheath 
Fluid
Laser Beam
Sample
Detector 
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the FSC, SSC and fluorescence are collected by photomultiplier tubes (PMT) which amplify the signals 
of the light interactions233,234. 
 
3.5.1.1.c. Optics and detectors 
 
The light emitted from the interaction of the cell with the laser is then detected and measured using 
different channels of the PMTs. The optical filters, lens and mirrors (optics system) gather and direct 
the light that is emitted to control the specificity of the detection by the PMTs (Figure 21). The optics 
system comprises of three major dichroic filters; long pass, short pass and band pass filters, which block 
and transmit different wavelengths (either above/below a set wavelength or within a wavelength band 
width) allowing for selective light detection at the PMT detectors230,232,234. The light selectivity directs 
only specific light to the PMTs, which each PMT is set to detect i.e. forward scatter is detected by the 
FSC PMT detector and fluorescence light (FL) emitted at ~530 nm is detected by the 530 nm FL PMT 
detector; therefore, each detector measures a different parameter. The signal from the PMTs is then 
digitized allowing for quantification of the parameter being measured through the height, width and 
area values of the signal detected by the PMT. These values can be plotted for each parameter as 
histograms or dot plots allowing for analysis of population differences based on fluorescence intensity, 
size and complexity of the cell population sample.  
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Figure 21. Depiction of the optics system, showing the different detectors FSC, SSC and PMT. Left 
blue arrow (A) shows a laser beam passing through and interacting with a cell (B), which results in light 
being scattered in different directions and detected by the various detectors in the optics system Image 
sourced from Bio-Rad Laboratories234. 
 
3.5.1.2. Controls 
 
An integral aspect of flow cytometry is the use of an appropriate control to help accurately distinguish 
the target cell population and its respective protein expression. Controls help to reduce the likelihood 
of falsely identify signals as a positive reading. Unstained cells are one form of control in a flow 
cytometry experiment, these are cells being analysed in the experiment but not stained with the 
antibody-fluorophore. The lack of staining provides information regarding the background or 
autofluorescence of the cells, which allows for analytical gates to be set that can distinguish positive 
fluorescence signal from the background signal.  
 
Isotype controls are another form of control used in flow cytometry, these are antibodies that are raised 
against an antigen that is not present in the target cell population. As a result, they provide information 
of any non-specific binding, this allows for confidence that the fluorescence signal being detected is 
A
B
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due to the specific antibody interaction with the protein of interest. The same fluorescent marker is used 
for both the binding antibody and the isotype antibody to ensure that any differences are not due to the 
fluorescent marker. Additionally, the isotype should be of the same immunoglobin class and host 
species as the primary antibody.  
 
Fluorescence minus one (FMO) controls are used to determine which fluorescence signal should be 
used for analysis. FMOs are a sample of the cells of interest stained with all but one (minus one) of the 
fluorescent markers as shown in Table 7. This allows for the fluorescence spread of the other markers 
in the detection channel of the minus one channel to be determined, again allowing for more appropriate 
analytical gates to be set so that any signal from the other fluorescent markers being analysed are 
accounted for230,232,208 . 
 
Table 7. An example of how a FMO matrix is setup, the example shows an FMO matric for a three 
colour panel. Separate samples are stained with a staining mix that is missing one of the fluorophores. 
 
 
Biological controls are particularly useful for determining differences in cell shape and size, as both 
these attributes can change due to cell treatments such a differentiation process and be distinguished by 
the different signals from their interaction with laser light. Furthermore, biological controls can be used 
to determine cell that are positive or negative for a protein. For instance, pluripotent cells can be used 
as biological control to distinguish between cells that have successfully differentiated and those that 
have not: the differentiated cells should not express pluripotency proteins such as OCT3/4. As such the 
differentiated cells would not have the appropriate antigen to bind the OCT3/4 antibody so no signal 
would be detected.  
 
3.5.2. Procedure and solution preparation 
A minimum of 1×106 cells were obtained from a harvested cell suspension as described in sections 
3.2.4.1.a, 3.2.4.2.a and 3.2.4.3.a. The cells were centrifuged at 300xG for 5 min, the supernatant was 
removed and treated as described below (Fisher Scientific, accuSpin Micro 17). Resuspension of cells 
FMO type Staining Mix 
APC FITC-PE
FITC APC-PE
PE APC-FITC
 - 87 - 
 
was performed by pipetting the cell suspension up and down 10 times using a 1000 µL pipette. The 
specific antibodies, fluorophores and reagents used within the present work are described in further 
detail in the relevant chapters. The samples were analysed on a Becton Dickinson (BD) FACSCantoÔ 
II flow cytometer (BD Biosciences, USA); the resulting FSC files were obtained and analysed using 
the FlowJo™ software (version 10.4.2, USA) 
 
3.5.2.1. EP buffers and solutions  
 
BD Cytofix™ fixation buffer (cat#560477) and BD Cell stain buffer (cat#554656) were used as 
provided. To achieve the appropriate working concentration for safe permeabilization of cells, the BD 
Perm/Wash™ (10X) buffer (cat#560477) was diluted 1:10 with distilled water before use (i.e. 1 mL of 
Perm/Wash™ (10X) buffer plus 9 mL of deionized/distilled water).  
 
3.5.2.2. EC 2102 Ep cell sample preparation 
The cells were resuspended in 100 µL of BD Cytofix buffer per 106 cells and incubated 20 min at RT 
away from light (all incubation steps were performed at RT and away from light), to preserve them in 
their biological state at the time of harvest. Following 20 min, the cells were washed twice with 1 mL 
of PBS and centrifuged for 5 min at 500xG. Following the second wash the cells were resuspended in 
a permeabilisation ion buffer and left to incubate for 10 min in order to permeabilise the cell membrane 
to allow for intracellular staining. Following 10 min the conjugated antibodies were added and 
incubated for 30 min. Following 30 min the cells were washed twice with 1 mL  permeabilisation buffer 
and centrifuged for 5 min at 500xG. Following the final wash, the cells were resuspended in cell stain 
buffer and analysed on the flow cytometer.  
 
3.5.2.3. H9 buffers and solutions  
 
All buffers and solutions were prepared fresh on the day of analysis to prevent ion chelation with EDTA 
in the PEB buffer and degradation of both the permeabilization buffer and fixation solution.  
   
3.5.2.2.a. Fixation solution 
 
To achieve the appropriate working concentration for safe fixation and permeabilization of cells, the 
Fixation/Permeabilization Solution 1 (Miltenyi Biotec, Germany, cat#130-093-142) was diluted 1:4 
with the Fixation/Permeabilization Solution 2 (Miltenyi Biotec, Germany, cat#130-093-142) (i.e. for 
106 cells use 0.25 mL of Fixation/Permeabilization Solution 1 plus 0.75 mL of 
Fixation/Permeabilization Solution 2).  
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3.5.2.2.b. PEB Buffer 
 
Solution prepared with PBS, pH 7.2, 0.5% v/v HSA, and 2 mM EDTA (Thermo Scientific, UK, 
cat#155757-038) (i.e. 10 mL solution: 10 mL PBS, 50 µL  HSA (0.5 %) and 40 µL EDTA (2 mM)). 
 
3.5.2.2.c. Permeabilization Buffer 
 
To achieve the appropriate working concentration for safe permeabilization of cells, the 10× 
Permeabilization Buffer (Miltenyi Biotec, Germany, cat#130-093-142) was diluted 1:10 with 
Endotoxin-Free water (Thermo Scientific, UK, cat#SH3052903) distilled water before use (i.e. 1 mL of 
10× Permeabilization Buffer 9 mL of distilled water).  
  
3.5.2.4. H9 cell sample preparation  
 
The cells were resuspended in 1mL of fixation solution per 106 cells and incubated 30 min at 4°C away 
from light (all steps of the process were performed away from light), to preserve them in their biological 
state at the point of harvest. Following 30 min, the cells were washed with 1 mL of cold PEB buffer 
and centrifuged for 5 min at 300xG. A second wash step was performed with 1 mL of permeabilization 
buffer. Following the second wash the cells were resuspended in 110 μl of the staining master mix and 
left to incubated for 30 min at 4°C in order to permeabilised and stain the cells. Following 30 min the 
cells were washed with 1 mL permeabilisation buffer and centrifuged for 5 min at 300xG. The cells 
were then resuspended in PEB buffer and analysed on the flow cytometer.  
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3.6. Cell genotyping 
 
Cell genotyping was performed through quantitative gene expression analysis using quantitative real 
time polymerase chain reactions RT-qPCR  
 
3.6.1. Sample preparation –EC 2101Ep 
 
1x105 cells were obtained from a cell suspension and centrifuged at 300xG for 5 min, the supernatant 
was aspirated, and the resulting pellet was frozen at -80 °C. Gene expression quantification was then 
carried out using qRT-PCR. All procedures were performed on surfaces and using equipment that had 
been decontaminated with RNaseZap solution (cat# 10708345, Fisher Scientific, Loughborough, UK) 
and were performed on ice to prevent sample degradation. 
  
3.6.1.1. RNA extraction and isolation  
 
Total ribonucleic acid (RNA) was isolated using the RNeasy Mini Kit (Qiagen, Cat# 74104) according 
to the manufacturer instructions. RNA yield and purity were determined using the NanoDropä 2000 
Spectrophotometer (Thermo Scientific, UK), measurements at an absorbance wavelength of 260 nm 
were carried out and the 260/280 nm absorbance ratio was used to assess purity; a value of ~2 was 
putative of RNA. RNA integrity was assessed using an Agilent 2100 Bioanalyser (Agilent 
Technologies, Germany) which performs automated electrophoresis to assess the RNA samples235. 
 
3.6.1.2. cDNA synthesis  
 
1 µL of total RNA was reverse-transcribed using the QuantiTect Reverse Transcription Kit (Qiagen, 
Cat# 205311) according to manufacturer instructions. A mix of genomic DNA (gDNA) Wipeout buffer, 
template RNa and RNase-free water was incubated for 2 min at 42°C then stored on ice, this step 
eliminated residual gDNA. Reverse transcriptase, reverse transcription (RT) buffer and RT Primer mix 
were added to the gDNA eliminated RNA template. The solution was incubated 15 min at 42 °C and 
then for 3min at 95 °C (Veriti Dx Thermal Cycler, Applied Biosystems, USA, cat#4452299. 
Complementary deoxyribonucleic acid (cDNA) yield was determined using the NanoDropä 2000 
Spectrophotometer and cDNA samples were stored at -80 °C. 
 
3.6.1. qRT-PCR  
 
1 µL of the cDNA synthesis reaction was used as template for each real-time PCR using VeriQuest Fast 
SYBR Green qPCR Master Mix (cat# 756901000RXN, Fisher Scientific, Loughborough, UK), a 
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forward primer, reverse primer and ultrapure PCR water (cat# 11538646, Fisher Scientific, 
Loughborough, UK), which were all vortexed for 2 min at 350xG. PCR was run in a StepOnePlus™ 
Real-Time PCR System (Applied Biosystems, USA) for 40 cycles of 95°C for 3 seconds to denature, 
and 60°C for 30 seconds to anneal. The relative amounts of PCR product were quantified using the 
relative threshold cycle (DDCt) method corrected for efficiency for each amplification. The gene 
quantities for each sample were normalised against the geometric mean of expression of the 
housekeeping genes. The primers used for each experiment are detailed in the relevant methods section.  
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3.7. Cell Adhesion 
 
In order to measure cell adhesion and obtain quantitative results, the xCelligence® RTCA was used in 
combination with standard light microscopy.  
 
3.7.1. xCelligence® RTCA 
 
The xCelligence® (San Diego, USA) is a real time cell analyser (RTCA), capable of performing cell 
assays, the technology is based on monitoring cell behaviour changes that results due to changes in 
electrical impedance236. The system continuously monitors the cells in real time, providing information 
regarding changes in morphology, proliferation and viability. The xCelligence® provides a quantitative 
mode of accessing cell behaviours that is not possible through visual microscopy whilst also providing 
a direct comparison between wells and plates in a standardised manner. The system is label-free, 
allowing for cells to be in their natural physiological state, which provides the ability to monitor live 
cells in real time, resulting in experimental data that is significantly better than assays that use dead or 
fixed cells237,238. Moreover, cells analysed by the xCelligence® can be used for further experiments or 
other modes of analysis as the assay is not end-point based.  
 
The system is comprised of three parts which are the E-Plate RTCA SP station, RTCA Analyzer and a 
RTCA Control Unit computer. Bespoke microtiter plates called E-Plates® are used in combination with 
the system.  The E-Plates® have gold plated microelectrodes that are integrated onto the bottom of the 
plates, covering 70 or 80 % of the surface area. 70% coverage is due to a subtype of E-Plates® that 
have a viewing strip, allowing for cells to be imaged through microscopy, whereas 80% coverage is on 
non-viewable plates. The RTCA SP plate station provides electrical potential to the E-Plate® (22mV) 
through the contact pins on the cradle of the station which connect to conductive pads on the E-
Plate®239. The resistance experienced by the microelectrodes on the E-Plate® is measured by the RTCA 
analyzer which digitises the analogue signal and processes it for analysis on the computer control unit. 
The analyzer can measure a whole 96 well E-Plate in 15 seconds.(approx. 150 ms per well).  
 
Use of growth medium which has ionic components provides a conductive solution that passes electrical 
potential from a negative terminal to a positive terminal. The voltage applied across the microelectrodes 
on the E-plate® is small, therefore little resistance experienced on an empty surface. The settling down 
of cells towards the surface and their adherence disturbs the flow of electrons and ions on the electro-
medium interface, resulting in impedance which is measured as resistance in Ohms (Ω) (Figure 22). 
The impedance that is produced is reported as Cell Index (CI), where CI = (impedance at time point n 
– impedance in the absence of cells)/nominal impedance value of 15 Ω. The CI reported is an arbitrary 
unit that can be used to compare differences between wells and plates of different experiments. 
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Graphical plots of the CI can be used to show the adhesion and detachment profile of an experiment as 
shown in the illustrative example in Figure 23. 
 
 
Figure 22. Cell are added to the plate which has integrated gold micro electrodes, the growth surface 
is tissue culture treated and can have a matrix such as laminin added onto it. Upon seeding the cells 
attach and grow, as the cells proliferate the measured impedance experience by the micro electrodes 
will increase over time. Changes in cell morphology, adherence and viability will result in a change in 
impedance which is continuously monitored by the RCTA analyser which is converted into cell index 
readings by the computer control unit. Imaged sourced from ACEA Bio239. 
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Figure 23. Illustrative example showing Cell Index measurements during a generic exponential cell 
growth and cell detachment experiment. Imaged adapted from ACEA Bio239    
 
3.7.2. Procedure and sample preparation  
 
E-Plate® microtiter plates (ACEA BIO, USA, cat#6472451001) were coated with either Biolaminin-
521 or Biolaminin-111 (0.5 and 1.0 µg/cm2, respectively) by adding a laminin and PBS solution to the 
well plate and incubating for 2 h at 37°C. Following 2 h the coating solution was removed and 50 µL 
of culture media was added to obtain a baseline impedance reading. A cell suspension was obtained as 
previously described (see 3.2.4. Standard culture), 100 µL of the suspension of a known density was 
used to seed the cells onto the plate resulting in a total volume of 150 µL. The plate was then left to 
equilibrate at RT for 45 min, after which the plate was placed on the xCelligence® RTCA SP station in 
an incubator at 37°C. Readings were recorded continually for different time intervals, based upon the 
experiment, details of which are described in the relevant chapters. Data from the analyser was plotted 
using the RTCA 2.1.0 software on the computer control unit. 
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3.8. Cell time  
 
Cell time can be used to quantify the capability of a given volume of medium to sustain the growth of 
a given number of cells for specific period. Cell time (CT) permits the analysis of cell growth medium 
capacity/medium exhaustion. CT is expressed in cell hours/days.  
 
 56 = 89:;<.= − 9:= ? 
Equation 6 
.  
Where NO is the initial cell density, k is the specific growth rate and t is the time period of culture 
(hours/days). It is the area underneath the curve of a [cell] vs. time graph and it can be obtained using 
Equation 6. 
 
CT permits for analysis of media utilisation (MU) within a cell culture system. The total MU obtained 
is averaged as the initial volume of media has less cells to support compared to the latter volumes. CT 
is the same as the MU but for equivalent conditions, MU is useful as it considers changes in volume. 
Essentially MU is the CT supported per unit volume and can be obtained using Equation 7: @A =	56B  
Equation 7 
 
Where V is the volume of media that has been used for the culture period. 
 
With the progression of time in a cell culture system the MU will be high, resulting in an incapability 
of the media to sustain cell growth and the growth rate. This provides evidence that the media would 
be unable to sustain the given number of cells at that point of time and density. 
 
 CT and MU facilitate calculation of densities to seed cells at, for a given growth medium volume 
without having to feed. This can provide an optimal seeding density (C) at which a minimum 
intervention protocol with no interim feeding prior to passaging/harvesting could be used. C is obtained 
at outlined below. 
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Equation 8 can be used calculate the supportable cell hours (D), using the CT and the input volume (E) 
e.g. in a T75 cm2 flask (15 mL)  
 D	 = 56	 × 	E 
.  
Equation 8 
 C can be obtained using Equation 9, where k is the growth rate, D is the supportable cell hours in the 
given media amount and t is the length of time before passage (hours/days). 
 
N.B: t must be kept in the same units throughout 
 
 C = 	=(D + 1);<.  
Equation 9 
 
  
 - 96 - 
 
3.9. Statistical Analysis 
 
Unless otherwise stated, statistical significance was determined using Graphpad Prism 7 Version 7.0d 
(CA, USA). Statistical significance was assigned as indicated in the figure legends. “ns” indicates no 
statistical significance “*” indicates p< 0.05, “**” indicates p< 0.01, “***” indicates p< 0.001, and 
“****” indicates p<0.0001. A range of tests including but not limited to Tukey and Sidak’s multiple 
comparisons tests were used to compare means between groups. Specific details can be found in the 
corresponding legends and captions.  
3.10. N number covering statement  
 
Since some of the experiments performed were proof of concept or for experimental exploration 
purposes, only one replicate was used. Cell counts were run in technical duplicates (i.e. two counts for 
each condition). Specific details regarding the number of experimental biological replicates can be 
found in the corresponding legends and captions.   
 - 97 - 
 
 
 
 
 
Chapter 4: 
 
EC 2102Ep Cell Line Standardisation 
  
 - 98 - 
 
Chapter 4. EC 2102Ep cell line standardisation    
 
4.1. Introduction 
 
The continuing progression of cell therapies from basic research to clinical products has prompted 
excitement in the field of regenerative medicine over the last ten years. However, there are currently 
many challenges that still need to be addressed prior to clinical realisation24,106,118. One such challenge 
is the characterisation of cell therapy products (CTPs). This is due to the innately complex biological 
nature of CTPs; as a result, their characterisation is equally complex. Unlike traditional pharmaceutical 
products which already have well established standards that can be easily produced and used to compare 
and control the quality of product batches, CTPs currently do not have such a capability132,224,240. 
Therefore, reference cell lines are, at present, being utilised as the closest proxy in CTP manufacturing. 
However, the problem lies in that cell lines are as equally complex and dynamic as the CTPs they are 
being used to assess. This challenge is further exacerbated by the current lack of consensus and 
standardisation of protocols used to culture reference cell lines; this inherently produces an additional 
level of uncontrolled variability to the product manufacturing quality control (QC) process241,242. 
 
To this end, the present work aims to highlight the need for standardisation of cell culture protocols, 
especially in the cases when they are used for QC of cell-based products. This work has been executed 
using the Embryonic Carcinoma (EC) 2102Ep cell line (EC 2102Ep) derived from primary human 
testicular teratocarcinoma243. An initial procedure provided by the National Institute for Biological 
Standards and Control (NIBSC) was followed. However, it was revealed that there were inconsistencies 
in cell growth including discrepancies in population doubling times and growth rates when this 
procedure was followed. Therefore, it is hypothesised that a major contributing factor to culture 
inconsistency was due to the ambiguity of an undefined protocol that is reliant on manual intervention. 
Furthermore, parameters including unspecific time points for medium exchange and passage were 
subject to user interpretation. This issue is concomitant with many published protocols241,243–248, for 
instance a range of timings for passage, i.e. 3-4 days, was suggested for the cells to reach adequate 
confluency; observed confluency in itself being a highly subjective parameter which is user-dependent. 
Additionally, the use of defined seeding densities is absent in many protocols, instead split ratios are 
often prescribed, typically with a range of ratios i.e. 1:3 or 1:5247. These current methods of culture do 
not account for the dynamic nature of cell culture, resulting in inappropriate practices which are not 
based on what the cells are doing and need, but are instead based on user convenience.  
 
The requirement to understand how cells grow and consume growth medium is important, since gaining 
greater control of the cell environment through manipulation of feeding regimes can result in increased 
reliability in terms of cell growth performance. When it comes to scaling up processes for 
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manufacturing, unnecessary feeding results in the redundant use of reagents and time resources; this 
rapidly increases the costs associated with CTP production136,153. There is evidence of existing protocols 
that design feeding regimes to specifically avoid working at weekends; therefore, cells are over- or 
double-fed to ‘sustain’ them outside of the operator’s working hours. Although operator-convenient, in 
many instances there is no quantitative reasoning or evidence to support the use of double-feeding 
regimes. Furthermore, as evidenced by cell growth literature, cells innately grow exponentially249–251, 
and consequently their essential consumption of nutrients would be expected to increase exponentially 
too. This seems to be a vital detail that is not taken into consideration for the majority of cell culture 
protocols, since typically the volume of medium used to culture cells is maintained throughout the entire 
culture chain99,243,252. 
 
The aim of this chapter was to develop a defined protocol in-house, with the existing NIBSC procedure 
being used as the initial benchmark. The optimisation work carried out in this chapter was carried out 
after the process/protocol had been transferred from the collaborators at NIBSC. The resulting in-house 
protocol applied a predefined seeding density with time-defined passage points. This was in an effort 
to produce a more standardised protocol, with minimised human-based sources of variation including 
observed confluency and uncontrolled parameters such as split ratios. The protocol was then used to 
realise the impact of different culture conditions on cell characteristics measured by cell metabolic rate, 
cell specific growth rates, flow cytometry and genetic analysis. A streamlined version of the in-house 
protocol, which removed the medium exchange step and used a different seeding density, was used to 
experimentally compare the effect of different culture conditions. The streamlined protocol is 
representative of a culture state that the cells enter if there were under fed as a result of using split ratios 
and observed confluency to determine culture periods.  
 
4.1.1. EC 2102Ep selection 
 
EC 2101Ep cells were utilised for all work described in this chapter since they were an appropriate, 
“robust” candidate for training the author to culture cells and develop the appropriate analytical skills 
and techniques that would be later applied to clinically relevant cells lines. Furthermore, the low cost 
of culture associated with EC 2102Ep cells meant that the cells were an economical training material. 
A series of experiments were designed to explore protocol parameters including seeding density, culture 
periods and feeding regimes, to investigate their impact on cell behaviour and analytical outcomes such 
as growth rates and cell phenotype.  
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4.2. Methods 
 
4.2.1. In Vitro Cell Culture: 
 
All reagents and consumables were obtained from Fisher Scientific, UK unless otherwise stated. EC 
2102Ep (Passage 54, GlobalStem, USA) cells were thawed from cryopreservation and cultured in T25 
cm2 tissue-culture flasks to create a working cell bank. Each vial contained 6x106 cells in 1 mL of 
CryostorÒ CS10 (cat# C2874-100ML, Sigma Aldrich, UK) which were stored in liquid nitrogen. The 
cells were cultured at 37°C, 5% CO2 using Gibco Dulbecco’s Modified Eagle Medium (DMEM) high 
glucose with GlutaMaxÔ medium (cat# 10569010) and supplemented with Foetal Bovine Serum (10% 
v/v, cat# 10100139) herein referred to as growth medium. Unless otherwise stated, P54 cells were 
thawed and seeded at a density of 66,6667 cells/cm2 and cultured for 72 h with 100% medium exchange 
following 48 h, prior to the start of the experiment. Where stated spent media samples were collected 
then stored at -20o C; PCR samples were collected upon cell harvesting and stored at -80o C until 
analysis. Flow cytometry immunophenotyping samples were collected and fixed on the day of harvest 
and analysed up to 24 h later. 
 
4.2.1.1. Experiment 1  
 
The first experiment was designed to assess how the cells would grow under a range of different seeding 
densities. EC 2102Ep cells (P54) were cultured in a T75 cm2 tissue-culture flask, the growth medium 
was changed following 48 h. The cells were harvested and subculture after 72 h and seeded at four 
different densities (5,000; 10,000; 15,000; 20,000 cells/cm2) into T25 cm2 flasks. The flasks were 
sacrificial resulting in 32 flasks i.e. four days of culture, four densities and duplicated. The densities 
employed were chosen as they are in within the ranges of typical seeding densities for pluripotent cell 
culture, which is a key aspect of the present work.   
 
4.2.1.2. Experiment 2  
 
Experiment 2 explored a wider range of densities to investigate if seeding density would be a cause of 
cell growth inhibition. The six densities were chosen (5,000; 10,000; 20,000; 40,000; 66,667; 80,000 
cells/cm2).  66,667 cells/cm2 was used as this is the density that is recommended by NIBSC; 80,000 
cells/cm2 was chosen in order to investigate the effect of a higher seeding density on cell growth. EC 
2102Ep cells (P54) were cultured in a T75 cm2 tissue-culture flask, the growth medium was changed 
following 48 h. The cells were harvested and sub-cultured after 72 h and seeded at the six chosen 
densities into T25 cm2 flasks. The flasks were sacrificial resulting in 54 flasks i.e. three days of culture, 
six densities, in triplicate.   
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4.2.1.3. Experiment 3 
 
Experiment 3 was a series of experiments designed to investigate the relationship between cell seeding 
density and nutrient availability, to ascertain which of the two parameters had the most significant effect 
on cell culture variation. Cells were seeded at three different densities under three different volumes of 
growth medium to systematically assess the impact of both parameters on cell growth, this was 
experimental passage 1. The conditions used were chosen to further stress the cells as previous 
experimental conditions did not seem to be sufficiently hostile to induce inhibition of cell growth. 
Additionally, metabolic memory was explored by resetting all the conditions to the initial protocol 
culture conditions (66,667 cells/cm2, in 5 mL growth medium) after the passage period at different 
conditions, this was experimental passage 2 (Error! Reference source not found.). The experimental 
setup was to assess if the cells would retain the metabolic cell state induced by the hostile culture 
conditions or whether they would recover. Both the densities and volumes were set above and below 
the control protocol parameter of 66,667 cells/cm2 with 5 mL growth medium and a full medium 
exchange following 48 h. This resulted in a series of four experiments that observed the effect of 
different density and growth medium volume combinations; the densities ranged from 20,000 cells/cm2 
to 93,000 cells/cm2 (Table 8). The volumes used ranged from 1.5 mL to 7 mL, in all the experiments 
66,667 cells/cm2 with 5 mL growth medium and full medium exchange following 48 h was used at the 
control condition (Table 8 and Table 9).  
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Figure 24.Schematic of experiments 3.1 to 3.4 and table showing seeding densities used. 
 
Table 8. Culture details for experiments 3.1 to 3.4 
  
40,000 cells /cm2 (5 mL) 
40,000 cells /cm2 (7 mL) 
66,667 cells /cm2 (3 mL) 
66,667 cells /cm2 (5 mL) 
66,667 cells /cm2 (7 mL) 
93,000 cells /cm2 (3 mL) 
93,000 cells /cm2 (7 mL) 
66,667 cells /cm2 (5 mL) 
66,667 cells /cm2 (5 mL) 
66,667 cells /cm2 (5 mL) 
66,667 cells /cm2 (5 mL) 
66,667 cells /cm2 (5 mL) 
66,667 cells /cm2 (5 mL) 
66,667 cells /cm2 (5 mL) 
Experimental Passage 1 Experimental Passage 2
 - 103 - 
 
4.2.1.3.a. Experiment 3.1 Nutrients vs Density – 72-hour culture period  
 
 
Cells were seeded at a density of 66,6667 cells/cm2 and cultured for 72 h with medium exchange after 
48 h. The matrix below (Table 9) shows the different conditions that were used to test a range of 
medium volume and density conditions.  
 
Table 9. Parameters used in experiment 3.1.  
 
 
4.2.1.3.b. Experiment 3.2 Nutrients vs Density – 96-hour culture period  
 
The same experimental design from experiment 3.1 was applied to experiment 3.2, with the exception 
of the culture period increasing from 72 to 96 h.  
 
4.2.1.3.c. Experiment 3.3 Nutrients vs Density – 96-hour culture period including lower seeding density 
with phenotype analysis.  
  
Cells were cultured under similar conditions to experiment 3.2, except the condition of 93,000 cells/cm2 
with 7 mL growth medium was substituted to 20,000 cells/cm2 and 1.5 mL. Flow cytometry analysis 
was carried out at both passage harvest points. 
 
4.2.1.3.d. Experiment 3.4 Nutrients vs Density - 96-hour culture period with phenotype analysis.   
 
This experiment followed the same experimental design as experiment 3.2; flow cytometry analysis 
was performed on this experiment.  
 
4.2.1.4. Experiment 4: Longitudinal comparison of 2 protocol culture conditions  
 
This experiment investigated the growth performance of the cells over ten experimental passages (E.P1- 
10), two routes of culture were used throughout the experiment (Figure 25). Route A1 was based on 
the NIBSC protocol conditions over 72 h, which was used as a comparison against a streamlined 
protocol that was based on previous experiments (Experiment 1, 2 and 3.3) and a cell time calculation 
(Equation 6). EC 2102Ep cells (P55) were cultured in T75 cm2 tissue-culture flasks; the growth 
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medium was changed following 48 h. The cells were harvested and passaged following 72 h into 2x 
T75 cm2 flasks for another expansion passage (P56). The cells were pooled then separated into 2 routes 
of culture in T25 cm2 tissue-culture flasks, herein referred to as A1 and A2 (see Figure 25). Route A1: 
cells were seeded in triplicate at 66,667 cells/cm2 in 5 mL of growth medium. Medium was changed 
after 48 h. The cells were harvested and passaged following 72 h (P57). Cell counts were performed in 
duplicate for each flask and cultured for a further 9 passages. Route A2: cells were seeded in triplicate 
at 20,000 cells/cm2 in 5 mL growth medium. No medium exchange took place prior to passage. The 
cells were passaged following 72 h culture (P57). Cell counts were obtained in duplicate for each flask 
and cultured for a further 9 passages.  
 
 
 
Figure 25: Schematic detailing the different experimental culture routes investigated. Cells in each 
route were seeded according to the density stated in the figure. Following 48 h route A1, B1, C1 and 
C3 were subjected to a 100% medium exchange. Following 72 h, all routes were passaged. Route A1 
and A2 underwent a further nine passages (Experiment 4); Route B1 and B2 underwent one further 
passage (Experiment 4.1); Route C1, C2, C3 and C4 underwent a further two passages (Experiment 5). 
*M. Ex =medium exchange. **Cells from B1 were obtained from passage cycle 8 of route A2. *** 
Cells from B2 were obtained from passage cycle 8 of route A1. 
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4.3.1.4.a. Experiment 4.1:  Inter-experiment reversal of protocol culture conditions 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Cells from experiment A (see Figure 25) were passaged at cycle 8 for both route A1 and 
A2, the excess cells from route A1 were seeded to follow route A2 conditions, therein referred to as 
route B2. Excess route A2 cells were seeded under A1 conditions resulting in a switch of routes, therein 
referred to as route B1. 
 
In order to investigate whether observed changes in experiment 4 were an artefact of the cells being 
cultured under route A2 or a divergence of the cells not linked to the routes, a reversal mini experiment 
was carried out. Cells that had previously been cultured at a density of 66,667 cells/cm2 with medium 
exchange after 48 h (route A1) were harvested and used to continue experiment 4.  The excess cells 
from the harvest of route A1 were then seeded and cultured at a density of 20,000 cells/cm2 with no 
medium exchange after 48 h, resulting in a switch of culture conditions from the previous seven 
passages, leading to experiment 4.1 and the B2 culture route. These cells (now in experiment 4.1) were 
cultured in parallel with cells from experiment A for the remaining two passages of experiment A. The 
cells that had previously been cultured at a density of 20,000 cells/cm2 with no medium exchange after 
48 h (route A2) were also subjected to a switch of culture route in the same manner as mentioned above 
i.e. they were seeded and cultured at a density of 66,667 cells/cm2 with medium exchange after 48 h, 
leading to experiment 4.1 and the B1 culture route as depicted (Figure 26). 
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4.2.1.5. Experiment 5: 4-way comparison of the effects of medium of exchange.  
 
EC 2102Ep cells (P59) were cultured in a T75 cm2 tissue-culture flask, the growth medium was changed 
following 48 h. Cells were passaged following 72 h and were seeded into 2 x T75 cm2 flasks for a 
further expansion passage (P60). The cells were then separated into four different routes of culture (see 
Figure 25): Route C1 and C3, cells were seeded in duplicate at 20,000 and 66,667 cells/cm2, 
respectively in 5 mL growth medium. Following 48 h the growth medium was exchanged. The cells 
were then passaged following 72 h; cell counts were obtained in duplicate for each flask and cultured 
for a further two passages. Route C2 and C4, cells were seeded in duplicate at 20,000 and 66,667 
cells/cm2, respectively, in 5 mL growth medium. No medium exchange took place prior to passage. The 
cells were passaged following 72 h culture, cell counts were obtained in duplicate for each flask and 
cultured for a further two passages. 
 
4.2.2. Flow cytometry 
 
All reagents were obtained from BD Biosciences (Oxford, UK) unless otherwise stated. Flow cytometry 
immunophenotyping samples were collected for the following experiments: experiment 3.3, 3.4, 4, 4.1 
and 5. Samples were collected at experimental passage 1 and 2 for experiments 3.3 and 3.4. For 
experiment A, samples were collected at passage 1, 3, 7 and 9. For experiment 4.1 and 5 samples were 
collected at experimental passage 1 and 2.  The following steps were all performed in the dark at room 
temperature (RT). A minimum of 1×106 cells were collected and fixed for 20 min (RT, BD CytofixÔ). 
The cells were washed twice with PBS and centrifuged at 500 xG (Fisher Scientific, accuSpin Micro 
17) for 5 min. The cells were permeabilised for 10 min (BD Perm/WashÔ). Cell staining was performed 
using pre-conjugated antibodies OCT3/4-PerCp-Cy5.5, SSEA-1-PE and SSEA-4-Alexa 647, for 30 
min, a sample with respective isotype controls was used to account for non-specific binding (Table 10). 
Following 30 min two washes were performed using permeabilising buffer. The cells were resuspended 
in cell stain buffer prior to analysis. 250μL of each sample was used for multiparameter analysis using 
flow cytometry (BD FACSCantoÔ II, BD Biosciences, USA).  
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Table 10. Conjugated antibodies used for flow cytometry to determine pluripotency state of the cells 
 
 
4.2.3. PCR 
 
PCR samples were collected upon harvesting and stored at -80o C until analysis as dry pellets. For 
experiment 4 samples were collected at passage 1, 3, 7 and 9. Gene Expression quantification was 
performed using Quantitative RT-PCR. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, 
Cat#74104) according to manufacturer’s instructions. RNA yield and purity were determined using the 
NanoDropä 2000 Spectrophotometer (Thermo Scientific, UK). RNA integrity was assessed using an 
Agilent 2100 Bioanalyser (Agilent Technologies, Germany). 1µL of total RNA was reverse-transcribed 
using the QuantiTect Reverse Transcription Kit (Qiagen, Cat#205311) according to manufacturer 
instructions. 1µL of the cDNA synthesis reaction was used as template for each real-time PCR using 
VeriQuest Fast SYBR Green qPCR Master Mix. PCR was run in a StepOnePlus™ Real-Time PCR 
System (Applied Biosystems, USA) for 40 cycles of 95°C for 3 seconds to denature and 60°C for 30 
seconds to anneal. The relative amounts of PCR product were quantified using the relative threshold 
cycle (DDCt) method corrected for efficiency for each amplification. The gene quantities for each 
sample were normalised against the geometric mean of expression of the housekeeping genes GAPDH 
and b-actin243 (Table 11). 
 
Marker Relevant details Desired expression
Oct3/4-PerCp-Cy5.5 Pluripotency marker Positive
SSEA-1-PE Differentiation marker Negative
SSEA-4-Alexa 647 Pluripotency marker Positive
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Table 11. The genes used for qRT-PCR analysis of the EC 2102Ep cells in experiment 4243. 
 
 
4.2.4. Metabolite analysis: 
Spent media samples, 500 µL, were collected then stored at -20°C prior to analysis. For experiments 1 
to 3.4 media samples were collected at two time-points: prior to medium exchange at 48 h and prior to 
cell passage. Experiment 4 and 4.1 samples were collected prior to medium exchange at 48 h (A1 and 
B1only) and prior to cell passage for all routes.  In experiment 5, spent media samples were also 
collected on the medium exchange and passage time points for routes C1 and C3. Samples for route C2 
and C4 were collected only on the passage time point. Spent media samples were analysed for glucose, 
lactate, glutamine, ammonia and lactate dehydrogenase using Cedex Bio-HT (Roche, Germany). The 
results were used to obtain the Specific Metabolite Rate mmol. cell-1. d-1 (SMR). 
  
Gene Full name Relevant details
DNMT3B DNA-
methyltransferase 3 
beta
DNA (cytosine -5)-methyltransferase 3 beta:
abundantly expressed in ES cells but not 
detectable in  differentiated cell  and adult 
tissues 
DPPA4 Developmental 
Pluripotency 
Associated 4
Developmental Pluripotency Associated 4:
associated with inhibition of differentiation 
in ES cells 
NANOG Nanog Homeobox Involved in maintenance of pluripotent state 
of ES cells and work in concert with pou5f1 
and sox2 to marker ES identity 
POU5F1 octamer-binding 
transcription factor 4
Pluripotency marker involved in the self 
renewal of undifferentiated ES cells, also 
know as Oct-4 
REX1 Zfp-42 Pluripotency marker found in ES cells 
regulation of rex1 is essential to 
maintenance of pluripotent state of ES cells.
SOX2 SRY-box 2 Involved in the maintenance of self-renewal
of ES cells and neural stem cells 
TDGF teratocarcinoma-
derived growth factor
Link to signalling pathways that are essential 
to embryonic development and tumour 
growth
b-ACTIN Beta actin Putative housekeeping gene involved in 
cytoskeletal actin expressed in most cells 
GAPDH Glyceraldehyde 3-
phosphate 
dehydrogenase
Putative housekeeping gene found expressed 
in high levels in most cells and tissues 
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4.3. Results  
 
4.3.1. Experiment 1: Growth analysis of four seeding densities   
 
Overall, all the conditions behaved similarly, with the exception of cells seeded at 10,000 cells/cm2 at 
day 1, the specific growth rate (SGR) was similar between the different density conditions. Cells seeded 
at 10,000 cells/cm2 were observed to have a much higher SGR on day 1 (0.029 h-1) which dropped on 
day 2 to align with that other conditions (0.016 h-1). At day 4 the observed growth curve illustrated that 
all the conditions were still in a phase of growth or just beginning to plateau, with the 10, 15 and 20,000 
cells/cm2 conditions all having similar rates from day 2 to day 4 (Figure 27A). For all four densities 
there were no detrimental effects on the viability of the cells, it was observed in all conditions except 
for the 5, 000 cells/cm2 condition, that there was a higher percentage viability at day 4 compared to day 
2 and 3 (Figure 27B). Metabolite analysis shows a relationship between SGR and specific metabolite 
rate (SMR) i.e. the cells consumed more glucose as the cell number increased (Figure 27C)  
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Figure 27. (A). Specific growth (SGR) trend for the four different seeding densities, n=4 error bars showing standard deviation, SD. The 10,000 
cells/cm2 condition was significantly different to the other conditions (P range = 0.01 – 0.0007), no errors shown for this condition on day 1 as  
the SD between replicates was too small (B) Cell viability trend over 96-hour culture period, all conditions were above 90 % viable throughout 
the culture period, n=4 error bars showing SD. (C) Glucose SMR for all four seeding densities, no significance difference was observed 
throughout the culture period or between different densities, n=2 error bars showing SD. 
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4.3.2. Experiment 2: Growth analysis of six densities  
 
The three higher densities (40,000; 66,667; 80,000 cells/cm2) had a decline in cell number resulting in 
a neutral/ negative growth rate (-0.019 to 0.006 h-1), see Figure 28A. This is not likely to be due to cell 
death as the cell viabilities were all above 90% on day 1 (Figure 28B), this observation is most likely 
due to a seeding error at the beginning of the experiment, resulting a ~ 30% decrease in cell number 
from 0 to 24  h. The three higher density conditions behaved similarly to each other, whilst the three 
lower densities conditions also behaved similarly to each other, suggesting a grouping of cell growth 
behaviour dependent of seeding density. The SGR for the lower densities (5,000 and 10,000 cells/cm2) 
were on average slightly lower (0.021 h-1) over the 3-day period, whilst the higher densities had an 
average SGR of 0.022 h-1. Overall the cells grew exponentially and do not hit a phase of decline or 
inhibition within the 72-hour culture period, independent of cell density as the SGR between conditions 
was not significantly different at day 2 and 3. The metabolite data revealed that main significant 
differences were between the 5000 cells/cm2 condition and all the other conditions at day 1. At day 2 
and 3 notable differences in SMR were only observed between the three lower densities and three higher 
densities (Figure 28C), again highlighting a grouped behaviour pattern as seen in the SGRs.  
 
N.B. The seeding error mentioned above resulted in the adjustment of the initial cell number used in 
the SGR equation for the three higher densities. The error in seeding was due to a different operator 
carrying out the manipulations of the higher density conditions, this operator unknowingly seeded at a  
lower density. By comparing the average SGR of the lower three densities at day 1 in the experiment, 
it was demonstrated that the higher three densities would need to have their initial seeding cell number 
adjusted by 30 % in order to come in line with the SGRs observed in the lower conditions. For instance, 
for the 80,000 cells/cm2 condition, the initial seeding cell number should have been 2,000,000 cells in 
the T25 cm2 tissue-culture flasks used, however in order to account for the seeding error this was 
adjusted by 30% to become 1,400,000 cells (56,000 cells/cm2). Thus, the adjusted seeding densities for 
the three higher densities (40,000; 66,667; 80,000 cells/cm2) were 28,000; 46,667; 56,000 cells/cm2, 
respectively. Due to resource and time constraints this experiment was not repeated  with  correct 
seeding  densities. However, .experiments carried out after this experiment using the correct seeding 
densities for higher conditions e.g.  Experiment 3 and 4  also exhibit similar grouping between lower 
and higher densities, therefore it can be inferred that the results illustrated here are valid, despite the 
initial seeding error.  
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Figure 28: Data was collected every 24 h  over a 72-hour culture period, six difference seeding densities 
were investigated in the experiment. Error bars indicate standard deviation, n=3 for each condition; n=3 
for SMR data; n=9 for SGR and cell viability data. (A) SGR was shown to increase for all six conditions 
over the culture period. (B) Cell viability decreased uniformly for all conditions from day 1 to day 3. 
(C) Significant differences between conditions were at day 1, between 5,000 cells/cm2 and the other 
densities. “**” indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates p<0.0001 
 
Table 12. Experiment 2 SGR. Tukey’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions on that day. Summary shows only the conditions with 
significant differences, at day 1 it is evident that the 10,000 cells/cm2 condition had a higher SGR than 
all other conditions. At day 2 only two of the conditions were different and no differences between 
conditions were noted at day 3. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Experiment 2 SGR 
Day 1 Summary  P Value 
5,000 cells/cm2 vs. 10,000 cells/cm2 * 0.0119 
10,000 cells/cm2 vs. 20,000 cells/cm2 **** <0.0001 
10,000 cells/cm2 vs. 40,000 cells/cm2 **** <0.0001 
10,000 cells/cm2 vs. 66,667 cells/cm2 **** <0.0001 
10,000 cells/cm2 vs. 80,000 cells/cm2 **** <0.0001 
   
Day 2 Summary P Value 
10,000 cells/cm2 vs. 80,000 cells/cm2 * 0.0168 
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Table 13. Experiment 2 SMR. Tukey’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions on that day. Summary shows only the conditions with 
significant differences, at day 1 it is evident that the 5,000 cells/cm2 condition had a higher SMR than 
the other conditions. At day 2 the differences observed in SMR were predominantly between the lower 
densities and the higher densities, highlighting the grouped behaviour shown in Figure 28A and C. The 
lowest density and the two highest densities were the only conditions noted to be different at day 3. 
 
Experiment 2 SMR 
Day 1 Summary  P Value 
5,000 cells/cm2 vs. 10,000 cells/cm2 ** 0.0046 
5,000 cells/cm2 vs. 20,000 cells/cm2 ** 0.0054 
5,000 cells/cm2 vs. 40,000 cells/cm2 *** 0.0001 
5,000 cells/cm2 vs. 66,667 cells/cm2 **** <0.0001 
5,000 cells/cm2 vs. 80,000 cells/cm2 **** <0.0001 
Day 2 Summary  P Value 
5,000 cells/cm2 vs. 10,000 cells/cm2 * 0.0105 
5,000 cells/cm2 vs. 20,000 cells/cm2 ** 0.0027 
10,000 cells/cm2 vs. 66,667 cells/cm2 ** 0.0067 
10,000 cells/cm2 vs. 80,000 cells/cm2 ** 0.01 
20,000 cells/cm2 vs. 66,667 cells/cm2 ** 0.0017 
20,000 cells/cm2 vs. 80,000 cells/cm2 ** 0.0025 
Day 3 Summary  P Value 
5,000 cells/cm2 vs. 66,667 cells/cm2 ** 0.0089 
5,000 cells/cm2 vs. 80,000 cells/cm2 * 0.0136 
 
4.3.3. Experiment 3.1: Nutrients vs. Density  
 
 On the first experimental passage (passage 1) the cells exhibited similar growth behaviour to that 
observed in the previous experiments. The SGR values appeared to be independent of cell density and 
in this instance nutrient availability also, as some values were the same for different culture conditions. 
On the reset passage (passage 2) the cells had very similar SGR values regardless of which condition 
they had been previous cultured from, illustrating that there seemed to be no retention or effect on cell 
metabolic state (Figure 29A). No significant difference was observed between conditions and/or 
passages. Three graphical representations have been used to demonstrate the different behaviours 
exhibited by SMRs for the different conditions. (Figure 29B) demonstrates the SMR of the conditions 
at passage 1 and 2 of the experiment. There were differences in SMR within conditions with the same 
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density and those with different densities, suggesting that both feed volume and density result in SMR 
variation. At passage 2, significant differences were observed between the two 40,000 cells/cm2 
conditions (5 and 7 mL) and all the other conditions (Figure 29B). The SMR data highlights a cycling 
trend across the four passage points (1 = passage 1 feed day; 2 = passage 1 harvest/reset day; 3 = passage 
2 feed day; 4 = passage 2 harvest day). At passage point 1 all the conditions had a high SMR of glucose 
which dropped by ~ 25 % or more at passage point 2, then it reverted up by ~25% or more at passage 
point 3, to then decrease again at passage point 4  (Figure 29C). The SMR data in Figure 29D is 
presented in a way that better illustrates that during passage 1 the conditions exhibit variation, whereas 
when all the flasks are reset to the same culture condition at passage 2 there was no significant variation 
between the flasks regardless of the previous culture condition. 
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Figure 29: (A) SGR for the different conditions over the two passages, Error bars indicate standard deviation, n=2 for each condition; n=2 for SMR data; n=4 
for SGR data. (B) Differences were observed between the conditions over the 2 passages. “**” indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates 
p<0.0001. (B-D) Three graphical representations used to show the different behaviours exhibited by SMRs of the different culture conditions. Passage points 
shown in (C) correspond to: 1 = passage 1 feed day; 2 = passage 1 harvest/reset day; 3 = passage 2 feed day; 4 = passage 2 harvest day).
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Table 14: Experiment 3.1 SGR. Tukey’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions during that passage. The only difference observed was 
between the lowest density and highest density with normal and low feed volume, respectively. No 
differences in SGR were observed between conditions at the reset passage (passage2). 
 
Exp 3.1 SGR 
Passage 1 Summary  P Value 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (3 mL) * 0.0388 
 
 
Table 15. Experiment 3.1 SMR. Sidak’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions during that passage. Differences between the majority of 
the conditions were observed at passage 1, whilst at passage 2 when the conditions were reset 
differences were only observed between the lowest density and all the other condition. 
 
Exp 3.1 SMR 
Passage 1  Summary  P Value 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (5 mL) * 0.0399 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (7 mL) **** <0.0001 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (5 mL) ** 0.0012 
40,000 cells/cm2 (7 mL) vs. 66,667 cells/cm2 (7 mL) * 0.01 
66,667 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (5 mL) * 0.0171 
66,667 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (7 mL) **** <0.0001 
66,667 cells/cm2 (3 mL) vs. 93,000 cells/cm2 (5 mL) *** 0.0006 
66,667 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (7 mL) * 0.0494 
66,667 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (3 mL) ** 0.0019 
   
Passage 2  Summary  P Value 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (3 mL) ** 0.0053 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (3 mL) ** 0.0012 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (5 mL) *** 0.0007 
40,000 cells/cm2 (7 mL) vs. 66,667 cells/cm2 (3 mL) ** 0.0019 
40,000 cells/cm2 (7 mL) vs. 66,667 cells/cm2 (5 mL) * 0.0205 
40,000 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (3 mL) *** 0.0004 
40,000 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (5 mL) *** 0.0003 
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4.3.4. Experiment 3.2: Nutrients vs. Density  
 
For both the SGR and SMR the significant differences are observed within passage 1 where the cells 
were cultured under different conditions (see Table 16 and Table 17). At the reset passage (passage 2) 
no significant differences were observed for the SMR whilst some difference were observed for the 
SGR within passage 2 (Figure 30A). The SMR graphs (Figure 30B, C and D) demonstrate similar 
trends to the previous experiment (Experiment 1, Figure 27, Figure 30B). Differences in SMR were 
observed based on both density and feed volume within passage 1, at passage 2 no difference was 
observed between the conditions/flasks once they had been reset. (Figure 30C) The SMR data 
highlights a cycling trend across the four passage points (1 = passage 1 feed day; 2 – passage 1 
harvest/reset day; 3 = passage 2 feed day; 4 = passage 2 harvest day). Within all the conditions the SMR 
rate decreased from passage point 1 to 2, increased from passage point 2 to 3 and then decreased again 
from passage point 3 to 4. In the graphical illustration the consistency of SMRs between flasks at 
passage 2 is evident, whilst it can be observed that at passage 1 there was variation between the flasks 
cultured under the different condition (Figure 30D) 
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Figure 30: (A) SGR data revealed no retention of cell metabolic state as the SGR changes from passage 1 to passage 2 of the experiment (****, p<0.0001).  
Error bars indicate standard deviation, n=2 for each condition; n=2 for SMR data; n=4 for SGR data, “***” indicates p< 0.001, and “****” indicates p<0.0001. 
(B-D) Three graphical representations used to show the different behaviours exhibited by SMRs of the different condition. Passage points shown in (C) 
correspond to: 1 = passage 1 feed day; 2 = passage 1 harvest/reset day; 3 = passage 2 feed day; 4 = passage 2 harvest day).
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Table 16. Experiment 3.2 SGR. Sidak’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions during that passage. Differences were observed in most of 
the conditions at passage 1. At passages 2 regardless of being reset to the same culture condition the 
flasks demonstrated  significant inter-flask variation of SMRs 
Exp 3.2 SGR 
Passage 1  Summary P Value 
40,000 cells/cm2 (5 mL) vs. 40,000 cells/cm2 (7 mL) * 0.0399 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (3 mL) **** <0.0001 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (5 mL) ** 0.0017 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (7 mL) **** <0.0001 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (3 mL) **** <0.0001 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (5 mL) **** <0.0001 
40,000 cells/cm2 (7 mL) vs. 66,667 cells/cm2 (3 mL) ** 0.0046 
40,000 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (3 mL) **** <0.0001 
66,667 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (3 mL) **** <0.0001 
66,667 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (3 mL) ** 0.0027 
93,000 cells/cm2 (3 mL) vs. 93,000 cells/cm2 (5 mL) * 0.0107 
   
Passage 2  Summary P Value 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (3 mL) *** 0.0008 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (5 mL) *** 0.0002 
40,000 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (3 mL) ** 0.0071 
40,000 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (5 mL) ** 0.0015 
66,667 cells/cm2 (3 mL) vs. 93,000 cells/cm2 (3 mL) ** 0.0019 
66,667 cells/cm2 (3 mL) vs. 93,000 cells/cm2 (5 mL) *** 0.0004 
66,667 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (3 mL) * 0.0127 
66,667 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (5 mL) ** 0.0028 
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Table 17. Experiment 3.2 SMR. Sidak’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions during that passage. Most of the conditions had different 
SMRs compared to each other at passage 1, whilst no difference in SMR is observed at passage 2 when 
all the flasks were reset to the same culture condition.  
Exp 3.2 SMR 
Passage 1  Summary P Value 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (7 mL) * 0.0292 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (5 mL) *** 0.0008 
40,000 cells/cm2 (7 mL) vs. 66,667 cells/cm2 (5 mL) * 0.0441 
40,000 cells/cm2 (7 mL) vs. 66,667 cells/cm2 (7 mL) * 0.0127 
40,000 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (5 mL) *** 0.0004 
66,667 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (5 mL) * 0.0346 
66,667 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (7 mL) ** 0.01 
66,667 cells/cm2 (3 mL) vs. 93,000 cells/cm2 (5 mL) *** 0.0003 
 
4.3.5. Experiment 3.3: Nutrients vs. Density 
There is a notable difference in the SGR value of the lower density flasks (20,000 cells/cm2) compared 
to the higher density, as its SGR values at both feed volumes were higher compared to the higher 
densities (Figure 31A and Table 18). Similarly, the SMR data exhibited the 20,000 cells/cm2 condition 
had higher SMRs compared to the other densities, apart from the 40,000 cells/cm2 (1.5ml) condition 
(Figure 31B and Table 19). The SMR values were comparable at passage 2 when the cells were reset 
to the same culture condition. The cells cultured under the different conditions at passage 1 had lower 
expression (63 – 86 %)) of OCT3/4 at passage which uniformly increased at passage 2 (80 – 97 %) 
resulting in a significant difference overall between the passages (**, p=0.001). (Figure 31C). There 
was no significant difference in the SSEA-1 (Figure 31D) and SSEA-4 (Figure 31E), both within 
conditions and amongst conditions over the two passages.  
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Figure 31: (A) SGR data for all the conditions, most of the variation was observed at passage 1. (B) SMR data over the two passages, significant difference 
observed with passage 1 only, “****” indicates p<0. 0001. Percentage levels of experience for the flow cytometry pluripotency maker panel used, (C) OCT3/4 
positive marker, (D) SSEA-1 negative marker and (E) SSEA-4 positive marker. Significant difference between the two passages overall was only observed for 
the OCT/34 marker (**, p=0.001).  Error bars indicate standard deviation, n=2 for each condition; n=2 for SMR data; n=4 for SGR data
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Table 18: Experiment 3.3 SGR. Sidak’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions during that passage. The main differences were between 
the lowest density 20,000 cells/cm2 at both feed volumes and all the conditions at passage 1. Fewer 
differences were observed at passage 2 between the flasks upon reseeding at the condition 66,667 
cells/cm2 (5 mL) 
 
Exp 3.3 SGR 
Passage 1  Summary  P Value 
20,000 cells/cm2 (3 mL) vs. 40,000 cells/cm2 (1.5 mL) **** <0.0001 
20,000 cells/cm2 (3 mL) vs. 40,000 cells/cm2 (5 mL) ** 0.0061 
20,000 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (1.5 mL) **** <0.0001 
20,000 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (3 mL) *** 0.0009 
20,000 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (5 mL) **** <0.0001 
20,000 cells/cm2 (5 mL) vs. 40,000 cells/cm2 (1.5 mL) **** <0.0001 
20,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (1.5 mL) **** <0.0001 
20,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (5 mL) *** 0.0002 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (1.5 mL) *** 0.0008 
66,667 cells/cm2 (1.5 mL) vs. 66,667 cells/cm2 (3 mL) ** 0.0057 
   
Passage 2  Summary  P Value 
20,000 cells/cm2 (5 mL) vs. 40,000 cells/cm2 (1.5 mL) * 0.0283 
20,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (1.5 mL) ** 0.0073 
66,667 cells/cm2 (1.5 mL) vs. 66,667 cells/cm2 (5 mL) * 0.0288 
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Table 19. Experiment 3.3 SMR. Sidak’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions during that passage. 20,000 cells/cm2 at both feed volumes 
and 40,000 cells/cm2 (1.5ml) were different to all the other conditions during passage 1, when all flasks 
were reset to the same culture condition at passage 2 no differences were observed between flasks.  
Exp 3.3 SMR 
Passage 1  Summary  P Value 
20,000 cells/cm2 (3 mL) vs. 40,000 cells/cm2 (5 mL) *** 0.0007 
20,000 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (1.5 mL) ** 0.0017 
20,000 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (3 mL) **** <0.0001 
20,000 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (5 mL) **** <0.0001 
20,000 cells/cm2 (5 mL) vs. 40,000 cells/cm2 (5 mL) * 0.0107 
20,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (1.5 mL) * 0.0259 
20,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (3 mL) *** 0.0002 
20,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (5 mL) *** 0.0002 
40,000 cells/cm2 (1.5 mL) vs. 40,000 cells/cm2 (5 mL) ** 0.0013 
40,000 cells/cm2 (1.5 mL) vs. 66,667 cells/cm2 (1.5 mL) ** 0.0031 
40,000 cells/cm2 (1.5 mL) vs. 66,667 cells/cm2 (3 mL) **** <0.0001 
40,000 cells/cm2 (1.5 mL) vs. 66,667 cells/cm2 (5 mL) **** <0.0001 
 
4.3.6. Experiment 3.4: Nutrients vs. Density  
 
The SGR of the highest densities at both feed volumes and 66,667 cells/cm2 (7 mL) were lower than 
the other conditions at passage 1, (0.011 vs. 0.015 h-1). At passage 2 their SGRs increased to come in 
line with the other conditions, (Figure 32A). Differences in SMR between conditions were only 
observed at passage 1, the most significant of these are highlighted on the graph (Figure 32B), the rest 
are detailed in Table 20. The phenotypic marker expression profile did not change significantly from 
passage 1 to 2 for SSEA-4 (Figure 32E). SSEA-1 expression was observed, notably at passage 1 for 
the lowest densities and passage 2 for the highest densities. Expression was however below 2% in all 
cases and was deemed to be not statistically significant. In the case of Oct 3/4, difference in percentage 
expression is observed between passage 1 and 2 overall for all the conditions, from 85% to 95%, 
respectively (**, p=0.0011), (Figure 32C) 
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Figure 32: (A) SGR of the conditions investigated in the experiment. (B) Differences in SMR between 
conditions were only observed at passage 1, conditions with significant differences are highlight “**” 
indicates p< 0.01, “***” indicates p< 0.001. (C) Significant difference in % expression between passage 
1 and 2 for OCT3/4 was noted overall for all the conditions in each passage, (**, p=0.0011). (D) 
Expression in SSEA-1 was observed most notably at passage 2, however this was not significant. 
(E)The phenotypic marker expression profile did not change significantly from passage 1 to 2 for 
SSEA-4. Error bars indicate standard deviation, n=2 for each condition; n=2 for SMR data; n=4 for 
SGR data. 
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Table 20. Experiment 3.4 SGR. Sidak’s multiple comparisons test of the mean SGR in each condition 
compared the means of the other conditions during that passage. Differences in flasks under the various 
culture conditions were observed during passage 1, similar to previous experiments no differences were 
observed between flasks at passage 2. 
Exp 3.4 SGR 
Passage 1  Summary  P Value 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (7 mL) **** <0.0001 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (3 mL) ** 0.0017 
40,000 cells/cm2 (7 mL) vs. 66,667 cells/cm2 (7 mL) **** <0.0001 
40,000 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (3 mL) * 0.0219 
66,667 cells/cm2 (3 mL) vs. 66,667 cells/cm2 (7 mL) **** <0.0001 
66,667 cells/cm2 (3 mL) vs. 93,000 cells/cm2 (3 mL) * 0.0484 
66,667 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (7 mL) **** <0.0001 
66,667 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (3 mL) *** 0.0008 
66,667 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (5 mL) ** 0.0011 
 
Table 21. Experiment 3.4 SMR. Sidak’s multiple comparisons test of the mean SMR in each condition 
compared the means of the other conditions during that passage. Main differences observed between 
conditions at passage 1 were when between the lowest and highest densities within the experiment. No 
differences were observed during passage 2.  
Exp 3.4 SMR 
Passage 1  Summary  P Value 
40,000 cells/cm2 (5 mL) vs. 66,667 cells/cm2 (5 mL) ** 0.0013 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (3 mL) ** 0.0049 
40,000 cells/cm2 (5 mL) vs. 93,000 cells/cm2 (5 mL) *** 0.0002 
40,000 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (5 mL) * 0.0304 
66,667 cells/cm2 (7 mL) vs. 93,000 cells/cm2 (5 mL) * 0.0296 
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4.3.7. Experiment 4: Longitudinal comparison of 2 protocol culture conditions  
 
Data obtained demonstrated that over ten passages, culture route A2 on average had marginally higher 
SGR values (0.021 ± 0.004) compared to A1 (0.019 ± 0.004). The SGR values of both routes fluctuated 
throughout the 10 passages (Figure 33A) and the same can be observed of the Pd values. The fluctuation 
trend was similar for both routes with regards to the SGR values, Pd values and the cell viabilities. 
Route A2 had a marginally higher average cell viability (86.3 % ± 8.1) compared to route A1 (83.3 ± 
8.8) over the 10 passages (Figure 33B). The metabolite data demonstrated that route A1 had a very 
consistent SMR for all measured metabolites over the ten passages, which appears to be independent of 
the SGR value (Figure 33A & D). Route A2 had more SMR fluctuation over the ten passages and in 
some instances, the trend correlates to the SGR value (passage cycle 1 to 4). Marker expression analysis 
using flow cytometry showed no significant change in SSEA-4 expression over the ten passages or 
between route A1 and A2 (p=0.07 and p=0.10, respectively). However, for route A2 there was 
expression of SSEA-1 which is a negative marker; this was observed from passage cycle 3 onwards. 
OCT3/4 expression in route A2 is shown to decrease by 52% and by ~ 30% in route A1 at passage cycle 
7, which increased back to above 95 % in route A1 and only to 79.6 % by passage cycle 9 in route A2 
(Figure 33E and Figure 34).  
 
The PCR performed for experiment A demonstrated that for a selection of the genes analysed, DPPA4, 
POU5F1 and REX1, there is no significant difference between the two different routes throughout the 
10 passages (Figure 35). However, DNMT3B, TDGF and SOX2 exhibit significant differences between 
the two routes and between passage cycles as they have higher expression in route A2 Figure 35A, C 
and F). TDGF is the only gene that shows a significant difference at passage cycle 3, being much lower 
than the route A1 condition (** p = 0.018). DNMT3B, NANOG and SOX2 show differences at passage 
cycle 7 and/or passage 9 between the two routes, in all cases route A2 having a higher fold change. 
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Figure 33. (A) Specific growth rate trend for route A1 and A2 over ten passages, showing a fluctuation 
in SGR throughout all ten passages that follows the same trend regardless of route, n=3 error bars 
showing standard deviation, SD. (B) Cell viability trend of route A1 and A2 over ten passages both 
routes follow a similar trend in viability throughout all passages cycles, route A1 is shown to have lower 
viability during five of the passage cycles (4 -8) in comparison to route A2, n=2 error bars showing SD. 
(C) Cell diameters of route A1 and A2 over ten passages showing synchronised trend; some difference 
between the two routes is observed at passage cycle 3, 4 and 6, , n=3 error bars showing standard 
deviation, SD. (D) Glucose SMR from passage cycle 2 to 10 showing a significant difference between 
passages (***p<0.001), at each individual passage cycle route A2 is significantly higher than route A1 
(****p<0.0001) (E) OCT3/4 marker expression percentages for experiment Cat passage cycle 1, 3, 7 
and 9 significant differences between passages (****p<0.0001) and significant differences between 
culture route  A1 and A2 (p=0.0004, n=3).  
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Figure 34.Flow cytometry dot plot profiles showing marker expression change from (A) passage cycle 
1 to (B) passage cycle 7. OCT3/4 expression decreased from passage cycle 1 to 7 and an increase in 
SSEA-1 was observed, highlighted by the red hatched boxes. Oct 3/4 and SSEA-4 are positive markers 
for pluripotent human embryonic stems, SSEA-1 is a negative marker associated with pluripotency of 
human embryonic stem cells
 133 
 
 
Pa
ss
ag
e 3
Pa
ss
ag
e 5
Pa
ss
ag
e 7
Pa
ss
ag
e 9
0
1
2
3
DNMT3B 
Fo
ld
 C
ha
ng
e  
* **
Pa
ss
ag
e 3
Pa
ss
ag
e 5
Pa
ss
ag
e 7
Pa
ss
ag
e 9
0
1
2
3
Fo
ld
 C
ha
ng
e  
NANOG
Pa
ss
ag
e 3
Pa
ss
ag
e 5
Pa
ss
ag
e 7
Pa
ss
ag
e 9
0
1
2
3
Fo
ld
 C
ha
ng
e  
REX1
Pa
ss
ag
e 3
Pa
ss
ag
e 5
Pa
ss
ag
e 7
Pa
ss
ag
e 9
0
1
2
3
Fo
ld
 C
ha
ng
e  
TDGF
**
Pa
ss
ag
e 3
Pa
ss
ag
e 5
Pa
ss
ag
e 7
Pa
ss
ag
e 9
0
1
2
3
Fo
ld
 C
ha
ng
e  
DPPA4
Pa
ss
ag
e 3
Pa
ss
ag
e 5
Pa
ss
ag
e 7
Pa
ss
ag
e 9
0
1
2
3
POU5F1
Fo
ld
 C
ha
ng
e  
Pa
ss
ag
e 3
Pa
ss
ag
e 5
Pa
ss
ag
e 7
Pa
ss
ag
e 9
0
1
2
3
Fo
ld
 C
ha
ng
e  
SOX2
*
Route A1
Route A2
A B C
D E F
G
 - 134 - 
 
Figure 35: Gene expression analysis of experiment A at four passage points over the then passages, 
expression was measured by real-time quantitative reverse transcription-polymerase chain reaction 
(qRT-PCR). Fold change was calculated using the relative quantity of each gene was calculated by the 
DDCt method, using a correction for the amplification efficiency of that gene, and normalised to the 
geometric mean of two housekeeping genes: glyceraldehyde-3-phosphate dehydrogenase and b-actin. 
Significant differences in fold change at different passage cycles were seen only for A -DNMT3B (***, 
p=0.0007), NANOG (*, p=0.01) and SOX2 (**, p=0.004). Significant differences between route A1 and 
A2 were seen only for A -DNMT3B (**, p=0.0032) and F-SOX2 (**, p-0.006). Differences between the 
two routes within a passage cycle were only observed for G-TDGF (passage cycle 3, **, p=0.018), A -
DNMT3B (passage cycle 7, *, p=0.0221; passage cycle 9, **, p=0.0073), and F-SOX2 (passage cycle 
9, *, p=0.0191). Error bars indicate standard deviation (n=3 for all graphs).  
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4.3.8. Experiment 4.1: inter-experiment reversal of protocol culture conditions 
 
As observed in the previous passages of experiment 4 cells (A2) that were under route B2 had slightly 
higher cell viability and higher SGR values whilst the converse was true for route B1 cells (Figure 36). 
By the reversal harvest passage route B2 cells exhibited changes in marker expression as they started 
to express SSEA-1, which they had not expressed in the previous nine passages, whilst route B1 cells 
had a decline in SSEA-1 expression. However, the rate of conversion of B1 is seemingly slower 
compared to B2, as there is still SSEA-1 expression in route B1 cells (Figure 37C).   
 
N.B. This experiment was carried out during the middle of the longitudinal study. Therefore, to maintain 
a reasonable workload the experiment was performed without any replicates, as it was principally an 
explorative experiment: to ascertain if the behaviours observed were due to the conditions the cells were 
being cultured under.  
 
Figure 36. Growth data of the reversal route experiment over three analysis time points. B1 previously 
A2 overall has lower cell viability and SGR values compared to B2, previously A1, which had an 
increase in both cell viability and SGR.  
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Figure 37.  (A)Lactate SMR demonstrating a change in SMR due to culture route, B2 previously A1 
has an increase in SMR. (B) Percentage expression levels at the reversal point and after 2 passages in 
the reversal experiment (reversal harvest), both B1 and B2 had an increase in OCT3/4 expression. (C) 
SSEA-1 percentage positive levels illustrating a decrease in expression for B1 and an increase for B2, 
demonstrating a change in phenotype express due to the exchange of culture conditions. 
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4.3.9. Experiment 5: 4-way comparison of the effects of medium of exchange. 
 
SSEA-1 and SSEA-4 marker expression are both very stable with minimal variation throughout the 
three passages. The cells do exhibit variation in the OCT3/4 marker in all the conditions as expression 
decreased, most notably at passage 3, regardless of whether they subjected to medium exchange after 
48 h or not; the same trend was exhibited across all of the conditions independent of the seeding density 
(Figure 38C). Akin to experiment 4, the route C2 condition exhibits a higher rate of metabolism 
(Figure 38B); other significant differences between routes are noted in Table 22. The SGR values were 
similar across all the conditions used, independent of the culture conditions and density, apart from C4 
at passage 3 (Figure 38A). 
 
 
Figure 38: (A) SGR over three passages, similar values were observed in all culture routes, apart from 
C4 at passage 3 (n=2). (B) Glucose SMR over three passages demonstrating that route conditions C2 
and C4 that had no medium exchange after 48 h had higher SMR compared to route C1 and C3. 
Significant difference between routes at each passage shown on the graph highlight that seeding density, 
feeding regime and a combination of both parameters resulted in a different SMRs (n=2). (C) OCT3/4 
marker expression over three passages, expression levels are similar between routes, significant 
difference observed between passage 2 and 3 for all routes (*p<0.05) except route C4.  
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Table 22. Summary of the significance values at each passage, comparing the SMRs of the different 
routes using Tukey’s multiple comparisons test. Both seeding density and feeding regime were shown 
to result in significant difference between the four routes. The highest significant differences between 
routes, within passages, were observed when both parameters were changed e.g. C2 vs C3, (n=2 for 
each condition). 
 
 
 
 
Fvfg 
Fgf  
 
 
 
 
;,;,dfrg  
 
 
Passage 1 Passage 2 Passage 3
Condition Parameter Summary P Value Summary P Value Summary P Value
C1 vs. C2 Feed * 0.024 ** 0.0082 ** 0.0059
C1 vs. C3 Density * 0.0494 ** 0.0026 ns 0.0573
C1 vs. C4 Feed & density ns 0.998 * 0.0438 ns 0.1793
C2 vs. C3 Feed & density *** 0.0002 **** <0.0001 **** <0.0001
C2 vs. C4 Density * 0.0327 **** <0.0001 ns 0.2435
C3 vs. C4 Feed * 0.0364 ns 0.3936 ** 0.0013
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4.4. Discussion  
 
In the context of the growing cell therapy industry, it is important to develop robust protocols that are 
easily translatable, transferable and comparable, to ensure high quality cell products that satisfy 
regulatory requirements without being burdensome on the manufacturing process141,145,241. As such, 
before truly automated and closed systems can be employed, it is important to have standardisation in 
the manual and semi-automated protocols that are currently in use. This chapter set out to demonstrate 
that defined, specific protocols that are barred to user interpretation are necessary to maintain 
consistency, particularly in the context of reference standards and reference cell lines245,246,253. The 
simultaneous culture of the EC 2102Ep cells using two different culture routes was utilised to explore 
the effect that changes in protocols have on cell culture process characterisation and outcomes.   
 
Previous work within the lab by Dr Samantha L Wilson and Dr Maryam Shariatzadeh had shown that 
that even for embryonic carcinoma cell lines like EC 2102Ep, the growth is not consistent; however, it 
is unclear what causes the variability. It is our hypothesis that the root cause of the variability is due to 
the lack of controlled culture protocols; which results in differences in cell culture growth and 
characterisation outcomes. It is evident from the experiments that in terms of growth rate, the cells are 
robust to a wide range of seeding densities (5,000 to 93,000 cells/cm2), illustrating that at least in the 
case of EC 2102Ep cells, seeding density is not a limiting factor of cell growth, within the ranges tested. 
Instead, it is assumed that the differences observed are resultant of the cell system dynamics, as a 
consequence of the protocol parameters such as undefined seeding densities due to split ratios and 
inconsistencies in feeding regime. 
 
Density has been reported to be a major parameter that can influence undesirable cell differentiation, 
evidenced by the EC 2102Ep line and work carried out by Andrews (1982)244,254. Here the authors show 
that when seeded at a lower density (1,300 cell/cm2) the cells start to change their phenotype as they 
expressed SSEA-1 which is a negative marker of EC 2102Ep cell line pluripotency243,244. Interestingly, 
preliminary results in the present work, scanning through a range of densities showed no difference in 
cell growth; morphology and specific growth rates (Figure 27 and Figure 28). Therefore, additional 
cell characteristics such as gene expression, cell phenotype and SMR were measured to ascertain if 
density was the major driving force for differences previously observed. The experimental design 
employed explored feeding regime as an addition protocol parameter that could attribute to variation, 
either by itself or as a combined effect with seeding density. Akin to the work by Andrews (1982), it 
was observed that changes in seeding density did result in cell behaviour that suggests cell 
differentiation, however it was also observed that the feeding regime employed also resulted in other 
cell characteristic differences. These differences were assessed using secondary methods of appraisal 
that are based on rates and specific consumption/production of measured metabolites. These analyses 
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reveal that SMR is significantly affected by feeding regime regardless of seeding density, showing that 
density is not the only major factor that needs to be controlled, to ensure consistency in cell 
characteristics during cell culture. Although Andrews (1982) prescribe the route A1 density (66,667 
cells/cm2) as the optimal seeding density, it is evident that even at this density variation is observed 
through the passages and experiments carried out.  
 
The results from the experiments presented highlight the need to understand process parameters within 
cell culture protocols, as greater understanding can result in increased process control. It is evident from 
experiments 1 to 5 that the cells in terms of growth are robust to a wide range of densities and culture 
conditions, illustrating that at least in the case of EC 2102 Ep cells, neither density or nutrient levels are 
a limiting factor of cell growth within the relatively wide ranges tested. The experiments carried out do 
show that there are some behaviours and instabilities observed based on cell density. The hypothesis 
that poor or non-ideal culture conditions i.e. starvation over a period results in the poor growth 
performance is not supported by the present work as the cells do not seem to maintain their cell state 
(i.e. metabolic rate) based on their previous culture state. This is highlighted in experiment 4.1 where 
the cells switched behaviour instantly even after being cultured under certain conditions for eight 
passages previously. 
 
Experiment 4 was a longitudinal study that aimed to investigate the stability of the two routes and to 
assess the effect of feeding regime on the growth performance of the cells. The in-house defined NIBSC 
protocol condition, route A1, was compared to a streamlined protocol using a lower starting seeding 
density. The route A2 condition was chosen as previous experiments revealed that cells grown at 20,000 
cells/cm2 with 5 mL of growth medium performed well in terms of cell viability and SGR. The cell time 
for this condition was then calculated (Equation 6), a value of 2.22x107 cell hours per 5 mL of growth 
medium over 72 h was obtained, which was a more than sufficient medium capacity to sustain the cells 
over a 72 h culture period without medium exchange. From a manufacturing point of view this minimal 
intervention protocol is ideal as it allows for less human manipulation and use of reagents, which are 
simple means of reducing production costs133,240. The objective of experiment 4 was to elucidate 
whether the cell time defined protocol, route A2, would allow for cells to be cultured in a streamlined 
manner and still retain the same characterisation outcomes as the original protocol in terms of cell 
growth dynamics, phenotypic expression and metabolism. A paper by Josephson et al (2007) previously 
cultured the EC 2102Ep cells for ten passages and showed no notable characteristic changes in the cells, 
which made them an ideal human embryonic stem cell reference line candidate243. As such the 
experiment also cultured the cells for ten passages whilst tracking the growth and metabolic rates along 
with gene expression and phenotypic markers of the cells.  
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Over the ten passages of experiment 4, a fluctuation trend in growth rate and cell viability was observed. 
Interestingly this fluctuation is synched between the two different culture routes (Figure 33). This 
suggests that there is an artefact that synchronises the two routes in terms of cell growth and viability 
that is independent of the route of culture the cells are exposed to. It is unclear whether this is an innate 
feature of the cells or not, this synchronised behaviour is conserved throughout a range of experiments 
and even over ten passages of the same stock of cells, which alludes to the behaviour being an innate 
feature of the cells. Alternatively, although not considered to be the sole cause, it could be deemed that 
the synchronised behaviour is subject to a measurement system error. This notion is supported by 
observation of the behaviour across independent culture trains. However, different characterisation 
systems (cell counting, immunophenotyping, gene analysis and metabolic analysis) with different 
manipulation techniques in terms of sample handling were used. Therefore, it is unlikely that 
measurement error could be seen in all techniques used, suggesting instead, that the synchronised 
behaviour observed is an effect of the cells themselves; especially since some of the genes also support 
the synched behaviour that is seen in the SGR and cell viability. There is no difference in fold change 
between the two routes, and yet there were significant fold change differences between the passages for 
DNTM3B, NANOG and SOX2 within each route. Conversely, there is no difference in gene regulation 
between the two routes for DPPA4, POU5F1 and REX1, which all had consistently similar levels 
between routes and between passages (Figure 33). The high levels of consistency within the routes 
throughout the passages demonstrates that when a defined protocol is followed, less variation during 
cell culture is observed. 
 
The notably higher SMR for route A2 (Experiment 4) was an unexpected observation as this disparity 
in SMR has not been previously seen to the same magnitude. This behaviour was only observed in 
experiment 4, 4.1 and 5, suggesting that the change in SMR is due to the cells being cultured on the 
streamlined protocol without medium exchange. Implying that there is an ability to affect cell SMR and 
phenotypic marker expression by the culture conditions i.e. nutrient availability based on feeding. This 
effect is observed to be reversible both in terms of SMR and the phenotypic markers that are expressed. 
The change in expression levels of SSEA-1 and OCT3/4 shows that culture conditions do have an 
influence on marker expression in a reversible manner. It is interesting to observe that changing the 
culture environment conditions by manipulating nutrient levels, had such a significant impact on the 
cells even if they had been cultured under certain conditions in previous several passages. 
 
The change in expression levels of SSEA-1 was instantly noted following the first passage, illustrating 
that the culture feeding regime, can impact the metabolic behaviour of the cells and phenotypic marker 
expression (Figure 33C and D), but not necessarily the growth performance of the cells (Figure 33A). 
This implies that the cause of the different SMR is due to the lack of medium exchange following 48 h. 
This is substantiated by experiment 5, as conditions not subjected to medium exchange had higher 
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SMRs compared to the cells that were subjected to medium exchange. Evidenced through experiment 
5 were the differences between the routes at the three passages, the most significant differences are 
indicated (Figure 38B), other significant differences are reported in Table 22. This highlights that 
differences in culture protocol based on seeding density, feeding regime or both parameters result in 
notable SMR variation within the same stock of cells cultured simultaneously. The highest significant 
differences between routes, within passages, were observed when both parameters were changed e.g. 
C2 vs. C3, where both the seeding density and feed regime are changed. 
 
As the EC 2102Ep cells are destined as a reference line, it was assumed that there would be stability in 
the characterisation of the cells. In experiments 3.3, 3.4, 4 and 5 there were clear fluctuations in the 
expression of the OCT3/4 marker, implying that not only do the cells cycle in their SMR rate but also 
their phenotypic profile. However, it seems that the fluctuation can be exacerbated by the culture 
conditions. This was the case in conditions where 20,000 cells/cm2 were seeded; higher fluctuations 
were observed compared to the other conditions in the previous experiments. It is evident that the cells 
within both routes were in a linked state of cycling in terms of the metabolic rate and the phenotypic 
expression of OCT3/4. However, the cycling between the SMR and marker expression, are independent 
to each other, as the cycles are observed at different passage points. Over the ten passages some 
unexpected behaviours were observed; of interest is the presence of SSEA-1 which is a negative marker 
for pluripotent stem cells and the decrease in expression of the positive marker OCT3/4. The presence 
of SSEA-1 and the significant decrease in Oct-3/4 (declined by up to 52% in route A2 passage cycle 7) 
implies that the cells are differentiating (Figure 33E and Figure 34) 243,244,254. The significant 
differences in gene expression are observed at passage 7 and/or 9, which are the same passage cycles 
that demonstrate notable differences in phenotypic marker expression when cross validated through 
flow cytometry, particularly OCT3/4. It is unclear what causes the change in behaviour, in either cell 
SMR or marker expression246,255,256.  
 
All the experiments produced results that presented unexpected behaviours, of particular interest is the 
presence of SSEA-1 which is a negative marker for pluripotent stem cells and the decrease in expression 
of the positive marker OCT3/4 (up to 52% in route 2 E.P7). These results imply that the cells were 
differentiating which would not be expected as EC 2102Ep cells are a carcinoma cell line 243. However, 
Andrews (1982) reports that when cells are seeded at lower densities they have a propensity to 
differentiate although this not substantiated by analytical evidence of cell differentiation assays244,257. 
However, it is still unclear as to what causes the change in behaviour, in either cell growth or marker 
expression.  
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4.4.1. Rationalisations:  
 
The phenotypic change that was been observed in the experiments could be attributed to cell 
differentiation. This a possible effect of the culture conditions, the literature regarding embryonic and 
pluripotent cells suggests that seeding at low densities causes differentiation, much like the conditions 
that the cells were cultured under256–258. The gene expression fold changes observed for key pluripotency 
markers DNTM3B and SOX2 suggest that the cells are differentiating. Furthermore, the experimental 
data shows evidence of higher metabolite rate and phenotypic change, which is often concomitant with 
cell differentiation and/or the presence of a different cell population. However, there is evidence within 
the experiments that is contrary to the cells differentiating, suggesting it is the protocol parameters i.e. 
medium exchange which cause variation. For instance, no morphological change was observed under 
light microscopy throughout the ten passages; additionally, NucleoCounter cell analysis showed no 
significant change in the measured cell diameters between the two routes (Figure 33C) and even 
cultures seeded at higher densities exhibit levels of phenotypic change. 
 
Another proposed explanation of the observed phenotypic variation is that the change is linked to cell 
death. This rational is reinforced by the fact that the phenotypic change is not cumulative over time, 
suggesting that the expression presents just before the cells start to die, resulting in a non-cumulative 
expression of SSEA-1. However, cell viability and SGR data show evidence that is contrary to this, as 
cells in route A2 have on average, higher cell viability and growth rate which would not be expected 
with cell death (Figure 33A and B). Furthermore, at passage cycle 7 there is a drastic decrease in 
OCT3/4 yet in the next passage there is no significant decrease in cell number or cell viability.  
 
Density had been reported to be a crucial factor in some cell culture protocols, particularly those using 
embryonic cell lines, as it is reported to have an influence on metabolic behaviour and both directed 
and spontaneous differentiation87,125,257,259,260. In experiment 4 the observed differences in behaviour 
could be attributed to the seeding densities used, since this was the main parameter that was altered 
between the two routes. Nonetheless, density is unlikely to be the only driving force, since the initial 
experiments showed no drastic difference in SMR and growth based on density (Figure 29 and  
Figure 30). Furthermore, the results from experiment 5 demonstrated that growth medium exchange 
has a significant effect on the SMR on the cells regardless of density, implying that cell metabolism 
based on feeding regime had a notable impact on SMR and marker expression as well as seeding 
density. 
 
An alternative rationalisation that has been considered is that the phenotypic change is linked to a cell 
‘selection’ or ‘survival’ mode, which has no observed instances of support in the literature. It can be 
suggested that the cells are conditioned to metabolise nutrients differently under the excess nutrient 
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conditions which results in the marker expression change. Route A2 appears to be a favourable 
condition as the cells had higher cell viability and better growth performance. Therefore, it is unclear 
as to why the cells would default to selection or survival mode as they are in an optimal cell time range; 
thus, they should not experience any starvation or stress. Moreover, there is no observed response to 
excess nutrients in the metabolite data in experiments 3.1 to 3.4. Furthermore, if phenotypic change is 
a response to nutrient levels it would be expected that route A1 would also exhibit drastic changes in 
marker expression and/or SMR rate as fewer nutrients per cell were available in comparison to route 
A2 (due to a higher cell density in route A1). However, it is unclear if the feed/no feed regime is a 
potential driving force causing the observed change as no metabolic data is available until the passage 
day, resulting in unknown behaviour trends on the intermediate days of route A2. Furthermore, if the 
phenotypic change is linked to a cell ‘selection’ or ‘survival’ mode the most drastic change in marker 
expression during, E.P7 48.6 % (OCT3/4) and 6.5 % (SSEA-1), it would be expected to have occurred 
when the cells were performing at their best. This is not the case as the drastic change does not occur 
when the cells are at their highest rate of metabolism or growth rate. 
 
The above rationalisations highlight that even in a cell line that is considered to be a stable reference 
point; differences can be observed due to changes in parameters and conditions, over time. These 
different conditions such as when to perform medium exchanges and the use of seeding densities that 
vary i.e. through the use non-standardised seeding densities or split ratios, are often left to the user’s 
discretion in many protocols. Evidently, this results in noteworthy effects on cell behaviour and 
characterisation outcomes. Split ratios are not best practice as innately cells will grow differently from 
passage to passage. For example, a split ratio of 1:3 can be drastically different from passage to passage, 
particularly if the cells grow at significantly different rates at different passages, which is a concomitant 
feature of cells that are revived from cryopreservation. In addition, split ratios that are based on observed 
confluency, are also likely to cause variation in cell growth dynamics. This is due to the subjective 
nature of observed confluency and its lack of accurate representation of cell number, therefore 
potentially resulting in non-ideal metabolite profiles that can influence cell growth behaviour, 
producing further cell system inconsistency. Differing levels of variability and non-conformity are 
detrimental to the successful use of reference cell lines, especially for those intended to be a 
standardised QC reference247,261. This is of relevant importance as the use of reference cell line is likely 
to see prominence due to the increase in assays and product validation. The advent of chimeric antigen 
receptor T-cell (CAR-T) therapies, could potentially use reference cell lines as QC reference standards 
for flow cytometry. Interestingly, flow cytometry analysis revealed marker profile differences; even 
when the cells were at the prescribed density of 66,667 cells/cm2, showing that even when cultured in 
a consistent manner there is inherent variation on marker profile through the ten passages.  
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This further emphasises the need to standardise parameters within protocols to minimise and control 
variation. This can be achieved by obtaining cell counts, ensuring that the input and output cells 
numbers are used to maintain optimal culture conditions for cell growth, without entering regions of 
metabolic instability. Consequently, this allows for greater control and consistency of the culture system 
as the seeding density and nutrient levels are predefined. The use of cell time, which is a concept that 
can be used to quantify the capability of a given volume of medium to sustain the growth of a given 
number of cells for a specific period, ensures that the culture system given the set density and nutrient 
availability will not enter a region of metabolic strain. This is important since imbalances in glucose 
and lactate levels have previously been shown to result in limitation of cell growth241,260 and importantly 
for reference lines, metabolite imbalances have been shown to impact the stability of marker expression. 
Metabolic strain is potentially problematic if not controlled, as reference lines are used for QC of CTPs 
need to demonstrate their stability over time, using gene and phenotype marker expression. 
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4.5. Conclusions  
 
This chapter has illustrated that cell system behaviour is affected by culture conditions; experiments 4 
and 5 demonstrate that feeding regimes (medium exchange) also have a significant effect on SMR and 
phenotypic marker expression when compared to seeding density. This highlights that differences in 
culture parameters do cause variation, however, it is evident that when parameters are kept consistent 
less variation is observed. The initial experiments (Experiment 1 and 2) show that there is no significant 
difference in SGR between different seeding densities when feeding regime is kept consistent 
throughout the culture period. It has been demonstrated through a range of experiments that seeding 
density is not the sole factor that can cause variation especially when the flasks are seeded at the same 
density. Instead it is clear that other protocol parameter themselves or when compounded with seeding 
density result in variation, hence the need to ensure stringent control of protocol parameters. The present 
work has demonstrated that seeding density and the feeding regime employed, in terms of both the 
volume and frequency of medium exchange, have a major effect on cell culture variation. Lower 
densities have been shown to have distinctly different behaviours compared to higher density cultures 
in terms of their SMR. A combinatory effect of seeding density and feeding regime has been shown to 
cause variation in SGR, SMR, phenotype and expression of some genes. However, it is unclear under 
what mechanism medium exchange or lack of medium exchange influences cell characteristics such as 
SMR and marker expression. The present work demonstrates that culture conditions have an impact on 
cell characteristics, notably on specific metabolic rate and phenotypic marker expression. Thus, 
demonstrating that there is a complex interaction between gene expression, cell phenotype and the 
feeding regime that cannot be accurately represented by growth rate and cell counts alone. It is worth 
noting that the cells do not retain a detrimental cell metabolic state due to culture conditions as they can 
readily switch between culture condition dependent behaviours even after several passages under a 
certain condition, as shown in the reversal experiment (4.1).  
 
The lack of robust, well-defined and standardised cell-culture protocols results in compounded variation 
in the culture systems. This is due to differences in inter-lab and individual decision-making processes 
based upon protocol parameters, such as observed cell confluency as a gauge of when to perform a cell 
passage. This highlights that use of non-standardised, ambiguous protocols can easily produce 
differences over time, further illustrating the need for standardised protocols not only from an 
uniformity point of view but also in terms of reproducibility consideration; which is integral to the 
pragmatic and successful use of reference cell lines in cell therapy manufacturing. 
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4.6. Technique optimisation and knowledge acquired from EC 2102Ep work 
 
The work carried out in this chapter has highlighted that it is important to have an in-depth 
understanding of what the cells are doing within a cell culture system in order to have better-informed 
process control. Carrying out growth curve experiments both high resolution (everyday analysis such 
as in experiment 1& 2) and longitudinal provides information about how the cells grow and react to 
different conditions and how consistent their behaviour is at different time points. The EC 2102Ep 
experiments carried out have provided a framework that will be used in the following experimental 
chapters to explore the behaviours of the H9 cell line.  
 
The matrix experiments (3.1 to 3.4 and 5) acted as screening studies to investigate the effect of different 
parameters within the cell culture systems. This will be a methodology used in the following chapters 
through design of experiment (DoE) approaches to assess the patterning of the H9 cells into vmDA 
neuroprogenitor cells. Akin to experiments in this chapter different conditions looking at varying 
concentrations of the important small molecules will be investigated. During the expansion phase of 
the pluripotent H9 cells, the feeding regime will be investigated as it had been shown here that different 
feeding regimes can be employed without having a detrimental effect on cell characteristics. 
Optimisation of the feeding regime of the pluripotent H9 cells, currently subjected to 100 % medium 
exchange everyday of culture, would be beneficial as reducing the feed days would subsequently reduce 
the overall resources and labour required. Thus, lowering the associated production costs which is 
favourable for the commercial viability of the product.  
 
The work carried out in this chapter has also provided an opportunity to optimise techniques prior to 
carrying out the costlier and resource demanding work on the H9 clinically relevant cell line. The cell 
counting strategy used was developed within this chapter and has been standardised for use in the 
following experimental chapters, details of the counting procedure can be found in the materials and 
methods chapter section 3.3.2.  
 
As the nature of this chapter became highly focused on standardisation, it was clear that the sample 
preparation and procedure used during analysis would need to be standardised as well, in order to 
minimise variation within the results obtained. Therefore, storage time periods following fixation prior 
to flow cytometry analysis were kept the same. In some cases, it was observed that sampled stored for 
more than 48 h post fixation did not pellet correctly resulting in sample loss. As a result, all flow 
cytometry data report in this chapter was obtained using cells analysed after no more than 24 h post 
fixation. 
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4.7.  Chapter Bridge 
 
This work has provided a strong basis to carry out work on the clinically relevant and destined cell 
lines. It is evident that there are a wide range of parameters that are often over looked that can influence 
the behaviour of the cells e.g. cell feeding regimes. Although it might not be possible to control them 
all, it is important that they are monitored to ensure they do not cause any significant changes to the 
cell product or reference cell line. The experiments on the EC 2102Ep have allowed for experimental 
designs to be established and for optimisation of techniques that will be used on the clinically relevant 
cell lines. The next chapter will focus on the process understanding of the H9 protocol, as evidenced in 
this chapter, protocol consistency is crucial within a cell-based process. Therefore, understanding the 
protocol is a key element that must be achieved prior to any optimisation and development work being 
carried out, in order to provide the robust consistency needed for a viable product. 
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Chapter 5. Investigation of the pluripotent state of H9 human embryonic stem cells  
 
5.1. Introduction  
 
The focus of this chapter is on the expansion of the H9 pluripotent cells which are the  input cell material 
for differentiation into ventral mesencephalic dopaminergic (vmDA) neuroprogenitors. The H9 cell line 
is a human embryonic stem cell line obtained from the WiCell Research Institute (Madison, USA). The 
H9 cell line was selected due to it being a clinically relevant cell line that can be used for vmDA 
differentiation for a Parkinson’s disease (PD) cell therapy product. Understanding the culture dynamics 
of the pluripotent cells has been deemed important to the overall differentiation protocol, as input cell 
material can have an impact on the output cells158,262. The work in the previous chapter illustrates that 
expansion of embryonal cells is subject to variation, some of which can be controlled and measured via 
the implementation of robust and standardised cell culture protocols. Using the knowledge obtained 
from the EC 2102Ep cell line (Chapter 4), the work in this chapter aimed to understand the culture 
dynamics of the H9 cells in their pluripotent state, to produce a standardised protocol that can be used 
for the expansion phase prior to vmDA differentiation. The relatively low seeding densities (10,000 – 
30,000 cells/cm2) required to seed the cells for differentiation resulted in low levels of expansion prior 
to differentiation. Typically, one well of a 6-well tissue culture microtiter plate seeded at 20,000 
cells/cm2 (~177,000 cells per well) could yield an average of 1,600,000 cells per well (180,000 
cells/cm2), affording an almost ten-fold increase in cell number over three days of culture. The resulting 
pluripotent cells of each well can then be used to seed a further eight to nine well for differentiation, 
thus highly efficient in terms of cell usage. As such, the actual cell number yield was not a priority for 
optimisation, instead the consistency of obtaining the cell number yield, cell viability, cell phenotype 
and cell metabolic profile was the focus of the process optimisation of the present work. 
 
The Lund protocol stated that the differentiation process should be started with “good-quality starting 
material129. However, there is no quantifiable data related to what this explicitly refers to. At most the 
protocol states that “Before the differentiation is started, make sure that the hPSC [human pluripotent 
stem cell] colonies appear pluripotent by visual criteria (i.e., homogeneous-appearing colonies with 
clear borders and the absence of obvious differentiating zones). If you are using a hPSC culture system 
other than the one described here, manual removal of spontaneously differentiated colonies might be 
required. A desirable confluency of hPSC cultures is 70–90% of the well area at the start of 
differentiation”129. The description above is open to individual interpretation making it highly 
subjective, non-standardisable and ultimately prone to operator variation. This is problematic for 
standardisation of manufacturing protocols as the lack of defined parameters and procedures ultimately 
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results in product variation; if this variation is out of the specification range, it can nullify batches, 
hinder product release and waste financial and labour resources. 
 
As such the work in this chapter aimed to carry out characterisation studies that can provide information 
on what ‘good-quality’ starting cell material should be for the differentiation process. The optimisation 
work carried out in this chapter was carried out after the process/protocol had been transferred from the 
collaborators at Lund University. Using methods employed in the previous chapter (Chapter 4) such as 
metabolite analysis, flow cytometry and cell growth analysis, the present work aimed to produce a 
robust and informed understanding of H9 pluripotent cell behaviour. The ideal objective was to provide 
metrics including the minimum cell viability levels, specific growth rate (SGR) and levels of phenotypic 
markers such as Ki67 and OCT3/4, that are needed to qualify a pluripotent expansion culture as a source 
of ‘good-quality’ starting material. Adding these metrics would allow for quantifiable benchmarks that 
can be used to standardise the expansion protocol, which in turn would result in standardised input cell 
material for the differentiation process into vmDA neuroprogenitors. 
 
5.2. Methods   
 
5.2.1. H9 bank setup  
 
A vial of H9 cells (P5) was thawed and seeded onto a Biolaminin-521 coated T25 cm2 tissue culture 
flask as described in section 3.2.4.2. The cells were cultured for a longer period of time (eight days for 
the first passage and six days for the second passage) as they were being adapted for growth onto 
Biolaminin-521 from Matrigel (Corning, USA, cat#354320). Following two passages the cells were 
seeded into three T75 cm2 tissue culture flasks which resulted in a total of 54 x106 cells following one 
passage (the third passage post thaw of the original vial); these were cryopreserved at a density of 1x106 
cells/ml producing a working bank with a total of 54 cryovials at P8.   
 
5.2.2. H9 bank analysis 
 
A single vial of P8 cells from the H9 bank created above was thawed and seeded onto a Biolaminin-
521 coated T25 cm2 tissue culture flask. The cells are cultured for two passages at a density of 10,000 
cell/cm2. At passage 10 a total of fifteen T25 cm2 tissue culture flasks were seeded at a density of 10,000 
cells/cm2. Over five days, three of the flasks were harvested, counted and had their medium sampled, 
resulting in n=3 for the conditions harvested on each day. Following five days the remaining three 
flasks were passaged and used to seed an additional fifteen flasks which were treated as described 
above. Cells from passage 10 were sent for karyotype analysis at a third-party institution (TDL 
Genetics, London, UK).   
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5.2.3. Expansion: cell bank variability study 
 
Three vials of P8 cells were thawed and seeded at two densities (10,000 and 20,000 cells/cm2) onto 
Biolaminin-521 coated 6-well tissue culture microtiter plates. The cells were cultured for two four-day 
passages and analysed for their viability, SGR, SMR and phenotype at the end of each passage; using 
panel 1 of the Miltenyi protocol. The experiment was carried out in triplicate for each vial at each of 
the three densities (see Figure 39).    
 
 
Figure 39. Schematic of the experimental design used to assess the reproducibility and variability of 
vials from the H9 bank of cells. Each of the three vials was thawed and seeded at 2 densities 10,000 
cells/cm2 (10K) and 20,000 cells/cm2 (20K) and cultured for two passages: n=3 for each condition. 
 
5.2.4. Expansion: the effect of ROCK inhibitor on attachment and proliferation  
 
One vial of P8 cells was thawed and seeded at 20,000 cells/cm2 into a Biolaminin-521 coated T25cm2 
flask. The cells were cultured for one passage and seeded onto Biolaminin-521 coated xCelligence E-
Plate® 96-well microtiter plates at two densities; 10,000 and 20,000 cells/cm2. The cells were cultured 
for three days at the two densities, using four different concentrations of ROCK inhibitor (ROCKi), as 
detailed in the plate layout (Figure 40). The xCelligence was scheduled to run sweeps and measure the 
Cell Index (adhesion/proliferation) as detailed in Table 23 over the three-day passage.  
 
 - 153 - 
 
 
 
Figure 40. xCelligence® RTCA E-Plate® layout. Two densities, 10,000 and 20,000 cells/cm2, were 
seeded onto E-Plate® 96-well microtiter plates with medium containing four different concentrations 
of ROCKi ranging from 0 to 15 µM: n=6 for each condition used.  
 
Table 23. xCelligence® RTCA schedule used to measure the Cell Index. 
 
 
5.2.5. Expansion: the effect of cell seeding density 
 
Seven P8 vials from the H9 bank were thawed and seeded at three densities (10,000; 20,000 and 30,000 
cells/cm2) onto Biolaminin-521 coated 6-well tissue culture microtiter plates (Figure 41). The cells 
were cultured for a single four-day passage and analysed for their viability and SGR on day 2 and day 
4 of the passage. Cell phenotype was analysed at the end of the passage (day 4); using panel 1 of the 
Miltenyi protocol. The experiment was carried out in triplicate for each of the three densities. 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A 0 µM 0 µM 0 µM 0 µM 0 µM 0 µM
B 5 µM 5 µM 5 µM 5 µM 5 µM 5 µM
C 10 µM 10 µM 10 µM 10 µM 10 µM 10 µM
D 15 µM 15 µM 15 µM 15 µM 15 µM 15 µM
E 0 µM 0 µM 0 µM 0 µM 0 µM 0 µM
F 5 µM 5 µM 5 µM 5 µM 5 µM 5 µM
G 10 µM 10 µM 10 µM 10 µM 10 µM 10 µM
H 15 µM 15 µM 15 µM 15 µM 15 µM 15 µM
10,000 cells/cm2
20,000 cells/cm2
Sequence Step Sweeps Interval Time (mins)
Total Time 
(hh:mm:ss)
1 BACKGROUND 1 1 00:00:17
2 ADHESION 100 2 04:39:07
3 PROLIFERATION 30 60 21:25:52
4 DAY 1 POST FEED 100 2 24:44:11
5 DAY 1 PROLIFERATION 60 30 46:13:02
6 DAY 2 POST FEED 100 2 49:31:20
7 DAY 2 PROLIFERATION 60 30 70:43:57
8 DAY 3 POST FEED 100 2 74:02:09
9 DAY 3 PROLIFERATION 60 30 104:11:28
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Figure 41. Schematic of the experimental setup used to determine the growth curve of three different 
seeding densities: 10,000 cells/cm2 (10K); 20,000 cells/cm2 (20K) and 30,000 cells/cm2 (30K). n=3 for 
each condition was used. 
 
5.2.6. Expansion: the effect of feeding regimes 
 
One vial of P8 cells from the H9 bank were thawed and seeded at 20,000 cells/cm2 onto Biolaminin-
521 coated T-25cm2 tissue culture flask and cultured for one passage. To investigate the effect of 
different feeding regimes the cells were seeded into four different routes of culture as detailed in Table 
24 and cultured for two passages in triplicate for each route condition. The P9 cells were harvested and 
reseeded at 20,000 cells/cm2 onto Biolaminin-521 coated 6-well tissue culture microtiter plates. The 
cells were analysed for their viability, SGR, SMR and phenotype at the end of each passage; using panel 
1 of the Miltenyi protocol in the first run of the experiment.  
 
For the second run of the experiment, sacrificial wells for each of the four routes were seeded directly 
from thaw for daily harvests, the experiment was carried out in triplicate for each route. The cells were 
analysed daily for their viability, SGR and SMR: cell phenotype was analysed at the end of each 
passage; using panel 1 of the Miltenyi protocol. Four T25 cm2 tissue culture flasks were also seeded at 
20,000 cells/cm2 and cultured in parallel to the four routes in the 6-well tissue culture microtiter plates, 
the cells from the flasks were used to seed cells for the second passage.  
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Table 24. Details of the different experimental culture routes investigated. Control was subjected to 
M. Ex daily; route 1 was subjected to M. Ex on day 1 only; route 2 on day 2 only and route 3 was not 
subjected to a M. Ex throughout the passage. n=3 for each condition was used. M. Ex = medium 
exchange 
 
 
5.2.7. Expansion: the effect of density and medium exhaustion  
  
To investigate the effect of density and nutrient availability on cell growth inhibition, two conditions 
of culture were set up for a seven-day passage. The daily feed (DF) condition was subjected to medium 
exchange every 24 hours, while the one feed (OF) condition was only subjected to one medium 
exchange 24 hours following seeding (Table 25). Three vials of P8 cells were thawed and seeded at 
20,000 cells/cm2 onto Biolaminin-521 coated 6-well tissue culture microtiter plates. Sacrificial wells 
for each condition were seeded for daily harvests, the experiment was performed in triplicate for both 
conditions. The cells were analysed daily for their viability, SGR and SMR, cell phenotype was 
analysed on day 0, 6 and 7; using panel 1 of the Miltenyi protocol.  
 
Table 25. Details of the two conditions used to investigate density and nutrient availability-based 
growth inhibition. The DF condition was subjected to M. Ex daily, while the OF condition was 
subjected to M. Ex on day 1 only. Cells were harvested and counted everyday: n=3 for each condition 
was used. M. Ex = medium exchange; DF = daily feed; OF = one feed. 
  
Route Day 0 Day 1 Day 2 Day 3 Summary
Control Seed M. Ex M. Ex Passage/Harvest Daily M. Ex
1 Seed M. Ex Passage/Harvest M. Ex on day 1 only 
2 Seed M. Ex Passage/Harvest M. Ex on day 2 only 
3 Seed Passage/Harvest No M. Ex
Route Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Daily Feed Seed M. Ex M. Ex M. Ex M. Ex M. Ex M. Ex Endpoint harvest
One Feed Seed M. Ex
Endpoint 
harvest
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5.3. Results  
 
Initial efforts were focussed on creating a working bank of H9 cells, these cells were assessed for 
karyotype abnormalities, none were found via g-band analysis to stain the chromosomes. The growth 
and metabolic profiles of the cells were analysed to determine appropriate seeding densities, duration 
of culture period and optimal feeding regime to be employed for the H9 pluripotent cell expansion.  
 
N.B. For the purposes of discussion, passages are referred to as; passage 1 or passage 2, while in fact it 
is passage 8 + n, i.e. passage 1 corresponds to cells at passage 9, passage 2 to cells at passage 10 and so 
on; unless otherwise stated. 
 
5.3.1. Analysis of the bank:  
 
The SGR values in passage 1 were either negative or low for the first two days. However, an increase 
in SGR from day 2 onwards was observed (Figure 42A). The cell viabilities at passage 1 were lower 
in comparison to passage 2 which had the lowest viability recorded to be 82% ±1.3 in comparison 70% 
±2.1 at passage 1, day 2 (Figure 42B). A trend can be seen in the glucose SMR as the cells reduce their 
SMR as they increase in number over the five-day culture period (Figure 42C). The results from the 
karyotype analysis demonstrated that the cells had no karyotype abnormalities (Figure 43).  
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Figure 42. (A) Data was collected everyday over two five-day passages. SGR is shown to increase each 
day, with the greatest increases from day 1 to day 2. Cells at passage 2 started to decrease their SGR 
from day 4 while at passage 1 the cells still had an increase in SGR from day 4 to day 5. There is a 
significant difference overall in SGR between passage 1 and passage 2 on all of the days except day 5 
p<0.0001 (****). (B) Overall, passage 2 cells had significantly higher cell viabilities that eventually 
dropped at day 4 (p<0.0001 (****), while passage 1 cells continue to increase in cell viability from day 
2 to day 5. (C) Glucose SMR data of the cells throughout the five-day culture period of each passage. 
SMR is higher in passage 2 compared passage 1, however in both instances there was a general trend 
of a decrease in glucose SMR. As a result of the negative SGR on day 1 at passage 1,  the SMR 
calculation for consumption was not carried out as it requires an increase in cell number, thus the data 
was omitted from the graph as it was erroneously showing production of glucose due to the negative 
SGR. Error bars indicate standard deviation, n=6 for SGR and cell viability data, n=3 for SMR data. 
 
 
Figure 43. Karyotype analysis of H9 cells showing normal XX chromosomes, a sample of cells from 
passage 2 was used to produce this karyogram. 
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5.3.2. Expansion: cell bank variability study 
 
The cell counts obtained prior to seeding the thawed vials demonstrated that there were differences in 
cell numbers banked and recovered from each vial, the cell numbers ranged from 8.9x105 to 1.14x106 
cells (Figure 45). As expected, on the harvest days the cells seeded at 20,000 cells/cm2 yielded greater 
cell numbers in comparison to their 10,000 cells/cm2 counterparts. However, the cell number at the next 
passage was significantly higher but only in the 20,000 cells/cm2 conditions and not in the 10,000 
cells/cm2 conditions as shown in Figure 45C. The SGR increased from passage 1 to passage 2 in all 
the conditions except for vial 1 at 10,000 cells/cm2 (Figure 45A). Vial 1 and vial 3 both at 10,000 
cells/cm2 were the only conditions to have a significant drop in viability from passage 1 to 2, with the 
vial 1 condition dropping to as low as 45% ±1.9 cell viability in one of the biological replicates, 51.7 
% ±5.3 on average (Figure 45B). The increased SGR from passage 1 to 2 was accompanied by an 
increase in LDH production SMR in all conditions except for the cells in vial 2 seeded at 20,000 
cells/cm2 (Figure 44B). Lactate SMR was only significantly different for cells in vial 1 at 10,000 
cells/cm2 (Figure 44A).  The flow cytometry results demonstrated that there was a significant difference 
between the expression of Ki67 from passage 1 to passage 2 in all of the conditions as the median 
fluorescence intensity (MedFI) of Ki67 decreased (Figure 46B and Table 26). Similarly, there is a 
significant decrease in expression of OCT3/4 in all conditions, except for vial 3 at 20,000 cell/cm2. 
However, PAX6 was lowly expressed in the cells at both passage 1 and passage 2  
Figure 46C).  
 
 
Figure 44. (A) Lactate and (B) LDH SMR data. Both lactate and LDH SMRs increased from passage 
1 to passage 2. However, only vial 1 at 10,000 cells/cm2 had a significant increase in lactate SMR, for 
LDH all conditions except vial 2 at 20,000 cells/cm2 had a significant increase in LDH SMR. Error bars 
indicate standard deviation, n=3. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 
0.001, and “****” indicates p<0.0001.
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Figure 45. Growth dynamics results. (A) SGR increases from passage 1 to passage 2, only vial 1 at 
10,000 cells/cm2 did not have a significant increase in SGR. (B) All of the 20,000 cells/cm2 had a 
significant increase in cell number from passage 1 to passage 2. (C) Only vial 1 and vial 2, both at 
10,000 cells/cm2 had significant decreases in cell viability from passage 1 to passage 2. (D) vials 2 and 
3 had similar cell numbers directly from being thawed after cryopreservation and before being cultured, 
however no difference was determined between the three vials. Error bars indicate standard deviation, 
n=6. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates 
p<0.0001.   
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Figure 46. MedFI values for OCT3/4, Ki67 and PAX6, an insufficient number of cells to perform the 
phenotyping assay was obtained from the Vial 1 10K condition at passage 1, therefore no data was 
available. There is a decrease in MedFI from passage 1 to passage 2 in all conditions for both 
OCT3/4(A) and Ki67(B). PAX6 expression levels were low in comparison to OCT3/4 and Ki67, inset 
shows the very low levels of PAX6, all conditions are under 800 for their MedFI values (C). Error bars 
indicate standard deviation, n=3. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 
0.001, and “****” indicates p<0.0001. 
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Table 26. Sidak’s multiple comparisons test of the MedFI the two markers that were positively 
expressed by the pluripotent cells. The table indicates the conditions that were significantly different 
from passage 1 to passage 2. 
 
 
5.3.3. Expansion: the effect of ROCKi on attachment and proliferation 
 
The results from the xCelligence readout revealed that the concentration with the highest Cell Index 
and therefore cell attachment was the 10 µM condition followed by 0 µM, 15 µM and then 5 µM, 
highest to lowest, respectively (Figure 47). When the readout was split into the two different densities, 
the 10,000 cells/cm2 condition demonstrated that the 10 µM concentration results in the highest Cell 
Index. The results for 20,000 cells/cm2 however show that irrespective on ROCKi concentration the 
cells are able to attach and proliferate, achieving a similar or higher Cell Index to those in the 10,000 
cells/cm2 conditions at equivalent ROCKi concentrations. For instance, the Cell Index for cells at 0 µM 
at 20,000 cells/cm2 is higher in comparison to all the concentration at 10,000 cells/cm2 (Figure 48).  
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Figure 47. xCelligence® RTCA graphical summary of the Cell Index of values of the different ROCKi 
concentrations. The 10 µM condition had the highest overall Cell Index for the grouped data of both 
10,000 cells/cm2 and 20,000 cells/cm2. Error bars indicate standard deviation, n=12. 
 
 
 
 
Figure 48. xCelligence® RTCA Cell Index of the two densities with four different concentrations of 
ROCKi. Only the 0 µM condition had a significant difference in Cell Index between 10,000 and 20,000 
cells/cm2. Overall, cells seeded at 20,000 cells/cm2 had a higher Cell Index, across the four ROCKi 
concentrations that were investigated. Error bars indicate standard deviation, n=6. “*” indicates p<0.05, 
“**” indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates p<0.0001. 
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5.2.4. Expansion: the effect of cell seeding density 
 
There was no significant difference between the conditions in terms of their SGR from day 0 to 2. From 
day 2 to 4, there were significant differences in SGR when comparing the 10,000 cells/cm2 condition 
to both the 20,000 and 30,000 cells/cm2 conditions, respectively (Figure 49A). Furthermore, there was 
no significant difference in SGR overall between 20,000 and 30,000 cells/cm2 at the harvest point on 
day 4. For each condition there was a significant increase in SGR from day 2 to day 4. In terms of cell 
number yield, only the 20,000 and 30,000 cells/cm2 conditions had significant increases from day 0 to 
day 2 and day 2 to day 4 (Figure 49B). The cell viabilities across all conditions drops significantly from 
day 0 to 2 from ~80% to ~40 % and then increase from ~40 % back up to ~80 by day 4 (Figure 49C). 
The MedFI for Ki67 is the highest across the three markers analysed, there is expression of PAX6 
observed in all three conditions and all conditions highly express OCT3/4 (Figure 50A).  
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Figure 49. Growth dynamics. (A) SGR increased from negative SGR to positive SGR from day 2 to 
day 4 for all three densities. (B) Cell number decreased from day 0 to day 2 and then increased from 
day 2 to day 4, the 10,000 cell/cm2 density does not have significant increase in cell number during the 
4-day passage. (C) All three densities had a decrease in cell viability from day 0 to day 2 which 
increased from day 2 to day 4. Error bars indicate standard deviation, n=3. “*” indicates p<0.05, “**” 
indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates p<0.0001 
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Figure 50. MedFI values for OCT3/4, Ki67 and PAX6. OCT3/4(A) and Ki67(C) were both highly 
expressed. (B) PAX6 expression levels are lower in comparison to OCT3/4 and Ki67. 
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5.3.5. Expansion: the effect of feeding regimes 
 
Overall there was a significant difference in the SGR of the different routes with the exception of the 
control and route 1. Between passages each route differed in SGR from passage 1 to passage 2 with the 
exception of route 2 (Figure 51A). At passage 1 the significant differences were only between route 3 
and the other conditions, however this changed at passage 2, with differences being between the control 
and route 2. Similarly, there was no significant difference in cell number yield for route 2 between 
passage 1 and passage 2, while significant differences are observed for the other routes; the control and 
route 1 both had a decrease in overall cell yield, while route 3 had an increase (Figure 51B). Both Ki67 
and OCT3/4 were highly expressed in all conditions, while there is no expression of PAX6 (Figure 
52B). The control and route 3 both had a decrease in OCT3/4 and Ki-67 from passage 1 to passage 2. 
Conversely, route 1 and route 2 both had increases in OCT3/4 and Ki67 from passage 1 to passage 2 
(Figure 52A and C). 
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Figure 51. Growth dynamics. (A) SGR decreases from passage 1 to passage 2 for the control and route 
1 conditions, no significant difference was observed for route 2 while route 3 significantly increased 
from passage 1 to passage 2. (B) The same trend observed in the SGR was observed with the cell 
number yields from passage 1 to passage 2 i.e. only route 2 did not have a significant change in cell 
number between the two passages. (C) The control, route 1 and route 2 all have a decrease in cell 
viability from passage 1 to passage 2, which was not observed for route 3. Error bars indicate standard 
deviation, n=3. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 0.001, and “****” 
indicates p<0.0001.  
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Figure 52. MedFI values for OCT3/4, Ki67 and PAX6. OCT3/4(A) and Ki67(C) were both highly 
expressed. (B) PAX6 expression levels were very low in comparison to OCT3/4 and Ki67, inset shows 
the very low levels of PAX6, all conditions are under 1500 for their MedFI values. Uns = unstained; 
Iso = isotype; D0 = cells at day 0; R1 = route 1; R2 = route 2; R3 = route 3. 
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In the second run of the experiment at a higher resolution, out of thaw the cells had low SGR and total 
cell numbers at each harvest, which were lower at passage 1 compared to passage 2 (Figure 53A and 
D). At passage 1 there was a difference in SGR between the different routes with the exception of the 
control with route 1 and route 2 with route 3, which appeared to group together i.e. the control and route 
1 exhibited similar behaviours to each other and; route 2 and route 3 exhibited similar behaviours, thus 
the difference in SGR was between the respective set of conditions. Route 3 had the highest cell yield 
at the end of passage 1 (Figure 53E). Passage 2 showed route 3 had a significant difference compared 
to the other conditions, as it had both the lowest SGR and total cell number yield. In general, there was 
no difference in SGR from day 2 to 3 at passage 2. The viabilities were similar in passage 1 across the 
conditions as no significant differences were obtained, however, at passage 2 the conditions had 
significantly difference cell viabilities from day to day and overall (Figure 53C and F). Both route 2 
and route 3 dropped in SGR from day 1 to day 2 and then increased from day 2 to day 3. PAX6 is not 
expressed in the different routes and there was no significant difference between the routes and the 
passages for all three markers, all the conditions highly expressed OCT3/4 and Ki-67 (Figure 54). The 
rate of lactate production increased from day 1 to day 2 and then decreased from day 2 to day 3 in 
passage 1 for route 2 and route 3 (Figure 55A). The rate of LDH production was at its highest in route 
3 from day 2 onwards at passage 2 (Figure 55). There was no significant difference in the SMR for 
both LDH and lactate across the routes on day 1, however on day 3, route 3 was significantly higher 
than the other conditions for both metabolites, except in passage 1 for lactate SMR (Table 27 and Table 
28). 
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Figure 53. Growth dynamics (run 2). (A) Overall the SGR is lower at passage 1, with all four conditions 
having negative SGRs until day 3 of passage 1. (D)At passage 2, route 2 and route 3 had a positive SGR 
from day 1 onwards, only route 3 had a significant decrease in SGR by day 3 of passage 2. At both 
passages the cell number increased from day 0 to day 3, however at passage 1 (B) there was a decrease 
in cell number from day 0 to day 1, not observed at passage 2 (E). Generally, cell viability increased 
throughout passage 1, except for route 1 which had a decrease on day 2 (C). At passage 2, route 2 and 
route 3 had variable cell viabilities from day to day, while the control and route 1 had increased cell 
viabilities from day to day (F). Error bars indicate standard deviation, n=6.
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Figure 54. MedFI values for OCT3/4, Ki67 and PAX6 (run 2). OCT3/4(A) and Ki67(B) were both 
highly expressed. (C)PAX6 expression levels were very low in comparison to OCT3/4 and Ki67, inset 
shows the very low levels of PAX6, all conditions are under 800 for their MedFI values. Generally, 
OCT3/4 increased from passage 1 to 2 and Ki67 decreased from passage 1 to passage 2, however the 
changes were not determined to be statistically significant. N.B. Control Thaw = cells analysed for cell 
phenotype immediately following thawing from cryopreservation, without being cultured. 
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Figure 55. Lactate and LDH SMR data (run 2). Lactate SMR increased from passage 1 (A) to passage 
2 (C), at passage 2 lactate SMR decreased for all routes except route 3. LDH SMR is highest for route 
3 at passage 1 (B) and passage 2 (D), generally LDH SMR decreases for all routes except route 3 at 
passage 2. Error bars indicate standard deviation, n=3.  
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Table 27. Tukey’s multiple comparisons test of the mean lactate SMR in each condition compared the 
means of the other conditions during that passage. Differences were observed mainly between route 3 
and the other conditions, however at passage 2 most of the conditions were different to each other.  
Lactate SMR   
Passage 1  Passage 2   
Summary  P Value Summary  P Value 
Control vs. Route 1 ns 0.8799 ns 0.7092 
Control vs. Route 2 ns 0.4933 * 0.0198 
Control vs. Route 3 ** 0.0031 **** <0.0001 
Route 1 vs. Route 2 ns 0.8963 ns 0.1806 
Route 1 vs. Route 3 * 0.0133 **** <0.0001 
Route 2 vs. Route 3 ns 0.0504 **** <0.0001 
 
 
Table 28. Tukey’s multiple comparisons test of the mean LDH SMR in each condition compared the 
means of the other conditions during that passage. Differences were observed in most of the conditions 
at passage 2, at passage 1 differences were only between route 3 and the other conditions. 
LDH SMR   
Passage 1  Passage 2   
Summary  P Value Summary  P Value 
Control vs. Route 1 ns 0.9637 ns 0.9997 
Control vs. Route 2 ns 0.9872 * 0.0327 
Control vs. Route 3 ** 0.0091 **** <0.0001 
Route 1 vs. Route 2 ns 0.9984 * 0.0402 
Route 1 vs. Route 3 ** 0.0021 **** <0.0001 
Route 2 vs. Route 3 ** 0.0023 **** <0.0001 
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5.3.6. Expansion: the effect of density and medium exhaustion 
 
On day 1 and 2 both the daily feed (DF) and one feed (OF) conditions had a negative SGR which 
increased significantly from day 2 to day 3 (Figure 57A). The two conditions diverged in terms of total 
cell number yield from day 3 onwards, the DF condition started to plateau at day 4, as there was no 
significant difference in SGR and cell yield from day 4 onwards (Figure 57A and B). Meanwhile, the 
OF condition significantly dropped in cell number yield from day 5, which was also accompanied by a 
decline in cell viability down to 65 % ±2.1 by day 7 (Figure 57C). The MedFI of Ki67 and OCT3/4 
decreased overall from day 0 to day 7 and from day 6 to 7 in both conditions, the biggest decrease in 
MedFI was from day 6 to 7 of the DF condition for OCT3/4. There was very low expression of PAX6 
in the conditions across the sampling points, while expression of Ki-67 also decreased from day 6 to 7 
for both DF and OF (Figure 58). The rate of lactate and LDH production decreased over the 7 days for 
the DF condition (Figure 56). A similar trend was observed for the OF condition until day 5 when the 
rates of production significantly increased from day 5 to day 6 and then stabilised from day 6 to 7 
Figure 56.  
 
 
 
 Figure 56. Lactate and LDH SMR data. Lactate SMR decreases throughout the passage for DF, OF 
decreases until day 5 to day 6 where it increases significantly (p=0.0079) (A). LDH SMR is highest 
from day 5 to day 6 for the OF condition, the DF condition has low levels of LDH production over the 
7-day passage (B). Significant differences in SMR between the two. conditions for both lactate and 
LDH are observed at day 6 (p<0.0001) and day 7 (p<0.0001). Error bars indicate standard deviation, 
n=3. 
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Figure 57. Growth dynamics. (A) SGR increased from negative SGR to positive SGR from day 3 
onwards peaking at day 4 for the DF condition and day 3 for the OF condition. OF had a greater decrease 
in SGR over the 7-day passage, SGR differed between the two condition on day 1 (p=0.0012). (B) Cell 
number decreased from day 5 onwards for both conditions, similar to the SGR OF had the most 
significant decrease in cell number and cell viability (C). From day 4 onwards there was a significant 
difference in cell number yield between the two conditions: day 4 (p<0.0001); day 5 (p=0.0002); day 6 
(p<0.0001); day 7 (p<0.0001). Error bars indicate standard deviation, n=6. 
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Figure 58. MedFI values for OCT3/4, Ki67 and PAX6. OCT3/4(A) and Ki67(C) were both highly 
expressed in both conditions. (B)PAX6 expression levels were lower in comparison to OCT3/4 and 
Ki67, inset shows the very low levels of PAX6, all conditions are under 800 for their MedFI values. 
OCT3/4 and Ki67 decreased from day 6 to day 7, resulting in lower expression levels overall when 
compared to the control (day 0) and both conditions at day 7. 
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5.4. Discussion  
 
 The work carried out in this chapter demonstrates that the H9 cells are capable of growing, proliferating 
and have a normal genetic profile. The banking reproducibility and vial variability study revealed that 
there was no significant variation in the growth of different vials, however, varying cell numbers were 
recovered from different vials following thaw. This highlights the importance of cell counting both 
before cryopreservation and following thaw. Moreover, the use of defined seeding densities instead of 
split ratios is reinforced, as cell counting and set densities would standardise the seeding procedure 
following thaw. Therefore, negating the fact that banked vials, regardless of cell counting prior to 
cryopreservation, would have different cell numbers upon thaw. Inter-passage variation was observed 
in the expression of OCT3/4 and Ki67 which both decreased from passage to passage (Figure 46). It is 
unclear whether the expression continues to decrease through several passages or if it fluctuates as 
observed in the longitudinal EC 2102 Ep experiment where the pluripotent markers OCT3/4 and SSEA-
1 both fluctuated over 10 passages (Figure 33E). It can be inferred that the decrease in Ki67 is due to 
the higher cell numbers obtained in the following passage after thaw. Therefore, by the harvest point of 
the second passage the cells have started to slow down in terms of proliferation, which results in 
decreased expression of the proliferation marker, Ki67. Reduction on OCT3/4 could be attributed to 
spontaneous cell differentiation, however the lack of differentiation molecules and absence of PAX6 
expression suggests that if the cells are in fact differentiating, it is not towards a neural stem cell 
lineage122.  
 
The initial expansion experiments have illustrated that there is variation between different passages 
during H9 pluripotent cell expansion. Typically, post thaw cells have low cell viability and SGR values. 
Cells seeded at 10,000 cells/cm2 do not perform as well as those seeded at 20,000 and 30,000 cells/cm2 
as they have lower cell viabilities and take longer to reach confluency as their SGR is lower in 
comparison. This suggests that a lower cell seeding density influences the growth and quality of cells 
obtained during pluripotent expansion. These experiments have shown that the cells perform better at a 
higher seeding density such as 20,000 cells/cm2 and following a ‘recovery’ passage subsequent to being 
thawed from cryopreservation. Both the increase in density and recovery passage resulted in improved 
proliferation rates, total cell number yields and cell viabilities in comparison to both cells seeded at 
10,000 cells/cm2 out of cryopreservation and even cells seeded at 10,000 cells/cm2 one passage after 
cryopreservation. The high resolution growth curve studies demonstrated that one day after seeding the 
cells are often at a low or negative growth rate which increases significantly from day 2 onwards 
(Figure 42A, Figure 53Aand Figure 57A). Furthermore, in experiment 5.3.5 during passage 1 at day 
2 the cells are still at a negative growth rate while at passage 2 on day 2 they are at their peak, 
highlighting the necessity of a recovery passage. This could be due to lack of cell attachment in the 
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initial stages of culture caused by inadequate conditioning of the medium to sustain cell attachment and 
growth.   
 
Establishing that the cells need a recovery passage represents a key element for manufacturing 
considerations; as resources will need to be adjusted, while taking into account the impact of the 
recovery passage on overall production timelines and product costs. The growth limitation experiment 
similarly shows a negative SGR at day 1 and day 2 for cells in their first passage from cryopreservation. 
It is only from day 3 onwards that the SGR starts to increase, suggesting that the cells either need a long 
passage length out of cryopreservation, up to five days or they should have at least one passage prior to 
allow their SGR to stabilise. The length of an optimal culture period for cells out of cryopreservation is 
shown to be four days as after this point, growth limitation based on both density and nutrient 
availability (Figure 57) is observed. However, the total cell numbers suggest that cell growth starts to 
decline from day 5 onwards, with nutrient availability factoring in from day 3 onwards as the DF 
(density inhibition) and OF (nutrient availability) conditions diverge at the this point (Figure 57B). 
When the cells have been subjected to at least one passage, the passage length for cells seeded at 10,000 
cells/cm2, can be reduced to a four-day passage. This is due to the decrease in SGR and cell viability 
from day 4 onwards, due to the high levels of confluency resulting in cell death. For cells seeded at 
20,000 cells/cm2 the passage length can be decreased to a three-day passage as more cells would be 
seeded while the SGR is similar to 10,000 cells/cm2. 
 
Analysis of different feeding regimes demonstrated that route 2, when the cells were only subjected to 
a medium exchange on day 2, resulted in cells with higher or comparable cell viability, SGR and cell 
number yield to the control condition which was subjected to daily medium exchange (Figure 51 and 
Figure 53). Route 2 also exhibited an increase in OCT3/4 and Ki67 between passages, over the 2 
passages of the experiment. In general, the control and route 1 behave similarly, while route 2 and route 
3 behave similarly; this can be attributed to the time points in which the ROCKi is removed. The control 
and route 1 both have ROCKi removed on day 1 when they are subjected to a medium exchange (Table 
24). In the second run of the experiment it is evident that route 3 is significantly different to the other 
conditions in terms of SGR, cell number yield and its metabolite profile, typically in an undesired 
manner i.e. lower SGR, cell viability and higher LDH SMR.  
 
Interestingly between the two runs of the feeding regime experiment (section 5.3.5), the way in which 
route 3 performed at the end of each passage differed. For instance, route 3 had the lowest cell yield 
and SGR at the end of passage 1 in the first run but the highest in the second run at the end of passage 
1 (Figure 51A & B and Figure 53A & B). At passage 2 the opposite was observed as the cell yield and 
SGR at the end of the passage was one of the highest in the first run while being the lowest in the second 
run. This drastic change in behaviour and outcomes was not observed for the other routes, which 
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behaved fairly consistently between the two runs. It can be theorised that the changes observed in route 
3 were due to an inconsistency in cell behaviour due to the lack of medium exchange and build-up of 
waste within the culture vessel. Another potential cause for the variation could be attributed to 
differences in manipulation of the cells or measurement error, however both are unlikely as the variation 
is not observed in the other routes which were treated at the same time by the same operator. The 
observed inter-run variation could also be attributed to the fact that cells in the first run had a pre-
passage prior to being seeded into the experiment, while the cells in the second run were seed directly 
from cryopreservation. However, it is unclear how this would selectively impact the route 3 condition 
the most. 
 
These results suggest that it is not necessary to subject the cells to daily medium exchanges, however 
nutrient availability is important to prevent a decline in cell SGR and viability. Ideally the cells should 
be fed at least once and ideally on day 2 (route 2) as it appears to be an appropriate medium exchange 
time point. This is also evident in experiment 5.3.6 where the OF and DF conditions both significantly 
increased their SGRs from day 2 to day 3, therefore medium exchange to replenish nutrient availability 
as this time point would help to support and sustain cell growth, particularly for a four-day passage 
(Figure 57). Furthermore, day 2 is shown to be have the highest levels of lactate production, as such, a 
medium exchange to remove the accumulated lactate would be beneficial to the cells.  
 
The rate of metabolite production shows the impact of nutrient availability on cell growth i.e. in general 
the SMR per cell decreases as more cells proliferate as less nutrients are consumed. In the OF condition 
the impact of restricted nutrient availability as the cells reach growth limitation is highlighted. This was 
demonstrated at day 5 by the significant decrease in SGR, cell number yield and the decline in cell 
viability, which was accompanied by an increase in the rate of production of both lactate and LDH. The 
increase in LDH production showed that the cells were starting to undergo cell death and enter the 
decline phase260,263. Although lactate production would be expected to decrease with less cells, it 
actually increases; this can be attributed to having less cells in the same volume of medium from day 1 
(OF condition) leading to an accumulation of lactate since no medium exchange was performed. 
Therefore, the per cell rate of lactate and LDH production significantly increases at the point of the 
highest decline in cell number (day 5), despite there being less cells and less nutrient metabolism. 
 
The use of 20,000 cells/cm2 as the standard seeding density was further supported by the ROCKi 
experiment which illustrated that even in the absence of ROCKi, cells at 20,000 cells/cm2 are still able 
to attach and proliferate. For cells seeded at a density of 10,000 cells/cm2 the optimal ROCKi 
concentration was determined to be 10 µM as this resulted in the highest Cell Index in the range studied. 
Thus, cells at 20,000 cells/cm2 are more suitable for use as the standard culture density as they are less 
sensitive to ROCKi concentration, therefore alleviating growth variation due to ROCKi. In addition, 
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cells at 20,000 cells/cm2 require a shorter passage period, which reduces the use of resources required 
to culture the cells, which would be economically beneficial for manufacturing considerations. This 
highlights the notion that process optimisation work can aid process consistencies such as cell growth 
and quality, while additionally driving down costs, which is important for CTPs which have putatively 
high cost of goods. For instance, observations in this chapter (Chapter 6 as well) that highlight that 
ROCKi does not have a significant impact on the growth, quality or phenotype of the H9s, therefore it 
would be sensible to optimise the process by removing its use. As a result, the costs of goods would 
lower, as it is an expensive reagent and there would be less complexity in the formulation of the culture 
medium thereby removing an extra source of variation.   
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5.5. Conclusions 
 
Cells seeded at 20,000 cells/cm2 performed better than those seeded at 10,000 cells/cm2 and regardless 
of seeding density, the cells performed better after at least one passage. This suggests that cells should 
be cultured for at least one passage following cryopreservation, before they are used for further 
experiments and for differentiation; as the input cell material would be stabilised and therefore result in 
less variation. In addition, directly post thaw the cells have poor growth for the first two days of culture. 
Differences in the phenotype marker profile were observed, particularly the general trend of decreases 
in Ki67 from passage to passage and occasional decrease in expression of OCT3/4. At present, it is 
unclear whether the decreased expression in OCT3/4 and Ki67 has a detrimental impact on further 
passages and the subsequent differentiation process. Furthermore, experiment 5.2.4 (page - 165 -) 
resulted in notable expression of PAX6, which is unexpected for cells in their pluripotent state. Results 
from experiment 5.3.5 (page - 168 -) show that the cells do not have to be subjected to a medium 
exchange daily, as route 2 with only one medium exchange resulted in cells with desirable 
characteristics when compared to the control of daily medium exchange. Furthermore, the density and 
nutrient limitation points for the cells were determined, allowing for an informed three-day passage 
length to be defined at the optimal seeding density of 20,000 cells/cm2. 
 
The experiments in this chapter have allowed for parameters for H9 pluripotent expansion to be 
determined in an informed manner. These parameters have been shown to produce cells with suitable 
growth characteristics while maintaining the cells’ phenotypic profile. Therefore, the critical process 
parameters that would result in the critical quality attributes can be defined. It is proposed that H9 
pluripotent culture prior to differentiation should be cultured under the following conditions: a density 
of 20,000 cells/cm2, subjected to one medium exchange on day 2 of a three-day passage and cultured 
for at least one passage prior to differentiation if the cells are directly out of cryopreservation. These 
conditions result in an average SGR of 0.018 hour-1± 1.5x10-3 over three days and cell viabilities up to 
95% ±0.4, while producing cells which highly express pluripotent and proliferation markers, OCT3/4 
and Ki-67, respectively. The above provides operators with defined and quantifiable criteria for 
determining “good-quality” starting cell material which is offers less variation compared to the criteria 
offered in the prescribed protocol: “Before the differentiation is started, make sure that the hPSC 
colonies appear pluripotent by visual criteria (i.e., homogeneous-appearing colonies with clear borders 
and the absence of obvious differentiating zones). If you are using a hPSC culture system other than 
the one described here, manual removal of spontaneously differentiated colonies might be required. A 
desirable confluency of hPSC cultures is 70–90% of the well area at the start of differentiation”129. As 
the starting material of the differentiation process has been analysed, the following chapter will focus 
on the differentiation of H9 pluripotent cell into vmDA neuroprogenitors.  
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Chapter 6. Process understanding of H9 human embryonic stem cell differentiation into ventral 
mesencephalic dopaminergic neuroprogenitors 
 
6.1. Introduction 
 
The focus of this chapter is on the prescribed differentiation protocol of H9 human embryonic stem 
cells (hESCs) into ventral mesencephalic dopaminergic (vmDA) neuroprogenitor cells. The purpose of 
the differentiation is to obtain vmDA neuroprogenitors for cell characterisation and ultimately 
transplantation into patients suffering from Parkinson’s disease (PD). The work carried out 
demonstrates the challenges that are associated with process transfer, process development and 
reproducible, efficient cell culture protocol development. The work carried out in the previous chapters 
i.e. protocol standardisation has informed the work in this chapter. For instance, the densities and 
passage length of the pluripotent cells are based on information accrued in Chapter 5.  
 
6.1.1. The Lund University differentiation protocol 
 
Chapter 2 (2.2.3. In vitro differentiation of pluripotent cells into vmDA) discussed the recent advances 
that have been made with regards to vmDA neuroprogenitor differentiation protocols. This work is 
concerned with the process development of the Lund University differentiation protocol (Figure 59). 
This protocol is a sixteen-day hESC differentiation process that has had many iterations over the years, 
the current work is based on the 2017 method, which is the most recent published iteration129. This 
protocol is designed to produce vmDA neuroprogenitors which have been shown to innervate into the 
target site of the striatum24. The cells are cultured on Biolaminin-111 which was chosen as it is naturally 
expressed in the brain and does not support growth of pluripotent cells, this favours growth of the 
differentiated cells allowing for more efficient and purer differentiation. This Biolaminin-111 matrix 
allowed the cells to be cultured without a feeder layer and eradicates the use of a 
polyornithin/fibronectin/laminin matrix mixture negating the use of embryoid bodies. The removal of 
feeder layers facilitated translation of the protocol into a xeno-free protocol, making it more adaptable 
to good manufacturing practice (GMP) compliant manufacturing. Neural induction of the hESCs is 
achieved through a dual SMAD approach, previously discussed in Chapter 2. The collaborators at Lund 
University highlighted that CHIR99021 and SHH-C24II concentrations are important for correct vmDA 
patterning. In the prescribed protocol the cells should have a ventral mesencephalic identity by day 11, 
which can be assessed by the presence FOXA2, OTX2 and LMX1A, presence of these markers by day 
11 should proceed to give the rise to the desired vmDA neuroprogenitor cell population by day 16. 
LMX1A/B expression is integral to yielding vmDA neuroprogenitors as absence of these homeobox 
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factors has been shown to result in neurons of a non-dopaminergic fate due to LMX1A/B expression 
being necessary for downstream genes and factors of vmDA neuroprogenitors92,121. 
 
This protocol comprises of the medium formulations described in Chapter 3. A prescribed cocktail of 
small molecules consisting of SB431542, noggin, CHIR99021 and SHH-C24II are added when the cells 
are seeded and during medium exchange for the first seven days, specifically on day 2, 4 and 7 (Figure 
59). At day 9 the cells are subjected to medium exchange with the FGF8-N2 medium which has FGF8 
added whilst SB431542, noggin, CHIR99021 and SHH-C24II are removed. The B27 base medium has 
FGF8, BDNF and ascorbic acid added to it and is used to re-plate the cells at day 11 and for medium 
exchange on day 14 (Figure 59). The protocol revision used in the present work uses GMP reagents 
and procedures in an attempt to adapt the protocol for clinical manufacturing. 
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Figure 59. Schematic of the complete differentiation process from hESCs into late ventral mesencephalic dopaminergic progenitors. Medium exchanges are 
performed on day 2,4,7,9 and 14; on day 11 the cells are harvested and reseeded. ROCK inhibitor is added on day 0 and 11. SB431542 and noggin are used as 
neurulation factors in the medium, whilst SHH-C24II and CHIR99021 are used to pattern then neural stem cells towards a ventral midbrain linage. The timeline 
illustrates the time points at which the various differentiation molecules are added into the process. Image adapted from Nolbrant et al, 2017. 
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6.1.1.1. The small molecules used in the differentiation medium. 
 
This section briefly describes the essential differentiation molecules and media components used in the 
protocol and their relevance to the differentiation process. 
 
CHIR99021 – is a highly potent and selective, glycogen synthase kinase 3 (GSK-3) inhibitor, inhibiting 
the GSK pathway allows for activation of the Wnt/b-catenin pathway by allowing the secreted Wnt-
protein to bind to the appropriate receptors126,264. This pathway is important for the maintenance and 
function of hESC in terms of their growth and differentiation265.  
  
SHH-C24II – is part of the Hedgehog protein family, this family is involved in the production of signals 
that result in the body plan, late stage embryogenesis, creation of tissue boundaries and patterning in 
bilateral organisms105. SHH-C24II in particular is involved in the signalling and regulation of the CNS91.  
 
SB431542 – is one of the SMAD inhibitors, this targets the inhibition of the SMADs from the 
Transforming Growth Factor b (TGF-b) family through highly potent and selective phosphorylation 
blocking of the activing receptor-like kinase receptors (ALK4, 5, and 7)266.  
 
Noggin – is the second of the SMAD inhibitors, this targets particularly the inhibition of the SMADs 
from the bone morphogenetic protein (BMP) family122,125.  
 
FGF8-b – fibroblast growth factor 8b is involved in a range of biological processes including 
embryogenesis and morphogenesis. FGF8b plays a crucial role in the organisation and maintenance of 
the midbrain/hindbrain boundary267. 
 
BDNF – is a neurotrophic factor that belongs to the neurotrophin family which induces survival, 
development and function of neurons, in particular the differentiation of progenitors into neurons268.  
 
Ascorbic Acid – is an essential nutrient that is involved in a range of biological processes, particularly 
as an electron donor for certain enzymes as an enzymatic cofactor. In particular, it is an electron donor 
for dopamine B-hydroxylase which plays a role in the biosynthesis of norepinephrine from dopamine269. 
 
N2 supplement – is a commercially available premixed supplement for neural cell culture, the 
components within the N2 supplement encourage initial commitment and differentiation of stem cell 
populations towards a neural fate270. Neural specific genes are supported in N2 supplemented medium 
whilst the growth of undifferentiated is inhibited as post-mitotic neurons are favoured252,270,271.    
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B-27 supplement – is used towards the later stages of  neural differentiation protocols as it supports 
the growth and attachment of mature neurons, the supplement is particularly high in 
antioxidants260,272,273. 
 
RHO Kinase Inhibitor Y27632 (ROCKi) – is a rho-associated protein kinase inhibitor that increases 
cell survival after dissociation274. ROCKi is added to media used for cell seeding and replating for both 
the hESCs and cells undergoing the differentiation process.  
 
6.1.1.2. Characterisation strategy  
 
The characterisation strategy employed by Lund uses immunocytochemical (ICC) analysis and gene 
expression analysis to determine the progenitor cell identity. ICC analysis is carried out using a range 
of antibodies for vmDA progenitor stage markers including  FOXA2, LMX1A and OTX2, for mature 
neurons derived from the progenitors TH, MAP2, and EN1 are the markers used to identify terminally 
differentiated neurons, typically at day 44-50109,129. Polymerase chain reaction (PCR) and quantitative 
real-time PCR (qRT-PCR) are used in conjunction with ICC to analyse the genetic profile of the cells 
to ascertain their identity. The complete set used to profile the cells consists of fifteen genes, including 
two housekeeping genes (Table 29). Although not prescribed in the protocol, a flow cytometry panel 
was created for characterisation of the cells. The protocol was created by collaborators at Miltenyi 
Biotec who worked with both Lund University and Loughborough University on various aspects of the 
overall project. The markers used in the flow cytometry panel are detailed in Table 30. 
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Table 29. Genes used for qRT-PCR analysis by Lund University, table adapted from Nolbrant et al, 
2017.  
 
Gene Full name Relevant details
ACTB Actin beta Housekeeping gene 
BARHL1 BarH like homeobox 1 Ventral diencephalon/lateral midbrain VM/ventral
CORIN Corin, serine peptidase VM/ventral diencephalon/ventral hindbrain
EN1 Engrailed homeobox 1 Caudal VM
ETV5 ETS variant 5 Caudal midbrain
FOXA2 Forkhead box G1 VM/ventral diencephalon/ventral hindbrain
FOXG1 Forkhead box G1 Forebrain
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Housekeeping gene 
HOXA2 Homeobox A2 Hindbrain
LMX1A LIM homeobox transcription factor 1 alpha VM/ventral diencephalon
LMX1B LIM homeobox transcription factor 1 beta VM/ventral diencephalon
OTX1 Orthodenticle homeobox 1 Midbrain 
OTX2 Orthodenticle homeobox 2 Midbrain/forebrain 
PAX6 Paired box 6 Dorsal/lateral populations
PAX8 Paired box 8 Caudal midbrain
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Table 30. Flow cytometry markers and fluorophores used in the prescribed Miltenyi Biotech 
characterisation protocol. 
 
Marker-Fluorophore Marker function/specificity Desired expression in day 16
vmDA  neuroprogenitor cells
FOXA2 -APC Rostral ventral midbrain/ caudal 
ventral midbrain/ ventral 
hindbrain
Positive
IAP-PE vmDA specific surface marker 
integrin associated protein
Positive
OTX2-FITC Midbrain / forebrain Positive
NKX6.1-APC Gli transcription factor / 
generates red nucleus 
progenitors
Negative
NKX2.1-FITC Ventral forebrain / rostral 
ventral midbrain marker 
Negative
SOX1-PE Primitive neurectoderm / lateral 
floor plate
Negative
OCT3/4-APC Pluripotency marker Negative
Ki67-FITC Proliferation marker Between 10-60 % expected Positive
PAX6-PE Dorsal / lateral populations / 
roof plate
Negative
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6.1.2. Process transfer 
 
The aim of the present work was to enable efficient translation of the protocol (Figure 59) into a 
manufacturing process through process understanding and process optimisation activities. In order to 
optimise the protocol, it was first necessary to understand the protocol, thus site visits and meetings 
with collaborators at Lund University were organised. This served as a process transfer activity where 
the researchers from Lund University demonstrated the key aspects of the protocol, such as the seeding 
procedure, medium composition and cell manipulation at day 0 and medium exchange at day 7.  
 
A cause and effect diagram (Ishikawa diagram) was used to review the overall process and the important 
factors to consider that could result in a poor manufacturing outcome (Figure 60). A poor 
manufacturing outcome in this context would be cell death, low cell yields, incorrect differentiation and 
a highly heterogeneous cell population. Eight categories were used to assign causes to, these were 
process results; contamination; people; method; measurement; equipment; environment and materials. 
These categories were also used to carry out a failure modes and effects analysis (FMEA) to identify 
process steps that would result in failure of an experiment or production run in terms of obtaining vmDA 
neuroprogenitors. For the FMEA, the process results, contamination, people and method categories 
were merged into a single category labelled cell manipulation. The FMEA was carried out with Lund 
University personnel, fundamental process steps of the protocol were discussed, several points were 
raised and ranked in terms of their risk and frequency (Table 31). The FMEA provides details of the 
critical process parameters (CPPs), as determined by experienced users of the protocol, that are essential 
to the process in order to efficiently obtain the critical quality attributes (CQAs) of the vmDA product. 
The process controls detailed in Table 31 were controls that were used by the collaborators at Lund 
University in their process.  
 
A separate part of the process that also had to be transferred was the flow cytometry protocol provided 
by Miltenyi Biotec. The protocol was created considering the work being carried out by Lund University 
in order to provide a characterisation method that can be used for quality control, in terms of identifying 
and sorting for the desired differentiated cells. This protocol used a three-part panel with panel 1 
consisting of pluripotency/neurostem markers; panel 2 consisting of ventral midbrain dopaminergic 
neuroprogenitors markers and panel 3 consisting of lateral midbrain markers used to identify potential 
contaminant neuroprogenitors. A summary of the markers is shown in Table 30, the protocol utilised 
pluripotent cells as the control sample for the gating strategy. 
 
The FMEA formed the basis of the differentiation experiments carried out in the present work, which 
investigated issues of consistency; cell death; cell seeding density; and small molecule concentrations. 
These failure modes were deemed to have the most significant impact on the success of the 
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differentiation process. Initial experiments were carried out in order to gain experience in using the 
prescribed protocol, after which further experiments were designed to understand the protocol and the 
CPPs. Design of experiments (DoE) were used to carry out multifactorial analysis of the variation 
caused by factors such as seeding density and small molecule concentration. This was with the aim of 
executing protocol optimisation to increase the process efficiency whilst producing a translatable, 
robust protocol for clinical scale manufacturing. The purpose of the protocol would be to highly 
standardise the process, minimise human-based sources of variation, reduce uncontrolled parameters 
and increase consistency. 
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Figure 60. Cause and effect diagram (Ishikawa diagram) detailing potential causes of a poor experimental or manufacturing process for a cell-based product. 
Eight causal categories were used to determine potential root causes of an undesired effect.
People 
Method Measurement
Materials
Environment 
Equipment
Distracted/Fatigued
Ill health
Consistency
Not calibrated 
Incorrect procedures 
Non functional 
Poor planning 
Poor standardisation
Poor method  
Incubator temperature
Incubator humidity
Gas exchange 
Poor accuracy 
Incorrect controls
Non validated
Scarcity of reagents 
Incorrect reagents
Out of date reagents 
Poor 
manufacturing 
outcome 
EFFECTCAUSE
Process results
Poor growth rate 
Low cell viability
Cell detachment
Software failure
Staff turnover
Lack of experience 
Contamination
Bacterial
Fungal
Mycoplasma 
High and low grade  
Undetectable Batch variation 
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Table 31. Failure mode and effects analysis of the key process steps of the vmDA differentiation 
protocol, determined by discussion with collaborators at Lund University. The risk priority number was 
obtained by multiplying the severity ranking by the occurrence rating and by the detection rating 
(severity x occurrence x detection). The rankings were assigned values from 1 to 10, higher values for 
the severity and occurrence indicate a failure that would have a severe effect on the process and a high 
likelihood of occurring, respectively. For the detection rankings, a low value indicates a failure mode 
that would be easy to detect, while a higher value indicates a failure mode that is difficult to detect or 
not detectable until the end of the process. 
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PROCESS STEP
POTENTIAL
FAILURE
MODE
POTENTIAL
FAILURE
EFFECT
SEVERITY POTENTIAL
CAUSE
OCCURRENCE PROCESS
CONTROLS
DETECTION
RISK
PRIORITY
NUMBER
CELL
MANIPULATION
CONTAMINATION
CELLS WOULD BE
NOT USED, 
RESULTING IN
BATCH LOSS
10 POOR ASEPTIC
TECHNIQUE
2
PERSONNEL
TRAINING, 
DISINFECTING
MATERIALS
USED
1 20
CELL
DETACHMENT
REDUCED YIELDS 5
POOR COATING
EFFIECIENCY, 
CELL DEATH
6 PERSONNEL
TRAINING
4 120
POOR USER
CONSISTENCY AND
ADHERENCE TO
THE PROTOCOL
VARIATION
RESULTING IN OUT
OF SPECIFICATION
END PRODUCT
6
POOR TRAINING, 
POORLY DEFINED
PROTOCOL
5 PERSONNEL
TRAINING
8 240
MEASUREMENT
FLOW CYTOMETER
SAMPLER OR
LASERS NOT
WORKING
LOSS OF PRODUCT
CHARACTERISATION
CAPABILITY
5 UNKNOWN CAUSE 4
EFFICIENT
EQUIPMENT
MAINTENANCE
2 40
NO CONTROLS
POTENTIAL FOR
INCORRECT
CHARACTERISATION
5 POOR PLANNING
OR OVERSIGHT
2
EFFICIENT
INVENTORY
MONITORING
1 10
NO CALIBRATORS
POTENTIAL FOR
INCORRECT
CHARACTERISATION
5 POOR PLANNING
OR OVERSIGHT
3
EFFICIENT
INVENTORY
MONITORING
1 15
LASERS DRIFTING
SKEWED RESULT
READING
5
EQUIPMENT
ERROR, NO
CALIBRATION
4
EFFICIENT
EQUIPMENT
MAINTENANCE
4 80
CELLMILIEU
NUTRIENTS
INCORRECT
SUPPLEMENTATION
OR LOW
CONCENTRATIONS
POOR CELL
GROWTH
5
POOR OR
INEFFICIENT
FEEDING REGIME
3 INSPECTION OF
THE CELLS
3 45
CHIR99021 
CONCENTRATION
TOO LOW OR TOO
HIGH
INCORRECT OR
INEFFICIENT
DIFFERENTIATION
10
POORLY DEFINED
PROTOCOL, 
INACCURATE
PIPETTING
7 USE THE SAME
PIPETTE
8 560
SMALL MOLECULE
CONCENTRATION
TOO LOW OR TOO
HIGH
INCORRECT OR
INEFFICIENT
DIFFERENTIATION
9
POORLY DEFINED
PROTOCOL, 
INACCURATE
PIPETTING
7 USE THE SAME
PIPETTE
8 504
LAMININ COATING
NO CELL
ATTACHMENT AND
CELL
PROLIFERATION
8
POOR TRAINING, 
POORLY DEFINED
PROTOCOL
4 PERSONNEL
TRAINING
1 32
INCUBATOR
FAILURE
POOR CELL
GROWTH
10 UNKNOWN CAUSE 2
EFFICIENT
EQUIPMENT
MAINTENANCE
1 20
CELL SEEDING
DENSITY TOO LOW
POOR CELL
GROWTH
7
USE OF SPLIT
RATIOS, POORLY
DEFINED
PROTOCOL, 
INACCURATE
PIPETTING
6 PERSONNEL
TRAINING
7 294
MATERIALS
OUT OF DATE
INCORRECT OR
INEFFICIENT
DIFFERENTIATION
4 POOR PLANNING
OR OVERSIGHT
4
EFFICIENT
INVENTORY
MONITORING
1 16
NO STOCKS
PROCESS CANNOT
BE STARTED
10 SUPPLIER FAILURE 6
EFFICIENT
INVENTORY
MONITORING
1 60
SPOILT REAGENTS
INCORRECT OR
INEFFICIENT
DIFFERENTIATION
10 FRIDGE OR
FREEZER FAILURE
4
EFFICIENT
EQUIPMENT
MONITORING
4 160
EQUIPMENT
NON FUNCTIONAL
PROCESS CANNOT
BE STARTED
8 UNKNOWN CAUSE 3
EFFICIENT
EQUIPMENT
MAINTENANCE
1 24
NOT CALIBRATED
SKEWED PROCESS
OR RESULTS
6 POOR PLANNING
OR OVERSIGHT
3
EFFICIENT
EQUIPMENT
MAINTENANCE
1 18
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6.2. Methods 
 
6.2.1. In Vitro Cell Culture: 
Cells were cultured according to the method described in section 3.2.4.2. H9 Expansion: Standard 
culture route). The relatively low seeding densities (10,000 – 30,000 cells/cm2) required to seed the 
cells for differentiation resulted in low to modest levels of expansion prior to differentiation. Typically, 
one well of a 6-well tissue culture microtiter plate seeded at 20,000 cells/cm2 (~177,000 cells per well) 
can yield an average of 1,600,000 cells per well (180,000 cells/cm2), affording an almost ten-fold 
increase in cell number over three days of culture. The resulting pluripotent cells of each well can then 
be used to seed a further eight to nine well for differentiation, thus highly efficient in terms of cell usage.   
 
6.2.1.1. Differentiation: Run 1 (DR1) 
 
One vial of P8 cells from the H9 bank was thawed and seeded at 20,000 cells/cm2 onto a Biolaminin-
521 coated T25 cm2 tissue culture flask and cultured for two passages. Following the second passage 
the cells were seeded at 10,000 cells/cm2 into three Biolaminin-111 T25 cm2 tissue culture flasks with 
N2 differentiation medium containing CHIR99021 at a concentration of 0.9 µM. 
 
6.2.1.2. Differentiation: Run 2 (DR2) 
 
DR2 followed the same culture and experimental design as DR1, however CHIR99021 was added to 
the N2 differentiation medium at a concentration of 0.7 µM,  which was prescribed as the optimal 
concentration for mesencephalic neuronal differentiation using the H9 cell line129. 
 
6.2.1.3. Differentiation: Run 3 (DR3) 
 
DR3 followed the same cell culture procedure as DR1 and DR2, the experimental design was adjusted 
to investigate the effects of different concentrations of CHIR99021 on the survival and differentiation 
of the H9s. Five concentrations of CHIR99021 (0.6 – 1 µM (Table 32) were used in DR3 at a seeding 
density of 10,000 cells/cm2 onto Biolaminin-111 coated 6-well tissue culture microtiter plates, each 
condition was run in triplicate.  
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Table 32. CHIR99021 concentrations used within experiment DR3. N=3 for each condition was used.  
 
  
DR3.a DR3.b DR3.c DR3.d DR3.e
CHIR99021 
(µM) 0.6 0.7 0.8 0.9 1.0
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6.2.1.4. Differentiation: Run 4 & 5 (DR4 and DR5)  
 
Experiments DR4 and DR5 cells were seeded at three densities (10,000; 15,000; 20,000 cells/cm2) and 
cultured with media containing varying concentrations of CHIR99021 (0.3, 0.5, and 0.7μM) and the 
presence and absence of the B27 supplement (Table 33). A deviation from the protocol occurred at 
the replating stage (day 11) of DR4, where some conditions were reseeded at densities lower than the 
prescribed 800,000 cells/cm2 due to lower cell yields in those conditions at the day 11 harvest (Table 
34). Only one condition in DR5 was seeded lower than the recommended density. The cells were seeded 
on Biolaminin-111 coated 6-well tissue culture microtiter plates, each condition was run in triplicate. 
Cell counts were performed at day 11 and day 16, while phenotype analysis was carried out at day 16.  
 
Table 33. Experimental design for experiments DR4 and DR5 denoting the concentrations and densities 
used in the experiments. n=3 for each condition was used.  
 
Density (-) B27 (+) B27 
10,000 cells/cm2
0.3μM CHIR99021
0.5μM CHIR99021 
0.7μM CHIR99021 
0.3μM CHIR99021
0.5μM CHIR99021 
0.7μM CHIR99021 
15,000 cells/cm2
0.3μM CHIR99021
0.5μM CHIR99021 
0.7μM CHIR99021 
0.3μM CHIR99021
0.5μM CHIR99021 
0.7μM CHIR99021 
20,000 cells/cm2
0.3μM CHIR99021
0.5μM CHIR99021 
0.7μM CHIR99021 
0.3μM CHIR99021
0.5μM CHIR99021 
0.7μM CHIR99021 
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Table 34. The reseeding densities of the remaining experimental conditions at day 11. Densities were 
calculated for the conditions that did not have enough cells to seed at 800,000 cells/cm2. The replicate 
column indicates the number of replicates surviving at day 11. 
 
 
6.2.1.5. Differentiation: Design of Experiment - Definitive Screen 1 (DSD1) 
 
A DoE approach was used to screen the effect of different levels of N2 supplementation and a range of 
small molecule concentrations. A Definitive Screen Design (DSD) created on Minitab18® 
(Pennsylvania, USA) was used to produce a matrix for the formulation of different media compositions 
with different concentrations of the N2 differentiation medium components. A total of thirteen different 
media formulations were created using low, medium and high concentration levels of each of the small 
molecules (Table 35). To ascertain the effect of these small molecules on the first stage of 
differentiation process, the FGF8-N2 medium used on day 9 was kept at the same concentration for all 
the conditions i.e. 100 ng/ml. The experiment was performed up to day 11 which served as the endpoint, 
sacrificial harvests were performed on day 4, 9 and 11, resulting in three flow cytometry analytical time 
points and a cell count on day 11. The cells were seeded at 20,000 cells/cm2 on Biolaminin-111 coated 
24-well tissue culture microtiter plates, each condition was run in duplicate.   
 
N.B. One limitation of the work being carried out for GMP manufacturing translation is that 
experimental replicates had to be constricted, particularly in the DoEs, due to the high costs of the 
consumables. However, due to inherent methodology of the DoE such as the definitive screen designs 
employed, the experiments retained statistical power with fewer identical replicates. 
 
Parent density Replicate 0.3 CHIR (+ B27) 0.5 CHIR (+ B27)
10,000 cells/cm2 A 518,000 cells/cm2 129,000 cells/cm2
15,000 cells/cm2
A 800,000 cells/cm2
124,000 cells/cm2B 681,000 cells/cm2
C 457,000 cells/cm2
20,000 cells/cm2
A 800,000 cells/cm2 630,000 cells/cm2
B 800,000 cells/cm2 800,000 cells/cm2
C 800,000 cells/cm2 800,000 cells/cm2
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Table 35. Definitive Screen Design matrix of the different concentrations used within experiment 
DSD1. n=2 for each condition was used. 
 
 
6.2.1.6. Differentiation: Design of Experiments – scale up experiment  
 
A scale up experiment was set up to ascertain the most pragmatic and cost-effective well plate format 
that would provide a workable number of cells, to carry out both cell growth and cell phenotypic 
analysis at a higher resolution compared to DSD1(performed in 24-well plate format). One vial of P8 
cells from the H9 bank was thawed and seeded at 20,000 cells/cm2 onto Biolaminin-521 coated T25cm2 
tissue culture flask and cultured for one passage. The cells were seeded at three densities (15,000; 
20,000; 25,000 cells/cm2) and cultured with the M1 medium formulation from experiment DSD1 (page 
- 201 -). The three densities were seeded onto Biolaminin-111 coated 6-well and 12-well tissue culture 
microtiter plates, each condition was run in duplicate. Assessment of cell number yield was determined 
through sacrificial well harvests from each well format and density on day 4, 7 and 9 (Figure 61). 
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6.2.1.7. Differentiation: Design of Experiments – day 11 replating 
 
This experiment looked at the effect of density on day 11 when the cells were replated. In addition, two 
of the small molecules (FGF8 and ascorbic acid) used in the latter stages of the protocol were included 
in the experiment design. Cells from the scale up experiment were cultured until day 11 and reseeded 
into this experiment. Two densities and a midpoint were chosen and combined with a range of 
concentrations for the small molecules to create a three factor DoE. Nine conditions were obtained with 
three densities and three concentration levels of the small molecules (Table 36). The conditions were 
seeded onto Biolaminin-111 coated 12-well tissue culture microtiter plates, each condition was run in 
duplicate and cultured until day 16. Assessment of cell number yield was determined through sacrificial 
well harvests from each condition on day 14 and day 16. 
Figure 61. Schematic of the well plate formats used in the experiment to determine a suitable well plate 
format for a higher resolution DSD. 6-well and 12-well plate formats were used for the three densities 
10,000 cells/cm2 (10K); 20,000 cells/cm2 (20K) and 30,000 cells/cm2 (30K). n=2 for each condition was 
used. 
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Table 36. Experimental design matrix of the different concentrations and densities used within the 
day11 replating experiment. n=2 for each condition was used. 
 
6.2.1.8. Differentiation: Design of Experiment - Definitive Screen 2 (DSD2) 
 
The second DSD (DSD2) followed a similar design as DSD1, however FGF8b was also added to the 
list of small molecules in the screen. In addition, density was added as a factor, three densities were 
employed (20,000; 25,000; 30,000 cells/cm2). These factors resulted in an experiment with seventeen 
different conditions which were seed onto Biolaminin-111 coated 12-well tissue culture microtiter 
plates, each condition was run in duplicate (Table 37). The experiment was run for the full sixteen days, 
sacrificial harvests were performed on day 4, 9, 11 and 16, resulting in four cell growth and phenotype 
analytical time points. 
  
Culture condition 
reference code
Density 
(cells/ cm²)
FGF-8b 
(ng/ml)
Ascorbic acid 
(mM)
C1 400000 50 0.1
C2 800000 50 0.1
C3 400000 150 0.1
C4 800000 150 0.1
C5 400000 50 0.3
C6 800000 50 0.3
C7 400000 150 0.3
C8 800000 150 0.3
C9 400000 50 0.1
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Table 37. Definitive Screen Design matrix of the different concentrations used within experiment 
DSD2. n=2 for each condition was used. 
 
 
The concentration ranges of the small molecules investigated in DSD2 were based on the results and 
observations from DSD1. Some of the small molecules were kept at the same concentration ranges, 
while others were changed or removed from the design (i.e. ROCKi). The justifications for changing or 
not changing the ranges and the addition of density are summarised below.   
 
Density: 20,000; 25,000; 30,000 cells/cm2 
Reasoning: Previous experiments with 10,000, 15,000 and 20,000 cells/cm2 showed that cells seeded at 
10,000 cells/cm2 started to detach and die by day 4 unless B27 supplement was added upon seeding. 
Therefore, this experiment was designed to look at higher densities, 15,000 cells/cm2 was excluded as 
the scale up experiment illustrated that cells at 15,000 cells/cm2 in a 12-well plate format had poor 
growth characteristics. As a result, 30,000 cells/cm2 was added to the experimental design.  
 
N2: No change. 0.5:100; 1:100 and 1.5:100. 
Reasoning: N2 was kept the same as it is a complex mixture of compounds which would be difficult to 
ascertain exactly what mechanisms and which components within it are responsible for the supportive 
effects observed in DSD1. Therefore, N2 was kept the same and density was added as an extra factor 
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which might interact significantly with N2 due to its supportive effect i.e. less support for higher 
densities due to less availability. 
 
SB431542: Changed. 5, 10 and 15 µM 
Reasoning: The concentration ranges for SB431542 were broadened to see if there is an effect based on 
SB431542 as DSD1 did not result in significant interactions based on SB431542. The decision to 
broaden the ranges was made under the assumption that the observed non-linearity is not valid in the 
ranges previously employed. 
 
Noggin: Changed. 50, 100 and 150 ng/ml 
Reasoning: Similar to SB431542, the concentration ranges for noggin were broadened to determine if 
a change in the interactions would be observed, in comparison to DSD1. 
 
CHIR99021: Changed. 0.5, 1.0 and 1.5 µM 
Reasoning: Previous experiments showed that lower concentrations of CHIR99021 result in cell 
survival, however the cells were not of the desired phenotype. 1µM has been shown to result in the 
correct phenotype and result in survival, therefore conditions either side were employed to assess if 
1µM is the optimal CHIR99021 concentration. 
 
SHH-C24II: Changed. 300, 600, 900 ng/ml 
Reasoning: DSD1 showed that SHH-C24II was highly influential, however the ranges used resulted in 
a failure mode as SHH-C24II is needed for survival. Higher concentrations were also shown to result 
in improved phenotypic progression, particularly when coupled with higher concentrations of 
CHIR99021. For DSD2 the concentration range was shifted upwards, removing the 0 ng/ml condition 
and adding a higher concentration of 900 ng/ml. 
 
FGF8: 50, 100 and 150 ng/ml 
Reasoning: This was the first use of FGF8b as a factor in the design. The concentration ranges used 
followed the same ranges used in the other small molecules, making it similar to the protocol in terms 
of ratio between factors i.e. noggin is also at 50, 100 and 150 ng/ml.  
 
ROCKi: 10 µM 
Reasoning: ROCKi did not have any significant influence within the thirteen conditions in DSD1 as 
there was no linearity/interaction observed. In addition, the cells are only exposed to ROCKi for the 
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first two days of the protocol. Furthermore, the ROCKi and cell attachment experiment illustrated that 
a concentration of 10 µM is optimal for H9 cells. As a result, ROCKi was not deemed as a priority 
factor to be investigated and was therefore it was removed from the design. 
 
6.2.2. Flow Cytometry: 
 
The prescribed Miltenyi Biotec protocol was used to analyse the conditions in experiments DR4 and 
DR5. This protocol followed the three-part panel design (Table 38). The samples were prepared as 
described in Chapter 3.The pluripotent cells were used as the gating control within both experiments.  
 
Table 38. The three panels used in the Miltenyi Biotec protocol, each panel contains three phenotypic 
markers used to determine the differentiation outcome and loss of H9 pluripotency. The colour of the 
text represents the laser that excites the fluorophore. 
 
 
6.2.2.1. Flow Panel Optimisation for the Definitive Screens  
 
The three-part panel was deemed unsuitable for the high-resolution experiments such as DSD1 and 
DSD2. Therefore, an in-house single multiplex (six-colour) panel was designed for high frequency flow 
cytometry analysis, that requires small amounts of sample cells (Table 39). This was not achievable 
with the Miltenyi Biotec protocol as each condition would be required to be put into each of the three 
panels, which was not practical when working with small culture vessels such as microtiter plates. The 
relevant isotype controls for each channel were used as gating controls.  
 
Panel 1 Panel 2 Panel 3 
Pluripotency vmDA subtype Undesired neuronal subtype 
OCT3/4-APC FOXA2 -APC NKX6.1-APC
Ki67-FITC OTX2-FITC NKX2.1-FITC
PAX6-PE IAP-PE SOX1-PE
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Table 39. The in-house six colour flow cytometry panel used for DSD1 and DSD2. The colour of the 
text represents the laser that excites the fluorophore. 
N.B. DSD1 flow cytometry analysis was performed without OTX2-FITC as part of the panel due to the 
antibody not being available at the time of analysis.  
6.2.3. Minitab definitive screen analysis.  
 
Minitab18® (Pennsylvania, USA), version 18.1 was used to analyse the definitive screen design 
experiments. Statistical design of experiment analysis was used to analyse the MedFI and Pd response, 
using quadratic analysis of the model parameter terms. Main effects plots were presented to exhibit the 
parameters that had an effect on MedFI and Pd at different levels of the respective parameter e.g. the 
effect of differing CHIR99021 concentrations on FOXA2 expression. Pareto charts presenting the 
standardised effect of model parameters were also utilised. The charts present the magnitude of the 
effect (from largest to smallest) of the parameters and therefore the extent to which a factor drives an 
outcome such as Pd away from the mean in terms of standard deviations. The red reference line depicted 
on each chart represents the level at which standardised effect becomes significant, calculated using the 
user defined significance value, which in these instances was 0.15.   
Marker Fluorophore Indicates Expression (in differentiated cells)
Oct 3/4 BV421 Pluripotency Negative
Otx-2 FITC DA cell fate Positive
Pax-6 PE Neuro stem cell fate Negative
Sox1 PerCP Cy5.5 Neuroectoderm Negative
Ki-67 PE Cy7/ Vio770 Proliferation Transient
Foxa2 APC DA cell fate Positive
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6.3. Results 
 
6.3.1. Differentiation: Differentiation Run 1 and 2 – Lund protocol exploration. 
 
In both experiments the cells were observed to be lifting off the culture surface at day 2, leaving very 
sparse small colonies of cells on the surface (Figure 62). As a result, no cell counts, or other 
characterisation was carried out due to lack of cell material.   
 
 
Figure 62. Representative light microscope image of the cells from DR1 (A) and DR2 (B) showing 
small sparse colonies and detached cells floating. Scale bar = 400 µm. 
 
6.3.2. Differentiation: Differentiation Run 3 - multivariate analysis of CHIR99021 concentrations 
 
Poor cell attachment was observed on day 1 in the majority of conditions when imagined, using light 
microscopy. By day 2, most of the cells had attached and small colonies were forming. However, an 
increase in detached cells and cell debris was also observed. At day 3, most cells had lifted from the 
surface and those remaining were in the process of detaching (Figure 63E). Complete cell detachment 
was observed at day 4 in the longest surviving condition (DR3.a) which was cultured with 0.6 μM 
CHIR99021. Overall, cells at all CHIR99021 concentrations lifted from the wells within the first four 
days of the sixteen-day differentiation process. The two lowest CHIR99021 concentrations (0.6 and 
0.7μM) showed the greatest attachment of all the conditions, however this was only sustained until day 
4.
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Figure 63. Progressive cell detachment during the early stages of differentiation using medium containing 0.6μM CHIR99021. Light microscope images show 
cell morphology and the progressive cell detachment. (A) Cells at day 1 imaged prior to medium exchange, showing a large number of unattached cells. (B) 
Cells at day 1 following medium exchange, showing very few attached to the culture surface. (C) Cells at day 2 imaged prior to medium exchange, showing a 
lot of cell debris. (D) Cells at day 2 imaged following medium exchange, showing colony formation and increase surface coverage. (E) Cells at day 3 imaged 
following medium exchange, poor cell attachment and cell lifting from the surface is observed. (F) Cells at day 4 imaged following medium exchange, very 
few individual cells are observed on the surface and all colonies from day 3 have detached.  Scale bar = 400 µm.
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6.3.3. Differentiation: Differentiation Run 4 – CHIR99021, Density and B27 multivariate analysis  
 
Six of the eighteen conditions survived the sixteen-day differentiation process. All seeding densities 
cultured with CHIR99021 at concentrations lower than the recommended 0.7μM were supplemented 
with B27 from day 0 (Figure 64). Cell detachment was observed in all of the other conditions on or 
before day 7, including the experimental control condition (0.7 μM CHIR99021 at 10,000 cells/cm2 in 
absence of B27) which failed by day 2 (Figure 64). In all the surviving conditions, confluent sheets of 
cells were formed by day 9, this was observed earlier in conditions seeded at higher densities (Figure 
65E). An increase in cell detachment was observed with increasing confluency however, a dense sheet 
of cells remained on the surface (Figure 65). By the replating stage (day 11), due to large amounts of 
cell death, only half of the surviving conditions had sufficient cell yields to allow for replating at the 
prescribed density of 800,000 cells/cm2. The remaining conditions were replated using the total cell 
number yielded from the cell harvest (Figure 66). All conditions survived until day 16 following 
replating, however the yields of the cell numbers at day 16 were much lower than the cells numbers 
used on day 11, for some of the conditions (0.3 and 0.5 μM CHIR99021 at 20,000 cells/cm2, Figure 
67B).  
 
The SGR data demonstrates that the different conditions were growing at different rates and revealed 
an increase in SGR between day 11 and day 16 (Figure 67A). Phenotypic analysis of the conditions 
that survived until day 16 (shown in Figure 64) revealed that the desired marker expression: OCT3/4-, 
Ki67-/+, PAX6-, FOXA2+, OTX2+, IAP+, NKX2.1-, NKX6.1- and SOX1- had not been obtained. Panel 
1 illustrated that the cells experienced a decrease in both OCT3/4 and Ki67, however, the cells were 
still expressing the neural stem/roof plate marker, PAX6 (Figure 68.). In addition, there was a lack of 
dopaminergic cell marker expression (FOXA2, OTX2 and IAP) in panel 2 (Figure 69) and the 
expression of SOX1 in some of the conditions in panel 3 (Figure 70).  Overall, none of the conditions 
expressed the correct phenotype regardless of density, CHIR99021 concentration and addition of B27 
supplement.
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Figure 64: A comparative timeline illustrating cell death time points during the differentiation process. The end points represent the day that the respective 
condition was terminated due to excess cell death within the culture condition. Three conditions (10k 0.3µM CHIR + B27, 10k 0.5 µM CHIR + B27, and 15k 
0.5 µM CHIR + B27) had inconsistent behaviour between their biological repeats, the single surviving wells were carried forward (shown in pink).  
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Figure 65. An overview of H9 hESC to vmDA progenitor differentiation. Single cell suspensions were seeded (A) which attached start to proliferate and form 
colonies (B and C). By day 6 (D) the cultures were mostly confluent and increased in confluency to cover the culture surface by day 9 and 11 (E and F). 
Following replating at day 11 the cells were fully confluent with no visible culture surface, an increase in cell detachment was observed from day 14 (G: inset) 
and continued to day 16 (H: inset). A=Day 0; B=Day 2; C=Day 4; D=Day 6; E=Day 9; F=Day 11; G=Day 14; H=Day 16.  Scale bar = 400 µm, insets scale 
bar = 100 µm. 
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Table 40. Condition labels used in the differentiation run 4 and 5 (DR4 and DR5) experiments, detailing 
both the density and concentration of CHIR99021 used.  
 
 
 
 
 
 
 
 
 
 
Figure 66. A graph displaying the initial replating density at day 11 plotted against the final density on 
day 16. On day 11, cells were harvested and reseeded at 800,000 cells/cm2 where possible. The replating 
densities were calculated for the conditions seeded below 800,000 cells/cm2. Conditions replated at 
800,000 cells/cm2 had a range of final cell densities from 14,000 to 833,000 cells/cm2; this corresponded 
to 125,000 to 7.4 million total cells per well. Conditions replated at densities <800,000 cells/cm2 also 
had a range of final densities with some of them having higher final densities than the conditions at 
800,000 cells/cm2. N.B. A, B and C relate to the replicate within each condition. 
Code Condition 
10k 0.3/[0.3] 10,000 cells/cm2, 0.3 µM CHIR99021 
10k 0.5/[0.5] 10,000 cells/cm2, 0.5 µM CHIR99021 
10k 0.7/[0.7] 10,000 cells/cm2, 0.7 µM CHIR99021 
15k 0.3/[0.3] 15,000 cells/cm2, 0.3 µM CHIR99021 
15k 0.5/[0.5] 15,000 cells/cm2, 0.5 µM CHIR99021 
15k 0.7/[0.7] 15,000 cells/cm2, 0.7 µM CHIR99021 
20k 0.3/[0.3] 20,000 cells/cm2, 0.3 µM CHIR99021 
20k 0.5/[0.5] 20,000 cells/cm2, 0.5 µM CHIR99021 
20k 0.7/[0.7] 20,000 cells/cm2, 0.7 µM CHIR99021 
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 Figure 67. (A) Specific growth rate (SGR) and (B)total harvested cell numbers from each of the culture conditions that survived in DR4 at both day 11 and 
16. The SGR data demonstrated that there were inconsistencies in growth within the conditions, with significant differences in SGR from day 11 to 16 within 
each condition. The total cell number data demonstrated an increase in cells from day 0 to day 11, followed by a decrease in cell number when the cells were 
harvested on day 16. In the conditions that did not perform as well such as 10k [0.5] there was little difference in cell number between day 11 and day 16. 
Conversely, in conditions that initially performed well such as 20k [0.5] the cell number decreases from day 11 to 16 i.e. less than half the cells that were 
reseeded on day 11 were harvested on day 16. Error bars indicate standard deviation, n=2 for each count. “*” indicates p<0.05, “**” indicates p< 0.01, “***” 
indicates p< 0.001, and “****” indicates p<0.0001. 
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Figure 68. Dot plots of the pluripotent cells, the 0.3 and 0.5 µM CHIR99021 at 20,000 cells/cm2 with B27 conditions. The key difference between the cell 
samples is the concentration of CHIR99210. The results show that there was no phenotypic marker profile difference due to CHIR99210 concentration. In 
the two conditions the seeding density and B27 supplementation remained the same. In comparison to the control, both differentiated sample cells 
demonstrated a decrease in OCT3/4 and a population shift in terms of reduced proliferation marker Ki67. However, the samples expressed PAX6 at day 16 
which is not representative of the desired vmDA cell phenotype.   
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Figure 69. Comparable to panel 1 the cells have differing CHIR99021 concentration (0.3 vs 0.5 µM), however the seeding density was equivalent and B27 
was supplemented at day 0. In this panel (Miltenyi panel 2) the differentiated cells for both conditions showed little difference in comparison to the pluripotent 
control cells. The dot plots demonstrate that both of the differentiated conditions are negative for FOXA2 and OTX2 in comparison to the pluripotent cells. 
Only the IAP markers showed a slight increase in expression when compared to the pluripotent controls.  
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Figure 70. Panel 3 demonstrates the negative expression of NKX6.1 and NKX2.1; however, expression of SOX1 was observed. For the desired cell 
phenotype all three markers should be negative as these markers are associated with lateral or rostral cell fates which would be considered a contaminant 
cell type within the cultures. 
 - 219 - 
 
6.3.4. Differentiation: Differentiation Run 5 - CHIR99021, Density and B27 multivariate analysis  
 
The culture conditions in DR5 resulted in similar observations in comparison to DR4. For instance, the 
0.7 µM CHIR99021 conditions in DR5 were the first experimental conditions to be terminated, due to 
extensive detachment and cell death. However, all conditions in DR5 demonstrated greater consistency 
regarding the behaviour of the experimental biological replicates, unlike the conditions in DR4. 
Furthermore, in DR5 the earliest termination point was day 7 (Figure 71); much later than the first 
termination point of day 2 in DR4 (Figure 64). SGR and total cell number data also demonstrated less 
variation between experimental conditions in DR5 compared to DR4 (Figure 67 vs Figure 72). 
Additionally, in DR5 there was an increase in cell number from day 0 to 11 and also from day 11 to 16 
in all conditions, yielding overall better growth and survival compared to DR4 (Figure 67 vs Figure 
72).  
 
The flow cytometry data revealed that although the cells were no longer pluripotent due to low levels 
of OCT3/4, the desired cell phenotype was not obtained from any of the experimental conditions 
investigated. This was evident from the low expression levels of FOXA2, OTX2 and IAP within panel 
2, the dopaminergic neuronal subtype panel of markers. In all conditions the untreated pluripotent cell 
control had higher MedFI values within panel 2 (Figure 73). Three of the conditions (15,000 cells/cm2 
0.3 µM CHIR99021; 20,000 cells/cm2 0.3 µM CHIR99021+ B27 and 20,000 cells/cm2 0.5 µM 
CHIR99021+ B27) had higher MedFI levels of NKX2.1 in comparison to the control, whilst NKX6.1 
levels were similarly lower compared to the control in all of the conditions (Figure 73, panel 3).   
 
N.B. The codes used in DR4 (Table 40) are the same for DR5. 
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Figure 71. A comparative timeline illustrating point of cell death during differentiation run 5. The end points represent the day that the respective condition 
was terminated due to excess cell death within the culture condition, if early than day 16. Higher levels of consistency were observed in DR5 in comparison to 
DR4, all replicates with the conditions behaved the same in DR5, the earliest termination time point was day 7.  
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Figure 72. (A)Specific growth rate (SGR) and (B)total harvested cell numbers from the conditions that survived in DR5 at both day 11 and 16. The SGR data 
demonstrated a significant difference between day 11 and day 16 in all of the experimental conditions. The cell number data showed an increase in total cell 
number from day 0 to day 11 and from day 11 to day 16 in all of the conditions. This illustrates a greater consistency and performance in all of the conditions 
in comparison to DR4. Error bars indicate standard deviation, n=3. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 0.001, and “****” indicates 
p<0.0001. 
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Figure 73. Median fluorescence intensity values of the different markers for all experimental 
conditions. The OCT3/4 MFI data showed that there was negligible expression of OCT3/4 by day 16. 
There were varying levels of Ki67 expression in the experimental conditions, however they were all 
lower compared to the untreated pluripotent cell control samples. For the panel 2 markers the MedFI 
values showed that none of the experimental conditions had higher expression of the putative vmDA 
markers FOXA2 and OTX2 than the control. Panel 3 showed that all conditions were lower in 
comparison to the control for NKX6.1 yet some of the conditions had higher NKX.2.1 MedFI value 
compared to the controls. SOX1 MedFI values showed similar or lower values compared to the controls. 
The x axis codes are detailed in Table 40 
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6.3.5. Differentiation: Design of Experiment - Definitive Screen 1 (DSD1) 
 
The medium formulations in the definitive screen illustrated that different concentrations of some of 
the small molecules (N2 supplement, SB431542, SHH-C24II and CHIR99021) had an impact on cell 
growth, survival and differentiation of the desired vmDA neuroprogenitor cell type ( Figure 78). In 
particular, higher concentrations of SHH-C24II and CHIR99021 are required for cell growth and 
survival ( Figure 78A); four of the thirteen conditions did not survive until day 11 (M3, M8, M12 and 
M13), with M12 and M13 being terminated at day 7, M3 and M8 at day 9 due to extensive cell 
detachment and death (Figure 74). In the case of M3, M8 and M12, the concentration of 0 ng/ml SHH-
C24II was used (Table 35). All other conditions survived until day 11, however there were varying 
levels of cell yield (~ 5x105 to 2x106) and cell viability (~84 to 98 %) amongst the conditions. The 
M1and M6 conditions had the highest cell number yield at day 11 (~2x106 cells), cell viability (97- 98 
%) and the highest population doublings (0.54 doublings per day) (Figure 75). M2 and M5 had low 
cell number yields of ~ 5x105 at day 11 and cell viabilities below 90 %. The M2 and M5 conditions 
also had the highest levels of PAX6 at all time points analysed, whilst the M1 and M6, M9 and M11 
experimental conditional had the lowest PAX6 MedFI values and M1 and M6 had high FOXA2 MedFI 
values that increased incrementally until the day 11 endpoint (Figure 76 and Figure 77). 
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Figure 74.Schematic detailing the termination time points for DSD1. The lighter blue colour represents conditions that were inconsistent throughout the 
experiment. For instance, some replicates under the M2 conditions were terminated at day 7; however, some were continued until day 11 prior to harvest. The 
darker blue colour demonstrates the conditions that behaved consistently throughout the experiment both in terms of when they were terminated and when they 
were harvested i.e. all replicates in M8 were terminated on day 9. M12 and 13 were the first conditions to be terminated due to extensive detachment at cell 
death by day 7. 
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Figure 75. Cell growth and viability data of the different conditions of the definitive screen. For the 
majority of the culture conditions, the population doubling rate was 0.5 doublings per day, resulting in 
~6 population doublings over the 11-day culture period (A). The number of cells harvested at day 11 
ranged from 5x105 to 2.1x106 with M2 having the lowest cell yield and M6 having the highest (B). The 
cell viabilities ranged from 84 % to 98 %, M2 had the lowest and M6 the highest viability (C). Error 
bars indicate standard deviation, n=4.
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Figure 76. Median fluorescence values. (A) Ki67 was observed to decrease from day 4 to 9 in the 
majority of the conditions. (B) SOX1 decreased from day 4 to day 9 and remained at similar levels at 
day 11. (C) PAX6 expression varied amongst the different conditions, initially expressing low 
fluorescence prior to increasing in some of the experimental conditions (M2, M3 and M5); whilst in 
other conditions PAX6 expression remained low throughout the eleven-day culture period (M1, M6 
andM9), other conditions had a decrease in PAX6 MedFI (M4, M7 and M10). Conditions M2, M8, 
M12 and M13 were terminated prior to the day 11 time-point, therefore no values were obtained. Uns 
= unstained; Iso = isotype.  
 - 228 - 
 
 
  
Figure 77. (A) OCT3/4 decreased from day 4 to day 9 followed by an increase from day 9 to 11, 
however this was not to the same level as the MedFI values on day 4. (B) FOXA2 increased from day 
4 to day 9 in all the conditions except for M3 and M7 where they decreased from day 4 to 9. Some 
conditions had a decrease in FOXA2 MedFI from day 9 to 11(M4, M5, M10 and M11) while other 
conditions had an increase in fluorescence (M1, M6 and M7) with M1 having the highest MedFI of all 
the conditions investigated. Conditions M2, M8, M12 and M13 were terminated prior to day 11, 
therefore no values were obtained. Uns = unstained; Iso = isotype.
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 Figure 78. (A) Main effects plot of the factors that impacted population doubling rate at the 
experimental end point day 11. N2 and SHH-C24II had a significant impact on the population doubling 
rate, higher concentrations of both factors resulted in an increase of doubling rate. (B)Pareto chart 
detailing the level of effect that the different factors had on population doublings at the experimental 
end point day 11. N2 and SHH-C24II, combined and individually had the largest effect on population 
doubling rate.   
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Figure 79. Pareto chart detailing the level of effect the different experimental factors had on FOXA2 
expression at the experimental end point day 11. SHH-C24II had the largest impact on FOXA2 
expression.  
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Figure 80. Pareto chart detailing the level of effect the different experimental factors had on PAX6 
expression at the experimental end point day 11. N2 supplement by itself and in combination with other 
factors such as SHH-C24II and noggin influenced PAX6 expression.  
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Figure 81. Pareto chart detailing the level of effect the different experimental factors had on SOX1 
expression at the experimental end point day 11. N2 supplement, CHIR99021, SHH-C24II and noggin 
had a significant impact on SOX1 expression.  
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Figure 82. Main effects plot of the factors and their influence on marker expression at the experimental 
end point day 11. (A) N2 supplement, noggin and CHIR99021 exhibited a linear relationship to SOX1 
expression, SHH-C24II concentration at the ranges used did not have an impact on SOX 1 expression. 
(B) PAX6 expression had a strong positive linear relationship to N2 supplement and ROCK-inhibitor, 
SHH-C24II and CHIR99021 had a strong negative correlation to PAX6 expression. (C) FOXA2 marker 
expression main effects, noggin and SHH-C24II had a positive linear relationship with FOXA2 
expression, higher levels of both factors resulted in higher levels of FOXA2 MedFI. CHIR99021 had a 
non-linear relationship to FOXA2 expression, the mid-point concentration afforded the lowest levels of 
FOXA2 MedFI.  
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6.3.6. Differentiation: Design of Experiments – scale up experiment. 
 
The SGR of all the conditions decreased from day 4 to day 9 and from day 9 to 11. The decreases were 
significant for all of the conditions across the days, with the exception of the 6 well plate format at 
25,000 cells/cm2 where no significant decrease from day 9 to day 11 was observed (Figure 83A). The 
cell number yield across the conditions increased overall from day 4 to day 9 and also from day 4 to 11 
day. At each time point the SGR increases were significant for the majority of conditions, with the 
exception of the 12 well plate format at 20,000 cells/cm2 which had no significant increase in cell 
number, instead the cell number decreased (Figure 83B). This decrease in cell number was also seen 
in the 12 well plate format at 15,000 cells/cm2 which had a significant decrease in cell number from 4 
to day 9 and also from day 4 to 11. This decreased cell number was also accompanied by a decrease in 
cell viability in both the 15,000 and 20,000 cells/cm2 conditions in the 12 well plate format (Figure 
83C). At day 4 the average cell number yield in the 12-well plate format was ~1.5x106 cells per well, 
while at the lower density of 15,000 cells/cm2 an average of ~8x105 cells were harvested per well on 
day 4. The 6-well format plates had yields between 1.5x106 to 2x106 cells by day 4, at day 11 the 6 well 
plate format had cell yields between 2x106 to 4x106 cells. 
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Figure 83. Cell growth dynamics detailing the SGR, total cell number per well and cell viability. (A) 
SGR significantly decreased from day 4 to day 9 and from day 9 to day 11 for all conditions. (B) Cell 
number decreased overall for the 12-well plate format at 15,000 cells/cm2 and 20,000 cells/cm2, all other 
conditions had a significant increase overall in cell number by day 11. (C) All of the conditions had a 
significant decrease in cell viability by day 11, apart from the 6-well plate format seeded at 25,000 
cells/cm2. The 12-well plate format seeded at 15,000 cells/cm2 and 20,000 cells/cm2 had the greatest 
decrease in cell viability from day 9 to day 11, compared to the other conditions.  Error bars indicate 
standard deviation, n=2. “*” indicates p<0.05, “**” indicates p< 0.01, “***” indicates p< 0.001, and 
“****” indicates p<0.0001. 
6.3.7. Differentiation: Design of Experiments – day 11 replating 
 
Results indicated that seeding at a lower (400, 000 cells/cm2) density allowed the cells to proliferate, as 
these conditions had positive SGR values, whilst those seeded at 800,000 cells/cm2 had very low or 
negative SGR values (Figure 84). However, SGR values were not significantly different within the 
conditions in each density i.e. C1, C3, C5 and C7, all at 400, 000 cells/cm2 did not significantly differ 
in SGR. Across the two time points the high-density conditions did not have significant increases in 
cell number, this was also the case for the mid-point condition of 600,000 cells/cm2 (Figure 84B). 
Differences in cell viability were predominantly observed at day 14 in a range of the conditions, whilst 
at day 16 the only significant difference was between C1 and C9. Conditions C1 to C6 increased in cell 
viability from day 14 to day 16, while C7 to C9 had a decrease in cell viability (Figure 84C). Images 
of the cells 2 h after seeding showed that when seeding at a density of 800,000 cells/cm2 the cells 
immediately attached and covered the entire available culture surface, leaving a high number of cells 
unattached.  
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Figure 84. Growth dynamics detailing the SGR, total cell number per condition and cell viability. (A) 
SGR significantly decreased from day 14 to day 16 in all of the conditions p=0.0443 (*). The 400,000 
cells/cm2 density conditions (C1, C3, C5 and C7) had SGR values over 0.005 hour-1 whilst the 
conditions replated at 800,000 cells/cm2 had very low (<0.001 hour-1) or negative SGR values (B) 
Overall, the cell number increased for all the conditions with average yields between 2x106 and 3.5x106 
per well at day 16; p>0.0001 (****). (C) Conditions C1 to C6 had a slight increase in cell viability from 
day 14 to day 16, while C7, C8 and C9 had a decrease in cell viability. Error bars indicate standard 
deviation, n=2.  
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6.3.8. Differentiation: Design of Experiment - Definitive Screen 2 (DSD2) 
 
Cells in DSD2 maintained a viability above 85% during the sixteen-day period with all conditions ≥95% 
by day 16 (Figure 87). For the majority of the conditions the cell viability increased from time point to 
time point or stabilised by day 9, whereby there was a significant increase recorded from day 4. The 
overall SGR decreased with the majority of the conditions having a negative SGR by day 16 (Figure 
85). Generally, the cell number increased over the 16 days, however in more than half of the conditions 
cell number yield decreased from day 11 to day 16 (Figure 86). Conversely, the in the remaining 
conditions there was an incremental increase in cell number yield at each time point, these conditions 
were: 2, 3, 6, 8, 10,11,13 and 15.  
Phenotype analysis revealed a ~six-fold decrease in OCT3/4 MedFI for all of the condition when 
compared to the pluripotent control sample which resulted in a decrease of OCT3/4 positive cells from 
90 % at day 0 to ~ 0.1 % at day16 (Figure 88A). On day four all of the conditions were significantly 
higher in Ki67 MedFI compared to day 9, 11 and 16, with some conditions expressing higher compared 
to the pluripotent control (Figure 88B). The conditions that had the highest FOXA2 MedFI levels were: 
1,5,9,11,16, and 17 by day 16, these conditions were largely >60 % positive for FOXA2 (Figure 89A 
and B). In addition, these conditions were higher in OTX2 expression at day 16 compared to day 11 whilst 
being >90 % positive for OTX2 (Figure 90A and B). Other conditions such as: 3, 4, 6, 7, 8 and 10 had 
higher FOXA2 MedFI on day 9 or 11 in comparison to day 16. Low PAX6 levels were observed for 
conditions 1, 5, 9, 16, 17 (Figure 91A). Conditions 1, 4, 9, 16, 17 had high SOX1 MedFI expression at day 
4 which decreased significantly by day 16 (Figure 91B), of these conditions 1, 9, 16, and 17 also had high 
FOXA2 expression on day 16.  
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Figure 85. The SGR decreased overall from time point to time point p<0.0001 (****), the majority of the conditions had a negative SGR by day 16, when 
there was the most significant decrease in SGR. Error bars indicate standard deviation, n=4.  
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Figure 86. The cell number yields differed amongst the conditions, in particular at day 11 and 16, overall there was an increase in cell yield, however in more 
than half of the conditions cell number yield decreased from day 11 to 16. Conversely, the other conditions had their highest cell yields on day 16, these 
conditions were: 2, 3, 6, 8, 10, 13 and 15. Both the time point (p<0.0001 (****)) and the culture condition culture (p<0.0001 (****)) resulted in significant 
differences in cell yield. Error bars indicate standard deviation, n=4.  
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Figure 87. The cell viabilities were high across the 17 different conditions; all conditions were above 85% viability. All conditions except condition 5 and 13, 
had their most significant increases in cell viability from day 4 to 9; at day 16 the average cell viability was 97.4 ±1.1. Both the time point (p<0.0001 (****)) 
and the condition of culture (p<0.0001 (****)) resulted in significant differences in cell yield. Error bars indicate standard deviation, n=4. 
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Figure 88. (A) OCT3/4 MedFI significantly decreased in expression of OCT3/4 for all conditions when compared to the pluripotent control p<0.0001 
(****). Overall, the conditions retained a low level of OCT3/4 expression. (B)  Ki67 MedFI values at day 4 were not significantly different between the 
pluripotent control and the culture 17 conditions, with the exception of condition 7. However, for all 17 conditions the MedFI at day 4 was significantly 
higher compared to day 9, 11 and 16, p <0.0001 (****). At day 9 all of conditions differed in Ki67 MedFI compared to the control, p<0.0001 (****). Error 
bars indicate standard deviation, n=2.  
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Figure 89. (A) FOXA2 MedFI values did not increase significantly over the time points; Except for conditions 1, 9, 11, 16 and 17 at varying time points. 
Some conditions, such as 12 and 13 had significant decreases in FOXA2 MedFI expression, particularly from day 11 to 16. At day 16 conditions 1 
(p=0.0001 (***)); 5 (p=0.0306 (*)); 9 (p=0.0025 (**)); 11 (p=0.0025 (**)); 16 (p=0.0079 (**)) and 17 (p=0.204 (*)) were the only conditions with 
significantly higher FOXA2 values when compared to the pluripotent controls. (B) In general, there was an increase in the percentage of cells that were 
FOXA2 positive compared to the pluripotent controls. Between day 4 and 9 there was a significant difference in the percentage of FOXA2 positive cells 
p<0.0001 (****). Between day 9 day 11 there was no significant difference whilst between day 11 and 16 there was a lesser degree of significance (p=0.0224 
(*) compared to day 4 to day 11 p<0.0001 (****) and day 4 to  16 p<0.0001 (****). Error bars indicate standard deviation, n=2. 
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Figure 90. (A) Overall, the OTX2 MedFI values did not increase significantly over the time points in comparison to the pluripotent controls, except for 
condition 2 (p=0.0143 (*)) and 6 p=0.0003 (***)) on day 4, conditions 6 (p=0.0074 (**)) and 15 (p=0.0007 (***)) on day 11. (B) The OTX2 percentage 
positive date illustrates that, with the exception of condition 5 (day 4 to 11 p<0.0001(****); day 9 to 11 p<0.0001(****); day 11 to 16 p<0.0001 (****)) and 
condition 14 (day 4 to 11 p<0.0001(****); day 9 to 11 p<0.0001(****); day 11 to 16 p<0.0001 (****)) there was no significant difference in the percentage 
of OTX2 positive cells across the different conditions and across the different time points. Furthermore, the percentage of OTX2 positive cells in the culture 
condition 17 was not significantly different to the untreated pluripotent control. Error bars indicate standard deviation, n=2. 
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Figure 91. (A) Conditions 2, 6, 8, 10 and 15 were significantly different to the pluripotent control on day 4 with higher expression of PAX6. After day 4 the 
conditions had decreased PAX6 MedFI expression p<0.0001(****), which decreased to similar or lower levels compared to the pluripotent controls at 
subsequent time points. (B) SOX1 MedFI expression was highest at day 4 for all conditions; conditions 1, 4, 5, 7, 9, 11, 12, 14, 16 and 17 had the highest SOX1 
MedFI expression overall, which were significantly higher in comparison to all other conditions p<0.0001(****). Error bars indicate standard deviation, n=2. 
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Figure 92. Main effects plot of the factors that impacted marker expression and population doublings 
at the experimental end point day 16. (A) FOXA2 marker expression main effects, both seeding density 
and SHH-C24II have a positive linear relationship with FOXA2 expression, higher levels of both result 
in higher levels of FOXA2 MedFI. CHIR99021 has a non-linear relationship to FOXA2 expression the 
mid-point concentration affording the highest levels of FOXA2 MedFI. (B) Seeding density, N2 
supplement and noggin have a positive linear relationship to OTX2 expression whilst CHIR99021 and 
FGF-8b have a negative correlation; SHH-C2411 has non-linear relationship where the mid-point 
resulted in lower OTX2 expression. (C) Five of the factors showing differing levels of effect and no 
effect, in the case of N2 supplement, on the population doubling rate.   
  
 
 
 
 
 
- 249 - 
 
 
Figure 93. Pareto chart detailing the level of effect the different experimental factors had on population 
doubling rate at the experimental end point day 16.  Seeding density, CHIR99021 and SHH-C24II, 
individually and when combine with other factors, had the most significant impact on population 
doubling rate. SB431542 and FGF-8b demonstrated no significant impact on population doubling rate. 
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Figure 94. Pareto chart detailing the level of effect the different experimental factors had on FOXA2 
expression at the experimental end point day 16. The most significant factor on FOXA2 expression was 
CHIR99021; SB431542 did not have a significant effect. CHIR99021 and SHH-C24II combined, had 
a significant effect on FOXA2 MedFI expression. 
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Figure 95. Pareto chart detailing the level of effect the different experimental factors had on OTX2 
expression at the experimental end point day 16. The most significant factor on OTX2 expression was 
CHIR99021; SHH-C24II and SB431542 did not have a significant effect. CHIR99021 and SHH-C24II 
combined had a significant effect on OTX2 MedFI expression. 
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6.4. Discussion 
 
This chapter illustrated the challenges that are associated with the translation of a protocol from another 
institution. In a series of publications24,124 Lund University presented results that reported the protocol 
to be capable of yielding the desired vmDA cell type with proven functionality in preclinical studies of 
rat PD models85,106. However, the efforts of five researchers within Loughborough University have not 
been able to yield cells with the characteristics described in the literature published by the collaborators 
at Lund University, using their protocol as prescribed109,129. As a result, the range of experiments 
described in this chapter were performed to ascertain the optimal conditions for successful H9 hESC to 
vmDA differentiation. The following sections discuss the key findings from the present work, 
specifically discussing parameters including seeding density; small molecule concentration; cell death; 
cell identity and protocol reproducibility. A summative discussion is presented in order to address how 
these issues have impacted on protocol optimisation and highlight the key learnings from the current 
work.  
 
Initial work carried out highlighted the issues concerning process transfer and inter-lab variation 
concerning differentiation outcomes. A range of experiments were used to ascertain the sources of 
variation and to investigate conditions that would result in cell survival and appropriate vmDA 
phenotypic profile. Results from these experiments revealed that the protocol conditions as prescribed 
did not result in successful differentiation and cell survival without significant changes to the protocol. 
For example, increased seeding density, changes to the small molecule concentrations and 
supplementation with B27 from an early stage.  
 
To further investigate the most appropriate conditions needed to obtain the desired cell phenotype a 
definitive screen DoE was used for six of the different factors used within the initial seven days of the 
differentiation protocol. These factors were N2 supplement, ROCKi, noggin, SB431542, SHH-C24II 
and CHIR99021. This resulted in an experiment with thirteen different medium compositions using 
three levels of concentration for each factor, using the protocol conditions as the midpoint. The results 
of the definitive screen demonstrated that N2 supplement supported a range of different outcomes based 
on both the measured outcomes of cell phenotype (Day 4, 9 and 11) and cell growth dynamics (cell 
counts on day 11). ROCKi was observed to have a negligible impact on the differentiation process, as 
it supported cell growth and differentiation in all of the experimental conditions investigated. With 
regards to noggin, SB431542, SHH-C24II and CHIR99021, the experiments revealed a variety of 
different outcomes; demonstrating the sensitivities of these factors and their influence on cell survival 
and phenotype. Both linear and non-linear interactions were observed which had not been previously 
detected in prior experiments. SHH-C24II in particular was significantly influential as since conditions 
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void of SHH-C24II completely failed. This did however reduce the power of the experiment due to the 
failure of the cells cultured under these conditions; furthermore, the low cell numbers resulted in a lack 
of experimental duplicates as the conditions had to be pooled which reduced the overall resolution of 
data produced.   
 
As a result of the first definitive screen, information regarding the supportive and non-supportive ranges 
of the six factors investigated was accrued. The second definitive screen was designed to further probe 
into the behaviours observed in the first screen. The ranges of the factors were adjusted in the second 
screen, moving away from protocol conditions as thus far all previous experiments had proven the 
prescribed protocol parameters and concentrations to be inadequate for obtaining vmDA neurons 
(typically the protocol conditions were the first ones to fail). The culture vessel size was changed and 
scaled up to increase cell yields, as low cell numbers reduced the resolution and power of the first 
definitive screen in terms of growth dynamics. Therefore, more cells in duplicate could be obtained 
without pooling the samples, such as the case in DSD1. FGF8b and density were added as additional 
factors, resulting in an investigation to determine the key factors impacting the first nine days of the 
differentiation process. 
 
6.4.1. Seeding Density  
 
Prior chapters have shown that the densities at which cells are seeded at have an impact on both yield 
and the cell dynamics within a culture system. Overall, density plays a crucial role in cells survival 
during the differentiation process. The experiments highlighted a synergistic relationship between 
seeding density and cell survival, typically higher seeding densities performed better than the prescribed 
density of 10,000 cells/cm2. Conditions with cells cultured at the prescribed density of 10,000 cells/cm2, 
without B27 supplementation, detached within the first seven days of the protocol, in all the experiments 
carried out. However, this lower density when supplemented with B27 from day 0 resulted in increased 
cell survival, for instance as seen in experiment DR5. Moreover, results from Chapter 5 show that 
expansion cultures seeded at 10,000 cells/cm2 fail to perform even when cells are in a pluripotent state. 
Thus, the data suggests that increasing seeding density has a beneficial effect on survival of conditions 
not supplemented with B27, since conditions seeded at 15,000 or 20,000 cells/cm2 survived until day 7 
as a minimum in DR5 and in the definitive screen experiments (DSD1 and DSD2). Amongst the 
conditions that survived, initial seeding density contributed not only to how quickly the cultures became 
confluent, but also whether or not they were replated at 800,000 cells/cm2 in DR4 and DR5. All but one 
of the conditions initially seeded at 20,000 cells/cm2 were replated at 800,000 cells/cm2, whilst none of 
the 10,000 cells/cm2 conditions had sufficient cell yields at day 11 to allow for replating at the 
recommended density (in DR4).  
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In DSD2, density was added as an additional factor to the DoE, to investigate its impact on cell 
feedback/ self-cell influencing factors. Prior to the experiment, the scale up experiment was devised to 
establish a culture vessel format with a range of densities that would result in a countable number of 
cells at day 4 (the first harvest time point), whilst also being economically favourable and manageable 
in terms of scale and manipulation. The results demonstrated that the 12-well plate format had higher 
SGR values compared to the 6- well plate format. However, in the 12-well format a density of ≥20,000 
cells/cm2 is favourable, since the 15,000 cells/cm2 condition did not perform well. This was evidenced 
by lower SGR values compared to the 20,000 and 25,000 cells/cm2 conditions in the 12- well format 
group. The lower SGR resulted in lower cell number yields at day 11 for the 15,000 cells/cm2 condition 
in comparison to 20,000 and 25,000 cells/cm2; in addition, the 15,000 cells/cm2 condition had the lowest 
cell viabilities at day 11.  
 
The present work illustrates the importance of seeding density and it is an element of the protocol that 
should be highly defined and standardised (Figure 93), as operators and different laboratories have 
different methods of cell counting275–277. This easily introduces variation into the outcomes of the 
protocol, as shown in the present work, incorrect cell seeding densities can be a failure mode of the 
process. Here, lower densities have been shown to result in poor cell growth dynamics and poor cell 
viability. 
 
6.4.2. Replating 
 
At the replating stage of the protocol it was not apparent why the Lund protocol prescribed such a high 
seeding density; 800,000 cells/cm2. The data showed that seeding densities up to four-fold less of the 
protocol replating density are capable of yielding similar cell numbers to conditions replated at 800,000 
cells/cm2 (Figure 66). In DR4, some conditions had poor cell attachment and growth, therefore, these 
conditions were replated using the total harvested cell number, resulting in seeding densities differing 
from the prescribed 800,000 cells/cm2 (Figure 66). As anticipated, the cells seeded at lower densities 
initially had lower culture surface coverage, however images collected at day 14 illustrated that 
resulting cultures looked “cleaner” (Appendix 5) with less cell debris in comparison to those seeded at 
800,000 cells/cm2. Images recorded of the cells seeded at the protocol density showed complete 
coverage within two-hours post replating, with a number of non-adhered and floating cells observed 
due to the lack of available culture surface (Figure 96). 
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Figure 96. (A) Images of cell at day 11 before replating, inset shows zoomed in sections of the well. 
(B) Image of cells at day 11, two hours after replating, the culture surface is fully covered, the inset 
image shows cells attached (black arrows) and unattached cell (red arrows) due to lack of available 
culture surface. Scale bar = 400 µm, inset scale bar = 100 µm. 
 
The day 11 replating experiment further explored the effect of seeding density, highlighting a grouping 
in SGR behaviour (400,000 cells/cm2 vs. 800,000 cells/cm2), based on replating density. The 
concentrations of FGF8b and ascorbic acid were represented equally in the two groups, suggesting that 
the observed behaviour was influenced by the density and not the small molecule concentrations. In 
addition, SGR values were not significantly different within the density conditions, suggesting that the 
different concentrations of small molecules do not have an effect on cell proliferation, in the ranges 
explored. The 400,000 cells/cm2 conditions had positive SGR values, whilst those seeded at 800,000 
cells/cm2 had very low or negative SGR values. Observations of the cells showed that the cells 
immediately attached and covered all of the available culture surface when seeded at such high densities 
(Figure 96). This resulted in a high number of cells that remained unattached, attributing to the negative 
SGR observed in the high-density conditions (C2, C4, C6 and C8). Furthermore, no changes in cell 
phenotype were observed in conditions replated at densities lower than 800,000 cells/cm2. This 
indicated that it is not necessary to replate the cells at such a high density, instead less cells can be used, 
potentially increasing the efficiency of the protocol.   
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6.4.3. Small Molecule concentrations 
 
The experiments explored a range of different small molecule concentrations, with some of the small 
molecules having more of an influence (N2, SHH-C24II and CHIR99021) compared to others 
(ROCKi). DSD1 showed that the influence of ROCKi was insignificant since it was supportive of cell 
attachment for all conditions and the inhibitor is only used to supplement the medium in the first 48 
hours of the protocol. DoE analysis of the small molecules demonstrated that ROCKi did not have an 
impact on desired marker expression for FOXA2 (Figure 79 and Figure 82C). Therefore, ROCKi was 
removed from the experimental design used in DSD2.  
 
The effect of CHIR99021 concentration on cell survival initially seemed to be dependent on both 
seeding density and addition of B27; with the addition of B27, a lower CHIR99021 concentration was 
desirable, whilst without B27 a higher seeding density was required. Interestingly, the original 
prescribed protocol concentration (0.7 µM) only survived when other protocol parameters such as the 
seeding density was increased and/or B27 supplement was added at day 0. The definitive screen results 
again demonstrated that 0.7 µM CHIR99021 is not a favourable concentration as the M12 and M13 
conditions (both at 0.7 µM CHIR99021) were terminated at day 7 due to extensive cell detachment and 
death; with M13 being the protocol control medium formulation. This further illustrated that 0.7 µM 
CHIR99021 is not a conducive concentration for successful cell survival and differentiation, even at an 
increased seeding density, as used in DSD1 this concentration results in lower FOXA2 expression 
(Figure 82C).  
 
The definitive screens highlighted the complex interactions between the different concentrations of 
supplements and small molecules, such as N2 supplement, CHIR99021 and SHH-C24II, the two vmDA 
patterning factors. Interactions between N2 supplement and SHH-C24II were observed to have an effect 
on expression of markers such as PAX6 (Figure 80) and SOX1(Figure 81) The M2 and M5 conditions 
in DSD1 had the highest levels of PAX6 expression at all sample points, suggesting incorrect cell 
lineage fate and/or preservation of a neurostem cell phenotype. This can be attributed to the absence of 
SHH-C24II and lower concentrations of CHIR99021, which highlights the necessity of SHH-C24II in 
the patterning and differentiation process. Moreover, M1 and M6, M9 and M11 had the lowest PAX6 
MedFI values and M1 and M6 had high FOXA2 MedFI values that increased incrementally until day 
11. Both M1 and M6 in DSD1 and conditions 1, 6, 9, 11, 16 and 17, in DSD2, performed well in terms 
of cell number yield, cell viability, population doubling rate and phenotypic marker expression. A 
common feature of these conditions was the higher levels of both SHH-C24II and CHIR99021. 
Although lower concentrations such as 0.3 µM and 0.5 µM CHIR99021 resulted in improved cell 
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survival and growth (Figure 92C), they did not result in the correct cell phenotype (Figure 92A). 
Instead, the work carried out has revealed that higher concentrations than prescribed, such as 1 and 1.5 
µM CHIR99021 and 600 and 900 ng/ml SHHC24II, are required to achieve expression of the desired 
cell phenotype in terms of FOXA2 expression. 
 
However, the results demonstrated that N2 supplement and noggin had a positive linear relationship to 
OTX2 expression whilst CHIR99021 and FGF-8b had a negative correlation; interestingly SHH-C2411 
reveals a non-linear relationship where the mid-point resulted in lower OTX2 expression (Figure 92B). 
This exhibited further complexities in small molecule concentrations, as low concentrations of SHH-
C24II (300 ng/ml) afforded higher OTX2 expression but lower FOXA2 expression while lower 
CHIR99021 concentrations (0.5 µM) resulted in higher OTX2 expression but lower FOXA2 expression 
(Figure 92A and B). This highlighted the challenge in determining the optimal concentration 
combinations to achieve the desired FOXA2 and OTX2 co-expression.  
 
6.4.4. The effects of B27 supplementation on day 0 of the protocol  
 
The data illustrated that the addition of B27 supplement significantly improved cell survival in 
conditions containing a low concentration of CHIR99021 and those seeded at 10,000 cells/cm2 (Figure 
64 and Figure 71). This highlights the supportive effect of the B27 supplement which was 
recommended in the troubleshooting section of the Lund protocol129 . It is unclear exactly under what 
mechanism the supplementation of B27 aids cell survival, but it can be inferred that the additional 
nutrients and antioxidants in the B27 formulation provide a beneficial effect in terms of cell 
survival171,278. However, this does lead to successful differentiation as B27 supplemented conditions 
were not of the desired cell phenotype in any of the conditions in DR4 and DR5. It is worth noting that 
B27 supplementation may interfere with the initial commitment and differentiation of the cells normally 
induced by N2 medium171. Especially, as B27 supplement is normally used in later stages of 
differentiation as it favours attachment and growth of mature neuroprogenitors273, whilst N2 inhibits 
growth of undifferentiated cells279. 
 
6.4.5. Cell identity  
 
Cell phenotype was the predominant measure of outcome success as cell survival itself did not 
guarantee the desired cell phenotype would be obtained. The high-resolution cell phenotyping revealed 
interesting expression patterns related to some of the markers used in the flow cytometry panels. 
Indicative markers such as PAX6, which are meant to confirm that the cells have successfully 
progressed into neural stems cells are essential for determine the trajectory of differentiation. PAX6 is 
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expected to be transient in neuroprogenitors25,122, particularly those that are vmDA fated and thus should 
not express PAX6 at the end of the differentiation process as it is an early neuroectodermal marker107,280. 
Thus, the observed expression of PAX6 at day 16 in some conditions suggested incorrect cell linage 
fates.  
Another observed pattern of PAX6 showed that lower levels of expression on all of the days (the four 
sample points used) is concomitant with higher FOXA2 expression on day 16 as seen in conditions 1, 5, 9, 
16, 17 in DSD2 (Figure 89 and Figure 91). Conversely, conditions with high PAX6 on day 4 did not result 
in high FOXA2 at any time point analysed. This seems to suggest that the phenotypic expression (PAX6) of 
the cells day at 4 has an impact on their ability to further differentiate towards the desired vmDA cell lineage, 
particularly in terms of FOXA2 expression. Conditions 1, 4, 9, 16, 17 had high SOX1 on day 4 which 
decreased significantly by day 16; of these conditions 1,9,16, and 17 also had high FOXA2 expression on 
day 16. These conditions, 1, 4, 9, 16 and 17, had high levels of CHIR99021, either 1 µM or 1.5 µM and ~ 
70% or above of the cells in these conditions were FOXA2 positive. The best condition was M1(DSD1) 
and condition 1 (DSD2); cells cultured in DSD2 were able to achieve high FOXA2 expression levels 
that peaked on day 9, followed by a decline in expression at day 11 and 16. This expression decline was 
observed in the range of experiments carried out and by collaborators at Miltenyi Biotec (Appendix 4). 
Expression of the vmDA markers, FOXA2 and OTX2, was demonstrated to be highly influenced by 
SHH-C24II and CHII99021 as these factors individually and/or combined had the most significant 
effect on vmDA marker expression (Figure 94 and Figure 95).   
 
In terms of other markers, the OCT3/4 MedFI data demonstrated that there was negligible expression 
of OCT3/4 in the experimental conditions by day 16, which is expected since the cells should no longer 
be pluripotent. There were varying levels of Ki67 in the experimental conditions, however they were 
all lower than the pluripotent control sample, which is expected as the cells would still be proliferating, 
albeit at a slower rate. In DR4 and DR5 when the Miltenyi Biotec flow cytometry protocol was 
employed, panel 3 revealed that all of the conditions has lower NKX6.1 expression compared to the 
pluripotent control, while some of the conditions had higher NKX.2.1 MedFI values compared to the 
control. SOX1 MedFI values showed similar or lower values compared to the control, suggesting that 
panel 3 does not identify the presence of contaminant/incorrectly differentiated cells. Thus, a more 
definitive panel of markers should be devised to adequately distinguish between pluripotent cells, 
desired cells and contaminant cells. 
 
Although the cells did not express the contaminant phenotypic markers including NKX6.1 they were 
also not expressing high levels of the desired cells phenotype. This suggested that alternative 
containment markers, such as GBX2 known to be present in midbrain-hindbrain boundary should be 
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explored94,267.  The use of these markers might capture the cells that were expressing high level of PAX6 
on day 4 and low levels of FOXA2 on day 16. It was apparent that cells with lower levels of PAX6 
expression were obtained from conditions with higher concentrations of CHIR99021, highlighting that 
the GSK inhibitory effect of CHIR99021 interacts with the mechanisms that governs FOXA2 (Figure 
92A) and PAX6 expression25,127,264,265. Further studies concerning the use of PAX6 are necessary to 
understand its influence on the differentiation trajectory of the cells and its relationship to the small 
molecules. For instance, systematic alteration of N2 supplement concentration and the neurulation 
factors, noggin and SB431542, which were shown to significantly impact PAX6 expression (Figure 81 
and Figure 82B). In addition, daily sacrificial analysis of the cells would provide greater resolution of 
differentiation trajectory under the culture conditions. 
 
6.4.6. Flow cytometry results and protocol alteration:  
 
Flow cytometry analysis made it apparent that the Miltenyi Biotec protocol panel setup (Table 38) had 
limitations, particularly for use in high frequency phenotyping; as it is inefficient from a cell resource 
perspective. The Miltenyi Biotec protocol requires each condition/sample to be divided into three 
separate aliquots so that each aliquot is analysed by one of the three panels. This is because simultaneous 
analysis of the all nine markers is not possible due to each panel using the same three fluorophores 
APC, FITC and PE. Hence a single multiplex panel was formulated, which facilitated more efficient 
use of the cell samples, particularly in the DoEs whereby the samples were limited in terms of cell 
number.  An alteration to the gating strategy was made by forgoing the use of the pluripotent cell sample 
as the control. Instead, an isotype control strategy was employed to better distinguish between positive 
and negative populations within the panel. This change in control was due to high levels of fluorescence 
observed in the pluripotent cells in panel 2, where the cells were in the upper decade on the log scale 
for the dopaminergic markers (Figure 69A), which is unexpected since the cells had not been exposed 
to differentiation molecules. As a consequence, the gates for panel 2 were skewed towards the higher 
decades on the scale (Figure 69B and C), making it difficult to ascertain if the fluorescence signal was 
due to the effects of the differentiation or not.  
 
 In the majority of the experiments performed, the putative vmDA markers FOXA2 and OTX2 (panel 
2 markers of the Miltenyi Biotec protocol) expression was low in terms of MedFI. This suggested that 
either the markers themselves are not highly expressed in the cells obtained, therefore resulting in low 
levels of fluorescence, or that the current markers are not adequately definitive for identifying the 
product. The latter can be deduced to be the case, as the percentage positive data of OTX2 expression 
showed that ³98% of the cells were positive for OTX2 expression. This was regardless of the cells 
being in a pluripotent state or having undergone differentiation. Furthermore, the percentage of cells 
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expressing OTX2 remained high across the 16-day process as evidenced by the data from the four 
sampling points at day 4, 9, 11 and 16. 
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6.4.7. Discussion summary of the key experimental findings. 
 
Overall, the protocol in its prescribed form failed in terms of successful vmDA differentiation. The data 
highlighted the inadequacy of the culture parameters outlined in the differentiation protocol provided129. 
Despite the completion of process transfer activities (discussed in section 6.1.2. Process transfer) and a 
strict adherence to the protocol, all efforts to differentiate the H9 cells using the protocol were 
unsuccessful. Furthermore, issues concerning protocol reproducibility were raised since the 
experimental control conditions also failed to survive. Alterations to various aspects had to be 
employed, in an attempt to get the cells to survive past day 4. As aforementioned the FMEA looked 
into the critical process steps that were deemed to have a potential significant effect on the process. The 
experiments carried out in the present work aimed to dissect, interpret, analyse and attempt to control 
these process failure modes. In the adapted FMEA, Table 41 control actions provided by the present 
work are detailed. The majority of the controls were linked to the cell manipulation process and cell 
milieu steps, this highlighted the high variability that is observed due to these steps. This illustrated 
how poorly defined protocols can hamper the outputs of the process, due in part, to inadequate process 
understanding and control. Consequently, initial attempts were unsuccessful with regards to yielding 
vmDA neurons, moreover, initial attempts did not succeed in maintaining cell survival past day 4. The 
suggested controls and troubleshooting provided by Lund University were also incapable of 
successfully yielding vmDAs, and despite the cells surviving until day 7 when suggested changes were 
employed, the cells failed to survive the entirety of the 16-day differentiation process. In addition, the 
controls themselves, such as the earlier addition of B27 at day 0, are vague and offer limited 
understanding to the root cause of the variability/failure observed. 
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Table 41. Adjusted FMEA of Table 31. Detailing the process optimisation steps taken to improve or 
understand the corresponding failure mode. Recommended actions to improve the protocol are given 
as a result of the experiments and observations of the present work. 
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PROCESS STEP POTENTIAL
FAILURE MODE
PRESCRIBED
PROCESS CONTROLS
RISK PRIORITY
NUMBER
PROCESS OPTIMISATION
STEPS
RECOMMENDED
ACTIONS
CELL MANIPULATION
CONTAMINATION
PERSONNEL
TRAINING, 
DISINFECTING
MATERIALS USED
20 N/A
FREQUENT ASEPTIC
TECHNIQUE COMPETENCY
TESTING, LABORATORY
MAINTENANCE, ROUTINE
TESTING
CELL DETACHMENT
PERSONNEL TRAINING
B27 
SUPPLEMENTATION
120
HIGHLY DEFINED CELL
CULTURE PROTOCOL TO
INCREASE STANDARDISATION
AND CONSISTENCY
STANDARDISED COATING
PROCEDURES
POOR USER
CONSISTENCY AND
ADHERENCE TO THE
PROTOCOL
PERSONNEL TRAINING 240
HIGHLY DEFINED CELL
CULTURE PROTOCOL TO
INCREASE STANDARDISATION
AND CONSISTENCY
USE OF DEFINED PROTOCOL
WITH MINIMAL OPERATOR
DECISION MAKING. 
MEASUREMENT
FLOW CYTOMETER
SAMPLER OR LASERS
NOT WORKING
EFFICIENT
EQUIPMENT
MAINTENANCE
40 N/A EFFICIENT EQUIPMENT
MAINTENANCE
NO CONTROLS
EFFICIENT
INVENTORY
MONITORING
10 N/A EFFICIENT INVENTORY
MONITORING
NO CALIBRATORS
EFFICIENT
INVENTORY
MONITORING
15 N/A EFFICIENT INVENTORY
MONITORING
LASERS DRIFITNG
EFFICIENT
EQUIPMENT
MAINTENANCE
80 N/A EFFICIENT EQUIPMENT
MAINTENANCE
CELLMILIEU
NUTRIENTS
INCORRECT
SUPPLEMENTATION
OR LOW
CONCENTRATIONS
INSPECTION OF THE
CELLS
45
CARRIED OUT EXPERIMENTS
TO UNDERSTAND THE
METABOLIC PROFILE OF THE
CELLS
USE OF DEFINED PROTOCOL
WITH MINIMAL OPERATOR
DECISION MAKING. 
MONITORING OF NUTRIENT
CONSUMPTION, ONLINE IF
POSSIBLE TO ALLOW FOR
INFORMED FEEDING
STRATEGY
CHIR99021 
CONCENTRATION
TOO LOW OR TOO
HIGH
USE THE SAME
PIPETTE
560
CARRIED OUT A SERIES OF
EXPERIMENTS TO DETERMINE
THE OPTIMAL CHIR99021 
CONCENTRATION IN A
SYSTEMATIC MANNER USER
DOE
EMPLOY A DOE TO
DETERMINE OPTIMUM
CONCENTRATION FOR CELL
LINE OF CHOICE. USE
REGULARLY CALIBRATED
PIPETTES
SMALL MOLECULE
CONCENTRATION
TOO LOW OR TOO
HIGH
USE THE SAME
PIPETTE
504
CARRIED OUT A SERIES OF
EXPERIMENTS TO DETERMINE
THE OPTIMAL
CONCENTRATIONS IN A
SYSTEMATIC MANNER USER
DOE
EMPLOY A DOE TO
DETERMINE OPTIMUM
CONCENTRATION FOR CELL
LINE OF CHOICE. USE
REGULARLY CALIBRATED
PIPETTES
LAMININ COATING PERSONNEL TRAINING 32
HIGHLY DEFINED CELL
CULTURE PROTOCOL TO
INCREASE STANDARDISATION
AND CONSISTENCY
STANDARDISED COATING
PROCEDURES
INCUBATOR FAILURE
EFFICIENT
EQUIPMENT
MAINTENANCE
20 N/A EFFICIENT EQUIPMENT
MAINTENANCE
CELL SEEDING
DENSITY TOO LOW
PERSONNEL TRAINING 294
HIGHLY DEFINED CELL
CULTURE PROTOCOL TO
INCREASE STANDARDISATION
AND CONSISTENCY.  
EXPERIMENTATION TO
EXAMINE THE EFFECT OF
DIFFERENT SEEDING
DENSITIES AT VARIOUS STAGES
OF THE PROCESS AND THEIR
IMPACT OF CELL GROWTH AND
DIFFERENTIATION SUCCESS. 
USE OF DEFINED PROTOCOL
WITH MINIMAL OPERATOR
DECISION MAKING AND
AUTOMATED CELL
COUNTING. PERSONNEL
TRAINING
MATERIALS
OUT OF DATE
EFFICIENT
INVENTORY
MONITORING
16 N/A EFFICIENT INVENTORY
MONITORING
NO STOCKS
EFFICIENT
INVENTORY
MONITORING
60 N/A EFFICIENT INVENTORY
MONITORING
SPOILT REAGENTS
EFFICIENT
EQUIPMENT
MONITORING
160 N/A EFFICIENT INVENTORY
MONITORING
EQUIPMENT
NON FUNCTIONAL
EFFICIENT
EQUIPMENT
MAINTENANCE
24 N/A EFFICIENT EQUIPMENT
MAINTENANCE
NOT CALIBRATED
EFFICIENT
EQUIPMENT
MAINTENANCE
18 N/A EFFICIENT EQUIPMENT
MAINTENANCE
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The initial experiments DR1- 3 illustrated that culturing the cells under the Lund prescribed protocol 
conditions such as seeding at 10,000 cells/cm2 did not result in successful cell differentiation. A 
multivariate experimental design (DR4 and DR5) and definitive screens (DSD1 and DSD2) were 
employed to the survey different culture conditions and media formulations. This approach 
demonstrated the complexity of the differentiation process whilst also highlighting the difficulties that 
arise with attempting to control such multifaceted culturing conditions. In DR4 and DR5 the more 
favourable culturing conditions during differentiation were identified to be those where the medium 
contained lower concentrations of CHIR99021 (0.3 and 0.5 µM) and the addition of B27 supplement at 
day 0 (1:100 concentration). In conjunction with these, a higher seeding density (15,000 and 20,000 
cells/cm2) was also more favourable for cell survival, this resulted in subsequent experiments employing 
higher seeding densities. Alterations to CHIR99021 and SHH-C24II concentrations have been shown 
to be key components in improving the outcomes of the differentiation process. As previously 
mentioned lower concentrations (of CHIR99021 in particular) have been shown to increase cell 
survival, however they did not yield vmDA cell types but were more likely to form diencephalic cells 
due to a lack of GSK inhibition87,94,129. The definitive screen experiments showed that a range of 
different medium formulation can support vmDA differentiation, typically these formulations are high 
in CHIR99021 (1 and 1.5 5 µM) and SHH-C24II (600 and 900 ng/ml). This resulted in a shift away 
from the concentrations prescribed (0.7 µM and 300 ng/ml, CHIR99021 and SHH-C24II, respectively) 
in the Lund protocol in order to achieve cell survival post day 7 as a minimum whilst maintaining 
increased levels of FOXA2. This highlighted that small molecule concentrations are a key CPP that 
should be controlled in order to achieve the desired CQAs.   
 
The lack of survival in the control conditions may be attributed to common process transfer issues, such 
as pipette calibration discrepancies between institutions. Pipette inaccuracy and cell count inaccuracy 
may be responsible for the prescribed, yet sub-optimal differentiation conditions, visualised as the 
purple cross in Figure 97. If variability in equipment is assumed, this can be inferred to be the cause 
for the necessary alterations to both the seeding density and the small molecule concentration. 
Discrepancies in the actual concentrations and cell numbers reported in the protocol would result in the 
observed inconsistency when executed at different laboratory sites, as the actual concentrations and cell 
numbers being employed would differ. For instance, the perceived optimal conditions for H9 
differentiation is 0.7 µM CHIR99201 at 10,000 cells/cm2, would actually be 1.0 µM CHIR99201 at 
20,000 cells/cm2 due to the pipette and counting procedures being offset; i.e. non-calibrated pipettes 
and the variability of manual cell counting. The data in the present work does show that upward shifts 
in cell seeding density and shifts either side of the protocol for the small molecule concentrations 
resulted in improved outcomes, in particular, upward shifts (depicted as the blue box in, Figure 97). 
The data showed improved survival with better phenotype outcomes when cells were seeded at higher 
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densities and altered small molecule concentrations were utilised, predominantly with higher 
concentrations of CHIR99021 and SHH-C24II.  
 
 
 
 
 
Figure 97. Process Transfer diagram, showing the range of densities and CHIR99021 concentrations 
explored. Central purple area shows the space studied, parameters in purple text represent the protocol 
conditions and the perforated boxes show the range of conditions that resulted in cell survival and/or 
vmDA differentiation. The grey box and crosses represent the parameter conditions that were observed 
to be optimal for cell survival given the results from DR4 and DR5. The blue box and crosses represent 
parameters from DSD1 and DSD2 that induced vmDA cell phenotype and cell survival. 20,000 
cells/cm2 is a common feature in the best performing conditions, while the prescribed Lund protocol 
density, 10,000 cells/cm2 and central CHIR99021 concentrations (0.6-0.9 µM) do not perform well in 
the range of conditions explored. 
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6.5. Conclusions    
 
It is evident that there were process transfer challenges that required a significant amount of process 
optimisation to be performed. Regarding seeding density, higher densities 15,000 to 30,000 cells/cm2 
were shown to be conducive to cell survival and growth. However, lower seeding densities, 150,000 – 
600,000 cells/cm2, at the replating stage have the potential to increase the efficiency of the protocol by 
50% as a density of 400,000 cells/cm2 was shown to have higher SGRs; therefore, 50% less cells can 
be used to replate at day 11 whilst still obtaining a similar yield at day 16. From a product manufacturing 
standpoint, this would fully exploit the cells and double the product yield that can be obtained at day 
16; this ultimately increases the resultant batch sizes from the same volume of input cell material. This 
is highly desirable in a manufacturing context as production cost could be reduced and overall 
production efficiency would be increased. High resolution phenotypic tracking has provided insight into 
the phenotype trajectory of the cells, i.e. levels of PAX6 at day 4 had an impact on cell lineage fate. Process 
knowledge such as this can be used to develop assays to ensure that the process is achieving the CQAs 
throughout. For instance, determination of PAX6 levels early in the process can be used as go/no-go criteria 
for proceeding with a manufacturing run, which can result in cost and resource savings if a batch going 
towards the wrong lineage is halted prior to the end of the process.    
 
Adjustments to the initial Lund protocol has resulted in the development of culture conditions capable 
of surviving the differentiation process however, the validity of the vmDA identity has not yet been 
adequately achieved to allow for translation into a manufacturing process. Moreover, further 
characterisation and process understanding are required in an effort to build a portfolio of cell markers 
that can be used to definitively identity and potentially quantify optimal ranges of the CQAs for a 
manufacturing process. This information would be valuable for any further efforts centred around 
identity and potency assay development. In addition, further investigations are required to ascertain the 
explicit optimal conditions for H9 differentiation, since current ranges that are either side of the protocol 
(0.7 µM), in terms of CHIR99021 concentration, have resulted in cell survival with low expression 
yields of the desired vmDA cell type (range explored 0.3-0.6 µM and 0.8-1.5 µM). Further 
experimentation with the most promising candidates from the DoE such as M1 and condition 1 (DSD1 
and DSD2, respectively), would facilitate validation of a design space that produce a robust and 
reproducible protocol, suitable for translation into a manufacturing process. 
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6.6. Chapter Bridge 
 
The work detailed in this chapter demonstrates the challenges in translating a research protocol into a 
robust manufacturing process, whilst highlighting the value of informed-DoE based protocol 
conception. Early consideration of process control and multivariate process understanding would allow 
for the product development timeline to progress with ease and greater efficiency, by negating the 
laborious process optimisation that has been the focus of this work. Early consideration of the whole 
product development journey is the key takeaway from this body of work and this chapter in particular, 
as such the following chapters will explore how early economic considerations can have a beneficial 
impact for developers as they are more informed about their product. Specifically, if developers have 
an understanding of resource utilisation, cost of goods and the ability to make informed data-based 
process changes that do not have a detrimental impact on the budget; they are likely to progress 
effectively through the product development pathway.   
 
The next chapter will explore the key challenges in CTP adoption and reimbursement. These challenges 
are pertinent to the current CTP climate, which is favourable due to the onset of some of the first cell 
and gene therapies such as the CAR-T therapies by Gilead (Yescarta) and Novartis (Kymriah) being 
approved281. However, CTPs such as Yescarta and Kymriah have very high price tags (£272,000 and £ 
282,000 respectively) and thus there are adoption and reimbursement challenges that need to be 
addressed, to ensure sustainable and efficient adoption of CTPs281–283. The following chapter will 
explore  health technology assessment, reimbursement, adoption and implementation of CTPs in the 
context of the UK and Canadian healthcare systems, with a focus on the former.  
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Chapter 7. Exploration of the Challenges in the Adoption of Regenerative Medicine Therapies   
 
7.1. Introduction  
 
The focus of this chapter is on the exploration and evaluation of key challenges in the adoption and 
reimbursement of CTPs. Scientific success in terms of positive clinical trial data for safety and efficacy 
is a milestone achievement in the development process of therapeutic products, however, this alone 
does not guarantee that a product will be commercially successful. Instead, commercial success is 
determined by a product’s ability to demonstrate value through both clinical effectiveness and financial 
cost-effectiveness within a health care setting. The objective of this chapter is to determine the post-
regulatory challenges associated with economic evaluation, adoption, reimbursement and commercial 
success of CTPs. In Chapter 2 the basic principles of health economics, health technology assessment 
(HTA) and product commercialisation considerations were discussed, and these themes provide context 
to the challenges being addressed in this chapter. The challenges will be explored in the context of the 
UK and Canadian healthcare systems, with a focus on the former. These two healthcare systems share 
commonalties in some aspects of their provision to healthcare as they are both publicly funded systems. 
In addition, the work carried out in this chapter has been in collaboration with institutions both in the 
UK and Canada. 
 
N.B. Due to the specialist nature of this topic area, it is recommended that the  glossary from Chapter 
2 is reviewed to ensure that the correct meaning of the terms are understood in the context of the present 
work.   
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7.1.1. Healthcare in the UK 
 
The Department of Health and Social Care (DHSC) oversees the development of polices and guidelines 
that aim to provide the best quality healthcare to patients. Healthcare in the UK is provided publicly by 
the National Health Service (NHS) which was established in 1948284. There are currently four versions 
of the NHS, one for each of the countries in the UK: NHS England, NHS Scotland, NHS Wales and the 
Health and Social Care in Northern Ireland. NHS England is the largest of the 4 systems as it caters to 
a population of over 54 million people and manages over 85% of the ~ £147 billion budget which 
equated to £124 billion in 2019 284. Unless otherwise stated, NHS England will be the service discussed 
in this thesis and will be referred to herein as the “NHS”. The NHS is funded through general taxation, 
national insurance contributions and fee-for-service income, although the latter represents a small 
proportion of the total budget income284. Residents of the UK are entitled to healthcare that is free at 
the point of use, with the exception of specific care such as dental treatment and ophthalmic care285. 
Under the DHSC there are three executive non-departmental public bodies of interest in the area of 
health economics and reimbursement, which are NHS England, NHS Improvement and The National 
Institute for Health and Care Excellence (NICE).  
 
7.1.1.1. NHS England and NHS Improvement.   
 
Under the Health and Social Care Act 2012, NHS England and NHS Improvement are jointly 
responsible for pricing of healthcare resources286,287. NHS England is responsible for budgeting, 
amongst other responsibilities such as the organisation, operation and commissioning of the English 
NHS through allocating funds to the Clinical Commissioning Groups (CCGs). NHS Improvement sets 
the rules for determining the tariff for the NHS services and ensures that procurement, choice and 
completion of healthcare services are performed with the patients’ best interest in mind. NHS 
Improvement specifies the “currencies, national prices, the method for determining those prices, the 
local pricing and payment rules, the methods for determining local modifications and related guidance 
that make up the national tariff payment system”287. The work carried out by these two agencies is 
multifaceted since the healthcare needs of over 50 million people must be considered; therefore, it is 
necessary to take account of high cost interventions that have significant impacts on the budget. These 
costs are separated so that the representative reimbursements costs are not skewed due to high cost 
drugs, chemotherapy, devices and therapies such as the recently approved CAR-T therapies for cancer 
treatment. As part of the mandate of providing high quality care to patients, NHS England and NHS 
Improvement have mechanisms to ensure that the reimbursement system is dynamic and current, such 
as facilitating the appraisal of new drugs and innovative technologies287. This enables patients to have 
access to the best available care and for the healthcare budget to be used in the most efficient and 
effective way to ensure equity of healthcare. In general, it is the responsibility of NHS England to 
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specify which healthcare interventions and services should be reimbursed using a national tariff price, 
once these services have been identified it is the duty of NHS Improvement to set the price.   
 
7.1.1.2. The National Institute for Health and Care Excellence and its role in health technology 
assessment 
 
The National Institute for Health and Care Excellence (NICE) is an independent non-governmental 
institution that is funded by the DHSC288. The institution was initially established in 1999 in order to 
standardise care and health outcomes within the NHS, as variations in health outcomes up to this point 
had become prevalent289. For example, patients with the same clinical condition were receiving different 
types and standards of care depending on where they were in the country, leading to the phenomena of 
the ‘postcode lottery’288. As a result, there were differences in health outcomes and quality of life for 
patients due to their geographical location. The role of NICE is to provide guidance in matters of health 
and social care to the NHS and ensure that appropriate services of a high quality are made available 
without variation amongst patients, thus, abolishing the notion of the health postcode lottery. NICE also 
helps to resolve uncertainty regarding the best interventions to use that provide the best value for money 
within the NHS by appraising the available options. Additionally, the institute also provides clinical 
guidance to set the national standard on how people with certain conditions should be treated, to ensure 
the best care is provided.  
 
NICE has core principles that it operates on, these are (i) Scientific rigour, which ensures the best 
available evidence is assessed in order to develop guidelines and recommendations289. (ii) inclusiveness 
and (iii) transparency are also important since NICE is a publicly funded entity. Therefore, the relevant 
stakeholders are involved in the development of a recommendation or guidance, typically this includes 
the relevant healthcare professionals and patient advocacy groups. In order to ensure transparency, the 
recommendations and guidance carried out by NICE is available and free to access on their 
website290.(iv) Independence is a founding principle of NICE, therefore it is operated at arm’s length of 
the government as a public body. As such the public has the right to challenge NICE’s guidance and 
recommendations or even take it to court. (v) Timeliness and (vi) being current are also import aspects 
of NICE so that the healthcare being provided is up to date, meaning that they regularly review their 
guidelines and support their implementation. Ultimately NICE should be reasonable and accountable 
for its guidance decisions290. 
 
There are four main guidelines that NICE provides guidance over which are; NICE guidelines, 
interventional procedure guidance, technology appraisals guidance and the medical technologies and 
diagnostics guidance290. Of importance to this is work are the latter two guidance, since the technology 
appraisals guidance assesses the clinical and cost-effectiveness of health technologies such as medical 
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devices, treatment procedures, diagnostic tools and pharmaceutical products in addition to 
biopharmaceuticals. Medical technologies and diagnostics guidance helps with the timely adoption of 
clinically effective and cost-effective technologies within the NHS.  
 
In terms of appraisals, assessing the value of new interventions is a key activity carried out by 
NICE289,291. This activity is challenging as “value” is subjective and expressed differently for different 
stakeholders i.e. for patients value often refers to the perceived health benefits and improvements 
achieved from an intervention; whereas for payers value would refer to cost-effective interventions that 
provide patient benefits and cost savings. In such a case NICE carries out assessments to determine if 
the new intervention provides more benefits than the current standard of care within the NHS290,291. The 
use of cost-effectiveness and quality adjusted life years (QALYs) in these assessments provides a 
standardised and comparable assessment of the value of a new intervention. Value is not considered at 
an individual level but for the averaged population since budgets do not currently allow for value to be 
based on each individual within the NHS; opportunity costs are also an important element of the value 
as funds have to be redirected to fund new interventions291–293. NICE also considers value for the 
developers as they understand that developers have to make a return on investment for the products 
they provide to the NHS, which is the main buyer of healthcare services and products in the UK.  
Following a recommendation from NICE it is the responsibility of NHS England to commission the 
recommended technology, this involves implementation and reimbursement decisions on how the 
technology will be adopted and paid for through the NHS’ payment system.  
 
7.1.1.3. The NHS payment and reimbursement system. 
 
The payment system uses different models to account for the complex challenge of budget control, 
resource allocation and healthcare quality improvement. Two of the main payment models include 
block payments and capitation294,295(Table 42). Block payments are used for making payments for 
hospital services through an agreed fixed sum payable in instalments for a broad set of specific services, 
independent of the number of patients that may use the service. Capitation payment is a model used for 
providing payments for general practitioner (GP) services, again for an agreed fixed sum, however in 
the capitation model the sum is based on the size of the population served by the GPs296. Capitation is 
designed to allow healthcare providers to offer availability and access to comprehensive services.  
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Table 42. Summary for the four main payment models used in the UK healthcare system, adapted from 
Wright et al (2017)297. 
 
 
In 2003 a new case-based payment model was introduced287,298, which was termed payment by results 
(PbR), in PbR providers of care are reimbursed on based on the number of patients seen and their 
respective diagnosis and treatment. Currently, PbR is now referred to as the national tariff payment 
system (NTPS) which is updated annually. Under this system there are different tariffs for different 
service types and each tariff covers the full cost of the activity e.g. the consultant fees, nursing, bed 
space, meals, consumables, equipment used and most drugs over a treatment spell287. The tariffs are set 
against different currencies which are applied to different categories of services such as in-patients, 
outpatients and emergency services287. For inpatients the currency used is called Health Resource 
Groups (HRGs – section 7.1.1.3.a.), for outpatients the currency is based on attendance and the 
procedures carried out; emergency service currencies are based on attendance and critical care days. In 
simpler terms, currencies are the unit of healthcare for which a payment is made, for example an elective 
day case major hip procedure with no complex complication is a currency287,296,299. Currencies can take 
several forms covering different time periods from an outpatient attendance, a stay in hospital or a year 
of care for a long-term chronic condition. Tariffs are the set prices paid for each currency, for example, 
the elective day case major hip procedure with no complex complication from admission to patient 
discharge was priced at £5,431in 2018287. 
 
There are four key elements to the tariff system which include; the treatment, coding, grouping and the 
tariff itself. Treatment refers to the procedure and care provided for all patient settings (inpatient, 
outpatient and emergency services). The care provided during treatment is then coded by clinical coders 
to reflect the currencies used in the system. These codes provide information regarding the diagnosis, 
interventions and procedures that the patient receives. In addition, data such as the age of the patient 
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and the length of their stay in the care setting are included in the coding. Grouping is the process that 
applies an HRG based on the codes and data provided regarding the patient’s treatment (explained in 
section 7.1.1.3.a.). Once the grouping has been carried out, a tariff can be applied based on the HRG 
and type of admission, payments from the commissioner to the provider are then made based on the 
calculated tariff (Figure 98). Providers are paid for the number and complexity of the patients they see; 
each provider is paid the same for providing the same services so there is no competition due to national 
pricing. 
 
 
 
Payment
Providers may be paid a variable amount based on the activity undertaken as reported through SUS. Alternatively,
monthly payments from commissioner to provider may be agreed in advance based on an estimated activity plan in
the NHS standard contract. Actual activity transmitted from provider to commissioner via SUS is used to adjust
these payments.
Tariff 
Tariff price depends on the HRG and type of admission. There are tariff adjustments for long or short stays,
specialised care and best clinical practice. A market forces factor (MFF) unique to each organisation is applied to
reflect the fact that it is more expensive to provide services in some parts of the country than in others.
Grouping 
Data are submitted to the Secondary Uses Service (SUS) which assigns a HRG based on clinical codes and other
patient data.
Coding 
Occurs upon discharge, the care provided is coded into a standardised format by clinical coders. The data used to
code depends on classification systems i.e. the diagnoses and interventions, which takes into account other
information including age and length of stay
Treatment
Covers services in hospital such as admitted patient care, outpatients (attendances and some procedures) and A&E.
The tariff covers the patient from admission to discharge.
Figure 98. The process of healthcare provision, from treatment to payment under the PbR 
national tariff payment system. 
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7.1.1.3.a. Health Resource Group coding:  
 
A Healthcare Resource Groups (HRG) code is derived from a combination of age, gender, diagnosis, 
procedures, complications and length of stay295,300. HRGs were first introduced in 1991, and since then 
there have been several revisions with the latest set being HRG4+ updated in 2017301. HRGs are updated 
annually to ensure that the payments to service providers are appropriate for the work being carried out, 
updates are based on consultation from expert working groups which include practitioners and policy 
makers. The composition of the HRG is based on clinical detail whereby treatments which consume a 
similar amount of resources are grouped together. This is based around HRG chapters, there are 
currently 22 chapters which are broadly based on anatomical areas i.e. HRG E refers to treatments 
related to cardiac disorders. These chapters are further defined to take into account treatments and 
complexities, resulting in over 1,600 HRG codes302. Upon discharge clinical coders apply the HRGs to 
code the diagnosis and interventions applied to the patient on a local hospital level using a patient 
administration system (PAS). The data is then sent to the national secondary uses service (SUS) which 
group clinical codes into HRGs and calculate the payment to be made based on the most applicable 
HRG, currency and tariff287,303,304. An example of two case studies of the HRG system and payment 
process is shown in Appendix 6. 
 
7.1.2. Healthcare in Canada 
 
Similar to the UK, healthcare in Canada is publicly funded and it available to all Canadian citizens and  
permanent residents within the thirteen provinces and Canadian territories. The Canadian healthcare 
system, Medicare, is a product of the Medical Care Act of 1966, which was later encompassed into the 
Canada Health Care Act of 1984305,306. In comparison to the UK healthcare system, Canada has a more 
decentralised approach to the administration and delivery of healthcare. The Health Care Act sets the 
standards which each of the thirteen provinces and territories must meet in order to be reimbursed for 
their expenditure under the Canada Health Transfer305,306. In brief, the Health Care Act aims to ensure 
that health care is provided under five core principles: (1) under public administration thus on a not for 
profit basis; (2) comprehensively in terms of medically necessary services; (3) universally to all 
Canadian residents; (4) portability in cases where residents are temporarily out of their province and 
finally; (5) with ease of accessibility and uniformity regardless of one’s ability to pay305,306. While the 
Canada Health Care Act provides federal level guidance on the provision of health, spending decisions 
are made at a provincial and territorial level by each of the thirteen provinces and territories.  
In Canada, ~70% of total health care spending is by public means and the services provided are free at 
the point of use307. The remaining 30% is spent privately through out-of-pocket payments and private 
insurance on services such as optometry and dentistry307,308. Additional health insurance covers the cost 
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of services not covered under Medicare. Most hospitals in Canada are publicly funded and are set to 
operate on a fixed budget as a means of controlling costs309–311. However, GPs are private and typically 
operate on a fee-for-service basis under the coverage of the province or territory they are situated 
in309,312,313. 
Medication costs are also a private expense however; prices are negotiated at a federal level by the 
Patent Medicine Prices Review Board (PMPRB) for Canada’s federal, provincial and territorial drugs 
plan314. Drugs plans are managed by the provincial and territorial governments, whose responsibility it 
is to determine what prescription drugs are publicly funded and the associated eligibility criteria. Not 
all citizens and residents are eligible for coverage through public drugs plans, typically coverage is 
given to “those most in need, based on age, income, and medical condition.”177 Pricing and 
reimbursement decisions regarding medication in Canada occur at three levels; federally by the 
PMPRB, by the individual provincial and territorial drug plans, and by the Common Drug Review315,316. 
 
7.1.2.1. Canadian Agency for Drugs and Technologies in Health 
 
Adoption and reimbursement in Canada is multistage process, initially the new product must be 
approved by Health Canada for safety and efficacy measures. Once approved the maximum ceiling 
price for the new drug is set by the PMPRB and this value is submitted for HTA for clinical and/or cost-
effectiveness evaluation. The Canadian Agency for Drugs and Technologies in Health (CADTH) is a 
national agency similar to NICE in the UK, in that it provides healthcare decision-makers information, 
advice, evidence and recommendations related to the use of medication and medical devices317. CADTH 
has a range of programs and services, of particular interest to the present work are their common drug 
review (CDR) and health technology management programs.  
 
7.1.2.1.a Common Drug Review 
 
The CDR is a process that most drugs must go through prior to entering the public system. The CDR 
provides recommendations concerning reimbursement and funding decisions for the provincial and 
territorial public drug plans, with the exception of Quebec317. Publicly funded drug plans in the 
provinces and territories must work within their budgets to provide equity and value for patients, thus 
the CDR assists the drug plans in decision-making with regards to which drugs they should pay for316. 
The CDR receives and reviews submissions by systematically evaluating the clinical evidence provided 
by the developer/manufacturer, followed by pharmacoeconomical analysis to determine the cost-
effectiveness and economic impact of the drug.315,318. To do this, the CDR must bring together medical 
experts and patients to frame the investigation by comparing the benefits and side effects of the product 
in relation to existing treatment options. In addition, the cost effectiveness of the drug is compared to 
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existing options, the CDR can also include the societal impact of a new treatment as part of their 
analysis. The CDR process produces summarised evidence for the Canadian Drug expert committee 
(CDEC), the CDEC uses this information to provide a non-binding recommendation to the drug 
plans319,320.  
 
The CDEC’s recommendations cover the optimal use of the drug and the level of funding that the drug 
might receive. The committee is usually comprised of a chair, public members, and experts in areas 
such as health economics and drug utilisation320. The committee deliberates on aspects such as the 
available clinical studies, comparators, therapeutic advantages, cost and cost-effectiveness. The 
deliberations result in a non-binding recommendation from the committee, detailing whether the drug 
should be publicly funded or not. It is then up to the individual drug plans to make a decision whether 
to fund the drug or not and how the drug will be funded based on the CDEC recommendation.  
 
7.1.2.1.b. Health Technology Assessments 
 
The health technology management programs provide assessments concerning the “clinical and/or 
economic evidence on health technologies”321. In Canada health technologies relate to “prescription 
drugs, diagnostic tests, and surgical, medical, or dental devices and procedures — but not broad health 
system issues, such as information technology, program delivery, staffing, and finance.”321 . HTAs are 
performed by ad hoc multidisciplinary teams created to suit each project being assessed. Similar to 
NICE, HTA assessments by CADTH are published and made freely available to anyone.  
 
The HTA function of CADTH has a national approach, such that HTAs are “normally reserved for 
topics of pan-Canadian interest”316,321. The assessments provide evidence for health policy, purchasing 
and clinical practice decision-making. These analyses evaluate both the clinical and cost-effectiveness 
of a treatment, taking into account its budget impact as well as any potential ethical, legal and social 
impacts of the treatment321,322. CADTH also offer a Technology Review, which is used for reviews that 
do not require a comprehensive HTA i.e. a review with an economic component only.  
 
CADTH HTAs undergo a rigorous prioritisation process, whereby each technology must be assessed 
for appropriateness under CADTH’s mandate before it can progress further322. The criteria include:  
duplication of effort i.e. determining if similar reviews are being carried out elsewhere; need i.e. does 
a decision need to be made and is the impact of the decision substantial to patient care; and stage of 
diffusion i.e. is the technology currently or imminently available323. These criteria are considered to 
ensure that efficient use of assessment resources are used and to determine the importance of the 
assessment for the benefit of patient care for technologies relevant to Canada.  Once a technology is 
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deemed appropriate it is prioritised based on its clinical, budget and population impact as well as the 
jurisdictional interest and its effect on health equity323. Details of the scores and categories used for both 
the appropriateness and prioritisation assessment can be found on CADTH’s website324.  
 
7.1.2.2. Patent Medicine Prices Review Board 
 
The Patent Medicine Prices Review Board (PMPRB) is a federal agency established in 1987 to ensure 
that Canadian consumers are not charged excessive prices for patented medicines314,325. The PMPRB 
only has jurisdiction over ‘factory-gate’ prices set by the manufacturers and not on the final prices set 
by the wholesalers and pharmacies that sell to the end consumer314,325. Furthermore, the PMPRB’s role 
is currently limited to patented medicines, thus the price of generic medications is not regulated by the 
PMPRB. 
 
As part of the review process a scientific and economic analysis is carried out to determine how 
appropriate the price is314. The scientific analysis considers the level of therapeutic improvement of the 
new drug; the levels range from breakthrough improvement to no improvement. The economic analysis 
determines the appropriateness of the price based on: the price of the drug in the relevant market; the 
price of similar drugs in the same therapeutic class; and the price of the drug and similar drugs in other 
comparator countries, typically the UK, USA and some western European countries177,325. The 
individual drug plans are then responsible for deciding at a provincial and territorial level the 
reimbursement conditions for the drug. The final price paid by the public drug plans is negotiated by 
the provinces, territories and the manufacturer through the pan-Canadian Pharmaceutical Alliance 
(pCPA). 
 
In addition to its regulatory role the PMPRB is also responsible for the reporting of pharmaceutics 
pricing trends in the industry. The reporting is carried out annually and reported back to Parliament. 
The annual report covers aspects such as:  sales of patented drugs, price trends, international drug prices 
vs. Canadian prices, patent drug utilisation and Canada’s drug expenditure in a global context314. In 
addition, the PMPRB also reports on research and development expenditure within Canada related to 
patented pharmaceuticals314. 
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7.1.3. Challenges in CTP adoption and reimbursement.  
 
Even with the understanding of healthcare systems and their reimbursement mechanisms covered 
above, CTPs still face the challenge of understanding how to navigate through the various adoption and 
reimbursement pathways, that have for so many years been aimed at pharmaceutical drugs and medical 
devices. Some of these challenges were previously discussed in section 2.4.6. Considerations for 
developers. 
 
These considerations highlight some of the key issues that have slowed CTP adoption. For instance, a 
prevalent issue is understanding the evidence requirements for “curative” CTPs to generate data that 
adequately supports adoption and reimbursement. The notion of a curative CTP would be desired by 
payers, particularly for chronic diseases such as PD and diabetes, however due to the lack of long-term 
clinical data these claims are yet to be affirmed. Thus, appropriate evidence generation is a challenge 
that CTPs face in order to satisfy both regulators and payers that their products will afford the clinical 
and cost benefits proposed326,327. Therefore, appropriate data generation to support decision making for 
CTPs is a challenge that still needs to be addressed. In addition, overcoming barriers to adoption such 
as hospital infrastructure, payment structures and how to offset costs are key challenges for CTPs.  
 
The small number of CTPs currently available typically target small populations (typically less than 
5,000 patients), thus they are given special or conditional designations as these therapies are often 
considered as a “last chance” therapy option for patients26. However, if CTPs are to ever become a 
mode of mainstream treatment, ad hoc evaluations and approvals will not be an efficient mode of 
adoption and sustainably growing the cell therapy industry (CTI). Instead, the aforementioned 
challenges need to be addressed in a holistic manner, meaning there should be clear understanding of 
the adoption pathways for CTPs, if they are indeed any different to drugs, biologics and medical devices 
in terms of evidence generation, economic modelling and payment structures.  
 
There is currently scarce evidence of policies and pathways for CTPs, although many countries have 
now begun to form regenerative medicine committees and expert groups for areas such as HTA326–328. 
However, areas such as payment mechanism, pricing, code generation (for payment) and 
reimbursement schemes still remain largely elusive. Bodies such as NHS England and NHS 
improvement currently do not have defined information on how payment and pricing will or will not 
differ for CTPs. Currently, CTPs such as Kymriah and Yescarta that have been approved are being 
reimbursed under specific funding, which in both cases is the Cancer Drug Fund329.  
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Should an onset of non-cancer CTPs be successful for market authorisation then it is not clear how these 
would be funded. Other important considerations include: 
 
• Tariff/Code structures - will they be different for each nuanced treatment or will they be 
blanketed? 
• Will there be budget impact adjustments to facilitate the costs of CTPs?  
• Will managed risk agreement structures be employed?  
• Are outcomes-based pricing/payment schemes going to be used for CTPs?  
• Would there be changes in the willingness to pay for these therapies due to their long time and 
potential curative benefits which could offset costs? 
 
The current lack of clear and defined understanding of the reimbursement and adoption pathways for 
CTPs in the literature and amongst some expert organisations, lead the author seek other avenues to 
understand what the key challenges in the adoption of CTPs were. As a result, the author founded a 
working group to address some of the key challenges that CTPs must overcome in order to successfully 
traverse the reimbursement and adoption pathway. The working group, Challenges in the Adoption of 
Regenerative Medicine Therapies (CHART), was set up in collaboration with Medicine by Design, a 
regenerative medicine initiative at the University of Toronto, the Centre for Commercialization of 
Regenerative Medicine (CCRM) and the Toronto Health Economics and Technology Assessment 
Collaborative (THETA). The working group setup a workshop, inviting selected UK and Canadian 
experts to discuss these adoption challenges.  
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7.2. Methodology 
 
In order to address the question of what the key challenges in the adoption of CTPs are, a quasi-action 
research methodology was utilised using the CHART workshop as a vehicle for obtaining the data to 
answer the question. An action research approach allowed active participation in the research. The 
action research methodology used followed an approach similar to that described by Bogdan and Biklen 
(2007), where by “systematic collection of information that is designed to bring about social change”330. 
In the case of the present work the goal was not to bring about social change, but to provide 
recommendations on what the key challenges that need to be addressed are, for CTP adoption to be 
better facilitated. There are various frameworks that exist for the purposes of action research330–332, in 
the present work a five-step process was employed (Figure 99).  
 
 
 
Figure 99. Schematic of the action research methodology framework employed, detailing the five-step 
process used to investigate the challenges in the adoption of CTPs. 
  
Selecting a focus
Clarifying theories
Identifying research question
Collection data
Reporting result
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The first step of selecting the focus was inspired by the limited literature and lack of general consensus 
concerning whether there are any key differences in the HTA methodology for evaluating CTPs and 
what the payment and reimbursement structure for these putatively expensive therapies would be. 
Overall the focus was on the adoption challenges of CTPs after the point of regulatory approval. In 
terms of clarifying the theories currently around CTP payment mechanisms and adoption, the literature 
provides some key perspectives. This mainly involves the use of managed entry agreements (MEAs) to 
facilitate payment of expensive therapies333,334. Most theories concerning adoption of CTPs are from 
manufacturing companies in the industry, mainly looking to ensure that they products can be adopted 
on the market. However, organisations such as the Cell and Gene Therapy Catapult have made efforts 
on a system level, with the creation of their manufacturing hub and the advent of the Advanced Therapy 
Treatment Centres (ATTCs). 
 
Step three of the process involved identifying the research questions; six theme areas were initially 
identified, which were: evidence of clinical effectiveness, health economics, social values towards 
regenerative medicine, health technology assessment, payment system mechanisms and adoption & 
implementation. To facilitate meaningful inquiry into the themes, more detailed questions where 
formulated, these are presented in the agenda under each theme/session (Appendix 7). Collecting the 
data to answer the question(s) was the fourth step in the process and this was achieved by realisation of 
the actual workshop in Toronto, Canada. The data collected was valid as the participants of the 
workshop were peers in the CTP, regenerative medicine, HTA and health economics areas therefore 
they were appropriate sources of information. Reliability of the data being collected was important to 
consider, the speakers and discussants in the workshop were experts who actively conduct the 
assessments, and actively perform research and work in the relevant areas that were discussed. 
Therefore, there is confidence in the reliability of the data collected as it was obtained credible sources 
who represent many of the varying aspects of the adoption pathway. In addition, the use of speakers 
and discussants from both the UK and Canada assisted in triangulation of the validity and reliability of 
the data as various speakers and discussants were asked to contribute to each session. This provided 
multiple sources of data for each session reducing the level of potential bias in the qualitative data being 
obtained. 
 
Data analysis was carried out following collection, for the purposes of the present work the discussion 
points from the workshop were sorted and sifted to identify the key trends and overall conclusions from 
each theme. This was performed by recapping the session recordings and identifying the crucial points 
from each session and where possible, finding published data to support the points. This led to step five 
of the process that is the reporting of the results/data, the report can be found in the following discussion 
section of this chapter. In addition, a white paper was commissioned as a result of the workshop 
discussions, providing a medium to demonstrate to policy makers to the issues that were identified and 
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need to be addressed to facilitate CTP adoption. 
 
In relation to the topic of bias and subjectivity it is important to note that each of the different parties 
participating in the workshop had varying intentions and expected outcomes for attending the 
workshop. For companies such as Takeda, Gilead and BlueRock, the workshop provided an opportunity 
to learn about and ask questions regarding the HTA process and the potential adoption and 
implementation pathways that are being considered for CTPs. For the HTA agencies, the workshop 
provided an opportunity for them to share their experience with CTPs to date whilst also allowing them 
to publicise the programmes they offer that can help developers through the pathway, such as early 
scientific advice. The academics within the workshop shared their current findings and the 
methodologies that they have been working on with regards to CTP HTA and considerations such as 
social value systems. The clinicians present were able to use the workshop as an opportunity to share 
their experiences with CTPs, in particular, CAR-T therapies and the current challenges they have 
encountered in the trials that have been run. It is important to acknowledge the subjective nature of the 
discussion points that arose, since these are based on the work of parties presenting their work and 
experiences, albeit in the context of the CTI. However, the majority of speakers present at the workshop 
were based from institutions that have the notion of producing unbiased, fact-based information; 
therefore, the work that they presented was adequately objective. In addition, due to the international 
audience present, the conference speakers were encouraged to provide factual based findings which in 
most cases had also undergone peer review.  
 
7.2.1 Workshop organisation  
 
The author was involved in all aspects of the workshop and took lead on aspects such as: formulating 
the agenda, inviting speakers and discussants/panellists, facilitating the running of the workshop on the 
days it ran and presenting at the workshop.  
 
The purpose of the workshop that was to facilitate discussion to identify the challenges faced in CTP 
adoption. Thus, the workshop acted as a method of primary qualitative research by means of expert 
opinion and formulated discussions. Expert opinion was sought from invited attendees specialising in 
regenerative medicine and other relevant areas with regards to HTA, adoption, reimbursement and 
health economics. The attendees were asked to be speakers or discussants/panellist on a specific area(s) 
considered to be hindering the adoption of CTPs, including evidence generation, economic evaluations 
and implementation challenges. The invited attendees were approached through collaborations, 
previous networking engagements and recommendations of the author and other members of the 
organising committee. An agenda was devised by the author and the organising committee to facilitate 
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targeted discussion during the workshop. 
 
The experts invited where from institutions that were deemed to be highly involved and influential in 
the topics set out in the agenda (Appendix 7 and Appendix 8). Representatives from NICE and 
CADTH were invited to discuss the HTA process and to establish if there are nuances to the process 
when CTPs are being assessed. Representatives from the Office of Health Economics (OHE) and the 
Centre for Health Economics – University of York (CHE) were invited to discuss the methodologies 
involved in economic evaluation and health economic analyses. The Oxford Academic Health Science 
Network (Oxford AHSN) provided insight into the challenge of adopting CTPs and the steps being 
taken to facilitate adoption. It was imperative to also engage with CTP industry and clinicians to ensure 
the discussion points were relevant to the challenges currently being faced. Therefore, Hitachi Chemical 
Advanced Therapeutics Solutions, LLC (HCATS) was invited to the workshop as they have broad 
understanding of CTPs at different phases of development. Thus, facilitating discussion of the issues 
around evidence generation and adoption for the developer perspective, while being agnostic as they 
have a range of client products. In addition, representatives from Gilead and Takeda were invited to 
provide insight into their experiences with market access for CTPs. Clinicians and academics in health 
policy and bioethics were invited to speak on issues of social values towards CTPs.  
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7.3. Discussion   
 
The workshop started with an introduction (Session 1 in the agenda, Appendix 7) highlighting the 
context in which the workshop was conceived, which is discussed in section 7.2.1. (page - 283 -) It was 
acknowledged that while there are many aspects involved in the adoption of CTPs, reimbursement and 
adoption were the main focus of the workshop. A definition of “advanced therapy medicinal products” 
(ATMPs) was provided to ensure a commonality of understanding within the workshop. ATMPs, are 
synonymous to the CTPs that have been discussed throughout the present work, however ATMPs 
include gene therapies as well as cell therapies. CAR-T therapies such as Yescarta and Kymriah were 
frequently used as examples to provide context as CAR- T therapies are currently the flagship therapy 
of the cell and gene therapy industry281,283.  
 
The following sections provide an overview of the presentations and outcomes of the workshop sessions 
and discussion panels. Prior to the workshop, presenters and discussion panellists were provided with 
questions to consider, these are presented at the start of the session summaries below and also in the 
workshop agenda, (Appendix 7). Where applicable references have been provided to support the 
discussion points, footnotes have been used to highlight discussion points specifically from the 
workshop. The presentation slides of the workshop presenters have been provided in the appendix, 
where permission has been granted for use in the present work.  
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7.3.1. Evidence of clinical effectiveness: Session 2   
 
The purpose of this session was to explore the key challenges in providing evidence of clinical 
effectiveness of CTPs. The presentations were provided by a Senior Scientific Adviser from NICE and 
a haematologist from the Princess Margaret Cancer Centre, Toronto, with experience of administering 
CAR-T therapies. The discussion panel was comprised of the NICE Scientific Adviser, the Princess 
Margaret Cancer Centre haematologist, the dean of Health Sciences at Simon Fraser University and a 
biomedical engineer from HCATS.  
 
Posed questions:  
• ATMPs (specifically CTPs) – does their promise of cure/long term effect make them 
different?  
• How to satisfy both payers and regulators by producing adequate data?  
• What is the evidence supporting the benefits and safety of ATMPs?  
• How do we ascertain the long – term clinical benefits for ATMPs?   
• What is the structure of the data/evidence?  
• What is the strength of the evidence?  
7.3.1.1. Session Summary  
 
Benefit to the patient was highlighted to be the key question for consideration when contemplating 
clinical effectives for the purposes of HTA and cost-effectiveness analysis. Demonstrating and 
understanding how well an intervention works compared to established modes of practice is crucial to 
the evidence data provided to decision makers and payers. The issues of evidence and demonstration of 
long-term clinical benefits is paramount as the cost of CTPs is high, thus they must present value. 
However, currently there is uncertainty regarding the long-term benefits and potential adverse effects 
of CTPs as the data currently available is immature and scarce, thus their potential curative effect cannot 
be substantiated173,335. Typically, CTPs are developed by academic institutions or start-up companies 
with limited funding and lack of experience with HTA process; this can result in inadequate evidence 
generation for the purposes of satisfying the HTA process. Another point that was highlighted was the 
lack of randomised clinical trials (RCTs) and small sample sizes associated with CTPs as single-arm 
trials that currently routine practice for CTPs335,336. Furthermore, current trials can only provide 
surrogate or intermediate data as the final clinical outcomes are unknown. In addition, due to the short 
length of trials (6 – 36 month follow up period) and the resultant data, how well clinical effectiveness 
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is maintained and the potential for future adverse effects is yet to be established. Therefore, current data 
is subject to extrapolation, follow-up and accruing observational and real-world datai. 
 
In the context of CAR-T therapies, evidence such as objective response rate (ORR); ongoing response 
(OR); complete response (CR); progression free survival (PFS); overall survival (OS); adverse effects 
such as cytopenia and Eastern Cooperative Oncology Group (ECOG) scores are required to provide 
robust data that can be assessed against comparators337,338(Table 43). Furthermore, the data should be 
obtained from randomised trials with larger sample sizes, to offer sufficient statistical power in each 
arm of the trials. This would adequately inform the HTA process and provide value to the decision 
makers and payers. Extended research post-market authorisation would be a mode of providing 
additional and real-world data. However, there are issues with adequately capturing the data in a 
valuable wayii.  
 
Table 43. Definitions of the typical outcome measurements used in the oncology area for CAR-T trials.  
  
 
i CHART workshop presentation/discussion point 
ii CHART workshop presentation/discussion point 
OutcomeMeasure Definition
Complete response (CR) Signifies the absence of all detectable cancer post
treatment, this is the best result that can be reported in
cancer prognosis
Eastern Cooperative Oncology Group
(ECOG) score
A performance scale used to assess disease
progression (in oncology) and assess the daily living
abilities a patient
Objective response rate (ORR) The percentage of patients whose cancer shrinks or
disappears after treatment
Overall survival (OS) The length of time from either the date of diagnosis or
the start of treatment for a disease, such as cancer, that
patients diagnosed with the disease are still alive
Progression free survival (PFS) The length of time during and after the treatment of a
disease, that a patient lives with the disease but it does
not get worse
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7.3.2. Health economics: Session 3  
 
Health economics are an important element of the reimbursement and adoption process; therefore, a 
session was dedicated to discussing cost-effectiveness evaluations and any methodological challenges 
that are related to evaluating CTPs. The presentation was provided by a member of the Centre for Health 
Economics (CHE), University of York. The panel included the research fellow from CHE, a senior 
principal economist from the Office of Health Economics, an assistant professor from the University of 
Waterloo (Canada) school of pharmacy and the senior scientific advisor from NICE. As in the previous 
session CAR-T therapies were referenced as a case study to provide context.  
 
Posed questions:  
 
● What is different about reimbursement strategies for ATMPs? 
● How to evaluate the cost effectiveness of ATMPs? 
● How affordable are ATMPs/can they be affordable?  
 
7.3.2.1. Session Summary  
 
Evidence, price and affordability were highlighted as some of the key challenges in economic 
evaluations. Evidence challenges encompass issues such as the appropriateness of surrogate endpoints 
used to inform evaluations when endpoint trial data is not available; evidence generalisability; assurance 
of sustained health outcomes and quantification of bias in non-randomised studies. These evidence 
challenges result in a high level of uncertainty as the input data for evaluation models would not be 
robust. For example, surrogate endpoints with an unclear relationship to overall survival and health 
related quality of life, offer no benefit to the HTA and decision-making processes.   
 
The challenge of price and affordability associated with CTPs can be attributed to the complexity of 
production and administration of CTPs. High cost of goods figures results in higher prices being 
demanded by the manufacturers, which ultimately increases the price for the payer. Furthermore, the 
complexity of introducing or adjusting infrastructure and acquiring accreditation to administer CTPs 
presents additional costs to the payer that have a significant budget impact. Consideration of these 
challenges and the uncertainty they result in prompted assessment of the appropriateness of current 
methodologies in HTA for evaluating CTPs. Two studies were commissioned to assess how fit for 
purpose the existing HTA and reimbursement process are for CTPs328,339. The reports by Hettle et al 
(2017) and Crabb et al (2016) provide a detailed summary of the assessment and appraisals carried out. 
In brief, the assessment found that the methodology and decision framework used for NICE technology 
appraisals is applicable to CTPs328,339. However, there are elements to CTP evaluation that present 
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challenges to the HTA process, for instance, appropriate extrapolation. Extrapolation is a key driver of 
cost-effectiveness and therefore results in pronounced decision uncertainty. Solutions to dealing with 
uncertainty were contemplated, a leasing method of payment was considered to be a method for 
reducing decision uncertainty328. This highlighted the need for practical, workable payment 
methodologies for CTPs that deal with uncertainty and reduce budget impact at a point were mature 
evidence is limited, for instance, MEAs328,334. In the period after the reports were released, two CAR-T 
products have been evaluated and recommended for use, both under a MEA using the NHS Cancer 
Drug Fund340,341. This mode of commissioning has thus far provided a reimbursement mechanism for 
CAR-T therapies; however, such bespoke commercial and payment arrangements do not provide a 
sustainable long-term strategy. Furthermore, as the advent CTPs continues non-oncology-based 
therapies will also need to be reimbursed and the Cancer Drug Fund would not be applicable to them, 
therefore, modes of routine and sustainable commissioning are needediii. 
 
The session presentation highlighted some of the key issues experienced thus far regarding CAR-T 
appraisals. For example, defining the target populations for marketing authorisation that is broader than 
the populations used in the trials; choosing appropriate comparators/ standard of care; extrapolation of 
survival data; cost and price; implementation; administration; and management of potential adverse 
effectsiv. While these are CAR-T-specific challenges that have been identified, these are likely to be the 
challenges faced by CTPs in general. Choosing the target population is an activity that needs to be 
carefully considered and appropriate controls should be used to ensure robust trial data is obtained that 
provides evidence of clinical effect. The costs that are used within HTA have a significant impact on 
the cost-effectiveness of a health technology. Therefore, the costs that are included in an evaluation 
should be justified and representative of the economic impact of the therapy. Costs associated with 
adverse effects and use of agents such as immunosuppressants should be included as they are likely to 
have an impact of the budget of the payer.  
 
The presentation illustrated the limitation of trials compared to real world evidence in the case of 
CAR- T appraisals. Patient selection was deemed to be important as data for ECOG 0-1 patients was 
reasonably consistent in comparison to ECOG 2 or greater patients. Furthermore, there were key 
differences in the rate of immunosuppressant use (three times higher); double the use of incentive care 
and higher readmission rates in the real world compared to the trials.  
  
 
iii CHART workshop presentation/discussion point 
iv CHART workshop presentation/discussion point 
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7.3.3. Social values toward regenerative medicine: Session 4 
 
Both clinical evidence of effectiveness and health economics are crucial pillars of the reimbursement 
and adoption pathway, however with new technologies such as CTPs, it is important to also consider a 
societal perspective, as ultimately the therapies and technologies are being assessed for the members of 
society that need them. Therefore, session 4 was included in the agenda to explore the role of social 
values in the context of CTPs such as CAR-T therapies. The presentation was provided by the director 
of the University of Toronto’s Joint Centre for Bioethics. The discussion panels included the Joint 
Centre for Bioethics director, the dean of Health Sciences at Simon Fraser University and a professor 
from the Institute of Health Policy, Management and Evaluation, University of Toronto. 
 
Posed questions:  
 
● What is the public/patient perception of ATMPs? 
● Can an appropriate case study example be used? 
● Should patient preferences be considered?  
 
7.3.3.1. Session Summary  
 
Regenerative medicine/CTPs have long offered the promise of personalised medicine that has higher 
efficacy compared to traditional “gold standard” therapies whilst also having the potential to be 
curative. This promise would provide a paradigm shift in the administration of health care, from a model 
that is ‘good for most’ to one that focuses on the individual patient and emphasises pragmatic issues 
regarding healthcare; rather than system level health policy for the general publicv. Such a shift in 
paradigm for public healthcare systems such as the NHS and those in Canada is almost unfathomable 
to healthcare providers due to the complexities of administration and budget restraints. This raises the 
question as to whether CTPs can ever truly be used in the mainstream and deliver on their promise.  
 
Responsible innovation offers a framework in which a collective approach towards future innovation 
can be fostered342. This approach can be used to address social needs and challenges by engaging 
stakeholders with a unified set of values in order to provide solutions in a sustainable way343. 
Responsible innovation in health can help address issues such as health equity, frugality and 
inclusiveness, which are all key consideration for HTA in publicly funded healthcare systems342.  
 
 
v CHART workshop presentation/discussion point 
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 The inclusivity of the societal perspective is required in order for HTA processes to be transparent. 
Many HTA committees also include a lay member, for instance the NICE technology appraisal 
committee and CADTH’s CDEC. In addition to this, policy makers should have public engagement that 
facilitates broad sampling of perspectives and elicitation of social values326,344. A societal voice would 
arguably result in increased public awareness and understanding of the value and potential of new 
therapies. This would improve trust between the public and the private institutions due to increased 
dialogue, particularly around the issues of effectiveness, so that there is reduced risk of over promising 
with new therapies. Furthermore, this would mitigate the risk of hype and the potential for public 
disappointment, as there would be greater awareness from the public that is appropriately informed, as 
opposed to the current reliance on sensationalised media reporting. Availability of information is 
important, and it should be appropriately disseminated and transparent, which is currently not that case 
i.e. less than 45% of clinical trials publish their resultsvi. Increased information regarding therapy 
efficacy would permit greater understanding of the how therapies work. This may also potentially 
reduce the occurrence of health and stem cell tourism, since the information provided allows potential 
patients to be better informed. Rather than the current reliance on claims made by the media and some 
unaccredited clinics which is often not supported by published scientific evidencevii.  
  
 
vi CHART workshop presentation/discussion point 
vii CHART workshop presentation/discussion point 
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7.3.4. Health technology assessment overview: session 5 
  
The previous sessions investigated some of the key considerations that are involved in the HTA process. 
This session combined those elements and provided an overview of the HTA process from both a 
Canadian and UK perspective. Presentations were given by the Senior Scientific Adviser from NICE 
and the Pharmaceutical Reviews Senior Advisor from CADTH. The discussion panel was comprised 
of both the advisors from NICE and CADTH, the Assistant Deputy Minister and Executive Officer of 
Ontario’s Public Drug Programs, Government of Ontario and the vice president of market access and 
external affairs from Takeda, Canada. Akin to the previous sessions CAR-T therapies were referenced 
as a case study to provide context to the HTA process.  
 
Posed questions:  
 
● What is the data and how is it packaged into a HTA process? 
● The specifics of an evaluation, what is the HTA journey like? 
● What is the decision-making process/formula? 
● HTA and clinical processes - do they differ? 
 
7.3.4.1. Session Summary  
 
From NICE’s perspective the two key questions to consider during the HTA process concern benefit 
and costs. In terms of benefits, the question is how well the technology works in comparison to 
established practice in the health service. The cost question considers how much the technology under 
assessment costs as a means of treatment/intervention, in comparison to the established practice in the 
health service. The appraisals are formally referred by the DHSC to NICE in order to carry out a review 
of the clinical and economic evidence provided by health technology developer/manufacturer. The 
review process leads to a recommendation on the use of new and existing technologies for use within 
the NHS (in England). Value is at the core of the HTA process and considers elements such as: clinical 
effectiveness; cost-effectiveness; end of life extension; innovation; degree of need; equity and non-
health objectives (Figure 100). NICE employs a standard cost-effectiveness threshold (£20,000 - 
£30,000 per QALY) which is stipulated by the voluntary scheme for branded medicines pricing and 
access agreement345,346. However, there is a certain range of flexibility if other elements of the value 
core are deemed to carry weight, for instance the threshold can be pushed as high as £50,000 per QALY 
if the technology addresses a non-health objective of the NHS or it is life extending at an end of life 
stage. The end of life criteria for technologies includes the ability to demonstrate that the technology is: 
suitable for patients with a short life expectancy (less than 24 months); capable of offering an extension 
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of life that is greater than three months, and that the estimates of life extension are robust, plausible and 
objective.  
 
 
Figure 100. The seven elements that NICE uses to determine value of a health technology during 
technology appraisals. Adapted with permission from NICE. 
In addition to clinical and cost-effectiveness, NICE also considers affordability; while a technology 
might be cost-effective it does not necessarily mean it can be afforded by the healthcare system. For 
instance, a technology might be cost effective in the long-term, however budget restraints might mean 
that there are no funds in the budget to pay for implementing and adopting the technology. Therefore, 
NICE performs budget impact tests to ascertain a balance between value and affordability. Currently, 
the budget impact threshold is set at £20 million per year in the first three years of the adoption of any 
new technology344. If a technology exceeds the threshold, negotiations for access arrangements can be 
considered in order to facilitate the adoption of cost–effective, high budget impact technologies. 
 
Managing uncertainty and risk is crucial for CTP appraisals; post-recommendation data collection is 
one way one mitigating risk when the clinical evidence is immature, as it generates evidence that can 
be used to reassess the effects and value of a technology in the mid and long-term. From a financial 
perspective, commercial negotiations can help reduce the financial risk and burden imposed on the 
payer by novel technologies, by lowering prices or entering risk sharing agreements. In the case of 
CAR-T therapies commercial negotiations were carried out after they were recommended for use 
through the Cancer Drug Fund. One of the conditions imposed in the agreement for reimbursement 
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requires that further data collection post-recommendation (currently five years of data collection) is 
obtained to avoid withdrawal from listing on the Cancer Drug Fund. The data collected in the managed 
access period includes PFS, immunoglobulin usage and OSviii. This mechanism provides access to the 
patients while allowing for uncertainty to be reduced as additional data is collected.   
 
NICE has been active for 20 years now and in that time many of its processes have been updated to 
keep up with healthcare developments. For instance, the advent of regenerative medicines resulted in a 
study of the appropriateness of NICE’s HTA methods for assessing regenerative medicine technologies. 
The study used a hypothetical example product based on early clinical data for related real products 
(CAR-T therapy) supplemented with hypothetical evidence. In addition, as of April 2019, NICE has 
started cost-recovery activities for technology appraisals and highly specialised technology appraisals. 
Another development is the expansion of NICE’s scope by reviewing all new drugs approved by drug 
licensing agencies in addition to new uses of already approved drugs by 2020ix. NICE has also been 
encouraging manufacturers to engage with the HTA process earlier in their product development 
timelines, in particular, prior to clinical development plans being finalised. NICE’s scientific advice 
service offers manufacturers the ability to obtain guidance on how to develop and generate appropriate 
evidence, consider cost-effectiveness and obtain an understanding of the HTA process from the 
perspective of decision makers. Furthermore, to streamline the adoption process NICE encourages 
manufacturers to plan for the regulatory and HTA pathway simultaneously.  
 
The Canadian/CADTH perspective to HTA is fairly similar to NICE, an overview is provided in section 
7.1.2.1. Unlike NICE, the HTA recommendations carried out by CADTH are non-binding and it is up 
to the individual provinces and territories to make a decision as to whether or not a new technology is 
adopted. CADTH broadly has two streams for HTA: one for pharmaceuticals, and one for clinical 
interventions/devices. In both cases CADTH assesses whether the technology should be adoptedx. 
Choosing which stream a technology is evaluated under depends on the mechanism of adoption, if the 
technology should be funded and placed on the drugs formulary list it will undergo HTA for a 
pharmaceutical. If the mechanism of adoption requires funding and a complex implementation system, 
HTA for a clinical intervention is used. In both cases, value, as with NICE, is the key consideration, 
however the deliberative work used differs between the two pathways within CADTH. The deliberative 
pathway evidence package for clinical interventions has additional elements such as legal, ethical and 
implementation considerations (Table 44).  
 
 
viii CHART workshop presentation/discussion point 
ix CHART workshop presentation/discussion point 
x CHART workshop presentation/discussion point 
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Table 44. A comparison of the elements evaluated in CADTH’s HTA process under the drugs and 
clinical intervention deliberative frameworks. These elements are used to determine the value of a 
technology and whether or not it should be adopted. Adapted with permission from CADTH.   
 
In the case of CADTH’s recent CAR-T assessment a clinical intervention deliberative framework was 
utilised that analysed clinical effectiveness cost-effectiveness, ethical issues, implementation 
considerations, patient perspective and care giver perspective. CADTH uses a Health Technology 
Expert Review Panel (HTERP) comprised of seven core members: a chair; public member; ethicist; 
health economist; three health care practitioners; there may also be up to five expert members included 
in the panel. The HTERP recommended Norvatis’ Kymriah CAR-T therapy for adoption on the 
condition that the initial price was reduced. The HTERP also recommended the consideration of an 
interprovincial agreement to ensure equity of health provision and the development of clear eligibility 
criteria. Furthermore, similar to NICE, the recommendation called for the collection of outcomes data 
post recommendation in order to generate real-world evidence. A pan-Canadian standardised approach 
with defined outcomes was proposed as means of obtaining data for future reassessments to assess long-
term effectiveness, safety and cost-effectiveness of the health technology.  
 
While there are differences in the manner in which NICE and CADTH perform their HTAs there is a 
lot of commonality in the results of their work, which is to provide recommendations (albeit non-
binding in Canada) for the adoption of health technologies. Although agencies assess for the value of 
the technology using independent frameworks, there are similarities in the way in which effectiveness 
is assessed, in particular, clinical effectiveness. As a result, NICE and CADTH now collaborate to offer 
parallel comprehensive scientific advice, which streamlines the process for technologies aiming to 
apply for recommendation in both countries. Those who participate in the service can obtain practical 
advice and clarification about the similarities and divergence between the two markets.  
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7.3.5. Payment system mechanisms: session 6 
 
In the previous sessions the way in which healthcare interventions are paid for was highlighted as a 
crucial issue. Despite the MEAs offering an ad hoc solution, this is not sustainable in the long-term. 
This session did not have a formal speaker to provide a presentation, however there was a decision 
panel that led the discourse comprised of the research fellow from CHE, the senior principal economist 
from the Office of Health Economics and the vice president of market access and external affairs from 
Takeda Canada. A round table approach was used in this session and all attendees were invited to 
provide their perspectives on CTP payment mechanisms.  
 
Posed questions:  
 
● Do we need novel systems or adjustment of codes for payment? 
● What are the funding mechanisms/risk sharing agreements? 
● Are there any novel payment mechanisms? 
 
7.3.5.1. Session Summary  
 
There is a lot of progress being made in terms improving payment systems and reimbursement in 
healthcare. In the UK efforts towards new payment models, integrated care systems, developing 
sustainable payment systems and assessing the future of Payment by Results are areas being addressed 
by organisations such as NHS Improvement and NHS Englandxi. However, paying for CTPs still 
presents a major challenge for public health care systems since both the UK and Canada have budget 
constraints. Highly priced health technologies such as CTPs require different solutions in comparison 
to traditional small molecule therapeutics, as the high up-front costs and uncertainty in health outcomes 
results in a lot of risk for the payer. Therefore, mechanisms such as MEAs are necessary to mitigate the 
financial risk of novel, immature and expensive technologies347.  
 
There is yet to be a fully defined approach to paying for disruptive and expensive technologies. 
Mechanisms such as the Cancer Drug Fund are only useful for oncological therapies such as CAR-T 
therapies, for other disease indications robust and sustainable modes of payment that do not 
significantly offset budgets are required. Even in the case of the Cancer Drug Fund, it is unsustainable 
to expect future CAR-T therapies such as those treating solid tumours to also be recommended within 
 
xi Westminster Health Forum Seminar - Priorities for improving payment systems and reimbursement 
in healthcare. 3rd May 2018. 
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this funding pot, as the funding source is finite. Therefore, long term strategies are required in order to 
be able to routinely commission and pay for CTPs.   
 
The aforementioned MEAs offer a means of providing reductions for the effective pricing of new 
technologies. The agreements can be outcome based or non-outcome based, and are typically associated 
with evidence generation post-recommendation334,347. The purpose of the agreements is to provide 
technologies where there are no other alternatives for patients while facilitating evidence development 
to reduce the payer’s financial risk due to the uncertainty associated with novel technologies. Figure 
101 outlines MEA options that can be used for reimbursement.  
 
 
Figure 101. Taxonomy depiction of the price reduction schemes that can be used for both outcome and 
non-outcome based managed entry reimbursement agreements. Adapted from Grimm et al (2016).  
 
Other financing schemes have been suggested to address the issues of high up-front costs and 
affordability associated with CTPs334. Amortisation, offers a financing route in which the high up-front 
costs of treatment are spread over time to reflect the time period over which benefits are realised335. 
“Pay for performance” is a mechanism in which the total price paid is linked to a measure of 
performance (e.g. Objective Response Rate). This requires monitoring of performance measures and 
the payment mechanisms to ensure that the appropriate reimbursement is obtained. Leasing is another 
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option that can be used, this is a method that combines the concepts of amortisation and pay for 
performance i.e. payments are made over a set time period for as long as the measure of performance 
is met335. Other innovative financing schemes are also being considered, for instance methods that aim 
to utilise the expertise of financial market solutions. This has the potential to better manage financial 
risk as the finance industry is well established and skilful in managing high financial riskxii.   
 
xii CHART workshop presentation/discussion point 
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7.3.6. Adoption and implementation of ATMPs: Session 7 
 
Implementation was a subject area that was mentioned repeatedly in the previous sessions. Following 
approval and reimbursement recommendation, defining how a technology is implemented is the final 
hurdle before it can effectively reach patients. This session was devised to explore how CTPs might be 
implemented in a manner that is efficient and sustainable. The presentation for this session was provided 
by the Head of Clinical Innovation Adoption from the Oxford Academic Health Science Network 
(AHSN). The discussion panel included the Head of Clinical Innovation Adoption, a haematologist 
from the Princess Margaret Cancer Centre, the Senior Director of Market Access and Government 
Relations from Gilead Sciences and the director of Health Solutions from MaRS Partnerships.   
 
Posed questions:  
 
● Do sessions 1-6 help address the adoption challenges (were any tangible action points raised?) 
● What were the key challenges identified and were there any solutions put forward?  
● Do we need changes in infrastructure? (ATTC – discussion point?) 
● How do we facilitate effective adoption of ATMPs? 
● What are the barriers to adoption? 
● Where are the evidence gaps? 
● Policy aspects? 
 
7.3.6.1. Session Summary  
 
The pathway to market access is established, however the pathway to adoption and implementation of 
CTPs is less clear. Implementation of CTPs requires specialised infrastructure, accreditation and 
personnel training that is not currently routinely available. Adoption and implementation require 
concerted efforts from multiple stakeholders such as health care commissioners, policy makers, 
clinicians and service providers. In the UK the NHS is a ‘single payer’ system which presents potential 
advantages compared to highly privatised and fragmented healthcare systems (e.g. USA healthcare 
system) for adoption and implementation. This potential advantage is due to the centralised 
commissioning, coordination, standardisation, risk and data management that is facilitated by having a 
single (predominantly) system for healthcare provision. 
 
The Consolidated Framework for Implementation Research (CFIR) was used to provide context into 
the key considerations related to the challenges of adoption and implementation of healthcare 
technologies348. Three elements of the framework (inner setting, outer setting and individual 
characteristics) were highlighted in a UK context concerning the adoption and implementation of 
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CAR- T therapies within the NHS. xiii The inner setting highlights the institutional barriers to adoption 
that have been faced by CAR-T centres in the UK. Accreditation resulted in highly resource intensive 
commitments in order to adjust policies, pathways and guidelines within the respective centres allowing 
for them to be deemed qualified to administer the therapies. Contracting associated with the CAR-T 
manufacturers was variable between the different hospital centres and it was highlighted that 
negotiations should be centralised to aid in the interpretation of contracts. Governance of the process 
and the key stakeholders involved in the implementation is highly sought after to ensure that all 
requirements of the multifaceted CTPs pathways are adequately managed. xiv The capacity to carry out 
the activities required to implement CAR-T therapies is a crucial element, the appropriate equipment 
and staff needs to be available as well as ward and intensive treatment unit capacity. In addition, staff 
training presented a challenge as releasing personnel for training time was not always achievablexv. This 
illustrated that generic training in CTPs is needed as it is not feasible or sustainable to release staff for 
training for each individual CTP prior to adoption. Patient management is important in to ensuring 
accessibility to eligible patients; this requires a national level effort to identify capacity and carryout 
referrals as appropriate.  
 
The outer setting to implementation and adoption of CTP is emergent, efforts by the Cell and Gene 
Therapy Catapult to drive adoption has resulted in innovation hubs that focus on different areas of the 
CTP realisation pathway. The Advanced Therapy Treatment Centres (ATTCs) develop models based 
on best practises in specific areas; processes are then shared amongst the network to improve efficiency 
amongst the system349. The ATTCs have been established to carry out the initial exploration of the 
infrastructural and process requirement challenges (Figure 102), the learnings from the centres will 
then be rolled out to other centres in the UK which will provide standardised approaches to the 
implementation and adoption of CTPs.  
  
 
xiii CHART workshop presentation/discussion point 
xiv CHART workshop presentation/discussion point 
xv CHART workshop presentation/discussion point 
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Figure 102. Adoption challenges being explored under the ATTC model. Adapted from the Cell and 
Gene Therapy Catapult.  
Under the CFIR, individual characteristics to consider include; patients; clinicians; managers and policy 
makers. Crucially patient education is important as patients are the recipients of the therapies; thus 
generating and maintaining positive public and patient perception of CTPs is important for social and 
ethical considerations of adoption. Equally as important is the support of clinical leaders as they are the 
stewards of successful adoption and patient experience. Therefore, clinicians should be involved in 
implementation and adoption activities so that there is clarity about their role and responsibilities. 
Commissioning managers, at a higher organisational level, are key to the implementation process as 
technologies that are adopted should be in line with the strategic priorities of the healthcare 
commissioner group. It is up to commissioning managers to provide compelling business cases and 
assess appropriate levels of risk and benefit associated with adopting technologies, especially those that 
are resource intensive such as CTPsxvi. The policy level is fundamentally overarching as without the 
political will to support the CTP industry efforts such as the ATTCs and their aim to foster 
implementation would not be possible. In addition, policy makers can work closely with organisations 
to ensure that training is adequate for future workforces that are skilled in the implementation of CTPs, 
instead of relying on unstainable ad hoc staff training for each new CTP. 
 
xvi CHART workshop presentation/discussion point 
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7.3.7. Workshop summary.   
 
The workshop highlighted several areas that need to be addressed in order for the adoption of CTPs to 
be better facilitated. In addition, the workshop presentations and discussions illustrated that while CTPs 
maybe novel in their mechanism of action, the way in which they are assessed for value is not novel 
and does not need to be bespoke. Ultimately, at the core of reimbursement and adoption is value; payers 
look at what value is being provided by a technology. There is no need to change the way in which 
health economic evaluations are carried out as essentially it is still a matter of assessing clinical benefits, 
risks and costs.  
 
Fundamentally, conventional HTA frameworks can be applied to CTPs; the challenge is ensuring that 
both value and risk are adequately captured by the methods, given the current commonness of immature 
CTP evidence. The CTI needs to address the uncertainties associated with the evidence currently being 
provided in the early onset of these CTPs applying for approval and funding. The challenge of evidence 
is exacerbated by schemes that allow for early regulatory approval, while this is beneficial for patient 
access, it presents a hindrance to HTA as the trials utilised for regulatory approval can only provide 
short-term follow-up data. The way in which evidence is generated for CTPs needs to be addressed in 
order to combat the issue of uncertainty, and randomised clinical trials with greater sample sizes, should 
be employed336,350,351. The value of real-world evidence is undisputed for emergent therapies, however, 
there should be consensus on how the data is standardised, captured and utilised for reassessments and 
analysis of long-term effects. 
 
This raises the question as to whether to apply pragmatic decisions based on available evidence or to 
delay decisions until further data becomes available. A solution that is gaining prominence in light of 
this question is the use of MEAs as a means of mitigating the long-term evidence risk associated with 
CTPs. MEAs have proven to be essential to the initial adoption of CTPs, however this requires 
engagement between multiple stakeholders to ensure appropriate sharing of risk. Of the MEAs currently 
being employed outcome-based payment methods offer a solution for CTPs that facilitate risk 
mitigation for the payer. In addition, outcome-based payment methods, encourage developers to provide 
high quality products to ensure they are reimbursed and avoid the penalty charges that are associated 
with not meeting defined clinical outcomes. It is important to take account of the anticipated benefits 
of the technology and the value of the uncertainty around these health outcome estimates in an objective 
manner when using MEAs. An objective perspective is necessary to ensure that only those technologies 
that have the potential to be effective are adopted. Thus, avoiding the adoption of expensive therapies 
with potentially limited benefits, albeit in a risk mitigated manner. Furthermore, there should be 
appropriate incentives employed for all stakeholders to ensure future evidence generation. The 
incentives help to provide accountability for the stakeholders i.e. the payer should ensure targets are 
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met to avoid paying with limited evidence of value and the providers should ensure the data is obtained 
in order to sustain reimbursement. Additionally, even under MEAs it is essential to consider the 
potential costs of implementation reversal associated with CTPs, should reversal be necessaryxvii.  
 
Funding pots such as the Cancer Drug Fund have thus far facilitated the commissioning and adoption 
of novel CTPs, albeit only within the oncology space. Thus, a vital point of scrutiny with regards to 
CTP adoption is sustainable affordability, it is important to question whether the healthcare system can 
sustainably bear the costs of implementing these technologies. This will become a prominent issue as 
more and more therapies for different disease indications are approved at a regulatory level; demand 
for access to these therapies will be inevitable. However, as to whether CTPs can be routinely 
commissioned remains to be seen. Therefore, although HTA and payment mechanism are two separate 
entities, they are both crucial to the feasibility of adoption, thus there is value in these activities being 
carried out simultaneously, so as to avoid recommended therapies that cannot be paid for. This is a 
lesson that should have been learned by cases such as Glybera (where the product obtained regulatory 
approval but was deemed too expensive to be adopted and reimbursed221). This emphasises the notion 
that a therapy may be available but if it cannot be paid for, it cannot be used to treat the patients that 
need it221.  
 
 People hold a vital role in the adoption process, ultimately people are the stewards to the adoption of 
therapies, from patients, to clinicians, administrators and the manufacturers themselves. Therefore, it is 
important to have a representation of all stakeholders during the adoption pathway as the perspective 
of all parties is crucial; i.e. if patients and clinicians do not want the technologies being offered, it serves 
little purpose to adopt them. The patients and clinicians should be advocates for new technologies, this 
requires them to be well informed to enable them to appropriately and critically assess the value of these 
technologies, from their perspectives. Furthermore, it is a question of social values when it comes to 
addressing how much risk should be taken to achieve potential benefits, especially with novel 
technologies where benefits and risk are not fully known. In addition, a societal perspective is important 
in public healthcare systems as equity is a major consideration, thus the opportunity costs posed to the 
public as a consequence of CTP adoption would be significant, particularly in times where budget 
constraints are ubiquitous. Moreover, in terms of equity, how to prioritise access and the justifications 
for it are significant social challenges that should be addressed. Public discourse about these social 
challenges should be encouraged, as well as discourse regarding the prices of therapies to ascertain 
whether or not they are justified to be so high form a societal perspectivexviii. Akin to this, discourse, is 
the need to appropriately disseminate information to the public so that media hype and overpromising 
is avoided.  
 
xvii CHART workshop presentation/discussion point 
xviii CHART workshop presentation/discussion point 
 
 
 
 
 
- 304 - 
Currently, most issues and lessons learned regarding the adoption of CTPs have been the result of CAR-
T therapies. It is important to note that some of the lessons may or may not be applicable to other disease 
areas and CTPs. However, the CFIR issues raised above are likely to be a universal challenge faced by 
all CTPs/ATMPs, for instance intensive treatment unit capacity, appropriate personnel training, robust 
supply chain management and cold storage logistics. This highlights the importance of an organised 
infrastructure in the successful implementation and adoption of CTPs. This is likely to require 
investment of capital in order for hospitals to be accredited and suitable for routine administration of a 
wide range of CTPs. This process will require coordination and collaboration to ensure sustainability 
and standardisation of procedures to guarantee patient equity of access and quality. Furthermore, for 
patients to benefit from future CTPs, changes are required in terms of infrastructure and other areas 
such as data collection and workforce training. Fundamentally, such drastic changes will require support 
from the ‘top down’, as well as the political will to advance the industry and foster adoptionxix. In the 
UK, institutions such as the Cell and Gene Therapy Catapult are examples of the support mechanisms 
and infrastructures that is needed. Furthermore, the ATTCs offer niche innovation hubs that should help 
to facilitate more efficient adoption and implementation approaches. 
 
Innovation in policy frameworks and business models is necessary to successfully and efficiently 
translate research from the bench to beside for the benefit of patients. Such innovation equally needs to 
be as informed by empirically grounded evidence. A system-level view is essential to avoid unintended 
consequences of targeted reforms. This not only requires policy level engagement, but also engagement 
from all stakeholders of the supply chain. In the UK, NHS England’s commercial deals with 
manufacturers allowed for early and rapid introduction of CAR-T therapies compared to the rest of 
Europe, highlighting the influence and power of political will in facilitating the adoption of 
technologies175. Thus, the main next steps that were outlined at the end of the workshop included: policy 
maker engagement, interacting with other relevant stakeholders, addressing the issues of evidence 
generation and understanding the future payment system mechanisms.  
  
 
xix CHART workshop presentation/discussion point 
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 7.4. Conclusions 
 
The adoption of CTPs is a multifaceted challenge that requires policy makers, academics, clinicians, 
patients and manufacturers to work together on all stages of the pathway in order to progress the CTI 
as a whole. HTA helps the decision-making process for the payer, since a fundamental issue with CTPs 
is the uncertainty of their long-term benefits. Thus, payers cannot be guaranteed the true value of what 
they are paying for, due to the immaturity of the evidence currently available. Expenditure of public 
budgets, in the case of both Canada and the UK, on such technologies requires both opportunity cost 
and equity to be strongly considered. Therefore, HTA for CTPs should be capable of providing robust 
analyses to aid the payer in their decision-making process. Global efforts in HTA have great value, the 
collaboration be between NICE and CADTH illustrates this; and this may be a mode that facilitates 
more streamlined assessments, especially in terms of clinical effectiveness, since it is inevitable that 
cost analysis will vary from country to country. However, such collaborations provide opportunities to 
learn from other existing systems, which is crucial for having adaptive and innovative internal systems 
for HTA and adoption.  
 
Data presents a considerable challenge within the CTI, in order to generate strong evidence clinical trial 
designs should aptly capture the necessary data to satisfy the needs of both the regulators and the payer. 
This should include safety, efficacy, clinical effectiveness, cost-effectiveness and the other value 
elements of the respective HTA agency. It is never too early to start thinking about how to generate 
evidence. Both NICE and CADTH offer scientific advice programmes on HTA process preparation that 
encourage developers to engage with the HTA process and its requirements as early as possible, to 
ensure that their data is as robust as possible when it comes to their final submission.    
 
In terms of adoption, it is mainly the implementation of CTPs that requires restructuring and adaptation 
to ensure that these technologies are provided efficiently and effectively. Efforts such as the UK’s 
ATTCs and personnel training are steps towards the right direction to adequately deliver CTPs. In 
addition, collaborative efforts between different treatment centres are required to effectively and 
efficiently implement CTPs, which presents a significant challenge in a jurisdictional structure such as 
the Canadian healthcare system. The NHS is well placed for outcomes-based payment mechanism as it 
is a single payer system, and all patients within the system have an identifier. Unlike in the USA/private 
payer systems where the patient is likely switch between different healthcare providers. Therefore, this 
organisational feature should be exploited in order to provide improved patient management whilst also 
providing real-world evidence of the long-term clinical effect of technologies post-recommendation.  
 
The topical and prominent example of CAR-T therapies has made HTA agencies evaluate how to assess 
CTPs, the studies carried out have shown that while HTA processes are applicable to CTPs, the 
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combination of great uncertainty coupled with the high potential for substantial patient benefits means 
that innovative payment methods are needed in order to provide access, while mitigating risk. How 
sustainable payment systems will be established currently remains unclear and this is an area that 
requires more work and understanding to ensure that more CTPs are approved and reimbursed in the 
near future. Siloed funds such as the Cancer Drug Fund are not a realistic solution for all therapies, thus 
arrangements for routine CTP commissioning is necessary which will undoubtedly require budgets 
allocations to be adjusted as appropriate. In addition, alternative ways of financing and paying for 
expensive therapies such as CTPs should be evaluated. Other industries such as the aviation and 
financial investment industries have the potential to provide alternative payment methods for these 
presently expensive therapies. In the interim, risk sharing offers a viable method that is set to be 
common practice until the true value and long-term benefits/effects of CTPs are established. 
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7.5. Chapter bridge 
 
This chapter has explored the key challenges in the adoption of CTPs, the valuable experience and 
expertise of the workshop participants illustrated that there are areas that need to be addressed. In 
addition it was demonstrated that CTPs are desirable and there is work and research being carried out 
to facilitate their adoption. The majority of the learnings from this chapter have been in the context of 
CAR-T therapies due to their current prominence. The following chapter returns focus back to the 
dopaminergic neuroprogenitor candidate therapy, the price headroom and potential cost-effectiveness 
of the candidate therapy were explored using validated assumptions. Early stage economic evaluation 
tools were also used to determine the potential economic impact and return on investment. In addition, 
the key points of consideration from this chapter, in terms of the different themes, were evaluated 
against the candidate therapy to ascertain how it would fair in areas such as social values, HTA and 
implementation. 
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Chapter 8. Exploration of the pricing, cost-effectiveness and adoption potential of the candidate 
therapy  
 
8.1. Introduction  
 
The work carried out in this chapter aimed to provide insight into the potential cost-effectiveness and 
commercial viability of a cell therapy product (CTP) based treatment for Parkinson’s Disease (PD). 
Furthermore, the challenges and workshop discussion points from the previous chapter were explored 
in the context of the candidate therapy to ascertain how it would perform, if it was to progress through 
development and apply for market authorisation, adoption and reimbursement. 
 
This chapter aims to demonstrate the use of the headroom method discussed in Chapter 2 (section 2.4.4. 
Headroom method) and an in-house cost of goods (CoGs) model as a means of determining the 
commercial viability of the candidate therapy, herein after referred to as the fictional product, 
“DopaCell”, for the purposes of the analysis. As aforementioned in chapter 2 the headroom analysis 
method is a tool that can be used throughout the product development timeline as an iterative means of 
assessing commercial viability and as a go/no-go decision-making tool during product development. At 
an early stage, the headroom analysis can be used to determine if further resources should be provided 
into a product’s development or not. In latter development stages, prior to efficacy data being obtained, 
headroom assessments can be used to assume the cost-effectiveness, adoption and gross profit potential 
of a product. 
 
8.1.1. The economic impact of PD  
 
PD is a progressive and debilitating disease that, unfortunately, currently has no cure and existing modes 
of treatment simply manage the symptoms67,225,352. Therefore, the quality of life of PD patients 
inevitably worsens over the course of the disease, with  medication decreasing in efficacy with time and 
the costs incurred increasing41,70,353. These outlays include but are not limited to: costs of higher 
medication doses, home modifications, adult care, personal care, loss of income (due to early retirement 
for either the patient and/or care giver), hospital visits and other lifestyle changes69,354,355. These costs 
impact different stakeholders: some costs are incurred by the healthcare payer i.e. the NHS, some are 
incurred by insurance companies (particularly in healthcare systems such as the USA) and some costs 
are incurred directly by the patients themselves214,356,357.  
 
The literature illustrates that the economic impact of PD is significant. In the UK, PD has a prevalence 
rate of 140,000 at a cost of ~ £2 billion annually , this prevalence rate is set to increase to ~160,000 and 
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200,000 per annum by 2025 and 2035 respectively358,359 (Figure 103). PD patients have a higher rate 
of non-elective hospital admissions for treatment of motor decline, urinary tract infections, pneumonia 
and hip fractures204. In a study commissioned by NHS England, it was reported that PD-related 
admissions amounted to £777 million over a four-year period between (2009 to 2013)204. Moreover, PD 
patients had higher rates of emergency admissions and higher costs due to longer hospital stays 
compared to a similar population without PD204. A study conducted in the USA reports that the national 
economic healthcare burden of PD in 2010 was ~ $14 billion, 55 % higher than a similar population 
without PD358. The disease burden suffered by the patients, the cost of PD to healthcare systems and 
the increasing elderly population highlights the need for improved treatment strategies that do more 
than merely manage the symptoms of PD. Thus, it is of paramount importance to formulate treatment 
options that significantly improve the quality of life of patients, address the underlying disease 
pathology and consequently reduce the economic impact of PD for both payers and patients. 
 
 
Figure 103. Summary of the economic burden of Parkinson’s disease. Data obtained from the literature 
204,358,359.   
8.1.2. Health economic evaluations for PD treatment strategies 
 
Economic evaluations of healthcare products and interventions are common practice nowadays due to 
the growing budget constraints that health care systems face. Health Technology Assessment (HTA) 
agencies such as the National Institute for Health and Care Excellence (NICE) and the Canadian Agency 
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for Drugs and Technologies in Heath (CADTH) have to assess the costs and benefits of new 
technologies to determine their value and cost-effectiveness. Approximately 30 model-based economic 
evaluations specifically assessing PD interventions have been carried out and reported in the literature 
over the last two decades, with the majority of these occurring  in the last decade360,361. Folse et al (2018) 
and Becerra et al (2016) provide a comprehensive overview of PD economic analysis and cost-
effectiveness studies360,361. The majority of evaluations for PD have been related to medication therapy 
and deep brain stimulation (DBS); however, evaluations for hypothetical cell and gene therapy 
interventions have also been performed344,362–366 (Figure 104). Markov models and decision trees are 
used to model the costs and disease progression and are typically set over a five to ten-year time horizon. 
The assessments reported in the literature use Hoehn & Yahr (H&Y) stages and the Unified Parkinson’s 
Disease Rating Scale (UPDRS) to measure health outcomes, patients at H&Y stages II to V with ‘off’ 
time >25% are usually chosen 360,361 (Table 45). This population is more likely to benefit from 
significant changes in quality of life from treatment due to the symptoms they experience such as 
pronounced rigidity and tremors. In addition, most models look at motor symptom changes as the means 
of evaluating treatment effect360,361, since motor symptoms are most common for PD patients. PD 
economic evaluations have been carried out in a wide range of countries, mainly developed countries 
(e.g. the UK, Germany and the USA) that have a larger geriatric population, thus PD is more prominent 
in comparison to lesser developed countries i.e. those in sub-Saharan Africa70,360 (Figure 104). In many 
cases, alternatives to therapies dependent upon oral medication such as Levodopa (L-DOPA) are found 
to be cost-effective, for instance DBS356,363,364. This is due to the lack of long-term benefits offered by 
medication therapies which are reliant upon mechanisms that try and increase the amount of dopamine 
available.  
 
N.B. A brief summary of the PD scales used. The Hoehn & Yahr (H&Y) stages describe the level of 
motor function symptoms as the disease progresses, the typical symptoms of each of the five stages are 
shown in Figure 3. The Unified Parkinson’s Disease Rating Scale (UPDRS) is a questionnaire based 
method of assessing both the motor and non-motor symptoms of PD, including mental functioning, 
mood, social interaction levels and the ability to carry out daily activities367–369.   
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Figure 104. Summary data of economic evaluations for the treatment of PD, detailing the interventions 
evaluated and the countries that have carried out evaluations. Numbers in brackets indicate the amount 
of studies that have been carried for the respective intervention and the amount of studies carried out in 
the respective country. Information summarised from literature searches and studies by Folse et al 
(2018), Nagpal et al (2019) and Becerra et al (2017).  
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Table 45. Summary of economic evaluations for the treatment of PD, detailing the measured efficacy 
outcomes and the PD characteristics of the populations that been evaluated. Information summarised 
from literature searches and studies by Folse et al (2018), Nagpal et al (2019) and Becerra et al (2017).  
PD = Parkinson’s disease; H&Y= Hoehn & Yahr; QoL = quality of life; UPDRS = Unified Parkinson’s 
Disease Rating Scale.  
 
 
To date, there have been very few studies conducted to economically evaluate cell and/or gene therapies 
for the treatment of PD, with only two studies identified by the author344,365. The study by Hjelmgren et 
al (2016) performed a predictive evaluation of dopamine cell replacement, for health outcome data they 
utilised clinical data from patients that had undergone neural transplantation using foetal derived ventral 
mesencephalic tissue365. Robust cost data was not included in the study as the authors did not provide 
cost of good estimations for the therapy due to the tissue being obtained from elective abortions. The 
study did however conclude that dopamine cell replacement therapy could result in long-term cost 
offsets and QALY gains for the patients327.  
 
More recently Jorgensen et al, used a Markov model to determine the cost-effectiveness and budget 
impact of a potential gene therapy for PD. Their model used a lifetime time horizon of 20 years, both 
costs and QALYs were discounted at a rate of 3.5% (the standard rate used by NICE) the analysis was 
carried out in the context of the UK and USA markets344. The study concluded that a PD gene therapy 
would provide substantial value, however the two markets would result in a difference in price 
potentials due to differences in willingness to pay and budget impact thresholds. Both of these 
hypothetical cell and gene therapy evaluations show the potential health gains and cost savings that can 
be obtained by disease modifying treatments for PD such as cell and gene therapies344,365. Akin to the 
study by Jorgensen et al, the present work will analyse the potential cost-effectiveness, price potential 
and budget impact of DopaCell in the context of a UK market.   
Outcome Measures Populations
H&Y stages changes OFF time > 25%
Motor function analysis Full range of H&Y stages
OFF time state Pre PD medication
UPDRS score Early PD
QoL score Advanced PD  
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8.1.3. CTPs as cost-effectiveness case study for PD 
 
The adoption of CTPs requires them to be highly efficacious and cost-effective as there are other 
therapeutic strategies such as DBS, L-DOPA, dopamine agonists and enzyme inhibitors available for 
PD patients, some of which (DBS) can be used for patients at the advanced stages of the disease370. 
Therefore, to be deemed as cost effective, CTPs must prove to have additional benefits in order to be 
cost-effective and receive positive health technology assessments (HTA) appraisals. For example, they 
should exhibit “(i) long-lasting, major improvement (60–70%) of mobility and suppression of 
dyskinesias and/or (ii) improvement of symptoms resistant to other treatments or modification of 
disease progression”370.  
 
PD is an ideal case study for exploring the reimbursement potential of a CTP. Firstly, since PD is an 
incurable and progressive disease with currently no disease modifying treatments available, thus there 
is an effectiveness gap a CTP such as DopaCell could cover. Secondly, PD affects a larger population 
in comparison to other disease such as the cancers that are treated by CAR-T therapies, therefore it is a 
good case study to explore the use of a CTP in a large population and its economic impact. Third, 
studies have been carried to determine transition times from one H&Y stage to the next  and the costs 
associated with the different stages of the disease195. Therefore, using assumptions of DopaCell’s 
efficacy, its potential effectiveness and QALY impact can be obtained in an informed manner for use 
in the headroom assessment. Finally, due to the allogenic nature of DopaCell, it has the potential to be 
an off-the-shelf product with lower associated production and logistics costs in comparison to CAR-T 
therapies; this could be favoured with regards to regulatory and reimbursement evaluation. 
 
8.1.4. CTP benefits and drawback for PD 
 
The potential benefits of a CTP for the treatment of PD are discussed in Chapter 2 section 2.1.6.3. Here, 
a brief summary of the potential benefits is given. The use of a CTP is potentially advantageous in 
comparison to current PD therapeutic strategies as a CTP can provide sustained/prolonged 
neurorestoration. Foetal tissue-based trials, which have a similar mode of action to DopaCell24, have 
demonstrated clinical improvements in patients for ≥18 years71,75,371. This has been evidenced by a 
restoration of normal striatal dopaminergic function, measured by fluorodopa (F-DOPA) uptake and 
imaged using positron emission tomography scanning371. This improvement has been observed three to 
five years postoperatively, resulting in some patients being able to discontinue their use of anti-
Parkinsonian medication for over 15 years. Other patients benefited from decreased medication dosage 
such as L-DOPA by 46 – 65 % per day post-operatively81; consequently, this could result in reduction 
of  polypharmacy, a strategy  associated with controlling PD medication side effects. Results from PD 
utility scales have also shown significant improvements, for instance average H&Y improvements from 
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H&Y 3.71 down to H&Y 2.5 have been reported78. This change in H&Y stages is significant enough to 
result in amelioration of patient quality of life aspects such as reduced time on the ‘off’ state, decreased 
sleep disturbance and less pronounced motor symptoms, permitting reinstatement of one’s driving 
license78.   
 
Although current cell-based trials for PD treatments have shown potential benefits, it must be noted that 
this mode of treatment does still face some drawbacks and challenges. For instance, graft induced 
dyskinesia (GID) has been observed in some trials, causing concern regarding the efficacy of cell-based 
treatments84. Furthermore, two double-blinded trials conducted in the 1990s showed no significant 
therapeutic benefit as a result of the procedures62,84,372. This triggered a decade long halt in CTP trials 
for PD, as the benefits of such an emergent and costly treatment strategy was brought to question. In 
addition, due to the allogenic nature of the foetal based therapies, immunosuppressants are a requisite 
of the therapy. The duration of use varies dependant on the chosen regime; the reported length of use 
ranges from 6 to 48 months postoperatively, with 6 – 18 months being the most common duration373. 
Furthermore, although the transplanted foetal grafts have demonstrated clinical benefit for up to 
eighteen years, the pathogenesis of the disease persists, evident from post-mortem analysis of 
transplanted patients showing the presence of Lewis bodies in the grafts13,71,84.  
 
Nonetheless, since the specific aetiology of the disease is not known, therapeutic targets to prevent 
disease pathogenesis and progression are not yet a reality. Therefore, even though it is currently not 
possible to stop the spread of the disease to the grafted cells, a dopaminergic CTP such as DopaCell 
offers a viable therapeutic option because “(i) disease propagation is slow, (ii) the majority of grafted 
neurons are unaffected after a decade, and (iii) patients experience long-term improvement”373. The 
neurorestoration offered by a PD CTP improves quality of life in terms such as reduced OFF-time; 
which is significantly important to PD patients; “patients with PD would likely seek treatment that 
would minimize the amount of 'off-time' experienced per day”366. This highlights the requirement and 
significance of a treatment strategy that provides such desired patient benefits.  
 
8.1.5. Proposed CTP patient criteria   
 
The ideal stage of intervention with a CTP for PD is not unknown, similar to DBS; although DBS is 
typically reserved for patients with advanced PD with life expectancy exceeding five years. In addition, 
commissioning criteria for DBS states that DBS candidates should “have symptoms of motor 
complications severe enough to significantly compromise function and quality of life”374. Furthermore, 
“strategies such as adding a catechol-O-methyl transferase (COMT) inhibiter, adding a monoamine 
oxidase inhibitor (MAOI), switching to long acting agonists or adding amantadine for dyskinesia should 
have been tried and failed or be considered unsuitable”374 prior to treatment with DBS. In addition, “All 
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options for best medical therapy will have been considered, tried or exhausted by a movement disorder 
consultant neurologist working with a functional neurosurgery team”374. Additionally, the DBS in 
movement disorders policy states that DBS “should not be performed in patients with clinically 
significant cognitive decline (dementia), marked postural instability, ‘on’ freezing or ‘on’ falls.”374 
These criteria form a sound basis for candidate selection for trials/treatment of PD with a CTP. 
 
Foetal tissue based and other cell-based PD trials have previously selected patients under the age of 65 
at H&Y stages III – V, with idiopathic PD for ten to fifteen years and no cognitive impairment upon 
assessment362,375–377. Patients at H&Y stage III are considered to be in the severe/advanced phase of PD 
where they spend an increased amount of time in the ‘off’ state regardless of medication (Figure 3 and 
Figure 4). Patients fitting this prolife, in addition to the above DBS criteria would be ideal candidates 
as the CTP has the potential to offer improvement in quality of life, possibly improving H&Y back to 
H&Y II.  
 
Treating patients prior to prolonged disease progression could result in prolonged states of higher 
quality of life, provided that the  disease is not permitted to rapidly develop to advanced and debilitating 
stages354,378. For instance, CTPs have allowed for patients to cease use of PD medication post-
operatively due to improved symptoms, prolonging higher quality of life84,373,379,380. Furthermore, CTPs 
could potentially delay the onset of advanced PD whilst inhibiting the incurrence of the substantial costs 
associated with disease progression381. This is pertinent, as worldwide increases in life expectancy, 
especially in westernised countries, will inevitably result in higher populations of patients with 
advanced PD. In addition, as PD is a disease of the elderly population, delaying the onset of advanced 
symptoms for ten to twenty years would significantly improve quality of life in the latter stages of 
patients’ lives and prove to be cost-effective for a healthcare resource intensive population. Therefore, 
delaying the costlier, later stages of PD is important, since this forms part of the valid argument for the 
use of a disease modifying treatment such as a CTP378. Despite CTPs such as the DopaCell not being 
curative, they have the potential to offer better patient benefits and increased cost-effectiveness for a 
range of stakeholders. 
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8.2. Methodology and analysis   
 
The purpose of the work carried in this chapter is to evaluate the commercial viability and potential 
cost-effectiveness of the candidate therapy (DopaCell). Using the headroom method, the author aimed 
to answer the following questions: 
 
• What is the price potential of a human embryonic stem cell (hESC) based therapy for PD? 
• Would a hESC-based therapy for PD be cost-effective?  
• Could a hESC-based therapy lower the economic burden of PD?  
 
8.2.1. Information required  
 
In order to attempt to answer the questions posed above, essential information including intervention 
costs and health utility data was required, to populate the evaluation models used to carry out the 
analysis. These information categories will be discussed in further detail in the following sections. 
 
8.2.1.1. Health Utilities  
 
Health utility values are used to quantify the quality of life levels of patients and are integral to cost-
effectiveness analysis. Due to the lack of clinical trial data for DopaCell, the outcomes from the 
literature of the foetal mesencephalic tissue transplants has been used as an informed estimate; of the 
health gains that could potentially be afforded by DopaCell. Health utility data for the comparators 
(generic medication therapy and (DBS) was also accrued from the literature.  
 
8.2.1.2. Costs 
    
Costs are equally as integral as health utilities to cost-effectiveness analyses. Understanding the 
components that make up the total costs used in economic evaluations is important, thus it is 
fundamental to qualify and quantify the resources used and validate the bearer of the costs. This helps 
to distinguish between direct and indirect costs (Table 46). Arguably, economic evaluations that 
consider indirect costs better reflect the cost-effectiveness of an intervention as they provide a holistic 
view of disease and the treatment option costs.  
 
 
 
 
 
 
- 318 - 
Table 46. The cost inputs that have been considered for cost-effectiveness analysis. 
 
 
8.2.2. The information used in the model and analysis:  
 
8.2.2.1. Health Utilities:  
 
The analysis assumes treatment for patients with a baseline health utility of 0.42 and stage III of the     
H &Y scale with high levels of ‘off’ time i.e. 50 % or more 382. The comparator used in the present 
work is generic anti-Parkinsonian medication which can provide a health utility of 0.55 (Table 48) and 
general DBS surgery, providing a health utility of 0.66 (Table 47). The DopaCell health-related quality 
of life data assumes that the patient is able to return to a perfect health state as a result of the therapy 
i.e. normal headroom assumption.   
 
Adjustments to the headroom were made to account for the fact that perfect health is not an achievable 
result from use of the therapy. Instead, treatment results in improvements to H&Y stage II with less 
than 50 % ‘off’ time were utilised, which corresponds to a health utility value of 0.72. This resulted in 
assessment of DopaCell as a perfect therapy (classic headroom) and in an attuned manner that is a 
clinically realistic and provides significant improvement of a whole stage in the H&Y scale (DopaCell 
adjusted). Literature analysis shows that this is an achievable level of improvement as average 
reductions of 1.2 H&Y stages have been reported78. The adjusted headroom health utility value is based 
on long term outcome analysis that has shown:  
 
1. Up to a 40 % decrease in motor symptoms35  
2. 40 % decrease in ‘off’ time observed in some patients35 
3. Significant quality of life improvements being obtained e.g. patients regaining their driver’s 
license due to improvements, ability to sleep with less disturbances, par-taking in hobbies etc.78 
4. Striatal F-DOPA returning to normal levels, resulting in cessation of medication383 
5. Decreases in L-DOPA dosages between 46 – 65 % per day post-operatively81 
 
Direct cost Indirect costs  
• Hospitalisation costs
• Procedure cost
• Product costs
• Loss of productivity costs
• Lifestyle change costs
• Side effects costs
• Societal costs
• Care costs
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Table 47. DBS heath utility data obtained from the literature and the averaged value used for the present 
work.  
 
 
Table 48. Heath utility data for medication therapy obtained from the literature and the averaged value 
used for the present work. 
 
Baseline Increment Health Utility Details Reference
0.29 0.47 0.76 Base line used was 0.29 in the study Yianni et al(2013)
0.42 0.224 0.644 - Moon et al(2017)
0.42 0.17 0.59
70% reduction in  motor 
complications. Quality of life 
improvement of 30% over 
medication 
DBS policy 
(2013)
0.42 0.3 0.72
Utility represents transition from 
H&Y III 50 -75 % OFF time to H&Y 
II OFF time 0- 25%
Eggington et al
(2014)
0.42 0.169 0.589 - Pietzch et al(2016)
0.394 0.2666 0.6606 Average
Study
Baseline Increment 
Study 
Health
Utility
Health
Utility from 
model 
baseline
Details Reference
0.564 0.08 0.644 0.5 Assumption: drugs carry on 
working in the best way for 
period analysed therefor the level 
of health utility is sustained, 
however increased doses would 
be necessary thus an increase in 
cost incurred 
Moon et al
(2017)
0.53 0.06 0.59 0.48 DBS policy 
(2013)
0.418 0.242 0.66 0.662 Eggington et al
(2014)
0.42 0.15 0.57 0.57 Pietzch et al
(2016)
0.483 0.133 0.616 0.553 Average
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8.2.2.2. Costs:  
 
The sensitivity analysis ranges used in the present work were obtained from a combination of typical 
ranges in the literature that are representative of the assumptions being made in the present work. In 
general, the value of 25 % above and below the baseline was utilised for the sensitivity analysis.  
However, for some factors, such as miscellaneous costs e.g. the use of immunosuppressants and loss of 
productivity, the sensitivity ranges were different and ranged from 0 – 100 %. The use of 
immunosuppressants ranged from no use of immunosuppressants i.e. 100% below the baseline and 50% 
above the baseline representing a 50 % longer period of immunosuppression. The miscellaneous costs 
for medication therapy ranged between 50 – 100%, representing further indirect costs other than care 
and hospital costs, 50% above the baseline representing additional indirect costs such as household 
modification and lifestyle changes; while no changes and no addition costs were represented by 100% 
below the baseline. For loss of productivity the range incorporated non-inclusion of loss of productivity 
such as loss of income representing 100% below the baseline and 25% above the baseline presenting a 
modest literature-based increase to indirect costs 
 
8.2.2.2.a. DopaCell and DopaCell adjusted  
 
The total cost of DopaCell to the payer is comprised of manufacturing costs with a 50% mark-up, 
surgery costs, hospitals costs, pre-operation costs and miscellaneous costs. The manufacturing cost is 
based on an in-house CoGs model that was employed for the present study. The administration of 
DopaCell would involve an invasive surgical approach which makes up 17.5 % of the total costs, 
furthermore the patients have to undergo pre-operative assessments and hospital stays which also 
increases the cost. Immunosuppressants (miscellaneous costs) also represent a substantial outlay 
contributor accounting for 25% of the total costs when administered for the first twelve months, post-
operatively. The amounts used to determine cost are shown in Table 49 and are based on taking an 
average of reported costs from the literature (Appendix 21).  
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Table 49. DopaCell costs, the costs are the same for both DopaCell and DopaCell adjusted. The CTP 
variable cost represents the development/manufacturing costs as determined by the in-house CoGs 
model with a 50% mark-up. All other variables were sourced from current literature.  
  
Variable Amount (£) Details References 
CTP 15,000
Development cost of £10,000 with 
a 50% mark up as the price to the 
payer 
Parmar (2018)
Eggington et al (2014)
Pietzch et al (2016)
Surgery 7,000 Stereotactic procedure, theatre costs and personnel costs 
Hospital 1,700 Neurosurgery follow up costs 
Pre-operative 712 Pre-operative stay and assessments
Miscellaneous 8,000 Immunosuppressants at a cost of £8000 per year 
Total £32,412
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Sensitivity analysis was performed on the DopaCell cost input variables mentioned above, to determine 
which input had the most significant impact on the price/cost of DopaCell to the payer. The baseline 
used the values reported in Table 49. The ranges used in the sensitivity analysis were 25% above and 
below the baseline for all the variables, except for miscellaneous costs. For the miscellaneous costs the 
range included no use of immunosuppressants i.e. 100% below the baseline and 50% above the baseline 
(Figure 105). 
 
Figure 105. Tornado plot showing the influence of each variable on the final total cost of DopaCell to 
the payer in the first year. Miscellaneous costs which represent the use of immunosuppressants are 
shown to be the most influential variable on final total cost. The lighter colour (left hand side) 
demonstrates the level of cost decrease from the baseline (centre line) due to the respective variable. 
The darker colour (right hand side) demonstrates the level of cost increase from the baseline due to the 
respective variable.  
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8.2.2.2.b. DBS  
 
The cost of DBS included device costs, surgery costs, hospital costs, pre-operative costs and 
miscellaneous costs. The device cost is based on an average of reported device costs in the literature, 
similarly the costs of the other inputs are based on the literature averages (Appendix 15). The values 
used to obtain the final cost are show in Table 50. The ranges used in the sensitivity analysis were 25% 
above and below the baseline for all the variables Figure 106. 
 
Table 50. Input variables for the total cost of DBS in the first year, the values reported are averages 
from data sourced from the literature. 
 
 
Variable Amount (£) Details References 
Device 11,928 Includes DBS device, extensions, leads  and patient programmer 
Moon et al
(2017)
Yianni et al
(2013)
DBS Policy
(2013)
Eggington et al 
(2014)
Pietzch et al 
(2016)
Surgery 7,000 Implantation procedure, theatre costs and personnel costs 
Hospital 1,776 Neurosurgery follow up costs 
Pre-operative 709 Pre-operative stay and assessments
Miscellaneous 1,572 Battery changes ever 3-5 years
Total £22,986
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Figure 106. Tornado plot showing the influence of each variable on the final total cost of DBS to the 
payer in the first year. Device costs are shown to be the most influential variable on final total cost. The 
lighter colour (left hand side) demonstrates the level of cost decrease from the baseline (centre line) due 
to the respective variable. The darker colour (right hand side) demonstrates the level of cost increase 
from the baseline due to the respective variable. 
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8.2.2.2.c. Medication  
 
The input outlay components for the medication therapy comparator include the cost of the medication, 
this is based on generic anti-Parkinsonian medication. As medication-based therapies simply treat PD 
symptoms and do not have a disease modifying effect, additional indirect costs are incurred due to 
dampened responses to the medication and worsening of symptoms as the disease progresses. 
Therefore, the total cost to the payer used in this analysis includes indirect cost such as care costs, 
hospital visit costs and loss of productivity costs (Table 51). The addition of indirect costs better 
illustrates the actual cost of medication therapy and living with PD. The 2017 Parkinson’s UK ‘The 
cost of Parkinson’s’ report highlights the importance of these indirect costs as they have a significant 
financial impact on PD patients and their families355,357. The values used to determine the cost are shown 
in Table 51 and are based on an average of reported costs from the literature (Appendix 18). 
 
Table 51. Input variables for the total cost of medication therapy in the first year, the values reported 
are averages from data sourced from the literature. 
 
  
Variable Amount (£) Details References 
Drugs 2,654
Typically costs increase as the disease 
progresses due to increased dose 
requirements 
Parkinson’s UK
(2017)
Weir et al
(2018)
DBS Policy 
(2013)
Eggington et al 
(2014)
Pietzch et al 
(2016)
Care 5,221 Personal care and assistance is require due to movement disorder 
Hospital 2,157
Require for catchup and stays after fall 
etc. that increase as the disease 
progresses
Loss of Productivity 11,069 Loss of income due to early retirement 
Miscellaneous 1,000 Modification to household, dietary intake
Total £22,103
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The ranges used in the sensitivity analysis were 25% above and below the baseline for all of the 
variables included, except for loss of productivity and miscellaneous costs. For loss of productivity the 
range incorporated non-inclusion of loss of productivity such as loss of income representing 100% 
below the baseline and 25% above the baseline presenting increased value to indirect costs (Figure 
107). For the miscellaneous costs the range included no further indirect costs other than care, hospital 
and loss of productivity costs i.e. 100% below the baseline and 50% above the baseline representing 
additional indirect costs such as household modification and lifestyle changes.  
  
 
Figure 107. Tornado plot showing the influence of each variable on the final total cost of medication 
therapy. Loss of productivity costs are shown to be the most influential variable on final total cost. The 
lighter colour (left hand side) demonstrates the level of cost decrease from the baseline (centre line) due 
to the respective variable. The darker colour (right hand side) demonstrates the level of cost increase 
from the baseline due to the respective variable.  
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8.2.2.3. Cost-effectiveness analysis assumptions  
 
Below are the assumptions used for determined the cost-effectiveness of the CTP: 
 
1. Outpatient hospital visit costs for ten years and medication costs for the first five years are 
included in the ten-year cost savings analysis for DopaCell/DopaCell adjusted. 
2. The patients stop taking medication after five years as a result of DopaCell/DopaCell adjusted. 
3. Patients have two years of immunosuppressant use as a result of DopaCell/DopaCell adjusted. 
4. Two device battery changes are included in the ten-year cost savings analysis for DBS as well 
as outpatient costs and medication costs. 
5. Medication costs for DBS decrease from year 6 onwards. 
6. No loss of productivity is experienced with the use of both DBS and DopaCell/DopaCell 
adjusted.  
7. 3.5% discount rate on the medication and hospital costs associated with DopaCell/DopaCell 
adjusted and DBS. 
8. Medication therapy costs increase by 25% every two years over the ten-year period as the 
disease progresses.  
9. A £30,000 per QALY willingness to pay threshold is assumed. 
 
The assumptions utilised in the analysis are based on typical trends and assumptions observed in the 
literature, for instance, the timeframe for hospital visits, DBS device battery changes and use of 
immunosuppressants. Standard practice by HTA agencies such as NICE i.e. the 3.5% discount rate and 
£30,000 per QALY threshold was used. The medication therapy cost increase by 25% every two years 
is based on studies that have demonstrated that patient medication costs increase as the disease 
progresses by 6 – 50 %  per year depending on disease severity. The median value of 25 % was used 
for the analysis. 
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8.2.3. Headroom assessment  
 
The headroom method makes assumptions regarding a therapy’s effectiveness, in the absence of clinical 
data, this tool is particularly valuable for product developers as it provides financial information from 
the supplier/developer perspective. Typically, the headroom assumes maximum effectiveness to 
ascertain cost-effectiveness, under the assumption that; if an intervention is not cost-effective at a 
maximum effect, then it is unlikely to be cost-effective under any other circumstance. This is especially 
the case when the intervention is more expensive than the comparator, which is typically the case for 
CTPs.  
 
To obtain the health utility data the average health utility from medication therapy (0.55) was used to 
determine the difference in health-related quality compared to the DopaCell/DopaCell adjusted. The 
difference was assumed over a ten-year period of fixed health utility due to use of the 
DopaCell/DopaCell adjusted, DopaCell assumes maximum health gains i.e. restoration to 1 QALY 
(Table 52). On the other hand, DopaCell adjusted uses the health utility value obtained from the health 
gains that have been observed from the foetal tissue trials thus far and relating these outcomes to the 
H&Y scale and the corresponding health utility (0.72). The difference in QALY (ΔQALY) was 
calculated as shown in Equation 10. 
 
Table 52. QALY calculation input variables for both the DopaCell/DopaCell adjusted. 
 
 
ΔQALY = (HRQoLND−HRQoLCT) x t = ΔHRQoL x t 
 
Equation 10 
Variable Equation symbol DopaCell DopaCelladjusted
Health Related Quality of Life (New 
Therapy) HRQoLND 1.00 0.72
Health Related Quality of Life 
(Current Therapy) HRQoLCT 0.55 0.55
Difference in HRQoL ΔHRQoL 0.45 0.17
Time in health State (Year(s)) t 10 10
QALY ΔQALY 4.47 1.67
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The ΔQALY was translated into monetary terms by multiplying it with the willingness to pay (WTP) 
threshold of £30,000 for one additional QALY (Equation 11). This determined the potential maximum 
price to the payer, thus the headroom price point of the CTP given the respective level of incremental 
health benefit. The greater the ΔQALY the higher the headroom per patient as shown in Table 53. 
 
Table 53. Headroom calculation input variables. 
 
maxCostPP = ΔQALY x WTP 
 
Equation 11 
 
Obtaining the headroom allows for other predictive outputs such as the potential income that can be 
acquired by the developer given the size of the eligible population of patients. Here an estimate of 100 
patients per year was used based on  treating ~ 1% of the ideal candidate population described in section 
8.1.4. The maximum income was obtained by multiplying the headroom per person with the number of 
potential patients (Table 54) as shown by Equation 12. 
 
Table 54. Market informed headroom input variables.   
 
maxRevenue = maxΔCostPP x N 
Equation 12 
 
Variable Equation symbol DopaCell DopaCelladjusted
QALY ΔQALY 4.47 1.67
Willingness to Pay WTP £30,000 £30,000
Headroom per person maxCostPP £134,100 £50,100
Variable Equation symbol DopaCell DopaCelladjusted
Headroom per person maxCostPP £134,100 £50,100
Number of potential 
patients N (per year) 100 100
Maximum revenue maxRevenue (per year) £13,410,000 £5,010,000
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8.2.3.1. Headroom based financial appraisals  
 
Information on the potential income can provide developers with early hypothetical financial appraisals 
that can be used to estimate the gross profit of their product. These estimates can be made using the 
headroom and information on potential sales volumes and the known or estimated development/ 
manufacturing costs. The potential gross profit and profit margin can be obtained as well (Table 55). 
The gross profit was calculated by subtracting the manufacturing costs from the maximum income and 
multiplying by the years of sales with N patients being treated per year (Equation 13). 
 
Table 55. Gross profit input variables for the first year, based on the treatment of 100 patients.  
  
 
AGP = (maxRevenue−CDD) x V 
Equation 13 
 
Budget impact is a key consideration for developers in the UK market as this can limit the potential 
sales volumes due to caps on the total expenditure per year a single product/intervention can have, as 
set by the NHS. This value is currently set at approximately £20 million, therefore using the headroom 
price points obtained in the present work the number of patients that can be treated per year are: 149 
and 399 for the DopaCell and DopaCell adjusted, respectively.  
Variable Equation symbol DopaCell DopaCelladjusted
Maximum income maxIncome (per year) £13,410,000 £5,010,000
Years of sales with N patients 
(total sales volume) V 1 1
Manufacturing costs CDD £1,000,000 £1,000,000
Gross Profit (per product) - £124,100 £40,100
Gross Profit (%) - 93 % 80 %
Annual Gross Profit AGP £12,410,000 £4,010,000
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8.2.4. Cost-effectiveness analysis 
 
The sections above reported the potential benefits and costs for the patients and developers regarding 
use of DopaCell/DopaCell adjusted compared to the standard of care medication therapy. The following 
sections focus on the potential cost-effectiveness of DopaCell/DopaCell adjusted compared to 
medication therapy and DBS. The analyses performed here aim to provide information for the payer to 
aid in adoption and reimbursement decision making. Similar to the analysis in sections 8.2.2 and 8.2.3 
the results in this section are over a ten-year time horizon period.  
 
8.2.4.1. Cost and savings of the interventions  
 
The cost of each intervention over the ten-year period is shown below, although DopaCell and DopaCell 
adjusted have different effectiveness levels there is no difference in the cost, thus only the DopaCell 
costs are shown. DopaCell expenses in the first year are based on the values shown in Table 49, with 
the addition of £2,655 for cost of medication, totalling up to £35,067. In the second-year outlays include 
the second year of immunosuppressants at £8,000, hospital visit costs at £500 and the cost of medication 
again, totalling up to £11,155. The third to fifth year expenses comprise of medication costs and hospital 
costs discounted at 3.5%. From year six onwards only the hospital visit costs are incurred as patients 
would have stopped taking anti-Parkinsonian medication and immunosuppressants, resulting in a 
significant decrease in costs (Figure 108).   
 
DBS costs include the outlays detailed in Table 50 with the addition of £2,655 for the cost of 
medication, totalling up to £25,641 in the first year. Second to fourth year expenses include medication 
and outpatient hospital visit costs. At year five, in addition to the fourth-year expenses, £2,000 is added 
to account for the cost of DBS device battery replacement. From year six onwards there is a decrease 
in costs as the outlay expense of medication decreases to £1,336. At year ten the cost of another battery 
replacement is added to the outpatient costs, resulting in a slight cost increase (Figure 108). 
 
The medication costs over the ten years are based on the total detailed in Table 51, expenditure then 
increases by 25% every two years over the ten-year period used in the analysis (Figure 108). The 25 % 
increase rate was chosen as it is in line with reported increases in PD cost as the disease 
progresses70,354,358. The indirect costs represent the highest cost proportion as the disease progresses. 
This is due to costs such as personal care and hospitalisation increasing considerably, as the patients 
lose their independence due to increased ‘off’ time and worsening of symptoms.  
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Figure 108. A comparison of the costs of the interventions over a ten-year period demonstrated that 
both DopaCell and DBS have significant decreases in costs at year two and at year five. Medication 
costs are shown to increase over the ten-year period, amounting to £53,962 per year, by year ten.   
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The cost savings were simply determined by taking away the expenditure of the alternative intervention 
(DopaCell and DBS) from the medication therapy costs for each year (Figure 109).  
 
 
Figure 109. Cost savings for both DopaCell and DBS are observed from year 2 onwards, DopaCell 
results in higher savings compared to DBS from year five onwards. The cumulative cost savings over 
the ten-year period are £304,951 and £317,270 for DopaCell/DopaCell adjusted and DBS, respectively. 
Bars above £0 indicate cost savings.   
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8.2.4.2. Cost per QALY comparisons  
 
The cost per QALY for each year was calculated by dividing the cost of the respective year by the 
health utility of the given treatment option, the results were plotted to show the cost per QALY trends 
over a ten-year period (Figure 110).   
 
 
 
Figure 110. The cost per QALY data shows that from year two onwards the DopaCell/DopaCell 
adjusted and DBS all fall under the £30,000 per QALY cost-effectiveness threshold (red dotted line). 
Medication therapy costs per QALY increase over the ten-year period.   
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The average cost per QALY was determined by dividing the cumulative yearly costs by the total 
QALYs over the ten-year period (Figure 111). In order to determine if the CTP would remain cost-
effective at higher prices the model was run with a range of sale prices from £15,000 up to £300,000 
(Figure 112). 
 
Figure 111. Cost-effectiveness ratios (CER) of the CTP under two health utility assumptions (DopaCell 
and DopaCell adjusted) with the use of immunosuppressants, DBS and medication over a ten-year 
period. DopaCell had the lowest cost per QALY, and medication therapy had the highest cost per 
QALY. Red lines represent the lower and upper willingness to pay thresholds, £20,000 and £30,000 per 
QALY (indicated by red dotted lines). All of the alternative interventions are below the two thresholds 
while medication therapy is notably above the upper threshold.  
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Figure 112. Comparison of costs per QALY for DopaCell and DopaCell (adjusted) over a ten-year 
period. Data shows the cost per QALY as a result of different sale prices. DopaCell crossed over the 
£30,000 WTP upper threshold at a sale price of £255,000 (cost/QALY = £31,284) while DopaCell 
(adjusted) crosses the threshold at a lower sale price of £180,000 (cost/QALY = £30,951). 
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Over a ten-year period, the alternative treatments are both cheaper and more effective than the standard 
of care. Thus, it is not necessary to determine the incremental cost-effectiveness as the standard of care 
(Meds) is dominated by DopaCell, DopaCell adjusted and DBS, which means it is the least cost-
effective option in the analysis. (Figure 113). 
  
 
Figure 113. Cost-effectiveness plane shows that DopaCell, DopaCell adjusted (DopaCell ad) and DBS 
treatment options are all more cost-effective than medication therapy (Meds) over the ten-year period 
shown by their position in the bottom right hand quadrant. Therefore, medication therapy is dominated 
by all the other treatment options analysed. Medication therapy is positioned in the top right-hand 
quadrant and above the WTP threshold of £30,000 (represented by the red line).  
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8.3. Discussion  
 
The analysis performed above demonstrates that, under the informed assumptions made, a CTP such as 
DopaCell/DopaCell adjusted would be a cost-effective mode of treatment for PD. In addition, the 
headroom shows that DopaCell/DopaCell adjusted would be a commercially viable product for the 
treatment of PD. Both DopaCell and DopaCell adjusted with their differing levels of QALY gains would 
allow developers to recover the associated development/manufacturing costs and whilst providing an 
adequate gross profit. Furthermore, the CTP can be priced considerably higher than the £15,000 used 
in the base conditions of the analysis model. Analysis of different sale prices revealed that DopaCell 
and DopaCell (adjusted) can be sold at prices up ~£255,000 and ~£180,000 respectively while 
remaining at under £30,000 per QALY over a ten-year period. Both of these figures are substantially 
higher than the headroom prices (£134,100 and £50,100 for DopaCell and DopaCell adjusted, 
respectively), therefore the developer, under the assumptions in the present work, would be able to have 
abundant gross profits and manufacturing cost recovery. A key driver for the high price potential and 
maximum headroom is the large effectiveness gap observed in current PD treatment. Although the 
headroom method operates on the basis of   pessimistic assumptions for the standard of care and 
optimistic assumptions for the new intervention; in the case of PD medication therapy as the standard 
of care, the afforded health outcomes are already minimal. The health utility scores for medication 
therapy are low and offer minimal improvement followed by a decrease in effectiveness in the long 
term. Consequently, the headroom potential for a therapy like DopaCell is high as the effectiveness gap 
that needs to be covered is large, thus even marginal improvements are considerably more valuable than 
the current standard of care.  
 
The use of a CTP e.g. DopaCell/DopaCell adjusted provides a cost-effective alternative for the 
treatment of PD as it offers QALY gains that cannot be provided by current modes of treatment such 
as medication therapy and DBS. Moreover, the quality of life gains reported in foetal tissues transplant 
trials show that patients can regain their livelihood and independence80,373. This would negate loss of 
productivity expenses, which have been identified as the biggest contributor to medication therapy 
costs. The CTP’s potential ability to reduce and/or stop the use of anti-Parkinsonian medication allows 
it to be cost saving, while reducing patient polypharmacy and the side effects associated with PD 
medication therapy. This is significant in the economic impact of PD as the direct annual costs 
associated with comorbidity, symptom management and medical treatment have been reported to 
increase from; ~ £3,000 during the initial stages of the disease to; ~£18,000 at the latter stages of the 
disease357. These costs do not include indirect expense such as hospitalisation costs, lifestyle change 
costs and personal care costs, which are also reported to increase as the disease progresses70,358. 
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 Conversely, whilst the expenditure for DopaCell/DopaCell adjusted is high in the first year (~£35,000) 
it decreases to an average of £1,400 after the patients stop taking immunosuppressants from year 3 
onwards with costs dropping to below £500 by year 10 (Figure 108). The cost per QALY results show 
DopaCell is the cheapest option. DopaCell adjusted, which represents a more realistic QALY gain level, 
is more expensive in comparison to both DBS and medication therapy, however this is only for the first 
two years, after which it is more cost-effective than both DBS and medication therapy. The expenditure 
reduction observed for DopaCell/DopaCell adjusted is ascribed to a decrease in medication costs, lower 
incidence of PD complications, fewer hospitalisations and no loss of productivity being experienced by 
patients. Thus, highlighting the value of treating PD before it progresses to the advanced stages where 
it becomes costlier378. Under the assumptions made in the present work, the use of a CTP for PD would 
provide significant cost savings from as early as year 2, even with the added cost of 
immunosuppressants. 
 
The cost-effectiveness comparison shows that the DopaCell/DopaCell adjusted dominates the current 
standard of care, suggesting it would likely result in a favourable NICE appraisal decision. Furthermore, 
as the QALY gains and improvements on quality of life are greater than those provided by DBS, 
DopaCell/DopaCell adjusted could still be recommended for adoption when appraised against DBS. 
Recommendation would be likely in the idealist case of DopaCell and in the case of DopaCell adjusted 
with ICERs of £3,924 and £22,422 respectively, when analysed against DBS for cost-effectiveness over 
a ten-year period.  
 
As demonstrated by the sensitivity analysis, some variables have a significant influence on the cost of 
the treatment mode. For medication therapy, loss of productivity was the most influential cost variable, 
highlighting the importance of including indirect outlays in cost-effectiveness analysis. This is apt for 
chronic diseases such as PD that have a high societal burden on top of the direct medical expenses.  
Therefore, including indirect expenses better represents the true cost of the disease, especially when 
analysed over a long period, such as the ten-year period used in the present work. Sensitivity analysis 
results of DopaCell/DopaCell adjusted and DBS outlays also showed their respective major cost 
influencers, which were miscellaneous (immunosuppressants) and device expenses, respectively 
(Figure 105 and Figure 106). For DopaCell/DopaCell adjusted, a point to consider is as to whether the 
expense of the immunosuppressants should be included in the cost-effectiveness analysis; as without 
them the DopaCell/DopaCell adjusted would be ~ 25% cheaper with the same QALY gains, making it 
even more cost-effective. From a payer’s perspective, it would be assumed that they would require all 
expenditures associated with the use of the therapy to be included, in order to fully evaluate the true 
cost of adopting DopaCell/DopaCell adjusted as a mode of treatment. Thus, shorter lengths of 
immunosuppressant use would result in higher cost-effectiveness/savings for DopaCell/DopaCell 
adjusted. 
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Due to the relatively low costs of the DopaCell/DopaCell adjusted assumed in the analyses, it could be 
eligible for reimbursement under a range of different payment mechanisms. Managed entry agreements 
(MEAs) might not be necessary as the costs are relatively low and the budget impact is not high given 
the population assumed in the analysis. As CTPs in general are still an emergent mode of treatment, an 
annuities-based payment structure could be used as means of risk mitigation by the payer328,334. If 
DopaCell/DopaCell adjusted is likened to DBS in terms of resource use, then the procedure employed 
to administer the DopaCell/DopaCell adjusted could be funded by the NHS Commissioning Board and 
reimbursed using the appropriate healthcare resource group374 (section 7.1.1.3.a.). Thus, there is scope 
for a pre-existing reimbursement funding pathway for the CTP to follow, which is different from the 
Cancer Drug Fund currently being used for CAR-T cell and gene based therapies329.  
 
8.3.1. Limitations and considerations about the analysis  
 
As with any model based on assumptions, there are certain limitations that cannot be overcome but 
should be noted. A major limitation of the analyses carried out is that the DopaCell data assumes full 
recovery and QALY gains which is not likely to be achieved. However, the purpose of this 
overestimation of efficacy is to ascertain if the DopaCell could ever a be cost-effective treatment option. 
Therefore, full gains are presumed on the basis that if the product is not cost-effective at full QALY 
gains, it is unlikely to ever be cost-effective. DopaCell adjusted aims to address this limitation by 
providing a scenario when the CTP provides more realistic QALY gains. These gains are informed by 
available data from foetal tissues transplant trials, which have a similar mode of action to the 
DopaCell/DopaCell adjusted, however the cell source is hESC (for DopaCell/DopaCell adjusted). 
 
 Another limitation of the analysis is the use of a static healthy utility value (0 % discounting rate) for 
all modes of treatment. In particular, for medication therapy this overestimates its costs-effectiveness 
as it is putative that health utility decreases overtime, with the use of medication as the patient 
experiences reduced response and efficacy. Thus, the cost per QALY would increase over the ten-year 
period as the cost increases and the healthy utility decreases. Lastly, the use of immunosuppressants 
until year two could be considered an overestimation as the typical length of use is 6-12 months. Thus, 
DopaCell/DopaCell adjusted would become cost-effective at an earlier time point, if shorter time 
lengths of immunosuppressant use are employed.  
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8.3.2. Adoption of the DopaCell/DopaCell adjusted under the context of the CHART workshop 
 
The following section aims to evaluate the adoption potential of DopaCell/DopaCell adjusted by 
employing the key points of consideration from the six adoption challenge themes from Chapter 7. 
 
Evidence of clinical effectiveness – DopaCell/DopaCell adjusted would face similar challenges to the 
CAR-T therapies in providing long-term evidence of clinical effectiveness. Using the preclinical work 
that has been carried out to demonstrate that hESCs are comparable to the foetal tissue cells, it could be 
inferred that the in vivo efficacy would translate for hESCs in human subjects. Currently only surrogate 
data from the foetal tissue clinical trials can be used as a measure of the efficacy of DopaCell/DopaCell 
adjusted. Thus far, some patients have shown notable clinical improvements and engrafted cells have 
been shown to remain intact for up to 24-years. However, these results have been obtained from clinical 
trials of small sample sizes (7 – 50 participants)84,384. In addition, the lack of randomised clinical trials 
(RCTs) would not be deemed favourable by regulators and payers, thus RCTs would need to be 
employed to ensure robust evidence generation. Progression free survival (PFS) would need to be 
demonstrated, however the length of adequate PFS would need to be established as PD is a disease of 
the elderly, thus the PFS could be shorter than other illnesses i.e. paediatric and cancer illnesses.  
 
Health economics – health economic evaluation of DopaCell/DopaCell adjusted would not be different 
to how other health technologies are evaluated. The NICE and CHE reports have demonstrated that the 
current methods of evaluation were applicable 328,339. The main challenge from an evaluation 
perspective is the uncertainty associated with a novel therapy, particularly if there is limited evidence 
of long-term clinical effectiveness. 
 
Social value towards regenerative medicine – as a form of treatment DopaCell/DopaCell adjusted is 
likely to be looked upon favourably as there is currently no mode of treatment that would offer the 
potential neuro restorative effects of DopaCell/DopaCell adjusted. PD patients and charities are 
advocates for CTP based treatments, this is evident from the encouragement and funding of research in 
the area stem cell therapies for PD. In addition, there are commercial companies such as BlueRock 
Therapeutics that have funded with vast amounts of money ( USD 225 million) to progress CTPs 
treatments385,386. For instance, their first product in their pipeline is a H9 hESC derived dopaminergic 
neuro progenitor product, similar to DopaCell/DopaCell adjusted, which will be commencing first-in-
human clinical trials in 201984,387.  
 
Health Technology Assessment – similar to the health economics, there would be no difference in 
methodology employed for DopaCell/DopaCell adjusted in terms of the HTA process. The 
requirements to demonstrate value would still be the same in the case of HTA through NICE or 
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CADTH. Under the CADTH deliberative framework, DopaCell/DopaCell adjusted would be evaluated 
as a clinical intervention therefore additional elements such as implementation would need to be 
considered, in addition to the core measures of cost and clinical effectiveness.   
 
Briefly, using NICE’s factors for value (Figure 100) (clinical effectiveness, cost effectiveness, end of 
life, innovation, degree of need, equity and non-health objectives) DopaCell/DopaCell adjusted would 
be cost effective as demonstrated by the analysis performed above. Assuming similar results to the 
foetal trials, DopaCell/DopaCell adjusted would result in clinical effectiveness and potentially extend 
patient end of life, particularly in terms of quality of life. Due to the difference in mode of action and 
the potential to be neurorestorative, DopaCell/DopaCell adjusted would likely provide value in terms 
of innovation. In addition, DopaCell/DopaCell adjusted could meet a high degree of need in a disease 
area were symptom management is typically the best that can be achieved. Both equity and non-health 
objectives are difficult to determine as they are subjective to the internal priorities and organisational 
strategies of healthcare providers such as NHS England and its clinical commissioning groups. Overall, 
under the cost and evidence assumptions made, DopaCell/DopaCell adjusted would be likely to undergo 
a favourable HTA through NICE. In addition, DopaCell/DopaCell adjusted is cost effective at a range 
of different price ranges and even at the realistic health utility level of DopaCell adjusted. This is in 
comparison to the CTPs such as Kymriah and Yescarta which have very high price tags of up to 
£282,000388. 
 
Payment system mechanisms – as highlighted in Chapter 7, sustainable methods of payments for CTPs 
are yet to be established. In the case of DopaCell/DopaCell adjusted how it would be commissioned 
would depend on the price that is offered to the payer. The prices shown in the present work have ranged 
from £15,000 to a realistic £180,000 per patient. Thus, depending on the position of the price on this 
spectrum, routine commissioning could be possible, potentially even without the use of MEAs assuming 
a lower price and sufficient evidence generation. Under the assumption that DopaCell/DopaCell 
adjusted is similar to DBS in terms of resource utilisation, it could be funded via payment for the 
appropriate Adult Neurosurgery and Neurosciences Clinical Reference Groups used by the NHS 
Commissioning Board. However, if a higher price tag is chosen (i.e. higher than the ~£23,000 price of 
DBS), MEAs and commercial agreements would be required, how these commercial agreements would 
work is unknown as the agreements are confidential, as in the cases of Yescarta and Kymriah175. 
 
Adoption and implementation – many of the lessons from the CAR-T therapies examples in Chapter 7 
would need to be considered for DopaCell/DopaCell adjusted, particularly in terms of surgical capacity 
and personnel training. However, DopaCell/DopaCell adjusted is arguably a well-placed CTP for 
adoption, the themes explored above demonstrated that it can be assessed and would potentially have a 
favourable recommendation on the condition that sufficient and robust evidence could be generated.  
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DopaCell/DopaCell adjusted’s similarity to DBS in terms of being a surgical intervention would suggest 
that it could be easily implemented using the current care pathway employed by DBS. Issues such as 
personnel training and infrastructure would still need to be considered, particularly in terms of the 
manipulation and supply chain logistics associated with the cells themselves, as they differ significantly 
to the DBS device considerations. Therefore, implementation would need to be focused on appropriate 
technologies for handling the cells to ensure they are thawed and formulated appropriately without 
impacting their quality, efficacy and safety profile. The allogenic nature of DopaCell/DopaCell adjusted 
presents the opportunity for a cryopreserved off-the-shelf product, which would make supply chain 
logistics much simpler and increase access to centres further away from manufacturing sites. This could 
also reduce costs and reduce waiting times for product access, which is presently a challenge for CAR-
T therapies due to their complex autologous manufacturing process.  
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8.4. Conclusions  
 
The analysis carried out has demonstrated the potential value and cost-effectiveness of a CTP for the 
treatment of PD. In comparison to the available treatment strategies, a CTP for PD could offer improved 
efficacy, clinical improvements, cost savings and a neurorestorative mode of action. This would benefit 
patients in terms of their health-related quality of life and reduce the economic burden associated with 
the treatment and management of PD. The headroom assessment and cost-effectiveness analysis 
provided information to answer the questions previously posed in section 8.2 (page - 317 -). 
 
• What is the price potential of a hESC-based therapy for PD? 
 
The potential price would vary on the level of efficacy achieved by the therapy, the headroom 
analysis performed here shows that the price could be between £50,000 – £134,000 per patient. 
This price is significantly lower compared to other cell and gene therapy products that have 
been recently approved such as Yescarta and Kymriah at £282,000 (Kymriah)388. However, the 
price setting results demonstrated that prices of between £180,000 to £255, 000 could be used 
while remaining cost-effective. 
 
• Would a hESC-based therapy for PD be cost-effective?  
 
Yes – the results demonstrate that a CTP such as DopaCell/DopaCell adjusted would be a cost-
effective treatment option for PD. Even with the use of immunosuppressants 
DopaCell/DopaCell adjusted dominates medication therapy, which is the current standard of 
care. In addition, the CTP is more cost-effective than DBS in the long-term and provides greater 
cost savings. This is rare for CTPs as they are often costlier than the standard of care, thus a 
CTP for PD would be likely to receive a favourable recommendation from NICE given the 
assumptions made, particularly as both DopaCell/DopaCell adjusted are below the £30,000 
WTP threshold. In addition, sale price analysis shows that the CTP can be priced at up to 
£255,000 per patient and still be cost-effective over the ten-year period analysed. 
 
• Could a hESC-based therapy lower the economic burden of PD?  
 
Yes – a CTP mode of treatment for PD would provide clinical and quality of life improvements 
that would reduce the majority of costs associated with PD. This is particularly the case as PD 
is a chronic disease, thus in the long-term significant cost savings would be realised by retarding 
the progression to the advanced and costlier stages of the disease. 
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Similar to the aforementioned cost-effectiveness analyses (8.1.2. Health economic evaluations for PD 
treatment strategies), the DBS and DopaCell analysis carried out in the present work has demonstrated 
that both interventions would be cost-effective over the use of medication therapy. Medication therapy 
such as L-DOPA has been in use before health economic evaluation became a prominent exercise. Thus, 
it can be inferred that if medication therapies such as L-DOPA were subjected to an economic 
evaluation in the present day, there is a high probability they would not be considered for adoption as 
they offer minimal health benefits and result in incremental costs in the long term. As a result, they 
would not be cost-effective, due to their high costs and inability to be disease modifying or to 
significantly delay the progression of the disease and worsening of symptoms. 
  
The climate for cell and gene therapies is currently emergent however, for the first time since the advent 
of the area there is continuing and improved understanding of the adoption and reimbursement pathway 
of these therapies. This is due to the precedence being set by products such as Yescarta and 
Kymriah175,283,328,388. Whilst a large number of assumptions have had to be made in the present work, it 
is likely that a therapy such as DopaCell would be adopted based on the adoption considerations 
addressed in Chapter 7. A CTP such as DopaCell/DopaCell adjusted is well placed for evaluation and 
adoption, particularly if it can afford health benefits and cost savings over a prolonged period, which 
are unattainable using current standard of care approaches. The true reality of these potential benefits 
will only be realised once clinical trials using hESCs have been performed, however foetal tissue trials 
offer hope as patient health improvements have been achieved and sustained over prolonged periods 
for some patients. 
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Chapter 9. Thesis conclusions   
 
 Chapter 2  
 
The present work used a multidisciplinary approach to investigate the translational requirements for 
successful product realisation of a dopaminergic cell therapy product (CTP). The scope for the use of 
CTPs for Parkinson’s disease (PD) was discussed and highlighted the limited benefits of current modes 
of treatment that only manage the symptoms of PD. A CTP mode of treatment was shown to have the 
potential to offer quality of life improvements that are unparalleled by therapeutic strategies such as 
medication therapy. The use of CTPs does not stop the progression of the disease, thus is it not a cure, 
however the engraftment of ventral mesencephalic dopaminergic (vmDA) neuroprogenitors results in 
restoration of native dopaminergic circuitry. This is a neurorestorative mode of action that significantly 
retards the progression of the disease and can potentially delay the onset of PD motor symptoms. This 
is a powerful mode of action, especially as the addition of ten to twenty years of improved quality of 
life and reduced medication intake would be invaluable for PD elderly patients. 
 
Progress has been made in deriving cells for engraftment and a range of different cell sources have been 
explored in the literature. The present work has focused on the methods that mimic embryogenesis, the 
resultant protocols have been through many iterations over the last two decades (Figure 8). Key markers 
such as FOXA2 and cell characteristics such as axon projection have been identified as critical quality 
attributes (CQAs) in the preclinical studies that have been employed. However, the challenge remains 
in being able to produce the cells to meet the CQAs in a highly reproducible, standardised, scalable and 
cost-effective manufacturing process, while satisfying regulators in terms of product safety and 
efficacy. 
 
Section 2.3. Manufacturing considerations explored some of the key manufacturing process 
considerations concerning the production of CTPs. Assay generation to ensure product purity and 
appropriate product identification were some of the key considerations. In addition, potency and safety 
were highlighted as an integral elements of CTP development, specifically when applying for regulatory 
approval. In particular, potency forms the basis of process understanding and closely involves concepts 
such as Quality by Design (QbD) and Design of Experiments (DoE). The role of effective and efficient 
supply chains was also addressed and crucially the role of technology in the development of CTPs. 
Fundamentally, it is necessary to consider all of these elements at an early stage of the product 
development timeline, as means of having a proactive stance and to mitigate risk. With complex 
products such as CTPs, information that is well characterised and well understood facilitates in depth 
process control and understanding that allows developers to make informed changes based on a defined 
design space. Ultimately this can help to increase the chances of commercial and regulatory success.  
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Commercial success is not guarantee even if a robust scientific program has been used that achieves 
regulatory approval. A product’s commercial success is determined by its ability to enter the market, to 
reach patients, to benefit patients and finally to be reimbursed. Reimbursement is a necessary goal to 
achieve as the development costs incurred need to be recovered by the developers in order to fund new 
research and provide gross profits. Health economics and economic evaluations are the concepts that 
must be addressed in order to determine the commercial viability and cost-effectiveness of a healthcare 
product. The basic concepts of health economic decision modelling and the headroom methods were 
discussed in Chapter 2 (section 2.4) to provide understanding of the essential considerations around the 
topic of health technology adoption. Issues such as evidence generation, (clinical trial designs), 
technology appropriateness and budgets concerns were touched upon to highlight the considerations for 
developers as payers determine the cost effectiveness of their products. For payers new technologies 
need to provide patient benefits at a cost that satisfies their budgets. On the other hand, developers want 
their new technologies to be adopted and reimbursed as much as possible. Thus, a difficult decision 
must be made to satisfy both parties while benefitting the patients. 
 
Chapter 4  
 
Hypothesis: Standardised cell culture procedures result in less variation in growth and cell 
characteristics.  
 
For successful product manufacture, the standardisation of processes and quality is desired, for CTPs 
this is not only desired but imperative as the products will end up being administered to patients. The 
work in this chapter highlighted the challenges associated with biological and protocol variation that 
has hampered the robust standardisation of CTPs. The use of the EC 2102Ep cell line illustrated that 
even when a putative reference cell-line is used, there is innate biological variation that cannot be 
controlled. This was highlighted by the use of data driven, robust and standardised culture conditions 
that provided an insight into some of the behaviours and characteristics of the cells. Importantly, the 
feeding regimes that the cells are exposed demonstrated a significant effect on SMR and phenotypic 
marker expression. Initially, seeding density was proposed to a major source of culture variation, 
however the experiments illustrated that while density has a role in the observed variation, it is actually 
a complex interaction between density and feeding regime that impacts cell growth, gene expression 
and cell phenotype. The longitudinal experiment highlighted the value of understanding the effects of 
long-term passaging as this in itself resulted in cell characteristic changes. For allogenic therapies that 
might require hESCs pre-culture processes, the effect of the pre-culture period will need to be 
understood so that the cells are guaranteed to have the same CQA upon initiation of all differentiation 
process. 
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The variation observed in this chapter demonstrated the issues that need to be addressed by the cell 
therapy industry (CTI) in order for products to be developed in a well standardised manner for better 
translation. Increased standardisation and process control allow for CQAs to be achieved, which is 
important for products that will be introduced to a patient’s body. This will become more of a challenge 
as the industry moves towards allogenic therapies as it will be imperative to ensure batch to batch 
variation is kept as low as possible and product potency is guaranteed in every release. Modes of 
standardisation that are employed will need to ensure that they have process monitoring capabilities to 
ensure that the product is within its CQA tolerance range.  
 
To further aid in variation reduction, human operators will need to be removed from processing cells 
as much as possible, systems such as the Miltenyi prodigy are potentially well placed to assist in the 
removal of operator variation. Automation along with well-defined and standardised cell-culture 
protocols should result in less variation in growth and cell characteristics. However, biological variation 
will still remain a challenge to address, nonetheless the removal of operator variation results in the de-
compounding of both sources of variation. This is integral for reproducibility and successful use of cell 
material in cell therapy manufacturing. 
 
Chapter 5 
 
Hypothesis: Variation of measured cell outputs can be reduced by characterising input cell material 
and standardised procedures.  
 
The importance of standardisation was highlighted in Chapter 4; standardisation is also crucial to the 
culture of input cell material for further processes. Critical material attributes (CMAs) of inputs such as 
pluripotent cells are important to the manufacturing process, the pluripotent cells that are used in the 
differentiation should be of the best quality. However, there is limited guidance as to what the best 
quality should be, thus the work in this chapter focused on creating a profile of characteristics that could 
be used to benchmark good quality input cells. This was important as the growth dynamics and 
characteristics of the cells prior to differentiation process should be understood and robust CQAs should 
be established. The culture process of the pluripotent cells should also be standardised to ensure that 
input cell material is consistent prior to differentiation, as inconsistency in the input cell material would 
inevitably result in variation of the end product. This is typically the case in autologous therapies such 
as CAR-T therapies where patient cell variation is common, resulting in differences in cell quality and 
cell yields. For allogenic therapies such as the candidate therapy, this can be easily mitigated by 
standardisation of input CMAs to ensure product quality consistency.  
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The range of experiments carried out established optimal culture parameters such as passage length, 
seeding density and feeding regime that would result in consistent output pluripotent cells for the 
differentiation. The reduction of passage length and feeding frequency that was demonstrated is 
desirable in product manufacturing as it uses less resources and thus reduces costs. Additionally, in a 
manual cell culture process this would result in less operator intervention, which would mitigate the 
risk of variation.  
 
Chapter 6  
 
Hypothesis: Multi-parameter analysis and high-resolution phenotype analysis can provide information 
on differentiation trajectory, critical process parameters and critical quality attributes. 
 
Chapter 6 illustrated that CHIR99021 is a major driving force for the differentiation process. In addition, 
SHH-C24II, by itself and in combination with CHIR99021, is important for obtaining cells with the 
putative FOXA2 dopaminergic marker. PAX6 exhibited interesting trends, particularly at the earlier 
stages of the differentiation process as its express or lack of, can potentially be used to determine the 
phenotypic trajectory of the cells. This predictive capability can potentially be used as an early screening 
assay to ensure that the cells are progressing towards the desired CQAs, particularly in terms of the 
determinant phenotypic cell markers. Density and nutrient supplementation were also key factors for 
successful cell survival and differentiation, the DoE results illustrated the relationship and complex 
interactions of the various factors involved in the differentiation process. These complex interactions 
need to be well characterised and linked to both the critical process parameters (CPP) and CQAs to 
ensure that the drivers of successful differentiation are identified and controlled.   
 
The appropriateness of characterisation tools and cell markers was an important element highlighted in 
Chapter 6. The flow cytometry panels utilised, both the Miltenyi Biotec and in-house protocol, 
illustrated that the distinguishing vmDA markers FOXA2 and OTX2 were not exclusive to the desired 
cell vmDA cell type. Both markers were found in pluripotent cells and in cells differentiated under a 
range of culture conditions, suggesting that the markers do not adequately discriminate/select for the 
desired cell type. This presents a fundamental issue to address, as only homogenous cell populations 
should be introduced to the patients, thus it is important to have discriminatory characteristics that can 
be used to sort the cells. Moreover, as cell identification and sorting information/assays form part of the 
technical dossier for the product, it is important they are robust and validated as early as possible. 
 
It is evident from the work carried out that cell differentiation is a very complex procedure that requires 
the consideration of various different processes and obtaining the correct cell phenotype is integral to a 
successful differentiation. In combination with the consideration of process standardisation, being able 
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to track and understand the trajectory of the cells in the differentiation process offers an invaluable 
ability to validate CQAs and their impact throughout the process. This facilitates data driven process 
control, which can allow for proactive decision making based on the behaviour of the cells at an early 
stage. For instance, a decision to terminate or progress with a differentiation process can be made using 
early signifiers to predict whether or not the cells are on the correct trajectory. This capability would be 
enabled by integrated process analytic technologies that allow for in-process sampling and monitoring.  
This ability is one that the CTI is striving for as it permits for enhanced data driven go/no-go process 
decision making and process control.   
 
The lack of adequate process transfer experienced in the present work offers a valuable lesson about 
the importance of robust process transfer activities. In addition, the value of validating processes before 
they are transferred to other parties is highlighted as this would allow for more streamlined process 
development activities. The complexity of the differentiation process and the multiple parameters 
involved means that it is imperative to remove any sources of ambiguity that could lead to process 
variation and ultimately product variation. Results from Chapter 6 revealed that the protocol conditions 
as prescribed in the published literature did not result in successful differentiation and cell survival.  
Significant changes to the protocol had to be made by the author and others within the research group 
at Loughborough University, in order for the cells to survive and differentiate towards the desired 
vmDA phenotype. Moreover, this highlights the necessity of a vigorous process transfer procedure in 
order to ensure that results can be recapitulated by different researchers in different institutions, which 
is imperative for process development and protocol translation.  
 
Therefore, standardisation is yet again highlighted as a key factor to consider, in addition the use of a 
DoE approach demonstrates the value of experimental designs that facilitate robust data collection 
which provides in depth knowledge of the CPP and CQA interaction. Employment of such experimental 
designs at an early stage of protocol and product development is encouraged as it permits for well-
informed product development in a validated manner. Furthermore, aspects such as the equipment used, 
staff training procedures and supply chain should be validated through comparability studies, to ensure 
that the resultant protocols are inherently robust enough to produce the desired end product. This will 
greatly assist future activities such as process transfer, protocol translation and scale up, which are vital 
activities for successful process development and product realisation of CTPs.   
 
Chapter 7  
 
Hypothesis: Cell therapy products are more complex than pharmaceutical therapies, therefore they 
should be evaluated differently for HTA, reimbursement and adoption.  
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Chapter 7 illustrated that there are challenges that needs to be tackled regarding CTP adoption, however 
the majority of these challenges are not unique to CTPs. The current methods of evaluation are 
applicable to CTPs, the biggest challenge for these novel therapies is providing evidence that reduces 
the uncertainty of their long-term effects. The generation of evidence of clinical effectiveness needs to 
be improved by ensuring trial designs employ robust controls and increase their sample sizes while 
collecting data in the relevant setting. In addition, trials should conduct comparisons with established 
practice and evaluate relevant outcomes based on their relationship to health-related quality of life and 
mortality. The use of modelling approaches based on clinical plausibility and presently available data 
can help to deal the uncertainty of evidence at the time of submission. Furthermore, incentives for real 
world evidence capture should be established to ensure that data is gathered and can be used to further 
evaluate the therapies for their long-term clinical effectiveness and adverse effects. The post-appraisals 
evidence of CAR-T therapies, albeit within a short period of time, has shown that patient selection is 
important; in addition, both rates of immunosuppressant use and readmission were higher than in the 
clinical trial setting. This highlights the value of data obtained in real world context, which can only 
add to the depth of knowledge and evidence about the use of a technology. 
 
The implementation of CTPs is an area that will require concerted efforts from multiple stakeholders to 
ensure that the pathway for CTPs is efficient and effective. As the CTI develops there needs to be 
greater interaction with policy makers, as political will is essential for research to progress into 
meaningful efforts. For instance, ‘top level’ buy-in from policy makers has been a key driving force in 
the rapid adoption of CAR-T therapies in the UK, where commercial deals were established within ten 
days of approval175. This illustrates the value of support from policy makers in order to profoundly 
tackle and amend the areas that need changes and adjustments to better support CTP implementation. 
One area identified in the workshop, is the need to improve patient management and data management 
to aid in evidence generation and facilitate outcome-based payment mechanisms. This is a significant 
challenge in a system such as Canada and will require interprovincial efforts to appropriately and 
adequately share data. This is essential as CTPs such as CAR-T therapies necessitate a collaborative 
effort to avoid duplication and ensure both value and equity. In the UK, it is important to effectively 
harness the value of the one payer system, to efficiently capture patient data and effectively operate 
outcome-based reimbursement models.  
 
Payment mechanisms remain a challenge that needs further clarification, in addition the sustainability 
of methods currently used to pay for expensive therapies will need to be evaluated, prior to the onset of 
more CTPs being approved. This will unavoidably entail creative payment models that are inspired by 
other industries such as the mining, finance and aeronautical industries, that finance high value projects 
and activities. This is vital as funding pots such as the Cancer Drug Fund are not a realistic solution for 
routine commissioning of all potential CTPs. 
 
 
 
 
 
- 353 - 
 
Ultimately, adoption is only necessary if the technologies in question can demonstrated value and 
address an unmet clinical need where other options have failed or are unavailable. This is because CTPs 
are very complex therapies that are concomitant with high risk and uncertainty; which can difficult to 
mitigate and would have burdensome high costs associated with disinvestment. 
Chapter 8  
 
Hypothesis: A cell therapy product treatment strategy can provide cost savings in comparison to 
current standard of care for PD  
 
Assessment of the hypothetical DopaCell CTP demonstrated that under the assumptions made, a CTP 
would be a cost-effective treatment for PD. Compared to the other options such as deep brain 
stimulation (DBS) and mediation therapy, DopaCell could result in significant cost savings even with 
the use of immunosuppressants. The advantage of DopaCell compared to DBS, which is also cost 
saving, is the potential neurorestorative mode of action that would lead to quality of life improvements 
and slow down progression of the disease to its advanced and costlier stages.  
 
The costs and finances of DopaCell are favourable for both the payer and manufacturer as both 
DopaCell and DopaCell adjusted are below the £30,000 cost-effectiveness threshold at prices up to 
£255,000 and £180,00, respectively. If the more realistic case of DopaCell adjusted is used, a £180,000 
price tag per patient would allow for significant gross profits while affording health gains currently 
unattainable through the standard of care. Given the £15,000 to £180,000 price setting range, a 
commercial deal would be necessary to obtain a price agreement that equates to value for both the payer 
and the manufacturer. Arguably, the lack of disease modifying therapies for PD, allows 
DopaCell/DopaCell adjusted to provide value by addressing an unmet clinical need and non-health 
objectives such as lowering the economic burden of PD, which medication therapy currently does not 
do.  
 
DopaCell/DopaCell adjusted is well placed for evaluation and adoption, however the success of such a 
therapy relies on an efficient manufacturing process and clinical trials that can generate robust evidence 
to appease both the regulators and the payers. Given the progress that has been made by BlueRock 
Therapeutics, it will be soon become evident how far a CTP for PD is for being a product and how cost-
effective it can be. 
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Overall Summary  
 
There is a clinical need for better treatments for PD that can reduce patient disease burden, improve 
quality of life and reduce the economic burden of PD on both patients and healthcare providers. One, 
promising mode of treatment is a CTP, this has the potential to be a both clinically and commercially 
viable option. There are currently several CTPs for PD at different development and clinical trial stages, 
illustrating the inclination towards this mode of treatment84. This has been intensified by the recent 
approval of products such CAR-T therapies, which have galvanised the CTI. Through the different 
aspects explored in the present work, key translational requirements for a manufactured dopaminergic 
neuroprogenitor CTP and CTPs in general have been identified.  
 
Progress has been made in terms of understanding the key process parameters for the differentiation 
process, lessons such as the importance of density and small molecule concentrations have highlighted 
the sensitivity of the differentiation to process parameters. This was illustrated by the range of 
experiments that demonstrated poor growth and/or cell death due to cell densities and small molecule 
concentrations that were inadequate for the process. Process transfer activities should be robust and 
validated to ensure that process development activities are streamlined and do not have to establish the 
CPPs, which is a protocol development activity. This has been shown to be necessary in the present 
work due to differences in cell behaviour and outcomes while following shared and published protocol. 
This has been the case on two occasions, using the NIBSC protocol and also the Lund protocol, 
highlighting the importance of protocol standardisation. In particular, the present work has shown that 
different seeding densities and feeding strategies can affect cell quality in terms of cell growth, cell 
viability, cell phenotype and cell metabolic rates. Thus, addressing process transfer, protocol 
reproducibility, process control, CQA definition and standardisation are activities that have been 
identified as key requirements in the present work, that should be focussed on at the earliest convenience 
to enable successful CTP translation.  
 
Speaking to regulators, HTA agencies and payers as early as possible and throughout the product and 
clinical development pathway is encouraged. In addition, iterative and informative process 
understanding should be carried out in order to facilitate robust and data driven product realisation. 
Early engagement with the adoption pathway is a crucial step for manufacturers to take as early as 
possible, both NICE and CADTH’s scientific advice programmes provide a platform for manufacturers 
to better understand the HTA evidence requirements prior to submission. There are many considerations 
that manufacturers need to account for at an early stage to ensure that they are well placed for regulatory 
and reimbursement assessment. For instance, it is evident that different countries have different costs 
associated with the treatment of different diseases such PD. Thus, different HTA and reimbursement 
mechanisms need to be considered at an early stage as economic evaluations would differ in each 
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country. Therefore, using techniques such as the headroom method and early discussions with payers, 
developers can determine which markets to enter and in which order. An informed sequence of market 
authorisation and reimbursement in different countries could facilitate in evidence generation, prior to 
applying to other payers from different countries, which might require more rigorous evidence of 
clinical effectiveness and cost-effectiveness. Overall, western countries spend more money on the PD 
care and therefore have the potential to result in higher reimbursement as they are likely to benefit from 
greater savings, as a result of offsetting costs spent on continuous treatment of such a progressive 
chronic disease.   
 
Price and affordability have been identified as factors hampering the adoption and reimbursement of 
CTPs. In some cases, it is unclear why the therapies are as expensive as they are, arguably the 
autologous nature of products such as CAR-T therapies inherently results in high cost of goods. In 
addition, due to their per patient manufacturing process, there are no economies of scale to offset 
production costs. However, it is probable that as the CTI develops and more therapies become available, 
costs will become lower. This is likely to the case for therapies such as DopaCell which would be 
allogenic with the potential of batch production that would reduce the per batch cost of goods. The 
challenge that will be faced at the juncture of a higher number of approved CTPs will be how to 
adequately implement and adopt such novel and destructive technologies into the healthcare systems. 
A broader framework to approaching implementation and adoption is a key requirement, one that 
demands coordinated efforts between policy makers, agencies, practitioners, patients, payers and 
industry promotors (i.e. the Cell and Gene Therapy Catapult and Canada’s Centre for 
Commercialization of Regenerative Medicine) to better facilitate change in a concerted, efficient and 
effective manner. Thus, another key translational requirement for CTPs is the engagement of relevant 
stakeholders to ensure the challenges of CTP adoption are on their agendas, particularly at the policy 
level, in order for meaningful change and support to be given to the CTI 
 
The present work has explored protocol understanding, optimisation and standardisation; economic 
evaluations and the state of reimbursement and adoption for cell therapies. The prominent message 
from these themes is that the scientific rigour and commercial viability of a product should be 
contemplated as early as possible. This is with the aim of facilitating the translation of basic scientific 
research into valuable and adoptable products, that can deliver on the promise of providing superior 
treatments and health benefits to patients in need.  
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Future Research  
 
The translational requirements identified in the present work have progressed understanding of the 
vmDA differentiation process, the potential cost effectiveness of a therapeutic PD CTP and the state of 
reimbursement and adoption for CTPs. Simultaneously the present work has also opened up further 
areas of exploration.  
For example, the H9 pluripotent cell culture parameters identified in Chapter 5 would need to be 
validated. Further comparisons between the control condition and  route 2 would need to be carried out, 
ideally in a longitudinal experiment as a means of observing the effects that route 2 might have on the 
long-term behaviour and characteristics of the cells. Orthogonal analysis of the SGR, cell viability, 
metabolism and phenotype would need to be performed, additionally gene expression and karyotype 
analysis should be employed to ensure that no fundamental and/or detrimental effects arise as a 
consequence of the route 2 parameters.   
 
Further research based on the present work will need to robustly identify the process and protocol 
parameters that can consistently deliver the desired vmDA CQA profile. Building on from the definitive 
screening studies in Chapter 6, the best conditions from the studies such as M1 and C1 would need to 
be further validated and optimised. Once optimised, rigorous characterisation studies would be 
employed to ensure that the CQA profile can adequately inform product purity, safety and potency 
assays. These assays could then be used to devise QC, QA and product release criteria within the 
preclinical stages of development. In addition, the robustness of the conceived protocol would need to 
be validated by assessing the cells in a preclinical setting, to ensure potency and functionality in an 
appropriate PD animal and/or disease model. This would ascertain whether or not the optimisation 
process would have yielded cells of equivalent or superior quality, functionality and potency.   
 
Another area of further research is the identification of superior phenotypic markers that can better 
distinguish the desired vmDA cells from other contaminant neuronal populations and pluripotent cells. 
This is crucial as some of the current markers used in the panels are expressed in both pluripotent and 
differentiated cells (even those differentiated under suboptimal conditions). Potential markers for 
exploration would be GBX2,  BARHL1 and LMX1A. In addition, studies could be conducted to further 
understand the implication of PAX6 presence/absence on the differentiation trajectory.   
 
Chapter 7 highlights that the key steps to progressing the adoption and reimbursement of CTPs will 
require appropriate engagement with policy makers; identifying advocacy steps; identifying partners; 
improving the clinical evidence base; and improving the scientific/research agenda concerning CTP 
adoption and reimbursement. Targeted approaches in engaging politicians to pay attention and invest 
in the infrastructure required to facilitate the adoption and implementation of ATMPs with the 
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appropriate evidence base and HTA are necessary next steps. One such approach will be the final output 
of the white paper being written as a result of the work in Chapter 7. From a more technical perspective, 
further analysis is needed regarding creative payment models. This can be achieved by looking to other 
industries, for example, accounting, natural resource extraction, aerospace, risk fund hedging, high 
financing, other, and partnering with these groups as appropriate. 
 
The work carried out in chapter 8 can be expanded upon by carrying out iterative headroom assessments 
as more information is obtained about the potency and efficacy of the product, during product 
development and eventually during the clinical trials. This will result in better informed data concerning 
the gross profit and price potentials of the PD CTP. Furthermore, as development progresses the cost 
of goods modelling would need to be iteratively carried out as additional development and 
manufacturing process data is obtained. Data such as batch/lot failure rates, facility costs and 
development amortisation would be gained and incorporated to ensure that the model is adequately 
representative of the development and manufacturing costs, which would ultimately be used for price 
setting negotiations 
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Chapter 11. Appendices  
Appendix 1. Miltenyi Biotec Panel 1 flow cytometry analysis of H9 vmDA cells cultured at the Centre 
for Biological Engineering, Loughborough University. 
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Appendix 2. Miltenyi Biotec Panel 2 flow cytometry analysis of H9 vmDA cells cultured at the Centre 
for Biological Engineering, Loughborough University. 
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Appendix 3. Miltenyi Biotec Panel 3 flow cytometry analysis of H9 vmDA cells cultured at the Centre 
for Biological Engineering, Loughborough University. 
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Appendix 4. Miltenyi Biotec Panel 2 flow cytometry analysis of H9 vmDA cells cultured by Miltenyi 
Biotec personnel. Plots show cells at six different time points with varying levels of FOXA2 and OTX2 
expression.  
 
 
Appendix 5. Images of cells on day 12 of the differentiation process. (A) Cells seeded at less than the 
recommended 800,000 cells/cm2. (B) Cells seeded at the recommended 800,000 cells/cm2. Cells in A 
have less debris and flowing cells in comparison to cells at the higher density B.  Scale bar = 400 µm. 
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Appendix 6. Payment by Results case studies. Extracted from Gateway Ref: 18135 – A simple guide 
to Payment by Results. 
  
Gateway Ref: 18135 
A simple guide to Payment by Results 
17 
Figure 6: PbR case studies 
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Treatment Elective caesarean during a 7 day 
spell in April  
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fracture in April  
Code ICD-10 codes are O300 (twin 
pregnancy and Z37.2 (twin both live 
born) 
 
OPCS-4 code is R17.2 (elective 
lower uterine segment caesarean 
delivery) 
 
Submitted to SUS in May  
ICD-10 codes are S7200 (fractured 
neck of femur) and W19.0 
(unspecified fall at home) 
 
OPCS-4 codes are W37.1 (primary 
total prosthetic replacement of hip 
joint using cement) and Z94.3 (left 
sided operation) 
 
Submitted to SUS in May  
Group HRG payment currency is NZ13A 
(planned lower uterine caesarean 
section with complications) 
HRG payment currency is HA12C 
(major hip procedures category 1 
for trauma without complications 
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Tariff Elective and non-elective spell tariff is 
£2,704 
Base tariff is £5,323 
Tariff 
adjustments 
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£394 is payable for each additional 
day’s stay, in this case 2 days. 
There is a best practice tariff for 
fragility hip fracture which applies to 
HA12C and some other HRGs. 
 
An additional best practice payment 
of £1,335 is payable where care 
complies with clinical characteristics of 
best practice.  In this case, surgery 
within 36 hours of arrival in A&E, 
under expert care of a consultant 
geriatrician.  
MFF Guy’s and St Thomas’ has an MFF 
payment index of 1.2770 
Leeds Teaching’s MFF is 1.0461 
Reimbursement Total payment is: 
 
(£2,704 + (2 x £394)) x 1.2770 = 
£4,459 
 
SUS extract in July informs monthly 
reconciliation between NHS Lambeth 
and Guy’s and St Thomas’  
Total payment is:  
 
(£5,323 + £1,335) x 1.0461 = £6,965 
 
SUS extract in July informs monthly 
reconciliation between NHS Leeds and 
Leeds Teaching  
 
                                            
3 Images from the NHS Photo Library.  The models (not their real names) have consented to make their 
images available for DH and NHS publications.  
Patient A Patient B 
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Appendix 7. CHART workshop agenda  
 
  
 
 
 
Challenges in the Adoption of Regenerative Medicine Therapies 
June 24-25, 2019 
Toronto, Canada 
Overview 
This workshop will bring together key stakeholders and policy-makers in academia, medicine, government and industry to 
discuss key challenges that will need to be overcome for advanced therapy medicinal products (ATMPs) to successfully 
traverse the reimbursement and adoption pathway. The workshop will focus primarily on issues faced by Canada, the 
United Kingdom and other government-funded health-care systems, including: 
x appropriate data generation to support decision-making for ATMPs;  
x overcoming barriers to adoption, such as hospital infrastructure, drug costs and financing; and 
x payment structures and cost offsetting considerations for ATMPs. 
The workshop is hosted by Medicine by Design, a regenerative medicine initiative at the University of Toronto, in 
collaboration with CCRM, the Toronto Health Economics and Technology Assessment Collaborative (THETA) and 
Loughborough University (U.K.).  
Outcomes 
The primary goal of the workshop is to create a network of stakeholders in Canada and the U.K. that will drive discussion 
and research and influence policy-making around ATMP health technology assessment (HTA), reimbursement and 
adoption. It will do this by strengthening relationships between key stakeholders, who will collaborate over time to 
understand challenges to the adoption of ATMPs and facilitate focused research, development and appropriate payment 
system modelling.  
Our short-term goals are to produce a white paper and doctoral thesis research exploring these issues from a Canada-
U.K. perspective, and catalyze further workshops and symposia. We will also explore opportunities to access funding for 
ongoing, collaborative work.  
Organizing Committee 
Medicine by Design 
x Allison Brown, Director, Strategy & Translation 
x Ann Perry, Manager, Communications & Operations 
x Jackie Denholm, Operations Assistant 
CCRM x Siofradh McMahon, Senior Manager, Clinical Translation & Regulatory Affairs 
Loughborough University x James Kusena, PhD candidate, Centre for Biological Engineering and Wolfson School of Mechanical and Manufacturing Engineering 
THETA x Dr. Murray Krahn, Program Director x Karen Bremner, Research Associate 
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Agenda 
 
 
Monday, June 24, 2019 
MaRS Collaboration Centre (101 College St.) 
South Tower, Main Level 
Collaboration Room 2 (CR2) 
8:30 am-9 am REGISTRATION 
9 am-9:10 am 
Welcome Speaker:  
Dr. Vivek Goel 
Vice-President, Research & Innovation 
University of Toronto (Canada) 
 
9:10 am-10:15 am 
Session 1: Introduction and context 
x Current/forthcoming challenges regarding pricing 
and reimbursement for ATMPs 
x Definition of ATMPs, product development, 
regulations and reimbursement context   
x HTA decision frameworks  
x Brief introduction of speakers, discussants and 
guests 
 
 
Speakers:  
Dr. Murray Krahn 
Program Director 
THETA (Canada) 
 
James Kusena 
PhD candidate 
Loughborough University (U.K.) 
 
Siofradh McMahon 
Senior Manager, Clinical Translation & Regulatory 
Affairs 
CCRM (Canada) 
 
10:15 am-10:30 am COFFEE 
10:30 am-12 pm 
Session 2: Evidence of clinical effectiveness 
x What is the evidence supporting the benefits and 
safety of ATMPs?  
x What is the structure of the data/evidence?  
x How do we ascertain the clinical benefits for 
ATMPs? Does their promise of cure/long-term 
effect make them different?  
x What is the strength of the evidence? 
x How can these technologies/therapies be 
evaluated when the sample size is very small?  
x How to satisfy both payers and regulators by 
producing adequate data? 
 
 
Speakers: 15 minutes each 
Discussants: 5 minutes each 
Open discussion: 50 minutes 
 
Speakers:  
Pilar Pinilla-Dominguez 
Senior Scientific Advisor 
National Institute for Health and Care Excellence 
(NICE) (U.K.) 
 
Dr. John Kuruvilla  
Hematologist 
Princess Margaret Cancer Centre (Canada) 
 
Discussants:  
Tania Bubela 
Dean, Faculty of Health Sciences 
Simon Fraser University (Canada) 
 
Alex Klarer 
Biomedical Engineer 
Hitachi Chemical Advanced Therapeutics Solutions, 
LLC (USA) 
 
12 pm-1:30 pm LUNCH 
1:30 pm-3 pm 
Session 3: Health economics 
x How to evaluate the cost effectiveness of 
ATMPs? 
x What are the methodological challenges?  
 
Speaker: 15 minutes 
Discussants: 5 minutes each 
Open discussion: 60 minutes 
Speaker:  
Ana Duarte 
Research Fellow, Centre for Health Economics 
University of York (U.K.) 
 
Discussants:  
Grace Hampson 
Senior Principal Economist 
The Office of Health Economics (U.K.) 
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Pilar Pinilla-Dominguez 
Senior Scientific Advisor 
NICE (U.K.) 
 
William Wong 
Assistant Professor, School of Pharmacy 
University of Waterloo (Canada) 
 
3 pm-3:15 pm COFFEE 
3:15 pm-4:45 pm 
Session 4: Social values toward regenerative 
medicine 
x What is the public/patient perception of ATMPs?  
x Patient preferences/experiences/perspectives 
x Bioethical perspectives 
 
Speaker:15 minutes 
Discussants: 5 minutes each 
Open discussion: 65 minutes 
Speakers:  
Jennifer Gibson 
Director, Joint Centre for Bioethics  
University of Toronto (Canada) 
 
Discussants:  
Fiona Miller 
Professor, Institute of Health Policy, Management and 
Evaluation 
University of Toronto (Canada) 
 
Tania Bubela 
Dean, Faculty of Health Sciences 
Simon Fraser University (Canada) 
 
4:45 pm-5 pm 
Wrap-up discussion Speakers:  
Dr. Murray Krahn 
Program Director 
THETA (Canada) 
 
James Kusena 
PhD candidate 
Loughborough University (U.K.) 
 
Siofradh McMahon 
Senior Manager, Clinical Translation & Regulatory 
Affairs 
CCRM (Canada) 
 
5 pm-7 pm BREAK 
7 pm Dinner for speakers and discussants 
Mercatto 
MaRS (Elizabeth Street side of building) 
http://college.mercatto.ca/ 
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Tuesday, June 25, 2019 
MaRS Collaboration Centre (101 College St.) 
South Tower, Main Level 
Collaboration CAFÉ 
8:30 am-9:45 am 
Session 5: Health technology assessment 
overview 
x HTA and clinical processes - do they differ?  
x What is the data and how is it packaged into the 
HTA process?  
x The specifics of an evaluation, what is the HTA 
journey like?  
x What is the decision-making process/formula? 
 
Speakers: 15 minutes each 
Discussants: 5 minutes each 
Open discussion: 35 minutes 
Speakers:  
Heather Logan 
Senior Advisor, Pharmaceutical Reviews 
Canadian Agency for Drugs and Technologies in 
Health (CADTH) (Canada) 
 
Pilar Pinilla-Dominguez 
Senior Scientific Advisor 
NICE (U.K.) 
 
Discussants:  
Suzanne McGurn  
Assistant Deputy Minister, Drugs and Devices and 
Executive Officer, Ontario Public Drug Programs 
Government of Ontario (Canada) 
 
Rebecca Yu 
Vice-President, Market Access & External Affairs 
Takeda Canada (Canada) 
 
 
9:45 am-10 am COFFEE 
10 am-11:30 am 
Session 6: Payment system mechanisms 
x Are there any novel payment mechanisms?  
x Do we need novel systems or adjustment of 
codes?  
x What are the funding mechanisms/risk sharing 
agreements? 
 
Discussants: 5 minutes each 
Open discussion: 65 minutes 
Discussants:  
Ana Duarte 
Research Fellow, Centre for Health Economics 
University of York (U.K.) 
 
Rebecca Yu 
Vice-President, Market Access & External Affairs 
Takeda Canada (Canada) 
 
11:30 am-12:30 pm LUNCH 
12:30 pm-2:30 pm 
Session 7: Adoption and implementation 
x How do we facilitate the effective adoption and 
implementation of ATMPs, and ensure we gather 
the relevant evidence? 
x How do sessions 1-6 help us address the 
adoption challenges (as tangible action points)?  
x Do we need changes in infrastructure? (ATTC – 
discussion point?) 
x What are the barriers to adoption and 
implementation?  
 
Speakers: 15 minutes each 
Discussants: 5 minutes each 
Open discussion: 75 minutes 
 
Speakers:  
James Rose 
Head of Clinical Innovation Adoption 
Oxford Academic Health Science Network (U.K.) 
 
Discussants:  
Dr. John Kuruvilla  
Hematologist 
Princess Margaret Cancer Centre (Canada) 
 
Linnea Doyle 
Senior Director, Market Access & Government 
Relations 
Gilead Sciences, Inc. (Canada) 
 
Shahira Bhimani 
Director, Health Solutions 
MaRS Partnerships (Canada) 
 
2:30 pm-3 pm 
Wrap-up 
x Next steps 
x Summary 
x White paper 
Speakers:  
Dr. Murray Krahn 
Program Director 
THETA (Canada) 
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x Next meeting?   
James Kusena 
PhD candidate 
Loughborough University (U.K.) 
 
Siofradh McMahon 
Senior Manager, Clinical Translation & Regulatory 
Affairs 
CCRM (Canada) 
 
3 pm WORKSHOP CONCLUDES 
3 pm-4 pm 
x Organizing committee debrief 
 
 
 
 
 
  
6 
 
 
 
Location 
All sessions will take place at the MaRS Discovery District (101 College St.), in the Collaboration Centre (main floor, 
South Tower). The closest subway station is Queen’s Park. For out-of-town participants, MaRS is a short walk (less than 
10 minutes) from the Chelsea Hotel.  
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ChallengeV in Whe AdRSWiRn Rf RegeneUaWiYe Medicine TheUaSieV 
June 24-25, 2019 
Toronto, Canada 
Participants 
 Name Title Organization Country Workshop Role 
1  Céline Bauwens Scientific Manager, Medicine by 
Design 
University of Toronto Canada Invited attendee 
2  Dr. Donna Berry Program Manager, 
Garron Family Cancer Centre & 
ENACT Committee  
The Hospital for Sick 
Children 
Canada Invited attendee 
3  Shahira Bhimani Director, Health Solutions MaRS Partnerships Canada Discussant – Session 7 
4  Diane Bigras Associate Director, Market 
Access and Government Affairs 
for Ontario 
Gilead Sciences, Inc. Canada Invited attendee 
5  Karen Bremner Research Associate Toronto Health Economics 
and Technology 
Assessment Collaborative 
Canada Organizing committee 
6  Allison Brown Director, Strategy & Translation, 
Medicine by Design 
University of Toronto Canada Organizing committee 
7  Tania Bubela Dean, Faculty of Health Sciences Simon Fraser University Canada Discussant – Session 2 
Discussant – Session 4 
8  Jackie Denholm Operations Assistant, Medicine 
by Design 
University of Toronto Canada Organizing committee 
9  Kathryn Deuchars Director, Ontario Personalized 
Medicine Network and Senior 
Manager, Sector Innovation and 
Programs 
Ontario Genomics Canada Invited attendee 
10  Linnea Doyle Senior Director, Market Access & 
Government Relations 
Gilead Sciences, Inc. Canada Discussant – Session 7 
11  Ana Duarte Research Fellow, Centre for 
Health Economics 
University of York U.K. Speaker – Session 3 
Discussant – Session 6 
12  Kristina Ellis MSc candidate (Supervisor: 
William Wong) 
University of Waterloo Canada Invited attendee 
13  Michael Farkouh Chair, Peter Munk Centre of 
Excellence in Multi-national 
Clinical Trials 
University Health Network Canada Invited attendee 
14  Aren Fischer Market Access Manager Takeda Canada Canada Invited attendee 
15  Jennifer Gibson Director, Joint Centre for 
Bioethics 
University of Toronto Canada Speaker – Session 4 
16  Dr. Vivek Goel Vice-President, Research & 
Innovation 
University of Toronto  Canada Speaker – Welcome  
17  Peter Goodhand Chief Executive Officer Global Alliance for 
Genomics and Health 
Canada Invited attendee 
18  Grace Hampson 
 
 
Senior Principal Economist The Office of Health 
Economics 
U.K. Discussant – Session 3 
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 Name Title Organization Country Workshop Role 
19  Rosemary Hannam Senior Research Associate, 
Centre for Health Sector 
Strategy, Rotman School of 
Management 
University of Toronto Canada Invited attendee 
20  Timothy Key Manager, Technology & Venture 
Development 
MaRS Innovation Canada Invited attendee 
21  Alex Klarer Biomedical Engineer Hitachi Chemical 
Advanced Therapeutics 
Solutions, LLC 
USA Discussant – Session 2 
22  Dr. Murray Krahn Program Director Toronto Health Economics 
and Technology 
Assessment Collaborative 
Canada Moderator 
Organizing committee 
23  Dr. John Kuruvilla Hematologist Princess Margaret Cancer 
Centre 
Canada Speaker – Session 2 
Discussant – Session 7 
24  James Kusena PhD candidate Loughborough University  U.K. Moderator  
Organizing committee 
25  Heather Logan Senior Advisor, Pharmaceutical 
Reviews 
Canadian Agency for 
Drugs and Technologies in 
Health 
Canada Speaker – Session 5 
26  John-Paul Marino Director, Market Access Gilead Sciences Inc.  Canada Invited attendee 
27  Lisa Masucci PhD candidate (Supervisor: Dr. 
Murray Krahn) 
University of Toronto Canada Invited attendee 
28  Suzanne McGurn Assistant Deputy Minister, Drugs 
and Devices, and Executive 
Officer, Ontario Drug Programs 
Government of Ontario Canada Discussant – Session 5 
29  Siofradh McMahon Senior Manager, Clinical 
Translation & Regulatory Affairs 
CCRM Canada Moderator 
Organizing committee 
30  Fiona Miller Professor, Institute of Health 
Policy, Management and 
Evaluation 
University of Toronto Canada Discussant – Session 4 
31  Allan Miranda Head JLABS @ Toronto Canada Invited attendee 
32  Ann Perry Manager, Communications & 
Operations, Medicine by Design 
University of Toronto Canada Organizing committee 
33  Pilar Pinilla-
Dominguez 
Senior Scientific Advisor National Institute for Health 
and Care Excellence 
(NICE) 
U.K.  Speaker – Session 2 
Discussant – Session 3 
Speaker – Session 5 
34  Nezar Rghei Vice-President, Strategic 
Partnerships & Resource 
Development 
Ontario Genomics Canada Invited attendee 
35  James Rose Head of Clinical Innovation 
Adoption 
Oxford Academic Health 
Science Network 
U.K. Speaker – Session 7 
36  Michael Sefton Executive Director, Medicine by 
Design 
University of Toronto Canada Invited attendee 
37  Soror Sharifpoor Research Program Manager, 
Translational Biology & 
Engineering Program 
Ted Rogers Centre for 
Heart Research 
Canada Invited attendee 
38  Nick Timmins Vice-President, Process 
Sciences 
BlueRock Therapeutics Canada Invited attendee 
39  Christine Williams Deputy Director Ontario Institute for Cancer 
Research 
Canada Invited attendee 
40  William Wong Assistant Professor, School of 
Pharmacy 
University of Waterloo Canada Discussant – Session 3 
41  Rebecca Yu Vice-President, Market Access & 
External Affairs 
Takeda Canada Canada Discussant – Session 5 
Discussant – Session 6 
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Appendix 9. CHART workshop, Session 1 presentation slides: Introduction  
 
7/22/19
1
CHART
Challenges in the Adoption of 
Regenerative Medicine Therapies
June 24 & 25, 2019
IN COLLABORATION WITH
2
Objectives and outcomes of this session
• Definition of ATMPs, product development, regulations and reimbursement context 
• Current/forthcoming challenges regarding pricing and reimbursement for ATMPs 
• HTA decision frameworks 
• Brief introduction of speakers, discussants and guests 
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3Organising committee
Dr. Murray Krahn - Program Director THETA (Canada)
James Kusena – PhD candidate, Loughborough University
Siofradh McMahon – Senior Manager, Clinical translation and Regulatory Affairs, CCRM
Karen Bremner – Research associate THETA (Canada)
Ann Perry – Manager, Communications and Operations, Medicine by Design
Allison Brown – Director, Strategy and Translation, Medicine by Design
Jackie Denholm – Operations assistant, Medicine by Design
4
ATMPs: definition and regulatory processes
• EU ATMP definition is being used throughout to describe these products
“An advanced therapy medicinal product (ATMP) is a medicinal product which is either: a gene 
therapy medicinal product. a somatic cell therapy medicinal product. a tissue engineered product.”
• Regulatory processes/approval to enter the market
• UK: EMA and national regulators 
• Canada: Regulated by Health Canada as “drugs” 
• (with a few exceptions for transplant material and minimally manipulated autologous homologous 
use cells)
• Health Technology Assessment
• UK: NICE
• Canada: CADTH and INESSS (Quebec)
• CAR-T therapies reviewed through the technology pathway (i.e. not drug)
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5
The Opportunity
OPPORTUNITY to get ahead of this potential influx of disruptive 
technologies and put in place a mechanism to evaluate technologies and 
facilitate adoption of those we want into healthcare systems.
Today
• HC approval of 3 cell 
therapies, two CAR-T
• Canadian leadership in RM/AT 
clinical trial 
• Phase I/II manufacturing 
capability
• ~246 T-cell immunotherapy 
trials worldwide
Within 1 – 2 Years
• Potentially numerous CAR-T 
products approved
• Increased delivery to upwards 
of ~3,000 patients per year 
• Potentially 30 – 40 RM/ATs 
approved worldwide
Within 5 – 10 years
• Potentially 35+ RM/ATs approved in Canada
• Routine delivery of RM/ATs to ~10,000 patients per year
6
Key Steps in the Adoption of ATMPs
Infrastructure 
Training
Monitoring
Patient 
management
Care guidelines
Adoption
Health Technology 
Assessment 
(Canada: CADTH / 
INESSS; UK: NICE)
Patented Medicines 
Pricing Review 
Board (PMPRB)
(Pan-Canadian 
Pharmaceutical 
Alliance)
Reimbursement
New Drug 
Submission
Health Canada/EMA 
review
Agreed commercial 
manufacturing 
process
Regulatory Review 
and Approval
New technology 
development
Clinical trials
Manufacturing 
process development
Scale up and logistics
Research and 
Development
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7
Challenges in pricing and reimbursement
8
Centre for Biological Engineering
Healthcare Engineering Group focusing on:
• Protocol optimisation 
• Protocol standardisation 
• Process automation 
• Regulatory frameworks 
• Cost and financial headroom  
• Economic evaluations 
• Headroom 
• Reimbursement pathway
• Adoption pathway
 
 
 
 
 
- 392 - 
 
 
 
7/22/19
5
9
Some  key questions,  as 
these therapies are being 
developed:
• Can they actually be 
afforded? 
• How do we pay for them? 
• How are they going to be 
implement?
People we work with: 
The challenge
10
HTA decision frameworks and the structure of the next 
2 days
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11
EARLY & CLASSIC HTA IN TECH DEVELOPMENT
12
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1. BENEFITS AND HARMS Rank
Be
ne
fit
s	a
nd
	H
ar
m
s
Benefit
Magnitude
Insert	measures	of	effectiveness.	For	example,	
gain	in	quality-adjusted	life	year	(QALY),	relative	
risk	reduction,	or	odds	ratio
Certainty
Insert	measures	of	certainty	that	the	benefit	is	
true.	For	example,	confidence	intervals	(for	
random/systematic	error)	or	GRADE	assessment	
(for	risk	of	bias).
Harm
Magnitude Insert	measures	of	harm.	For	example,	relative	
risk		or	odds	ratio	for	adverse	event.
Certainty
Insert	measures	of	certainty	that	the	harm	is	
true.	For	example,	confidence	intervals	(for	
random/systematic	error)	or	GRADE	assessment	
(for	risk	of	bias).
Patient	
perspective
Strongly	
for/against	or	not	
a	determinant
Patient	inputs	on	how	patients	perceive	the	net	
benefits	and	harms.
SUMMARY
Takes	into	account	both	the	
magnitude	and	certainty	of	
benefits	and	harms,	and	the	
ways	in	which	patients	
perceive	these	benefits	and	
harms,	to	produce	the	
likelihood	that	this	technology/	
intervention	will	produce	net	
benefit	or	harm.
Highly	likely	
to	produce	
net	benefit
Moderately	
likely	to	
produce	net	
benefit
Uncertain	
benefit/	
harm
Moderately	
likely	to	
produce	net	
harm
14
2. VALUE FOR MONEY
 Check	mark	("")	indicates	formal	analysis	completed.	X	mark	("")	indicates	no	formal	analysis	completed.
Ec
on
om
ics
Type	of	
analysis
Value	for	
money
Cost	effectiveness
CE	Threshold
Highly	likely	
to	be	CE
(80%-100%)
Moderately	
likely	to	be	
CE
(60%-79%)
Uncertain	
CE
(40%-59%)
Moderately	
likely	to	not	
be	CE
(20%-39%)
Highly	
likely	to	
not	be	CE
(0%-19%)
$50K/QALY
$100K/QALY
Adequacy
Downgrade	Consideration Adequate Not	adequate
Appropriateness	of	cost	
and	outcome	measures
Comprehensiveness	of	
cost	and	outcome	
valuation/	aggregation
SUMMARY
Taking	account	of	both	the	
probability	of	cost	
effectiveness,	and	the	
adequacy	of	the	measures	
used,	select	the	overall	
likelihood	that	this	
technolog(ies)/	
intervention	is	cost	
effective.
CE	Threshold
Highly	likely	
to	be	CE
(80%-100%)
Moderately	
likely	to	be	
CE
(60%-79%)
Uncertain	
CE
(40%-59%)
Moderately	
likely	to	not	
be	CE
(20%-39%)
Highly	
likely	to	
not	be	CE
(0%-19%)
$50K/QALY
$100K/QALY
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3. PATIENT CENTRED CARE
 Check	mark	("")	indicates	formal	analysis	completed.	X	mark	("")	indicates	no	formal	analysis	completed.
Pa
tie
nt
-C
en
tr
ed
	C
ar
e
Patients:
Values	&	
Preferences
Aligned	with	patient	values	&	
preferences
Do	patients	have	specific	values,	preferences	or	needs	related	to	the	
condition,	treatment	or	life	impact	that	are	relevant	to	this	
assessment?	(NB.	Values	and	preferences	of	family,	informal	
caregivers	or	the	public	to	be	considered,	as	appropriate)
Consistent	with	commitments	to	
autonomy,	privacy,	confidentiality
Are	there	concerns	regarding	accepted	ethical	or	legal	standards	
related	to	patient	autonomy,	privacy	or	confidentiality	that	are	
relevant	to	this	assessment?
Populations:
Equity	&	
Coordinated	
Care
Enhances	equity	in	access	or	
outcomes
Are	there	disadvantaged	populations	or	populations	in	need	whose	
access	to	care	or	health	outcomes	might	be	improved	(or	not	
worsened)	that	are	relevant	to	this	assessment?
Coordinates	care
Are	there	challenges	in	the	coordination	of	care	for	patients	that	
might	be	improved	(or	not	worsened)	that	are	relevant	to	this	
assessment?
SUMMARY
Taking	account	of	these	considerations,	
select	the	degree	to	which	the	evidence	
supports	the	use	of	the	technology(ies)/	
intervention.
Strongly	
supports
Somewhat	
supports
Neutral/
Unknown
Does	not	
support
Strongly	
discourages
16
4. HEALTH SYSTEM FEASIBILITY
Cost	
considerations
What	are	the	relevant	cost	considerations	associated	with	
implementing	this	technology/intervention	(e.g.,	budget	impact)?
Organizational	
implications
What	are	the	relevant	non-cost	implications	(e.g.,	logistical,	human	
resources)	associated	with	implementing	this	
technology/intervention?
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Appendix 10. CHART workshop, Session 2 presentation slides: Evidence of clinical effectiveness 
 
 
22/07/2019
1
© NICE 2019. All rights reserved. Subject to notice of rights. 
Pilar Pinilla-Dominguez, Senior Scientific Adviser, NICE Scientific 
Advice
Challenges in the Adoption of Regenerative Medicine Therapies Workshop
24 June, 2019
Session 2: Evidence of clinical 
effectiveness: NICE’s experience on 
the evaluation of cell and gene 
therapies
Key questions
• What is the evidence supporting the benefits and safety of ATMPs?
• What is the structure of the data/evidence?
• How do we ascertain the clinical benefits for ATMPs? Does their promise of cure/long-
term effect make them different?
• What is the strength of the evidence?
• How can these technologies/therapies be evaluated when the sample size is very small?
• How to satisfy both payers and regulators by producing adequate data?
2
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Key questions for NICE
How well does the technology work compared with established 
practice in the health service?
How much does this course of action cost compared with established 
practice in the health service?
Benefit
Cost
3
Exciting times
Challenges
High costs
Uncertain long-term 
benefits and adverse 
effects
Timely patient access 
while the evidence is still 
emerging
Pipelines of novel (bio)pharmaceuticals and advanced therapy medicinal 
products (ATMPs) with potential for major benefits – cures?
Immunotherapies / 
Chimeric antigen 
receptor T-cell 
Gene therapies Therapies targeting biomarkers
Combination 
therapies
4
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ATMPs: what is different/difficult?
• High upfront cost and uncertain long-term effectsPotential for a cure
• Lack of funding
• Multi-stakeholder expertise
• Expensive manufacturing
• Complicated logistics
• Limited experience of HTA requirements
ATMPs frequently developed 
by SMEs/academics
• RCTs – impossible?
• Limited generalisability and external validity
• Small sample sizes
• Surrogate/intermediate rather than final/clinical outcomes
• Short trials – maintenance of effect? Uncertain long-term effects
• Unknown future adverse effects
Limited evidence
5
ATMPs at NICE – not new
NICE Technology Appraisal 16: Autologous cartilage transplantation for full 
thickness cartilage defects in knee joints
Published date: 16 December 2000
6
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Many ATMPs withdrawn from market
Alipogene tiparvovec 
(Glybera)
Sipuleucel-T (Provenge) 
Characterised viable 
autologous cartilage cells 
(Chondrocelect)®
Matrix-applied characterised 
autologous cultured 
chondrocytes (MACI)
• Not evaluated by NICE
• Originally not 
recommended by NICE 
in TA332 
• MA withdrawn during 
TA447
• MA suspended during 
TA447
7
TA410: Talimogene
laherparepvec
TA467: Holoclar
TA477 & TA 508:
Autologous chondrocytes
HST7: Strimvelis
TA554 (paediatric ALL) 
& TA567 (adults DLBCL) 
Tisagenlecleucel
TA555: Darvadstrocel
TA559: Axicabtagene
ciloleucel
ATMPs evaluated at 
NICE
8
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NICE Technology Appraisals for CAR-T: case 
studies
9
Key issues in clinical and cost effectiveness in 
CAR-T cell appraisals
Generalisability 
Patient 
population
Place in 
treatment 
pathway
Comparator and 
evidence 
available
Clinical 
evidence: 
maturity
Curative 
effect 
assumption
Assumptions 
around 
comparators
Approach for 
overall 
survival 
extrapolation
Costs of side 
effects
End of life 
criteria and 
discount rate
10
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Clinical effectiveness
Single-arm trials
No appropriate comparative source of data for comparison: 
differences in patient characteristics and prognostic factors
Short-term evidence:
• Median overall survival just or not reached
• Curative assumptions proportion of patients
• Proportion of patients who subsequently have a transplant
• Uncertain adverse effects
11
Clinical effectiveness
ü No appropriate comparative source – differences in patient characteristics 
and prognostic factors between patients in the trials and comparative 
evidence include:
age 
proportion of 
primary 
refractory 
patients 
ECOG 
performance 
status
percentage of 
bone marrow 
blasts (ALL) 
number of 
previous 
treatments  
time since last 
relapse
proxy data for 
comparator 
from other 
treatments 
(ALL)
ALL = acute lymphoblastic leukaemia
12
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Clinical effectiveness issues with high impact on 
cost effectiveness
ü Short term evidence: overall survival
Ø Tisagenlecleucel-T – ALL (up to 25 years): 
median follow up less than 3 years; median 
overall survival only reached in the single 
centre trial, high degree of censoring
Ø Axicabtagene ciloleucel – DLBCL: Median 
overall survival not reached, with overall 
survival rates of 52% at 18 months (95% CI 
41 to 62).
Ø Tisagenlecleucel-T – DLBCL: Median 
overall survival between 11 and 22 months; 
high degree of censoring
Clinical experts 
highlighted the 
promising results; 
acknowledging 
the short-follow 
up
ALL = acute lymphoblastic leukaemia
DLBCL: diffuse large B-cell lymphoma 13
Clinical effectiveness issues with high impact on 
cost effectiveness
• No robust evidence of curative effect à assumed cure point 
between 2 and 5 years
Curative assumptions: 
cure point and 
proportion of patients
• number of patients who would have an SCT after having 
CAR-T is highly uncertain
• interim analyses of the ELIANA study showed that of 
patients having tisagenlecleucel, 11% had a subsequent SCT
Proportion of patients 
who subsequently have 
a transplant (ALL)
• Number of patients who will need intravenous 
immunoglobulin treatment for B-cell aplasia and for how 
long
Uncertain adverse 
effects (DLBCL)
ALL = acute lymphoblastic leukaemia
SCT: stem cell transplant
DLBCL: diffuse large B-cell lymphoma 14
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Experience in NICE scientific advice
15
• 25 ATMP NICE SA with 15 gene and 10 cell therapies 
Updated by March 2019
Alignment between regulators and HTA bodies
16
• Retrospective qualitative analysis of minutes of discussion meetings held 
at the EMA between 2010 and May 2015 (n=31)
Tafuri et al. (2016) How aligned are the perspective of EU regulators and HTA bodies? A comparative analysis 
of regulatory-HTA parallel scientific advice. Br J Clin Pharmacol
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Pilar Pinilla-Dominguez
Senior Scientific Adviser
Pilar.Pinilla-dominguez@nice.org.uk
www.nice.org.uk/scientificadvice
Follow us on Twitter
@NICESciAdvice
17
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1
© NICE 2019. All rights reserved. Subject to notice of rights. 
Pilar Pinilla-Dominguez, Senior Scientific Adviser, NICE Scientific 
Advice
Challenges in the Adoption of Regenerative Medicine Therapies Workshop
24 June, 2019
Session 3: Health economics;
Discussant points
Some challenges for HTA and decision-making
Non-comparative trials
Heterogeneity of populations
Surrogate endpoints with unclear relationship with OS and HRQL 
Small sample sizes 
Early regulatory approval with short-term follow-up and ethical 
consequences
2
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Challenges: how to deal with them?
• Small sample size: Limited generalisability & external validity
• Single arm-trials: Methods for comparison require strong assumptions:
- Matched adjusted indirect comparisons (MAIC)
- Simulated treatment comparison (STC)
- Before and after comparisons, historical controls…
• Surrogate outcomes: validity and relationship with clinical and patient relevant outcomes
• Short-term trial: need for extrapolation and assumptions:
- Parametric distributions, proportional hazard assumptions, splines, cure models (mixture 
cure models) and assumptions about cure fraction
• Discount rate: costs incurred in short term and benefits observed lifetime
3
Key questions
4
What is the 
impact on 
the ICER?
Do we 
need new 
methods?
Should we 
apply 
pragmatic 
decisions 
or wait for 
further 
data?
How to 
mitigate the 
risks?
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1
Health Technology Assessment 
of CAR T-cell Therapies
CHALLENGES IN THE ADOPTION OF REGENERATIVE 
MEDICINE THERAPIES
JUNE 24-25, 2019  
Heather Logan 
Senior Advisor, Pharmaceutical Reviews 
Disclosure
• No conflicts of interest to declare.
• CADTH receives funding from Canada’s federal, provincial, 
and territorial governments, with the exception of Quebec.
• CADTH is an independent, not-for-profit organization 
responsible for providing Canada’s health care decision-
makers with objective evidence to help make informed 
decisions about the optimal use of drugs, medical devices, 
diagnostics, and procedures in our health care system.
1
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OUTLINE
HTA
• What, Who ,When, How
HTA of CAR T-cell
• Is it different?
• Typical drug HTA?
• Typical clinical intervention HTA?
2
What is HTA?
WHO definition
• the systematic evaluation of properties, effects, and/or impacts of 
health technology
• health technology is the application of organized knowledge and 
skills in the form of medicines, medical devices, vaccines, 
procedures and systems developed to solve a health problem and 
improve quality of life. 
• A multidisciplinary process to evaluate the social, economic, 
organizational and ethical issues of a health intervention or health 
technology. 
• The main purpose is to inform  policy decision making 
3
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Who Does HTA?
HTA bodies
• NICE
• ICER
• CADTH
• INESSS
Hospital based units
• Hospital value analysis committees
oCentral difference is that HTA bodies conduct 
evaluation of a class of devices, while hospital based 
value analysis is done at the product level
4
Overview of Drug Review in Canada
Health Canada 
Regulator	
(Effect	&	
safety)
CADTH 
(CDR and pCODR)
INESSS 
(Quebec)
HTA	
(Assess	value)
Ministries of Health
Decision	
maker/
funder
Pan Canadian Pharmaceutical 
Alliance (pCPA)
Price	
negotiator
5
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When: Current framework
8
• Canada is a federal system that is highly decentralized.  
• Regulatory approval to enter the marketplace is conducted 
federally by Health Canada
• Majority of drug reviews conducted concurrent with 
regulatory review. Not true for devices/clinical interventions. 
o Drugs:  HTA and pan-Canadian price negotiation are required to enter 
marketplace
o Interventions: Neither HTA nor pan-Canadian price negotiation are required. 
Typically, once in the market place, funding is determined and 
provided at the provincial/territorial level
• Administration of health care delivery is done regionally 
within provinces 
Choice of HTA 
Is the value proposition different for a pharmaceutical 
versus a clinical intervention/device?
• Decision problem for both is whether it should be 
adopted
If the mechanism for adoption is predominantly that it should 
be funded and placed in the formulary
• HTA for a pharmaceutical
If the mechanism for adoption is funding and a complex 
implementation system,
• HTA for a clinical intervention 
9
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How are they different?
10
HTA CLINICAL INTERVENTION
Determination of value: Should 
this be adopted
Deliberative Framework: 
• Relevance and Unmet Need
• Benefits 
• Harms
• Patient perspective
• Economic impact
• Implementation 
• Legal 
• Ethical 
• Environmental impact
HTA DRUGS
Determination of value:  
Should this be adopted
Deliberative Framework: 
• Relevance and Unmet Need
• Benefits 
• Harms
• Patient perspective
• Economic impact
Specific HTA for CAR T-cell
11
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Is this a complex 
intervention?
12
13
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Decision Problem
How should the provision of tisagenlecleucel for children 
and young adults with relapsed or refractory B-cell acute 
lymphoblastic leukemia (r/r-ALL) and adults with relapsed 
or refractory diffuse large B-cell lymphoma (r/r-DLBCL) be 
structured?
14
Evidentiary Needs
1. Clinical effectiveness
2. Cost effectiveness
3. Ethical issues
4. Implementation considerations
5. Patient & care giver perspective
15
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What is Assessed?
EVIDENCE PACKAGE that includes comparative evidence on 
• Relevance and Unmet Need
• Benefits 
• Harms
• Patient perspective
• Economic impact
• Implementation 
• Legal 
• Ethical 
• Environmental impact
16
Health Technology Expert Review Panel 
(HTERP)
• 7 core members
• Chair
• Public member
• Ethicist
• Health economist
• Three health care practitioners
• Up to 5 expert members
17
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HTERP Deliberative Framework
18
Clinical	Context	/	
Need
Benefits	&	Harms Economic	Impact
Ethics
Implementation
Environmental	
Impact
Legal
Patient	
Perspectives
HTERP Overall Recommendation
On the condition that there is a reduction in price, the 
expert committee recommends the provision of 
tisagenlecleucel…. 
19
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HTERP Implementation Recommendations
1. The creation of interprovincial agreements to ensure equitable 
access to eligible patients in all jurisdictions, including 
consideration of financial and logistic support for required travel 
and short-term relocation.
2. the development of clear and transparent eligibility criteria that are 
acceptable to patients’ and clinicians’ needs, based on the 
approved indications
3. The collection of standardized outcomes data in a pan-Canadian 
registry of patients, which uses a defined set of outcomes and 
definitions to generate real-world evidence, for consideration in 
future reassessments to assess longer-term effectiveness, safety, 
and cost-effectiveness
20
Conclusion
• Cell and gene therapies are complex interventions
• HTA requires consideration of the many implementation and 
ethical issues in the deliberation. 
• Disruptive technologies, at the point of first implementation, 
require additional discussion and planning 
21
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1
© NICE 2019. All rights reserved. Subject to notice of rights. 
Pilar Pinilla-Dominguez, Senior Scientific Adviser, NICE Scientific 
Advice
Challenges in the Adoption of Regenerative Medicine Therapies Workshop
25 June, 2019
Session 5: Health technology 
assessment at NICE
Key questions
• HTA and clinical processes - do they differ?
• What is the data and how is it packaged into the HTA process?
• The specifics of an evaluation, what is the HTA journey like?
• What is the strength of the evidence?
• What is the decision-making process/formula?
2
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Key questions for NICE
How well does the technology work compared with established 
practice in the health service?
How much does this course of action cost compared with established 
practice in the health service?
Benefit
Cost
3
NICE Technology Appraisals
• Formal referral by the 
Secretary of State for Health 
(Department of Health and 
Social Care) to NICE 
required
• A review of clinical and 
economic evidence leading 
to recommendations on the 
appropriate use of new and 
existing technologies for the 
NHS in England 
4
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NHS Constitution 2012
You have the right to drugs 
and treatments that have 
been recommended by 
NICE for use in the NHS, if 
your doctor says they are 
clinically appropriate for 
you.
5
6
What does NICE value?
Value
Clinical 
effectiveness
Cost 
effectiveness
End of life
InnovationDegree of need
Equity
Non-health 
objectives
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7
Certainty of the ICER
HRQL inadequately captured
Innovative nature of technology
Non-health objectives of the NHS
Life extending treatment at the end of life
£20,000	
per	QALY
£30,000	
per	QALY
£50,000	
per	QALY
Flexible decision making
8
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What’s new at NICE
By 2020, NICE will expand its 
scope by reviewing all new drugs 
approved by drug licensing 
agencies in addition to most new 
uses of already approved drugs
Cost-recovery for NICE 
technology appraisals and highly 
specialised technology (HST) 
appraisals started in April 2019
11
NICE Regenerative Medicines Study (2016)
• Prompted by a recommendation 
from the  Department of Health 
Regenerative Medicine Expert 
Group 
• Included a broad exploration of 
the applicability of NICE TA 
methods to regenerative 
medicines
• Hypothetical example product 
based on early clinical data for 
related real products 
supplemented with hypothetical 
evidence
Source: https://www.nice.org.uk/Media/Default/About/what-we-do/Science%20policy%20and%20research/Regenerative-
medicine-study-march-2016.pdf 12
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NICE Regenerative Medicines Study (2016)
great 
uncertainty 
potentially 
very 
substantial 
patient 
benefits
innovative 
payment 
methods 
ü NICE appraisal methods and decision frameworks applicable
ü Key to quantify and present clinical outcome and decision uncertainty 
13
Managing uncertainty and risk
Data 
collection
Commercial 
negotiations
14
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Cancer Drugs Fund overview
Recommended
Not
recommended
No 
OIR
*
Yes
Cancer Drugs 
Fund
Yes, 
in 
CDFN
IC
E	
Ap
pr
ai
sa
l	C
om
m
itt
ee
No data 
collection
Data 
collection 
during 
specified 
time
Review 
Technology 
appraisal
Withdrawal of 
recommendations
Non 
recommended
No 
OIR
Yes Recommended
*OIR – only in research 
Cost effectiveness results: most plausible 
incremental cost-effectiveness ratio (ICER) for the 
CAR-T appraisals
Tisagenlecleucel-T – ALL 
(up to 25 years)
Tisagenlecleucel-T –
DLBCL 
Axicabtagene ciloleucel –
DLBCL
>£30,000 per QALY gained >£50,000 per QALY gained >£50,000 per QALY gained
ALL = acute lymphoblastic leukaemia
DLBCL: diffuse large B-cell lymphoma 16
 
 
 
 
 
- 425 - 
 
 
22/07/2019
9
Discount rate: the NICE Guide to the methods of 
technology appraisals says…
Cost-effectiveness results should reflect the present value of 
the stream of costs and benefits accruing over the time 
horizon of the analysis. 
The same annual discount rate should be used for both 
costs and benefits (currently 3.5%)
A discount rate of 1.5% for costs and benefits may be considered when 
treatment effects are both substantial in restoring health to full or near 
full health and sustained over a very long period (normally at least 
30 years), and if the committee is satisfied that the introduction of the 
technology does not commit the NHS to substantial irrecoverable costs
17
End of life (EOL) criteria
ü The treatment is indicated for 
patients with a short life 
expectancy (<24 months)
ü There is sufficient evidence to 
indicate that the treatment has 
the prospect of offering an 
extension to life, (>3 months) 
compared with current NHS 
treatment.
ü The estimates of the extension 
to life are sufficiently robust 
ü The assumptions used in the 
reference case economic 
modelling are plausible, 
objective and robust.
18
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Other factors
• No robust/mature evidence to support curative 
effect
3.5% for 
both costs 
and benefits
• Tisagenlecleucel-T – ALL (up to 25 years): not 
met à the life expectancy evidence is 
uncertain
• Tisagenlecleucel-T – DLBCL: met
• Axicabtagene ciloleucel – DLBCL: met
EOL 
criteria
EOL: end of life
ALL = acute lymphoblastic leukaemia
DLBCL: diffuse large B-cell lymphoma 19
Cancer Drugs Fund
2. Does drug have plausible potential to be cost-
effective at the current price, taking into 
account end of life criteria?
1. Why is drug not recommended? Is it due to 
clinical uncertainty?
3. Could data collection reduce uncertainty
4. Will ongoing 
studies provide useful 
data?
5. Is CDF data 
collection 
feasible?
Recommend enter CDF 
and
Starting point: drug not recommended 
for routine use
Indicate research question, required analyses and number of 
patients in NHS in England needed to collect data
Committee’s rationale in CAR-T appraisals
ü Not recommended
ü Yes
ü Yes
ü Yes
ü Yes
20
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CDF data collection 
Collection of data 
on
• Overall survival
• Convergence of 
progression-free 
survival and 
overall survival 
curves
• Rate of 
subsequent SCT
• Immunoglobulin 
usage 
Sources
• Ongoing clinical 
trials
• CDF through 
SACT data
Period of data 
collection
• 5 years
21
Pricing and managed access agreements
Tisagenlecleucel-T –
DLBCL
• List price: £282,000 
per infusion (company 
submission) 
• Commercial 
arrangement:
(managed access 
agreement with a 
simple discount [size 
of the discount is 
commercial in 
confidence]  and rebate 
scheme) 
Tisagenlecleucel-T –
ALL
• List price: £282,000 
per infusion (company 
submission) 
• Commercial 
arrangement (the size 
of the discount is 
commercial in 
confidence)
Axicabtagene ciloleucel
– DLBCL
• List price: submitted 
as commercial in 
confidence
• Commercial 
arrangement (details 
of the arrangement are 
commercial in 
confidence)
ALL = acute lymphoblastic leukaemia
DLBCL: diffuse large B-cell lymphoma 22
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The outcomes
• TA559: recommended for 
use within the Cancer Drugs 
Fund
Axicabtagene ciloleucel
(Yescarta, Kite-Gilead) for 
treating diffuse large B-cell 
lymphoma and primary 
mediastinal B-cell 
lymphoma after 2 or more 
systemic therapies
• TA567 –recommended for 
use within the Cancer Drugs 
Fund
Tisagenlecleucel- T 
(Kymriah, Novartis) for 
treating relapsed or 
refractory diffuse large B-
cell lymphoma after 2 or 
more systemic therapies
• TA554: recommended for 
use within the Cancer Drugs 
Fund
Tisagenlecleucel-T 
(Kymriah, Novartis) for 
treating relapsed or 
refractory B-cell acute 
lymphoblastic leukaemia in 
people aged 3 to 25 years
23
What outcome data is collected whilst a drug is 
available on the CDF?
24
Health 
technology 
appraisal
RCTs (phase 
IIb/III)
Review of 
health 
technology 
appraisal
Phase II single arm
Observational data
Observational 
data
Ongoing trial
Managed access period
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Planning regulatory and HTA pathway together
25
Support initiatives for innovative products such as 
ATMPs
PRIME 
• Designation granted by the European Medicines Agency
EAMS
• Designation granted by the UK Medicines and Healthcare 
Regulatory Agency 
Accelerated Access Collaborative
• Designation supporting rapid national uptake
Scientific 
advice
NICE Office 
for Market 
Access
26
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Key issues to consider early
• Clinical trial design and feasibility to conduct comparisons with 
established practice
• Relevant outcomes, their relationship with health-related quality of life 
and mortality, and frequency of data collection
• Proposed modelling approaches (based on clinical plausibility and data 
available to date) to deal with uncertainty at the time of submission
• Long-term evidence generation plans à increasing relevance of post-
marketing authorisation studies including clinical effectiveness and 
adverse effects data
• Data collection in the relevant setting
29
Pilar Pinilla-Dominguez
Senior Scientific Adviser
Pilar.Pinilla-dominguez@nice.org.uk
www.nice.org.uk/scientificadvice
Follow us on Twitter
@NICESciAdvice
30
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Appendix 14. CHART workshop, Session 7 presentation slides: Adoption and Implementation 
 
 
 
© GfK July 22, 2019 | Title of presentation 1
1James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Exploring Adoption and Implementation of ATMPs:
A UK Perspective 
James Rose, Head of Innovation Adoption, Oxford AHSN
CHART Workshop June 2019
2James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Oxford Academic Health Science Network
• Brings	together	Academia,	Industry	and	
Healthcare
• 700	life	science	companies
• 6	large	acute	hospital	trusts
• 5	universities
• 3	million	citizens
• Focus	on	spread	innovation	at	“pace	and	scale”
• improving	health	and	generating	economic	
growth	
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3James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Is the UK currently an attractive market for ATMPs?
• UK	a	leader	in	basic/clinical	research	– NHS	for	many	years	struggled	with	translation	and	adoption
• Investment	in	developing	people,	networks,	infrastructure,	capacity	and	capabilities	
• Almost	£250m	(C$421m)	provided	by	the	UK	government	to	drive	translation,	commercialisation	
and	adoption	of	ATMPs
• CGT	Catapult	
• CGT	Manufacturing	Centre
• Advanced	Therapies	Treatment	Centres	designed	to	help	translation	to	NHS	
• Uncertainty	around	Brexit	remains
• NHS	is	a	“Single-payer”	market		- advantages	of	potential	centralised	commissioning,	
coordination,	standardisation,	risk	management	and	data	access	to	support	adoption	
Source UK Government 2018 :https://bit.ly/2QemRu3    
4James Rose | June 25 2019 | Adoption and Implementation of ATMPs
10 licensed ATMPs / 7 with a positive NICE TA
Name	- Manufacturer Indication Authorisation NICE	TA
Strimvelis®	- GSK ADA-SCID 2015 APPROVED
Imlygic®	- Amgen Melanoma 2015 APPROVED
Holoclar®	- Chiesi Severe	limbal	stem	cell	deficiency 2015 APPROVED
Zalmoxis®	- Molmed Stem	cell	transplantation	(high-risk	blood	cancer) 2016 APPROVED
Spherox®	- co.don Cartilage	defects	in	the	knee	joint 2017 APPROVED
Alofisel®	- Tigenix Perianal	fistulas	in	Crohn´s	disease 2018 REJECTED
Yescarta®	- Kite/Gilead B-cell	lymphoma 2018 APPROVED	CDF
Kymriah®	- Novartis ALL,	DLBCL 2018 APPROVED	CDF
Zynteglo®	– Bluebird Transfusion-dependent	thalassaemia	(TDT) 2019 PENDING	
Luxturna®	- Spark Inherited	Retinal	Disease 2019 PENDING	
Data accurate as of June 2019
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5James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Source data from Schüssler-Lenz 2019 https://www.asgct.org/ASGCT/media/about/Approved-Marketing-authorisations-of-ATMPs-in-EU-_M.pdf
EMA expecting a steep rise in submissions and 
authorisations in coming years
18 20
22 21
24
30
40
43
54 52
20
1 3 1 1 3 2
0
10
20
30
40
50
60
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Year
Scientific 
Advice
Approvals
111
14
ATMPs 
Approved
~350
Scientific 
Advice Cases
22
MAA 
Submissions
10
MAA 
submissions 
expected in 
2019/20 alone
Collectively recognise the  need to be ready!
6James Rose | June 25 2019 | Adoption and Implementation of ATMPs
The pathway to market access is established…
Source: Kefalas CGT 2014 https://ct.catapult.org.uk/sites/default/files/publication/Achieving-market-access-for-cell-therapies-a-UK-perspective-May-2014.pdf
Pathway to adoption and implementation less so
Adoption and 
Implementation 
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7James Rose | June 25 2019 | Adoption and Implementation of ATMPs
The Consolidated Framework for Implementation Research 
Source: Damschroder et al, Implementation Science 2009  https://implementationscience.biomedcentral.com/articles/10.1186/1748-5908-4-50
Intervention Characteristics
Inner Setting
Outer Setting
Individual Characteristics
Implementation Process 
8James Rose | June 25 2019 | Adoption and Implementation of ATMPs
The Consolidated Framework for Implementation Research 
Source: Damschroder et al, Implementation Science 2009  https://implementationscience.biomedcentral.com/articles/10.1186/1748-5908-4-50
Intervention Characteristics
Inner Setting
Outer Setting
Individual Characteristics
Implementation Process 
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9James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Inner Setting - Institutional barriers to adoption
Looking at example of recent CAR-T implementation – 11 centres in UK 
Expression 
of Interest &
Accreditation
Contracting Governance Training Capacity Patient Mgmt
10James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Inner Setting - Institutional barriers to adoption
Looking at example of recent CAR-T implementation – 11 centres in UK 
Expression 
of Interest &
Accreditation
Contracting Governance Training Capacity Patient Mgmt
• Thousands	man	hours	invested	in	
accreditation
• Huge	resource	commitment	to	SOPs,	
policies,	pathways	and	guidelines
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11James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Inner Setting - Institutional barriers to adoption
Looking at example of recent CAR-T implementation – 11 centres in UK 
Expression 
of Interest &
Accreditation
Contracting Governance Training Capacity Patient Mgmt
• Rates	of	contracting	were	variable.	
• Hospitals	each	negotiating	independently,	
interpreting	contracts	and	levels	of	risk	
differently.	
12James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Inner Setting - Institutional barriers to adoption
Looking at example of recent CAR-T implementation – 11 centres in UK 
Expression 
of Interest &
Accreditation
Contracting Governance Training Capacity Patient Mgmt
• Critical	to	build-in	appropriate	
governance	and	oversight	around	ATMPs
• Role	of	Pharmacy	has	been	important	–
natural	fit	with	current	QA	
responsibilities.
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13James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Inner Setting - Institutional barriers to adoption
Looking at example of recent CAR-T implementation – 11 centres in UK 
Expression 
of Interest &
Accreditation
Contracting Governance Training Capacity Patient Mgmt
• Critical	to	build-in	appropriate	
governance	and	oversight	around	ATMPs
• Role	of	Pharmacy	has	been	important	–
natural	fit	with	current	QA	
responsibilities.
14James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Inner Setting - Institutional barriers to adoption
Looking at example of recent CAR-T implementation – 11 centres in UK 
Expression 
of Interest &
Accreditation
Contracting Governance Training Capacity Patient Mgmt
• Capacity	was	one	of	biggest	issues	
for	CAR-T	sites
- Apheresis	unit	capacity
- Stem	cell	freezing	
- Staff
- Ward	Capacity
- ITU	capacity
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15James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Inner Setting - Institutional barriers to adoption
Looking at example of recent CAR-T implementation – 11 centres in UK 
Expression 
of Interest &
Accreditation
Contracting Governance Training Capacity Patient Mgmt
• All	CAR-T	sites	in	UK	reported	challenge	in	
releasing	staff	for	the	required	training	time.	
• Not	considered	sustainable	for	providers	to	
redesign	processes	and	train	dozens	of	staff	
for	each	ATMP
16James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Inner Setting - Institutional barriers to adoption
Looking at example of recent CAR-T implementation – 11 centres in UK 
Expression 
of Interest &
Accreditation
Contracting Governance Training Capacity Patient Mgmt.
• Developing	appropriate	referral	and	patient	
review	pathways
• Regular	national	panel	reviews	and	approves	
requests
• Weekly	MDT	meetings	to	discuss	CAR-T	patient	
management	at	site	level	
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17James Rose | June 25 2019 | Adoption and Implementation of ATMPs
UK Reimbursement decisionsOuter Setting – Creating a netw rk of “Innovation niches”
18James Rose | June 25 2019 | Adoption and Implementation of ATMPs
UK Reimbursement decisions
OUTER SETTING 
Challenges the ATTCs are exploring
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19James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Individuals – Understanding different perspectives 
Datenrei… Datenrei… Datenrei…
Patients Clinicians Managers 
Datenrei…
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• Joint decision making
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Datenrei… Datenrei… Datenrei…
Patients Clinicians Managers 
Datenrei…
Policy Makers 
• Generating and 
maintaining healthy 
public perception
• Joint decision making
• Patient education 
• Clinic l l adership 
• Clarity around roles 
and responsibilities
• Embedding appreciate 
governance
• Fit with strategic 
priorities
• Compelling business 
case
• Levels of risk vs benefit
• Political will to support 
sector
• Alignment of policy with 
practice and patient 
need?
• Addressing needs of 
global workforce
• Significant	Hospital	resource	required	
for	implem ntation	around	CAR-T.	
• Estimated	~£42000	investment	
before	first	patient	treated	at	one	
site	(550	staff	hours)
Individuals – Understanding different perspectives 
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Datenrei… Datenrei… Datenrei…
Patients Clinicians Managers 
Datenrei…
Policy Makers 
• Generating and 
maintaining healthy 
public perception
• Joint decision making
• Patient education 
• Clinic l l adership 
• Clarity around roles 
and responsibilities
• Embedding appreciate 
governance
• Fit with strategic 
priorities
• Compelling business 
case
• Levels of risk vs benefit
• Political will to support 
sector
• Alignment of policy with 
practice and patient 
need?
• Addressing needs of 
global workforce
NHSE	and	CGT	Catapult	currently	looking	
closely	at	the	future	workforce.	
• Pharmacy’s	role
• Medical	training
• Apprenticeships	
Individuals – Understanding different perspectives 
22James Rose | June 25 2019 | Adoption and Implementation of ATMPs
Summary Points 
• ATMP	Implementation	is	not	straightforward	- needs	coordination	and	collaboration	to	ensure	
sustainability
• ATTCs	in	the	UK	will	offer	“innovation	niches”		for	more	efficient	adoption	and	implementation	
approaches	to	be	tested
• NHSE	played	key	role	in	CAR-T	adoption/	delivery	(e.g.	service	spec	development,	patient	panel,	
capacity	management	etc)	– contributions	to	other	parts	of	process	may	be	necessary
• For	patients	to	benefit	from	future	ATMPs,	changes	required	in	infrastructure,	data	collection	and	
workforce	training	will	be	required
• Opportunities	to	learn	from	outside	our	own	innovation	system	very	important
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Appendix 15. Deep Brain Stimulation cost data used to inform the final values used in the analysis  
 
 
 
 
Appendix 16. Deep Brain Stimulation health utility data used to inform the final values used in the 
analysis 
 
 
 
 
Device Cost Surgery Costs Hospital Costs Pre Op Costs Misc Costs 
Source Value Info Value Info Value Info Value info Value info Total 
Moon et al 
(2017) £12,202.00 - £7,772.00 - £1,903.00 
Averaged  
over 2 
years 
£641.00 - £616.00 battery change £23,134.00 
DBS 
Policy 
(2013)
£12,202.00 - £7,000.00 - £2,000.00 £700.00 - £4,000.00 
battery 
change/ 
follow up £26,058.00 
Yianni et 
al (2013) £11,104.00 - £6,115.00 - £1,593.00 £856.00 - £1,059.00 follow up £20,727.00 
Eggington 
et al
(2014)
£12,202.00 - £7,131.00 - £1,593.00 £641.00 - £616.00 battery change £22,183.00 
Pietzch et
al (2014) Broken down cost data not provided £24,680.00 
Average £11,927.50 £7,004.50 £1,772.25 £709.50 £1,572.75 £22,986.50 
Source Value Gain  from 
baseline of 0.42
Info Baseline QALY over 10 
years 
Increment over 10 
years 
Yianni et al (2013) 0.76 0.47 base line was 0.29 0.29 7.6 4.7
Moon et al (2017) 0.644 0.224
Improvement by 0.16 so 
intial health state would be 
0.484
0.42 6.44 2.24
DBS Policy (2013) 0.59 0.17
70% reduction in  motor 
complications . Quality of 
life improvement of 30% 
over medication 
0.42 5.9 1.7
Eggington et al
(2014) 0.72 0.3
from H&Y 3 50 -75 % off 
to H&Y 2 off 0- 25% 0.42 7.2 3
Pietzch et al (2014) 0.589 0.169 0.42 5.89 1.69
Average 0.6606 0.2666 0.394 6.606 2.666
 
 
 
 
 
- 444 - 
Appendix 17. Deep Brain Stimulation sensitivity analysis of the costs associated with the therapy for 
the payer. 
 
 
Appendix 18. Medication therapy cost data used to inform the final values used in the analysis 
 
 
 
Sensitivity Analysis Table 
Device Cost Surgery Costs Hospital Costs Pre Op Costs Miscellaneous Costs
level 1 £20,005 £21,235 £22,543 £22,809 £22,593 
level 2 £22,987 £22,987 £22,987 £22,987 £22,987 
level 3 £25,968 £24,738 £23,430 £23,164 £23,380 
Device Cost Surgery Costs Hospital Costs Pre Op Costs Miscellaneous Costs
Adjusted Sensitivity 
Table £(2,982) £(1,751) £(443) £(177) £(393)
£- £- £- £- £-
£2,982 £1,751 £443 £177 £393 
Range 5963.75 3502.25 886.125 354.75 786.375
Rank 1 2 3 5 4
Ordered Sensitivity 
Table Device Cost Surgery Costs Hospital Costs Miscellaneous Costs Pre Op Costs 
£(2,981.88) £(1,751.13) £(443.06) £(393.19) £(177.38)
£- £- £- £- £-
£2,981.88 £1,751.13 £443.06 £393.19 £177.38 
Medication Costs Care Cost Hospital Costs Loss of Productivity 
Costs 
Miscellaneous Costs
Source Value Info Value Info Value Info Value info Value info Total 
Parkinson's 
UK (2017) £2,297.00 per year £3,704.00 - - £11,093.00 - £1,000.00 - £18,094.00 
Weir et al 
(2018) £2,300.00 
Can go up to 
£4000 in the 
tenth year of 
the disease 
£3,700.00 - £2,722.00 - £11,000.00 - - £19,722.00 
DBS Policy 
(2013) £2,297.00 - £9,776.00 - - £11,093.00 - - £23,166.00 
Eggington et 
al (2014) £3,725.00 - £3,704.00 - £1,593.00 - £11,093.00 - - £20,115.00 
Pietzch et al
(2014) £1,948.00 - £3,704.00 - £1,593.00 - £11,093.00 - - £18,338.00 
Average £2,654.75 £5,221.00 £2,157.50 £11,069.75 £1,000.00 £22,103.00 
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Appendix 19. Medication therapy health utility data used to inform the final values used in the analysis 
 
 
 
Appendix 20. Medication therapy sensitivity analysis data of the associated costs for the payer. 
 
 
Appendix 21. DopaCell/DopaCell adjusted cost data used to inform the values used in the analysis 
 
 
QALY Value Gain  from 
base of 0.42
Info Baseline QALY over 
10 years 
Increment 
over 10 years 
Meds QALY
Moon et al 
(2017) 0.644 0.08
Improvement by 
0.16 so intial 
health state 
would be 0.484
0.564 5 0.8 0.5
DBS Policy 
(2013) 0.59 0.06
70% reduction in  
motor 
complications . 
Quality of life 
improvement of 
30% over 
medication 
0.53 4.8 0.6 0.48
Eggington et 
al (2014) 0.66 0.242
this is assumed 
that the drugs 
carry on working 
in the best way 
for period 
analysed
0.418 6.62 2.42 0.662
Pietzch et al
(2014) 0.57 0.15 0.42 5.7 1.5 0.57
Average 0.616 0.133 0.483 5.53 1.33 0.553
Sensitivity Analysis Table 
Medication Costs Care Cost Hospital Costs Loss of Productivity 
Costs 
Miscellaneous Costs
level 1 £21,439 £20,798 £21,564 £11,033 £21,103 
level 2 £22,103 £22,103 £22,103 £22,103 £22,103 
level 3 £22,767 £23,408 £22,642 £24,870 £22,603 
Medication Costs Care Cost Hospital Costs Loss of Productivity Costs Miscellaneous Costs
Adjusted Sensitivity 
Table £(664) £(1,305) £(539) £(11,070) £(1,000)
£- £- £- £- £-
£664 £1,305 £539 £2,767 £500 
Range 1327.375 2610.5 1078.75 13837.1875 1500
Rank 4 2 5 1 3
Ordered Sensitivity 
Table 
Loss of Productivity 
Costs Care Cost Miscellaneous Costs Medication Costs Hospital Costs
£(11,069.75) £(1,305.25) £(1,000.00) £(663.69) £(539.38)
£- £- £- £- £-
£2,767.44 £1,305.25 £500.00 £663.69 £539.38 
Therapy Costs Surgery Costs Hospital Costs Pre Op Costs Misc Costs 
Development cost Sell Price Info Value Info Value Info Value info Value info Total 
£10,000.00 £15,000.00 
Sale
price to 
payer 
£7,000.00 £1,700.00 £712.00 £8,000.00 Immunosuppressants£32,412.00 
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Appendix 22. DopaCell adjusted health utility data used to inform the values used in the analysis 
 
 
Appendix 23. DopaCell/DopaCell adjusted sensitivity analysis data of the costs associated with the 
therapy for the payer 
 
 
 
Appendix 24. Input data for headroom method, cost-effectiveness and financial analysis 
 
 
Value Gain  from base of 0.42 Info Baseline QALY over 10 years Increment over 10 
years 
0.72 0.3 Based on transitioning from H&Y III to H&Y II 0.42 7.2 3
Sensitivity Table 
Therapy Costs Surgery Costs Hospital Costs Pre Op Costs Misc Costs 
level 1 £11,250 £38,662 £39,987 £40,234 £24,412 
level 2 £15,000 £40,412 £40,412 £40,412 £40,412 
level 3 £18,750 £42,162 £40,837 £40,590 £48,412 
Therapy Costs Surgery Costs Hospital Costs Pre Op Costs Misc Costs 
Adjusted Sensitivity Table £(3,750) £23,662 £24,987 £25,234 £9,412 
£- £25,412 £25,412 £25,412 £25,412 
£3,750 £27,162 £25,837 £25,590 £33,412 
Range 7500 3500 850 356 24000
Rank 2 3 4 5 1
Ordered Sensitivity Table Misc Costs Therapy Costs Surgery Costs Hospital Costs Pre Op Costs 
£9,412.00 £(3,750.00) £23,662.00 £24,987.00 £25,234.00 
£25,412.00 £- £25,412.00 £25,412.00 £25,412.00 
£33,412.00 £3,750.00 £27,162.00 £25,837.00 £25,590.00 
HRQoLND HRQoLCT Duration WTP (£) C (£) N (patients) V (number of
years with N 
patients)
CDD (£) per 
patient
DopaCell 1 0.553 10 30000 32412 100 1 10000
Dopacell 
(adjusted) 0.72 0.553 10 30000 32412 100 1 10000
Medication 0.553 0.553 10 30000 22103 100 1 2654.75
Deep Brain 
Stimulation 0.6606 0.553 10 30000 22986.5 100 1 11927.5
